KEEP IN TOUCH WITH RHEUMATOLOGY

UPDATE YOUR CONTACT DETAILS!

Receive your access codes to the recorded sessions*

Receive your free subscription**

Annals of the Rheumatic Diseases - the EULAR Journal (ARD)**

Go to any Yellow Tower to update your contact information to secure delivery of the EULAR Journal and access to view the recorded presentations

*if purchased

** the patient and exhibitor registration categories do not include the complimentary subscription
Table of Contents

Welcome Message 3
Organising Committees 4
General Information 5
  – Information about your participation 6
  – EULAR Corporate Social Responsibility statement 9
  – Networking opportunities 9
  – Scientific information 10
  – Information on industry related activities 10

Scientific programme
Congress at a Glance:
  – Wednesday, 8 June 2016 13
  – Thursday, 9 June 2016 14
  – Friday, 10 June 2016 16
  – Saturday, 11 June 2016 18

Wednesday, 8 June 2016
  – Scientific Programme 19

Thursday, 9 June 2016
  – Scientific Programme 28
  – Guided Poster Tours 47
  – Scientific Poster Session 1 55

Friday, 10 June 2016
  – Scientific Programme 83
  – Guided Poster Tours 101
  – Scientific Poster Session 2 109

Saturday, 11 June 2016
  – Scientific Programme 136
  – Guided Poster Tours 146
  – Scientific Poster Session 3 154

Health Professionals in Rheumatology Programme and Posters 181
PARE Programme and Posters 192
EULAR Related Meetings 198

Partner programme
Satellite Symposia 201
Company Profiles 210
Acknowledgements 224

Congress Venue General Plan 226
Exhibitors’ List 228
Exhibition Plan 229

The acronym “PARE” used in the programme stands for “People with Arthritis/Rheumatism in Europe”
The acronym “HPR” used in the programme stands for “Health Professionals in Rheumatology”
The acronym “PReS” used in the programme stands for “Paediatric Rheumatology European Society”
Annual European Congress of Rheumatology EULAR 2017
Madrid, Spain, 14-17 June 2017

Scientific Secretariat
EULAR Secretariat
Seestrasse 240
CH-8802 Kilchberg / Zurich
Switzerland
Phone +41 44 716 3030
Fax +41 44 716 3039
E-mail: eular@eular.org

Organising Secretariat
EULAR 2017
c/o MCI Suisse SA
Rue de Lyon 75
CH-1211 Geneva 13 - Switzerland
Phone +41 22 33 99 590
Fax +41 22 33 99 601
E-mail: eular@mci-group.com

www.congress.eular.org
Dear Colleagues,

Welcome to this EULAR Annual European Congress of Rheumatology in London!

The annual EULAR Congresses which began in 2000 are today a major event in the calendar of world rheumatology. This meeting will again provide a unique occasion for the exchange of scientific and clinical information. It will facilitate interaction between patients, medical doctors, scientists, health professionals and professionals representing the pharmaceutical industry both from Europe and from around the world. You are certainly aware that participating in the congress is just one element of the annual educational package provided by EULAR. Thus in addition, the participants will have the opportunity to watch virtually all oral presentations through electronic capture and will be provided with a complimentary one-year access to the newest developments and publications in the field of RMDs.

EULAR has grown rapidly in terms of the number of participants and the quality of the submissions. Thus, more than 4’000 abstracts have been submitted to this congress in London and 199 sessions and poster tours are offered. This enormous success reflects the ever increasing interest in rheumatic and musculoskeletal diseases (RMDs) which has been seen in most societies and is now recognized also by the EU. It also reflects the availability of increased information on the size, burden and cost of these diseases for society, and a significantly improved ability to diagnose and treat them. The incorporation of health professional and patient organisations within EULAR has been a considerable stimulus for these advances.

The EULAR Congress 2016 in London will once again provide a wide range of topics including clinical innovations, clinical translational and basic science. In addition there will be significant contributions made by People with Arthritis and Rheumatism (PARE), by Health Professionals in Rheumatology (HPR) and by the health care industry. The core science and central activity of the congress will be the poster presentations and poster tours with their highly interactive exchanges between participants. The London meeting will further promote the reputation of the EULAR Congress as the most innovative and informative venue for clinical research for the practising physician. The EULAR EMEUNET organisation of young rheumatologists also hopes to attract young colleagues to the meeting and will disseminate the message that rheumatology is one of the most attractive and successful disciplines of medicine.

The city of London needs little introduction. “Tired of London, tired of life” is a quotation previously used for the 2011 EULAR congress in London, and it is even more reinforced by the recent accolade of “world city”, and indicates how ideal a venue this is for an international meeting such as the EULAR Congress which has truly become a world congress. The elegance of London with its architecture, galleries, theatres and ambience should again provide an excellent background for clinical exchanges, international collaborations and renewal of friendships. It is our great pleasure and a real joy in welcoming medical doctors, patients, health professionals and representatives of the pharmaceutical industry and hope their stay in London will be delightful, informative, and educational.

Gerd R. Burmester
President of EULAR
Organising Committees

**EULAR EXECUTIVE COMMITTEE**

- **President**
  Prof. Gerd R. Burmester, Germany

- **President-elect**
  Prof. Hans W.J. Bijlsma, Netherlands

- **Past President**
  Prof. Maurizio Cutolo, Italy

- **Vice-President representing national PARE organisations**
  Mr Marios Kouloumas, Cyprus

- **Vice-President representing the Health Professionals in Rheumatology**
  Prof. Christina H. Opava, Sweden

- **Treasurer**
  Prof. Iain B. McInnes, United Kingdom

- **General Secretary**
  Prof. Ruxandra Ionescu, Romania

- **Editor in Chief of the “Annals of the Rheumatic Diseases – The EULAR Journal”**
  Prof. Tore K. Kvien, Norway

- **Editor in Chief of “RMD Open”**
  Prof. Bernard Combe, France

- **Liaison to EMEUNET**
  Dr Anna Molto, France

- **Liaison to the American College of Rheumatology ACR**
  Dr Daniel Aletaha, Austria

- **Liaison Officer, EU Public Affairs**
  Mr Neil Betteridge, United Kingdom

- **Liaison to the FOREUM Foundation**
  Prof. Steffen Gay, Switzerland

- **President UEMS Section of Rheumatology**
  Prof. Nada Cikes, Croatia

- **Executive Director**
  Mr Heinz Marchesi, Switzerland

**EULAR STANDING COMMITTEE CHAIRPERSONS**

(Ex-officio members of the EULAR Executive Committee)

- **Investigative Rheumatology**
  Prof. Rik Lories, Belgium

- **Clinical Affairs**
  Prof. Ronald van Vollenhoven, Netherlands

- **Education and Training**
  Prof. Annamaria Iagnocco, Italy

- **Epidemiology and Health Services Research**
  Prof. Axel Finckh, Switzerland

- **Musculoskeletal Imaging**
  Dr Esperanza Naredo, Spain

- **Paediatric Rheumatology**
  Prof. Tadej Avcin, Slovenia

- **PARE**
  Mr Dieter Wiek, Germany

- **Health Professionals in Rheumatology**
  Prof. Anthony Redmond, United Kingdom

**CONGRESS PROGRAMME COMMITTEE**

**Scientific, Health Professionals, PARE**

- The EULAR Executive Committee Members (excluding functions marked with *)
- The EULAR Standing Committee Chairpersons
- Prof. Dirk Elewaut, Belgium
  Chairperson of the Scientific Programme Committee
- Prof. João Eurico Fonseca, Portugal
  Chairperson of the Abstract Selection Committee
- Prof. Maya Buch, United Kingdom
  Past-Chairperson of the Scientific Programme Committee
- Prof. Dominique Baeten, Netherlands
- Dr Stefan Bergman, Sweden
- Prof. Maxime Breban, France
- Prof. Leonard Calabrese, United States
- Dr Annette de Thurah, Denmark
- Dr Maarten de Wit, Netherlands
- Prof. Margreet Kloppenburg, Netherlands
- Prof. Robert Landewé, Netherlands
- Prof. Willem F. Lems, Netherlands
- Prof. Anne-Marie Malfait, United States
- Prof. Christian Mallen, United Kingdom
- Dr Elena Neumann, Germany
- Prof. Eliseo Pascual Gomez, Spain
- Prof. Ingemar Petersson, Sweden
- Prof. Gabriela Riemekasten, Germany
- Prof. Carlo Salvarani, Italy
- Prof. Zoltán Szekanecz, Hungary
- Dr Leonie Taams, United Kingdom
- Prof. Tsutomu Takeuchi, Japan
- Dr Lene Terslev, Denmark
- Prof. Dimitrios Vassilopoulos, Greece
- Prof. Reinhard E. Voll, Germany
- Prof. Francesco Zulian, Italy

* These functions are not included in the Congress Programme Committee
CONGRESS VENUE: DATES AND LOCATION

The Annual European Congress of Rheumatology EULAR 2016 will be held at:

**ExCeL London**
**One Western Gateway - Royal Victoria Dock**
**London E16 1XL - United Kingdom**
**Tel: +44 20 7069 5000**
**Website: www.excel-london.co.uk**

The congress opens on Wednesday, 8 June 2016 – 12:00 and closes on Saturday, 11 June 2016 – 15:00.

The EULAR Congress Opening Plenary Session, followed by a Networking Platform, is held in the evening of Wednesday, 8 June 2016 at the congress venue itself.

ExCeL London is situated in a stunning waterfront location in the heart of London’s Royal Docks and within easy reach of central London. The venue is part of a 100 acre campus, including two onsite DLR stations, easy access to the Jubilee Line and London City Airport.

REGISTRATION OPENING HOURS

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>07 June 2016</td>
<td>17:00 - 20:00</td>
</tr>
<tr>
<td>Wednesday</td>
<td>08 June 2016</td>
<td>08:00 - 20:00</td>
</tr>
<tr>
<td>Thursday</td>
<td>09 June 2016</td>
<td>07:45 - 19:15</td>
</tr>
<tr>
<td>Friday</td>
<td>10 June 2016</td>
<td>07:45 - 19:15</td>
</tr>
<tr>
<td>Saturday</td>
<td>11 June 2016</td>
<td>08:00 - 15:00</td>
</tr>
</tbody>
</table>

SCIENTIFIC SECRETARIAT

**EULAR Secretariat**
**Seestrasse 240**
**CH-8802 Kilchberg/Zurich**
**Switzerland**
**Tel: +41 44 716 3030**
**Fax: +41 44 716 3039**
**E-mail: eular@eular.org**
**Website: www.eular.org / www.congress.eular.org**

ORGANISING SECRETARIAT

In charge of registration, abstract handling, partnership & investment opportunities, hotel reservations

**EULAR 2016**
**c/o MCI SUISSE SA**
**Rue de Lyon 75**
**CH-1211 Geneva 13**
**Switzerland**
**Tel: +41 22 33 99 590**
**Fax: +41 22 33 99 601**
**E-mail: eular@mci-group.com**
**Website: www.mci-group.com**

LOCAL ORGANISING AGENCY

For social events, excursions, transfers, company events

**MCI UK Ltd.**
**22 Long Acre, Covent Garden,**
**London, WC2E 9LY**
**United Kingdom**
**Tel: +44 (0) 173 071 5222**
**Fax: +44 (0) 870 442 9940**
**E-mail: eular2016.soc@mci-group.com**
**Website: www.mci-group.com**
Information about your participation

ADMITTANCE TO THE EULAR CONGRESS

In respect of UK and European laws and regulations, as well as due to current health and safety rules and legislation in effect, registration and/or admittance to the EULAR congress shall be limited solely to participants who are 18 years of age or older. Any registration by anyone who is under 18 is unauthorized and in violation of these terms and conditions and will automatically result in the forfeit of their registration. Identification is to be provided to congress staff upon request. Participants below 18 years of age will not be granted access to any part of the congress at any time.

This is also valid for children accompanied by their parents and for any other unregistered person. If access to the congress is needed and no registration is available, the person should contact the registration desk. The congress management will take a final decision.

CANCELLATION OF CONGRESS

It is mutually agreed that in the event of total or partial cancellation of the congress due to fire, strike, natural disaster (either threatened or actual), government regulations or causes which would prevent its scheduled opening or continuance, the contractual relationship between EULAR and the participant will be terminated immediately and EULAR shall determine an equitable basis for the eventual refund of a portion of the registration or other fees after due consideration of expenditures and commitments already made. Under no circumstances is EULAR responsible for any participant expenses (such as travel and lodging) or any other incidental or consequential damages.

EULAR CONGRESS MOBILE APP

Since 2003 EULAR has offered a congress programme and guide for mobile devices, at that time pioneering in this upcoming technology. In the last five years, we have also offered a planning tool, the internet based Itinerary Planner. Schedules made in the Planner can be transferred easily to your smartphone or tablet on iOS, Android or WindowsPhone 8 and 8.1.

Apart from general information, the App contains the complete congress programme with all sessions and lectures, all abstracts in full text (after the embargo is lifted) and all symposia. Links between these elements allow easily changing content. The location of session and meeting rooms is shown interactively so you know instantly where the next event takes place.

A support desk for mobile devices is located in the exhibition.

DATA SCANNING SYSTEM

Congress badges will contain a barcode acting as an electronic business card and thus enables visitors to leave their contact details for exhibitors quickly and easily.

DRESS CODE

Dress will be informal throughout the congress. EULAR reserves the right to refuse access if it is deemed necessary for the comfort and safety of all delegates.

General Information

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be given with the congress bag to each participant.

CHARGING STATIONS FOR SMARTPHONES AND MOBILE DEVICES

Charging stations for smartphones and other mobile devices are available in the registration area and exhibition hall.

CLOAKROOM

A cloakroom service for coats and reasonably-sized luggage is available during the opening hours of the congress on level 0, next to Hall A. For security reasons, electrical items cannot be kept in the cloakroom.

CONTINUING MEDICAL EDUCATION (CME) CREDITS

EULAR 2016 London has been accredited for a maximum of 18 European CME credits. This is an equivalent of 18 hours Continued Medical Education. CME points are recognized by the American Medical Association towards the Physician’s Recognition Awards (PRA). To convert CME credits to AMA PRA, contact AMA.

CYBER CAFÉ

Two Cyber Cafés are located in the exhibition hall.

CONGRESS DOCUMENTS AND BADGES

Name badges can be printed at the self-service stations, located at the registration area in hall S11, for participants accessing ExCeL from the East entrance, and in the central boulevard, for participants accessing ExCeL from the West entrance. Alternatively, congress documents (including name badges) can be collected at the registration desks. Name badges must be worn visibly at all time during the congress and in the exhibition area.

CONGRESS EVALUATION

We would be grateful if you could take a few minutes to support the hostesses that might approach you to get your opinion about the congress and the scientific programme. This will help us to continue improving the congress in future years.

CLIMATE

London enjoys a typically oceanic climate. Summers (from June to September) are moderately warm to dry often above 23°C. Contrary to popular belief, it does not rain every day in London. However, it is always advisable to bring some type of waterproof clothing or an umbrella.
**CREDIT CARDS**

Credit cards - especially Visa and Mastercard - are widely accepted in London’s restaurants, bars, cafés and shops. American Express and Diners Club cards are less commonly accepted. There are plenty of cash machines (also known as cashpoints or ATMs) dotted around London. There are 3 ATM machines available at the congress venue. Most accept international cards with the Visa Plus, Mastercard, Cirrus or Maestro symbols. Some other systems are also recognised, but it’s a good idea to check with your bank or card company before you travel. If you have a non-UK account you will almost certainly have to pay a charge when you withdraw cash.

**CURRENCY**

The UK’s currency is the pound sterling (£ / GBP). Despite being a member of the European Union, the UK has not adopted the EURO. There are 100 pence (p) to the pound (£).

**ELECTRICITY**

United Kingdom, like most other European countries, uses 230-Volt/50 Hz AC current. Plugs have three rectangular prongs that form a triangle. Plan to bring an adapter plug and if needed a transformer for your personal appliances.

**FOOD AND BEVERAGE**

During official coffee breaks, complimentary coffee and tea will be served in the EULAR Village and exhibition/poster areas. Lunch will be provided on Thursday and Friday and will also be served in the EULAR Village and exhibition/poster areas. Various self-service restaurants and sandwich bars are available at the congress venue.

**HELP POINT FOR SMARTPHONES AND MOBILE DEVICES**

A Help Point for phones and other mobile devices as well as recharge options for such devices will be available in the EULAR Village. The EULAR Mobile Congress App can also be downloaded there.

**LONDON & THE UK (FACTS ABOUT)**

London is the natural meeting point for the world’s business networks. It is a leading city in the world’s economy and a centre of international trade and finance. London attracts visitors from all over the world due to its incredible size, renowned tradition and endless historic and modern attractions for all demographics. More than 300 languages are spoken within its boundaries making it the perfect destination for international conferences and events.
Enriched in tradition, the city offers a wide range of attractions with historic landmarks, such as the Tower of London, Westminster Abbey and Buckingham Palace. This by no means categorises London as a purely historic destination, home to millennium features such as the London Eye, drawing in 3.5 million visitors annually and presenting spectacular views across the city.

The Emirates Air Line Cable Car connects ExCeL London and the O2 via a 5-minute crossing. ExCeL’s onsite cable car station is located at the west end of the site - a 5-minute walk from the West (pyramid) entrance. Oyster Cards can be used on the Cable Car. For onward travel into central London take Thames Clipper (river boats) services from the O2 to all major London piers, including Greenwich, Canary Wharf, Tower, London Bridge, Embankment and London Eye.

INSURANCE AND LIABILITY

It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. EULAR and MCI as organisers accept no liability or responsibility for personal injuries, or loss of, or damage to, private property belonging to the congress participants.

LANGUAGES/OFFICIAL LANGUAGE

The United Kingdom does not have a constitutionally defined official language. English is the main language (being spoken monolingual by more than 70% of the UK population) and is thus the de-facto official language. The official congress language is English. No simultaneous translation is provided.

PRESS CENTRE

The press and media area is located in the London Suites, level 0, near the East entrance. Facilities such as computers, telephone, photocopier, and internet access are available for registered press representatives.

SECURITY

Please pay special attention to your personal belongings, especially when walking in the city centre or using the public transportation system, but also inside the congress venue.

Any security problems or concerns within the congress venue should be reported to a member of the EULAR or MCI staff.

Security staff will handle any emergency situation and everyone is required to follow instructions announced via the public information system.

Emergency exits are marked with green exit signs.

SERVICES FOR THE DISABLED

All session rooms at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly in the EULAR Village.

SCIENTIFIC SESSIONS (ACCESS TO)

The meeting rooms for scientific sessions vary in size. Should the room be full, we invite you to use the overflow facilities located in Capital Suite 09 and 17 and in the registration area or to attend a different session. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a scientific session. The maximum capacities of the rooms are determined by the local safety and security regulations and have to be respected by law.

SMOKING POLICY

Smoking is not permitted at the congress venue.

TRANSPORTATION

EULAR provides pre-charged Oyster cards to duly registered delegates, enabling them to travel once a day to and from the congress venue within zones 1-3.

SHOPPING IN LONDON

London is considered one of the best places in the world to shop along with Paris and New York. Visitors to London are often overwhelmed by the sheer variety of shopping options available to them. Some of the best shopping areas are Oxford Street, Regent Street, Bond Street, and Soho. Bond Street has some of the most elegant and expensive shops in London. Oxford Street is the best-known street for shopping in London, where many fabulous shops for clothes, souvenirs, etc. are located. There are so many famous brand shops available here that you will find it difficult to make a choice. Shops are generally open from 09:30 to 18:00. Some shops have evening hours until 21:00. Tourist shops open on Sunday.

TAXI

There are plenty of taxi services in London. It is recommended to rely on the most common “Black Cabs” where licensed black cab drivers have “the knowledge” – i.e. they undergo rigorous training and exams, to ensure knowledge of every central London street. Cabs are available to hire when you see the yellow light above the windshield illuminating, just stick your arm out to signal one. Fares are metered with a minimum charge of £2.20 and are more expensive in the evenings and overnight. In any case ask the driver if he is running on the meter.

Tips are not expected; however most people round them up to the nearest pound or add on approximately 10%. The Black London Taxicab - www.londonblackcabs.co.uk Ladycabs: Phone +44 (0) 20 7272 3300 (Women drivers only) Zingo Taxi: Phone +44 (0) 870 070 0700

TELEPHONES

Please respect your fellow colleagues and friends by switching off your mobile devices in all meeting and poster areas.
TIME

The UK follows Greenwich Mean Time (GMT) in the winter (October to March) and GMT +1 or British Summer Time during the summer.

TIPPING

Tipping is appreciated but not always appropriate in London. There are some situations where it is customary, for example in restaurants. Tips (or gratuities) are discretionary and depend on the quality of the service you receive.

Restaurants and most hotel bills include a service charge. If there’s no service charge added to your bill, it’s customary to tip (10-15% of the bill).

For room cleaning staff, you can leave an amount of your choosing on departure. Tips for other hotel staff such as concierges and door staff are discretionary and are mostly commonplace for porters. People generally do not tip in pubs in London.

For taxi drivers, it is polite to tip 10-15% of the taxi fare. However, most people simply round up the fare to the nearest £1 and tell the driver to “keep the change”. If you’ve had a longer journey and the driver has assisted you with luggage, you may wish to tip a little more, up to £5.

EULAR Corporate Social Responsibility Statement

EULAR is aware of the environmental, economic and social impact of holding a large congress, and is working closely with its partners to ensure that environmentally, economically and socially friendly policies are in place. For the London congress EULAR has made the following sustainable arrangements:

HEALTHY FOOD

All buffets for lunches and coffee breaks offer healthy options; meaning that there is always a choice of fresh fruits or vegetables. A smaller selection of dietary offerings is also available. Local products have been prioritized.

PRINTING

EULAR is committed to ensuring that printing is kept to a minimum to reduce the amount of waste paper. No abstract book will be printed this year. All abstracts will be available on-line. This will save the printing of about 20’000’000 pages.

LOCAL SUPPLIERS

EULAR wishes to have a positive local impact. When sourcing materials and supplies, EULAR gives priority to local partners to avoid associated impacts of transportation and to positively impact the local economy.

SERVICES FOR THE DISABLED

EULAR wishes to make the congress experience comfortable for all attendees. All rooms and areas at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly in the EULAR Village.

Networking Opportunities

OPENING PLENARY SESSION AND NETWORKING PLATFORM

Wednesday, 8 June 2016 - 18:45-22:00
The Networking Platform will be held after the Opening Plenary Session at the congress venue. All registered participants are cordially invited.

EULAR CONGRESS DINNER

Friday, 10 June 2016 - 20:30-24:00
Price: GBP 85 per person
(not included in the registration fee)
This year, the EULAR Congress dinner will take place in the beautiful Natural History Museum near South Kensington Underground station. Surrounded by the unique historic collections and attractions, you will wine and dine in the theme of the “The British Invasion”. Experience an unforgettable evening surrounded by dinosaurs, birds, butterflies, Neanderthals and many other species. Enjoy good food, music, and dancing around the famous Diplodocus dinosaur. The congress dinner is a great opportunity to network with friends and colleagues from around the world in a relaxed atmosphere and enjoy the unmatched charm and fascination of the Natural History Museum in London. Those who have shared in the congress dinner experience of previous years would not want to miss it, so come and join in!
Scientific Information

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be given with the congress bag to each participant.

CONTINUING MEDICAL EDUCATION (CME) CREDITS

EULAR 2016 London has been accredited for a maximum of 18 European CME credits. This is an equivalent of 18 hours Continued Medical Education. CME points are recognized by the American Medical Association towards the Physician's Recognition Awards (PRA). To convert CME credits to AMA PRA, contact AMA.

POSTERS

The scientific posters and health professionals in rheumatology posters are displayed in the poster areas in the exhibition hall from Thursday to Saturday. They are changed on a daily basis. PARE posters are displayed permanently close to the EULAR PARE booth, located in the EULAR Village.

Official Poster viewing will take place at the following hours:

- Thursday 9 June 2016 11:45 - 13:30
- Friday 10 June 2016 11:45 - 13:30
- Saturday 11 June 2016 10:00 - 12:00

Guided Poster tours on selected topics will take place during the official poster viewing times.

SPEAKERS’ PREVIEW ROOM

The Speakers’ Preview Room located in Capital Lounge 5&6 on the second floor is open at the following hours:

- Wednesday 8 June 2016 08:00 - 20:00
- Thursday 9 June 2016 08:00 - 19:00
- Friday 10 June 2016 08:00 - 19:00
- Saturday 11 June 2016 08:00 - 14:30

The speaker centre is equipped with computers. All speakers are required to check in their presentation at least 2 hours before their session, or on the day before for the early morning sessions.

Information on Industry Related Activities

EXHIBITION

During the congress, EULAR will present an attractive exhibition to the congress participants.

The abstract poster presentation areas are embedded in the exhibition. Coffee, sandwiches or other refreshments are available within the exhibition during breaks.

The exhibition hours are as follows:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday</td>
<td>8 June 2016</td>
<td>12:00 - 18:30</td>
</tr>
<tr>
<td>Thursday</td>
<td>9 June 2016</td>
<td>08:00 - 17:15</td>
</tr>
<tr>
<td>Friday</td>
<td>10 June 2016</td>
<td>08:00 - 17:15</td>
</tr>
<tr>
<td>Saturday</td>
<td>11 June 2016</td>
<td>08:15 - 14:00</td>
</tr>
</tbody>
</table>

EXHIBITION ACCESS (RESTRICTED)

Based on "DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 6 NOVEMBER 2011 ON THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE" and on information received from the Prescription Medicines Code of Practice Authority (PMCPA), the EULAR Board has decided to restrict the access for congress participants registered as PARE Representative or as Patient to the non-commercial part of the Exhibition Hall. The access to all other parts of the congress is unrestricted.

We ask the participants involved to follow the specific instructions they will receive together with the congress documents. Hostesses and special signs will help in navigating inside the exhibition halls.

PRIVATE EVENTS POLICY

All requests from companies/organisations to host private events during the congress must have been approved prior to the congress by the EULAR Secretariat.

SATELLITE SYMPOSIA (ACCESS TO)

The meeting rooms for satellite symposia vary in size. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a satellite symposium. The maximum capacities of the rooms are determined by the local safety and security regulations and have to be respected by law.

SATELLITE SYMPOSIA (TIMINGS)

A number of Satellite symposia are organised during EULAR 2016:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday</td>
<td>8 June 2016</td>
<td>13:00 - 14:30</td>
</tr>
<tr>
<td>Thursday</td>
<td>9 June 2016</td>
<td>08:15 - 09:45</td>
</tr>
<tr>
<td>Thursday</td>
<td>9 June 2016</td>
<td>17:30 - 19:00</td>
</tr>
<tr>
<td>Friday</td>
<td>10 June 2016</td>
<td>08:15 - 09:45</td>
</tr>
<tr>
<td>Friday</td>
<td>10 June 2016</td>
<td>17:30 - 19:00</td>
</tr>
</tbody>
</table>

Further information is available in the Satellite booklet, included in your congress bag and on pages 201 to 208 of this programme.

Satellite symposia are governed by EULAR guidelines.

Other symposia are strictly prohibited during the official programme, as outlined in the EULAR Code of Practice.
### ALL DATES AND TIMES

<table>
<thead>
<tr>
<th>DATE</th>
<th>REGISTRATION AREA</th>
<th>SPEAKERS PREVIEW</th>
<th>POSTERS VIEWING</th>
<th>NETWORKING OPPORTUNITIES</th>
<th>EXHIBITION</th>
<th>SATELLITE SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tuesday 7 June 2016</strong></td>
<td>17:00 - 20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Wednesday 8 June 2016</strong></td>
<td>08:00 - 20:00</td>
<td>08:00 - 20:00</td>
<td></td>
<td>18:45 - 22:00</td>
<td>12:00 - 18:30</td>
<td>13:00 - 14:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>Opening Plenary session &amp; Networking Platform</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Thursday 9 June 2016</strong></td>
<td>07:45 - 19:15</td>
<td>08:00 - 19:00</td>
<td>11:45 - 13:30</td>
<td></td>
<td>08:00 - 17:15</td>
<td></td>
</tr>
<tr>
<td><strong>Friday 10 June 2016</strong></td>
<td>07:45 - 19:15</td>
<td>08:00 - 19:00</td>
<td>11:45 - 13:30</td>
<td>20:30 - 24:00</td>
<td>08:00 - 17:15</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><em>EULAR Congress Dinner</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Saturday 11 June 2016</strong></td>
<td>08:00 - 15:00</td>
<td>08:00 - 14:30</td>
<td>10:00 - 12:00</td>
<td></td>
<td>08:15 - 14:00</td>
<td></td>
</tr>
</tbody>
</table>

---

**Future Congress**

**Annual European Congress of Rheumatology 2017**

![EULAR Congress 2017 Logo](image)
EULAR COURSES

EULAR offers the complete range of continuous medical education in rheumatology, combining live and on-line courses. Please check eular.org for all details and register now!

**On-line courses**
starting in September each year

- **EULAR On-line Course on Rheumatic Diseases**
  (2-year course)

- **EULAR/PReS On-line Course in Paediatric Rheumatology**

- **EULAR On-line Course for Health Professionals**

- **EULAR On-line Course on Connective Tissue Diseases (CTD)**

- **EULAR On-line Course on Systemic Sclerosis (SSc)**

- **EULAR On-line Introductory Ultrasound Course**

**Live courses**

- **23rd EULAR Ultrasound Course**
  5 - 7 June 2016 in London/Leeds, UK

- **5th EULAR Course for Ultrasound Trainers in Rheumatology**
  4 - 5 June 2016 in London/Leeds, UK

- **7th EULAR Course on Capillaroscopy**
  6 - 10 September 2016 in Genoa, Italy

- **17th EULAR Postgraduate Course**
  23 - 26 October 2016 in Prague, Czech Republic

- **24th EULAR Ultrasound Course**
  11-13 June 2017 in Madrid, Spain

- **6th EULAR Course for Ultrasound Trainers in Rheumatology**
  10 - 11 June 2017 in Madrid, Spain

Check registration details, programme, bursaries and prices on eular.org
**Congress at a Glance**

**WEDNESDAY, 8 JUNE 2016**

<table>
<thead>
<tr>
<th>TIME</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-14:30</td>
<td>ICC Auditorium</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td></td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>Hall B</td>
<td>What is New (WIN) : Vascularly Systemic sclerosis</td>
</tr>
<tr>
<td></td>
<td>Hall D</td>
<td>Challenges in Clinical Practice session: Catastrophising pain in RA</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
<td>Clinical Science session: Axial spondyloarthritis and psoriatic arthritis: emerging pathways</td>
</tr>
<tr>
<td></td>
<td>Hall C</td>
<td>How to Treat/Manage (HOT): HOT session 1: Gout and CPPD Imaging in diagnosis</td>
</tr>
<tr>
<td></td>
<td>Hall A</td>
<td>Clinical Science session: HIV session 3: Undifferentiated inflammatory &amp; early rheumatoid arthritis Modern management principles of RA</td>
</tr>
<tr>
<td></td>
<td>Capital Suite 07</td>
<td>Outcome Science session: Outcome measures in clinical practice in gout and CPPD. The use of the new EULAR guidelines</td>
</tr>
<tr>
<td></td>
<td>Capital Suite 11</td>
<td>HPR Welcome session</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td></td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td>17:00-18:30</td>
<td></td>
<td>Basic and Translational Science session: Muscle biology &amp; inflammation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Basic and Translational Science session: Lessons from the children (monogenic causes of aut immunology)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Young Rheumatologist: ABC of statistics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Practical skills session*: Crystals I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Practical skills session*: Capilaroscopy I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical/PARE joint session: Optimizing treatment and patient care through precision medicine: a threat or an opportunity for patients and patient organizations?</td>
</tr>
<tr>
<td>18:45-20:00</td>
<td></td>
<td>EULAR 2016 Opening Plenary session</td>
</tr>
<tr>
<td>20:00-22:00</td>
<td></td>
<td><strong>NETWORKING PLATFORM</strong></td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>Capital Suite 14</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td></td>
<td>Capital Suite 02</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td></td>
<td>Capital Suite 01</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td></td>
<td>Capital Suite 06</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td></td>
<td>Room S19</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td></td>
<td>Room S20</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td></td>
<td>Capital Suite 09</td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td></td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>Basic and Translational Science session: Nanomedicine in rheumatology</td>
<td>How to Treat/Manage (HOT): HOT session 2: Pain management: Fibromyalgia</td>
</tr>
<tr>
<td></td>
<td>PReS session</td>
<td>The Young Rheumatologist: Beyond EMEUNET: development of a European-wide network of young clinicians from different specialties focusing on inflammatory diseases</td>
</tr>
<tr>
<td></td>
<td>Practical skills session*: Data visualisation: tables and graphs for publication and presentation I</td>
<td>Practical skills session*: Ultrasound basic I</td>
</tr>
<tr>
<td></td>
<td>Practical skills session*: Capability I</td>
<td>Practical skills session*: PARE session: Patient organisations in action</td>
</tr>
<tr>
<td></td>
<td>Clinical/PARE joint session: EULAR projects in Paediatric Rheumatology</td>
<td>EULAR projects in Musculoskeletal Imaging</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td></td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td>17:00-18:30</td>
<td></td>
<td>Basic and Translational Science session: Hand osteoarthritis: state of the art and future perspectives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Basic and Translational Science session: Epigenetics solving the OA puzzle</td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11

** See detailed Satellite symposia programme on pages 201 to 208
Congress at a Glance

THURSDAY, 9 JUNE 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>ICC Auditorium</th>
<th>Hall B</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall C</th>
<th>Hall A</th>
<th>Capital Suite 07</th>
<th>Capital Suite 11</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Plasma cells as key players and therapeutic target in rheumatic diseases</td>
<td></td>
</tr>
<tr>
<td>09:45-10:15</td>
<td>COFFEE BREAK</td>
<td>POSTER VIEWING AND LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15-11:45</td>
<td>What is New (WIN) WIN session 2: RA therapy Gout and crystal diseases</td>
<td>Abstract session Prognosis and outcome in RA</td>
<td>Abstract session Advances in SLE therapeutics</td>
<td>How to Treat/Manage (HOT) HOT session 4: JIA and other paediatric rheumatic diseases IgG4 associated diseases</td>
<td>Abstract session Diagnosis and management of SSc</td>
<td>Abstract session Vasculitis</td>
<td>HPR Abstract session Developing evidence-based non-pharmacological care</td>
<td>Abstract session SpA and PsA clinical</td>
</tr>
<tr>
<td>11:45-13:30</td>
<td>WIN session 3: Early arthritis Clinical aspects of RA</td>
<td>Challenges in Clinical Practice session Combined cases: Sjögren’s and a paediatric case</td>
<td>Clinical Science session Advancements in the imaging of PsA</td>
<td>How to Treat/Manage (HOT) HOT session 5: SLE Sjögren’s syndrome</td>
<td>Clinical Science session When and how to treat Raynaud’s phenomenon and related complications</td>
<td>Outcome Science session Role of new imaging techniques as RMD outcomes</td>
<td>HPR/PARE joint session &quot;Fewer words - more action&quot; - tailored care for men with rheumatic diseases?</td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>COFFEE BREAK</td>
<td>POSTER VIEWING AND LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-17:00</td>
<td>What is New (WIN) WIN session 4: Rheumatic manifestations arising from endocrine/metabolic disorders Paediatric rheumatology</td>
<td>Challenges in Clinical Practice session Difficult vasculitis (pulmonary/renal &amp; CNS)</td>
<td>Clinical Science session Optimization of MTX in RA treatment</td>
<td>How to Treat/Manage (HOT) HOT session 6: Psoriatic arthritis Spondyloarthritis/ankylosing spondylitis</td>
<td>Clinical Science session Joint replacement in OA: friend or foe?</td>
<td>Clinical Science session How to identify and follow patients with inflammatory back pain?</td>
<td>HPR session Physical activity assessment - what do we know, what do we do, how does it work?</td>
<td></td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area S11
*** See detailed Satellite symposia programme on pages 201 to 208
**CONGRESS AT A GLANCE / THURSDAY 9 JUNE 2016 / 15**

<table>
<thead>
<tr>
<th>Capital Suite 14</th>
<th>Capital Suite 02</th>
<th>Capital Suite 01</th>
<th>Capital Suite 06</th>
<th>Capital Suite 13</th>
<th>Room S19</th>
<th>Room S20</th>
<th>Capital Suite 09</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic and Translational Science session</strong>&lt;br&gt;Global year against joint pain</td>
<td><strong>Satellite symposium</strong>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Satellite symposium</strong>*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COFFEE BREAK**

**Abstract session**<br>New horizons in osteoarthritis

**Abstract session**<br>Clinical osteoporosis: new insights

**Abstract session**<br>S/pA and P/rA basic and translational research

**Abstract session**<br>Cartilage, bone, synovium

**Abstract session**<br>New pathways to treatment

**PARE session**<br>Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease

**Abstract session**<br>New insights into imaging

**POSTER VIEWING AND LUNCH**

**GUIDED POSTER TOURS**

**Basic and Translational Science session**
- Lubricants: potential as osteoarthritis treatment?

**PReS session**
- Extra-articular complications of JIA

**The Young Rheumatologist**
- The elephant in the room: how to avoid biases in research?

**Practical skills session***<br>Crystals II

**Practical skills session***<br>Local procedures including aspirations, injections and biopsies I

**PARE session**<br>Digital applications for the benefit of the patient

**EULAR projects in Clinical Affairs**

**Satellite symposium***

**Satellite symposium***

**Satellite symposium***

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area S11

*** See detailed Satellite symposia programme on pages 201 to 208
# Congress at a Glance

## FRIDAY, 10 JUNE 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>ICC Auditorium</th>
<th>Hall B</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall C</th>
<th>Hall A</th>
<th>Capital Suite 07</th>
<th>Capital Suite 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15-09:45</td>
<td><strong>Satellite symposium</strong>*</td>
<td><strong>Satellite symposium</strong>*</td>
<td><strong>Satellite symposium</strong>*</td>
<td><strong>Satellite symposium</strong>*</td>
<td><strong>Satellite symposium</strong>*</td>
<td>Basic and Translational Science session News from kinase inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45-10:15</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15-11:45</td>
<td><strong>What is New (WIN)</strong> WIN session 5: Axial and peripheral spondyloarthritis Psoriatic arthritis</td>
<td><strong>Abstract session</strong></td>
<td><strong>Abstract session</strong></td>
<td><strong>How to Treat/Manage (HOT)</strong></td>
<td><strong>Abstract session</strong></td>
<td><strong>Abstract session</strong></td>
<td><strong>HPR Abstract session</strong></td>
<td><strong>Abstract session</strong></td>
</tr>
<tr>
<td>11:45-13:30</td>
<td><strong>POSTER VIEWING AND LUNCH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50-13:30</td>
<td><strong>GUIDED POSTER TOURS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-17:00</td>
<td><strong>What is New (WIN)</strong> WIN session 7: Systemic lupus and APS New developments in psoriasis: what rheumatologists should know</td>
<td><strong>Challenges in Clinical Practice session</strong></td>
<td><strong>Clinical Science session</strong></td>
<td><strong>How to Treat/Manage (HOT)</strong></td>
<td><strong>Clinical Science session</strong></td>
<td>Outcome Science session</td>
<td>HPR/Primary Care joint session</td>
<td><strong>Basic and Translational Science session</strong></td>
</tr>
<tr>
<td>17:30-19:00</td>
<td><strong>Congress at a Glance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area S11
*** See detailed Satellite symposia programme on pages 201 to 208
**COFFEE BREAK**

<table>
<thead>
<tr>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital Suite 14</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>Crystal arthritis</td>
</tr>
<tr>
<td></td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td>Capital Suite 02</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td>Capital Suite 01</td>
<td>Abstract session</td>
</tr>
<tr>
<td></td>
<td>An inflammatory update</td>
</tr>
<tr>
<td>Capital Suite 06</td>
<td>PReS Abstract session</td>
</tr>
<tr>
<td></td>
<td>Advances in paediatric rheumatology</td>
</tr>
<tr>
<td>Capital Suite 13</td>
<td>Abstract session</td>
</tr>
<tr>
<td></td>
<td>Scleroderma, myositis and related conditions</td>
</tr>
<tr>
<td>Room S19</td>
<td>Abstract session</td>
</tr>
<tr>
<td></td>
<td>Emerging concepts in genomics &amp; genetics</td>
</tr>
<tr>
<td>Room S20</td>
<td>Abstract session</td>
</tr>
<tr>
<td></td>
<td>Novel clues solved in RA development</td>
</tr>
<tr>
<td>Capital Suite 09</td>
<td>PARE Abstract session</td>
</tr>
<tr>
<td></td>
<td>Novel insights into B and T cell immunity in rheumatic disease</td>
</tr>
</tbody>
</table>

**POSTER VIEWING AND LUNCH**

**GUIDED POSTER TOURS**

<table>
<thead>
<tr>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital Suite 14</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>Joint EULAR - EFIS session: Do stromal cells house and cure immune cells?</td>
</tr>
<tr>
<td></td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td>Capital Suite 02</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>The Young Rheumatologist</td>
</tr>
<tr>
<td></td>
<td>Role of imaging in childhood-onset rheumatic diseases</td>
</tr>
<tr>
<td>Capital Suite 01</td>
<td>PReS session</td>
</tr>
<tr>
<td></td>
<td>Physician-patient relationship in the era of interactive media</td>
</tr>
<tr>
<td>Capital Suite 06</td>
<td>Practical skills session*</td>
</tr>
<tr>
<td></td>
<td>Capillaroscopy II</td>
</tr>
<tr>
<td>Capital Suite 13</td>
<td>Practical skills session*</td>
</tr>
<tr>
<td></td>
<td>Ultrasound advanced I</td>
</tr>
<tr>
<td>Room S19</td>
<td>PARE session</td>
</tr>
<tr>
<td></td>
<td>It's in your hands</td>
</tr>
<tr>
<td>Room S20</td>
<td>EULAR projects in Education and Training</td>
</tr>
<tr>
<td></td>
<td>The EULAR School of Rheumatology - a new era of education</td>
</tr>
<tr>
<td>Capital Suite 09</td>
<td>Practical skills session*</td>
</tr>
<tr>
<td></td>
<td>Data visualisation: tables and graphs for publication and presentation II</td>
</tr>
<tr>
<td></td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td></td>
<td>Ultrasound basic II</td>
</tr>
<tr>
<td></td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td></td>
<td>What's new: latest advances in treatment and management of systemic sclerosis and fibromyalgia</td>
</tr>
</tbody>
</table>

**COFFEE BREAK**

<table>
<thead>
<tr>
<th>Room</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital Suite 14</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>Potential targets in inflammatory fibrotic conditions in SSc</td>
</tr>
<tr>
<td></td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td>Capital Suite 02</td>
<td>The Young Rheumatologist</td>
</tr>
<tr>
<td></td>
<td>How to get into the international world of rheumatology</td>
</tr>
<tr>
<td>Capital Suite 01</td>
<td>Practical skills session*</td>
</tr>
<tr>
<td></td>
<td>Data visualisation: tables and graphs for publication and presentation II</td>
</tr>
<tr>
<td>Capital Suite 06</td>
<td>Practical skills session*</td>
</tr>
<tr>
<td></td>
<td>Ultrasound basic II</td>
</tr>
<tr>
<td>Capital Suite 13</td>
<td>PARE session</td>
</tr>
<tr>
<td></td>
<td>It’s in your hands</td>
</tr>
<tr>
<td>Room S19</td>
<td>EULAR projects Investigative Rheumatology</td>
</tr>
<tr>
<td></td>
<td>Satellite symposium***</td>
</tr>
<tr>
<td>Room S20</td>
<td>Satellite symposium***</td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area S11

*** See detailed Satellite symposia programme on pages 201 to 208
# Congress at a Glance

## SATURDAY, 11 JUNE 2016

<table>
<thead>
<tr>
<th>TIME</th>
<th>ICC Auditorium</th>
<th>Hall B</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall C</th>
<th>Hall A</th>
<th>Capital Suite 07</th>
<th>Capital Suite 11</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:30-10:00</strong></td>
<td><strong>What is New (WIN)</strong></td>
<td>Challenges in Clinical Practice session</td>
<td>Clinical Science session</td>
<td>How to Treat/Manage (HOT)</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Outcome Science session</td>
<td>HPR session</td>
</tr>
<tr>
<td></td>
<td>WIN session &amp; Sjögren’s syndrome Myositis</td>
<td>The elderly patient with osteoarthritis</td>
<td>SLE: What will it be and how will it be treated 5 years from now</td>
<td>HDT session 10: Osteoporosis Osteoarthritis</td>
<td>“Time Is Joint”: Early recognition and treatment of arthritis</td>
<td>Clinical outcomes for FMR/GCA</td>
<td>Getting active against rheumatoid arthritis fatigue</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
</tr>
</tbody>
</table>

**09:00-12:00**

**09:00-12:00**

**POSTER VIEWING AND COFFEE BREAK**

**10:05-12:00**

**GUIDED POSTER TOURS**

<table>
<thead>
<tr>
<th>TIME</th>
<th>ICC Auditorium</th>
<th>Hall B</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall C</th>
<th>Hall A</th>
<th>Capital Suite 07</th>
<th>Capital Suite 11</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12:00-13:30</strong></td>
<td><strong>What is New (WIN)</strong></td>
<td>Challenges in Clinical Practice session</td>
<td>Clinical Science session</td>
<td>How to Treat/Manage (HOT)</td>
<td>Clinical Science session</td>
<td>Clinical Science session</td>
<td>Outcome Science session</td>
<td>HPR session</td>
</tr>
<tr>
<td></td>
<td>WIN session &amp; Pain and fibromyalgia New developments in imaging for rheumatic diseases</td>
<td>Seronegative inflammatory arthritis: diagnostic and management challenges</td>
<td>Picking knowledge from other medical disciplines for SSC</td>
<td>HDT session 11: Recommendations</td>
<td>Paget’s and other rare bone diseases</td>
<td>Analytical issues of complex databases</td>
<td>Intimate life and sexual relations in RA</td>
<td>Basic and Translational Science session</td>
</tr>
<tr>
<td></td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
</tr>
</tbody>
</table>

**13:45-14:45**

**Clinical and Basic/Translational Highlight session**

<table>
<thead>
<tr>
<th>TIME</th>
<th>ICC Auditorium</th>
<th>Hall B</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall C</th>
<th>Hall A</th>
<th>Capital Suite 07</th>
<th>Capital Suite 11</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>13:45-14:45</strong></td>
<td><strong>Clinical and Basic/Translational Highlight session</strong></td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
</tr>
</tbody>
</table>

**TIME**

<table>
<thead>
<tr>
<th><strong>08:30-10:00</strong></th>
<th><strong>Basic and Translational Science session</strong></th>
<th><strong>PReS session</strong></th>
<th><strong>The Young Rheumatologist</strong></th>
<th><strong>Practical skills session</strong></th>
<th><strong>Practical skills session</strong></th>
<th><strong>Practical skills session</strong></th>
<th><strong>PARE session</strong></th>
<th><strong>EULAR projects in Epidemiology and Health Services</strong></th>
<th><strong>HPR/PARE joint session</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cell-cell interaction in joint inflammation</td>
<td>Transition of care</td>
<td>Career paths in research - how to start and where to go?</td>
<td>Laboratory II</td>
<td>Ultrasound advanced II</td>
<td>Ultrasound advanced II</td>
<td>New approaches to understanding and managing chronic musculoskeletal pain</td>
<td>Benchmarking of healthcare quality indicators and standard of care for RA and OA</td>
<td>There is more than drugs</td>
</tr>
<tr>
<td></td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
<td>08:30-10:00</td>
</tr>
</tbody>
</table>

**10:00-12:00**

**POSTER VIEWING AND COFFEE BREAK**

**10:05-12:00**

**GUIDED POSTER TOURS**

<table>
<thead>
<tr>
<th>TIME</th>
<th>ICC Auditorium</th>
<th>Hall B</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall C</th>
<th>Hall A</th>
<th>Capital Suite 07</th>
<th>Capital Suite 11</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12:00-13:30</strong></td>
<td><strong>Basic and Translational Science session</strong></td>
<td>Adiposity as a driver of arthritis through inflammatory mechanisms</td>
<td>The Young Rheumatologist</td>
<td>EULAR educational offer</td>
<td>Local procedures including aspirations, injections and biopsies II</td>
<td>MRI II</td>
<td>There is more than drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
<td>12:00-13:30</td>
</tr>
</tbody>
</table>

**13:45-14:45**

**PARE Highlight session**

<table>
<thead>
<tr>
<th>TIME</th>
<th>ICC Auditorium</th>
<th>Hall B</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall C</th>
<th>Hall A</th>
<th>Capital Suite 07</th>
<th>Capital Suite 11</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>13:45-14:45</strong></td>
<td><strong>PARE Highlight session</strong></td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
<td>13:45-14:45</td>
</tr>
</tbody>
</table>

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11  
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area S11  
*** See detailed Satellite symposia programme on pages 201 to 208
Scientific Programme

08:00 - 20:00  Registration area S11

Registration

13:30 - 14:30  Capital Suite 07

Health Professionals session

Health Professionals Welcome session

Learning objectives:
• To learn about EULAR Health Professionals activities
• To learn about planned mentoring and networking activities for EULAR Health Professionals

Chairperson(s):
Michael Backhouse (United Kingdom)
Patria Cornell (United Kingdom)
Christina H. Opava (Sweden)

Cees G. M. Kallenberg (Netherlands) 15:05
Abstract N° SP0001
Vasculitis

John Varga (United States) 15:45
Abstract N° SP0002
Systemic sclerosis

14:30 - 15:00  Exhibition (S5-S9)

Break

15:00 - 16:30  ICC Auditorium

What is New (WIN)

WIN session 1

15:05
Cees G. M. Kallenberg (Netherlands)

Vasculitis

15:45
John Varga (United States)

Systemic sclerosis

15:00 - 16:30  Hall B

Challenges in Clinical Practice session

Catastrophizing pain in RA

Learning objectives:
• To obtain knowledge on the impact of catastrophizing in obtaining remission in RA
• To obtain knowledge on how to assess chronic pain in RA in clinical practise

Chairperson(s):
Merete Hetland (Denmark)
Henning Bliddal (Denmark)

Alexander Mathiessen (Norway) 15:05
Abstract N° SP0003
Case 1 presentation: "An RA patient with catastrophizing pain"

Hilde Berner Hammer (Norway) 15:15
Abstract N° SP0004
Case 1 discussion: The impact of catastrophizing in obtaining remission in RA

Signe Riebjerg-Madsen (Denmark) 15:45
Abstract N° SP0005
Case 2 presentation: "An RA patient in remission with persistent pain"

Stine Amris (Denmark) 15:55
Case 2 discussion: The PDQ used as a clinical tool

15:00 - 16:30  Hall D

Clinical Science session

Axial spondyloarthritis and psoriatic arthritis: emerging pathways

Learning objectives:
• To obtain insight into the different pathways that form the pathophysiological basis of spondyloarthritis and psoriatic arthritis
• To better understand the processes of new bone formation in spondyloarthritis
• To obtain knowledge about the targeted pharmaceutical interventions for the treatment of spondyloarthritis and psoriatic arthritis
• To appreciate the importance of mechanical factors in the process of bone formation in spondyloarthritis

Chairperson(s):
Désirée van der Heijde (Netherlands)
Denis Podubnyy (Germany)

Dominique Baeten (Netherlands) 15:05
Abstract N° SP0006
The IL17-pathway

Dirk Elewaut (Belgium) 15:25
The IL 22/23-pathway

Rik Lories (Belgium) 15:45
The role of mechanostress

J. Braun (Germany) 16:05
Abstract N° OP0001
Effect of seucikinumab, an interleukin-17A inhibitor, on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of the phase 3 study, MEASURE I

D. van der Heijde (Netherlands) 16:15
A. Deodhar, J. C. Wei, E. Drescher, D. Fleishaker, T. Hendrix, D. Li, S. Menon, K. Kanik
Abstract N° OP0002
Tofacitinib in patients with ankylosing spondylitis: a phase 2, 16-week, randomised, placebo-controlled, dose-ranging study

Chairperson(s):
Marlies van der Goes (Netherlands)
José A. P. da Silva (Portugal)

Frank Buttgereit (Germany) 15:05
Abstract N° SP0008
Under what conditions may long-term glucocorticoids have a good benefit-risk ratio

Nele Caeyers (Belgium) 15:23
Abstract N° SP0009
Patients view on the EULAR recommendations

Maarten de Wit (Netherlands) 15:41
Can we change perceptions?

Johannes W. G. Jacobs (Netherlands) 15:59
Abstract N° SP0011
Long-term glucocorticoid use and the skin

J. H. Stone (United States) 16:17
E. M. Miloslavsky, R. L. Naden on behalf of Glucocorticoid Toxicity Index Development group
Abstract N° OP0003
Development of a glucocorticoid toxicity index using multi-criteria decision analysis

15:00 - 16:30  Hall E

How to Treat/Manage (HOT)

HOT session 1

Pascal Richette (France) 15:05
Gout and CPPD

Mikkel Østergaard (Denmark) 15:45
Abstract N° SP0007
Imaging in diagnosis

15:00 - 16:30  Hall C

Clinical Science session

Balancing benefits and risk of glucocorticoids; a challenge for implementation

Learning objectives:
• To value, both from patient and physician point of view, under what conditions long-term glucocorticoid use may have a good benefit-risk ratio
• How to counsel the patient to become a well-informed partner
• How to recognize the sequella to the skin and how to prevent/treat these

Chairperson(s):
Marlies van der Goes (Netherlands)
José A. P. da Silva (Portugal)

Frank Buttgereit (Germany) 15:05
Abstract N° SP0008
Under what conditions may long-term glucocorticoids have a good benefit-risk ratio

Nele Caeyers (Belgium) 15:23
Abstract N° SP0009
Patients view on the EULAR recommendations

Maarten de Wit (Netherlands) 15:41
Can we change perceptions?

Johannes W. G. Jacobs (Netherlands) 15:59
Abstract N° SP0011
Long-term glucocorticoid use and the skin

J. H. Stone (United States) 16:17
E. M. Miloslavsky, R. L. Naden on behalf of Glucocorticoid Toxicity Index Development group
Abstract N° OP0003
Development of a glucocorticoid toxicity index using multi-criteria decision analysis

15:00 - 16:30  Hall A

Outcome Science session

What CVD outcomes to use in clinical rheumatological practice?

Learning objectives:
• To understand which of the CV outcomes are increased in patients with RMDs
• What instruments to use to predict individual risk
• How to prevent CV morbidity

Chairperson(s):
Axel Finckh (Switzerland)
Lorna Clarson (United Kingdom)
Paola de Pablo (United Kingdom) 15:05
Which CV outcomes are increased in immune mediated diseases and to what extent?

Naveed Sattar (United Kingdom) 15:25
Abstract N° SP0012
How to assess the CVD risk in the individual patient?

Michael Nurmobhamed (Netherlands) 15:45
Abstract N° OP0004
Is it enough just to treat inflammation?

L. Gossec (France) 16:05
Abstract N° OP0004
Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France
Abstract N° OP0005
How to implement cardiovascular disease risk assessment for patients with inflammatory joint diseases in daily rheumatology practice: an overview of the nationwide NOCAR project

15:00 - 16:30  Capital Suite 07
Health Professionals session
Different perspectives on pain in osteoarthritis

Learning objectives:
• Understanding peripheral and central mechanisms of pain in patients with arthritis
• Influence of exercise and pain medication in patients with osteoarthritis
• Cognitive behavioural influences on pain in patients with arthritis

Chairperson(s):
Martin van der Esch (Netherlands)
Ricardo Ferreira (Portugal)

Lars Arendt-Nielsen (Denmark) 15:05
Abstract N° SP0014
Peripheral and central pain sensitivity in osteoarthritis

George M. Peat (United Kingdom) 15:23
Abstract N° SP0015
Pain trajectory groups in persons with osteoarthritis

Marike van der Leeden (Netherlands) 15:41
Abstract N° SP0016
Pain and inflammation in osteoarthritis: pharmacological and physical management

Jari P. Arokoski (Finland) 15:59
Abstract N° SP0017
The effect of non-pharmacological interventions for hand OA

T. Bieler (Denmark) 16:17
V. Siersma, S. P. Magnusson, M. Kjaer, N. Beyer
Abstract N° OP0006-HPR
Even in the long run Nordic Walking is superior to strength training and home based exercise for improving physical function in older people with hip osteoarthritis - a RCT

15:00 - 16:30  Capital Suite 11
Basic and Translational Science session
Epigenetics solving the OA puzzle

Learning objectives:
• To understand the major epigenetic mechanisms in the regulation of gene expression
• To get insights into epigenetic changes in osteoarthritis
• To learn about novel therapeutic targets in OA

Chairperson(s):
Anne-Marie Malfait (United States)
Caroline Ospelt (Switzerland)

Louise Reynard (United Kingdom) 15:05
Abstract N° SP0018
DNA methylation and osteoarthritis

Silvia Monteagudo (Belgium) 15:25
Abstract N° SP0019
Histone modification and osteoarthritis

Ian Clark (United Kingdom) 15:45
Abstract N° SP0020
Long and short RNA in osteoarthritis

M. Frank-Bertoncelj (Switzerland) 16:05
Abstract N° OP0007
Deep RNA sequencing reveals arthritis-specific IncRNA transcriptomes of synovial fibroblasts at different anatomic locations

F. M. Meier (United Kingdom) 16:15
Abstract N° OP0008
Synovial fibroblast proliferation is enhanced by microRNA-223 delivery through monocyte-derived microparticles

15:00 - 16:30  Capital Suite 14
Basic and Translational Science session
Muscle biology & inflammation

Learning objectives:
• To understand how exercise improves outcome of disease
• To discover novel targets in muscle disease and loss
• To get a grip on the importance of muscles in the progression and outcome of rheumatoid arthritis

Chairperson(s):
Ingrid Lundberg (Sweden)
Ellen de Langhe (Belgium)

Johanna Lanner (Sweden) 15:05
Abstract N° SP0021
Free radical signaling behind the muscle weakness associated with rheumatoid arthritis

Boel De Paepe (Belgium) 15:25
Abstract N° SP0022
Inflammatory mediators in inflammatory myopathies

Maurilio Sampaolesi (Belgium) 15:45
Muscle stem cells and regeneration
**The Young Rheumatologist**  
**ABC of statistics**

**Learning objectives:**
- To learn basic concepts of statistics and how one can get started into the world of statistics and incorporate it in own research, despite limited knowledge on statistics
- To learn the basic descriptive statistics used, how to compare groups and how to interpret and conduct a regression analysis
- To learn the important issue of confounding will also be approached, to further emphasise the need for analytical techniques

**Chairperson(s):**  
Daniel Aletaha (Austria)  
Sofia Ramiro (Netherlands)

**Kaleb Michaud (United States)**  
Statistics in research in rheumatology - how to make the best use of it?

**Sam Norton (United Kingdom)**  
Abstract No SP0026  
The basics of a regression analysis

**Loreto Carmona (Spain)**  
Abstract No SP0027  
Confounding - friend or foe? How to handle?

**J. C. Sergeant (United Kingdom)**  
Prediction of non-response to methotrexate therapy in the rheumatoid arthritis medication study (RAMS)

---

**Practical skills session**  
**Crystals I**

**Chairperson(s):**  
Eliseo Pascual (Spain)  
Anne K. Tausche (Germany)

**Tutor(s):**  
Eleonora Norkuviene (Lithuania)  
Francisca Sivera (Spain)  
José Pimentao (Portugal)  
Francesca Oliviero (Italy)
**Practical skills session**

**Capillaroscopy I**

**Learning objectives:**
- Learn to manage capillaroscopy in the early diagnosis of rheumatic diseases involving the microcirculation damage.
- Links with the analysis of the peripheral blood flow and with the predictive role of capillaroscopy will complete the annual review course.

**Chairperson(s):**
Ariane L. Herrick (United Kingdom)
Vanessa Smith (Belgium)

**Vanessa Smith (Belgium)**

Abstract N° SP0028
How to differentiate normal from abnormal capillaroscopic patterns: role of in early diagnosis

**Alberto Sulli (Italy)**

Abstract N° SP0029
Counting and scoring the capillaries: manual versus (semi)automatic systems

**Ariane L. Herrick (United Kingdom)**

Abstract N° SP0030
Capillaroscopic versus laser Doppler analysis of the microcirculation

**Maurizio Cutolo (Italy)**

15:45
Why capillaroscopy can predict severity and prognosis

**Walter Hermann (Germany)**

16:00
How to select the most appropriate capillaroscopic device: PROs and CONs

**Faculty**

16:10
Practical session with patients and case discussion

---

**EULAR projects in Musculoskeletal Imaging**

**Chairperson(s):**
Esperanza Naredo (Spain)
Lene Terslev (Denmark)
Annamaria Iagnocco (Italy)

**Maria-Antonietta d’Agostino (France)**

15:17
Development of EULAR recommendations/criteria for the appropriate use of musculoskeletal ultrasound in rheumatology clinical practice

**Ingrid Möller (Spain)**

15:29
Abstract N° SP0035
Development of EULAR standardised procedures for rheumatology ultrasound imaging

**Frédérique Gandjbakhch (France)**

15:41
Definition of rheumatoid arthritis bone erosion

**Stephen Kelly (United Kingdom)**

15:53
Development of a standardized training model for ultrasound-guided synovial biopsys in small and large joints

---

*In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11.*
Heidi Siddle (United Kingdom) 16:05
Abstract N° SP0036
The role and training needs of non-medical health professionals using musculoskeletal ultrasound for the management of patients with rheumatic and musculoskeletal diseases

Faculty 16:17
Q&A and discussion

16:30 - 17:00 Exhibition (S5-S9)
Coffee break

17:00 - 18:30 Hall B
Challenges in Clinical Practice session
Difficult osteoporosis

Learning objectives:
To learn which diagnostic steps are necessary and what therapeutic options are available in patients with difficult osteoporosis

Chairperson(s):
Gyula Poor (Hungary)
Irene E. M. Bultink (Netherlands)
Anne-Birgitte Blavnsfeldt (Denmark) 17:05
Case 1 presentation: Fragility fracture after prolonged treatment with oral bisphosphonates

Bente Langdahl (Denmark) 17:15
Abstract N° SP0037
Case 1 discussion: What to do when a fracture occurs after 3 years treatment with an oral biphosphonate

Emmanuelle Vignot (France) 17:45
Case 2 presentation: Still fragile after long-treatment: a clinical case from clinical practice

Serge Ferrari (Switzerland) 17:55

17:00 - 18:30 Hall D
Clinical Science session
Clinical relevance of immunogenicity and therapeutic drug monitoring

Learning objectives:
• To understand the utility of anti-drug antibody/drug level measurement as biomarkers of biologic treatment response and how it can inform future management
• To gain insight into daily-life practice with biosimilars
• To learn about potential consequences of the proliferation manufacturers of biosimilars

Chairperson(s):
Fernando Pimentel dos Santos (Portugal)
Meghna Jani (United Kingdom)

Gert-Jan Wolbink (Netherlands) 17:05
Value of immunogenicity and therapeutic drug monitoring in rheumatology

Tore K. Kvien (Norway) 17:25
Biosimilars: observational real-life data

Ronald van Vollenhoven (Netherlands) 17:45
Abstract N° SP0038
How can the proliferation of biosimilars’ manufacturers impact on R&D and quality?

D. Nagore (Spain) 18:05
Abstract N° OP0015
Antibodies to infliximab in remicade-treated rheumatic patients show identical reactivity towards biosimilar CT-P13

R. López-Rodriguez (Spain) 18:15
A. Martínez, C. Plasencia, A. Jochems, D. Pascual-Salcedo, A. Balsa, A. Gonzalez
Abstract N° OP0016
Increased frequency of anti-drug antibodies in patients carrying compatible IgG1 allotypes and treated with anti-TNF antibodies

17:00 - 18:30 Hall E
How to Treat/Manage (HOT)
HOT session 3

Tom Huizinga (Netherlands) 17:05
Undifferentiated inflammatory & early rheumatoid arthritis

Paul Emery (United Kingdom) 17:45
Modern management principles of RA

17:00 - 18:30 Hall C
Clinical Science session
Hepatitis C and rheumatology: the impact of new therapies

Learning objectives:
• To describe the evolving epidemiology of HCV infection globally
• To recognise the systemic aspects of HCV infection
• To recognise the advances in non-interferon based therapies and their impact on hepatic and extra-hepatic manifestations of HCV infection
• To apply current recommendations in rheumatology practices for screening; HCV therapy and hepatology - rheumatology partnership in overall management

Chairperson(s):
Dimitrios Vassilopoulos (Greece)
Luca Quartuccio (Italy)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 18:30</td>
<td>Outcome Science session</td>
<td>Hall A</td>
<td>Outcome measures in clinical practice in gout and CPPD.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The use of the new EULAR guidelines</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Learning objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• To get an update on the impact of gout and gout arthritis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• To get an overview of clinically available laboratory tests and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>crystal analysis for gout care</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• To get an update on clinical outcomes and PROs in gout care</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chairperson(s):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ingemar Petersson (Sweden)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ida K. Haugen (Norway)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lennart Jacobsson (Sweden)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>17:05</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstract N° SP0041</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gout-the coming epidemic. The impact on the health care system and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>the society</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Eliseo Pascual (Spain)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>17:20</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The role of crystal analysis in the management of gout</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Michael Doherty (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>17:35</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstract N° SP0042</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The role of imaging in the management of gout</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Till Uhlig (Norway)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>17:50</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstract N° SP0043</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clinical outcomes for gout patients in rheumatological care</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>L. E. Scheepers (Netherlands)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>18:05</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstract N° OP0017</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Medication taking behaviour of allopurinol treatment among patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>with gout: a retrospective cohort study in the clinical practice</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>research datalink (CPRD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>W. Raymond (Australia)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>18:15</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstract N° OP0018</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hyperuricemia increases mortality only in patients with gout and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>existing cardiovascular disease. A prospective analysis from the</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Busselton health study</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 18:30</td>
<td>Health Professionals session</td>
<td>Capital Suite 07</td>
<td>Hand osteoarthritis: state of the art and future perspectives</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Learning objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Increase knowledge about hand OA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Update on treatment, research and outcome measures</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chairperson(s):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rikke H. Moe (Norway)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jo Adams (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Francis Berenbaum (France)</td>
<td>17:05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>How do we understand hand osteoarthritis?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Kryisia Dziedzic (United Kingdom)</td>
<td>17:23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Functional consequences of hand osteoarthritis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Els van den Ende (Netherlands)</td>
<td>17:41</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Assessing hand OA in clinical care and research</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ingvild Kjeken (Norway)</td>
<td>17:59</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The effect of non-pharmacological interventions for hand OA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M. V. Nery (Brazil)</td>
<td>18:17</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A. Jones, F. Jennings, M. C. Souza, J. Natour</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstract N° OP0019-HPR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Effectiveness of a progressive resistance strength program on hand</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>osteoarthritis: a randomised controlled trial</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 18:30</td>
<td>Basic and Translational</td>
<td>Capital Suite 11</td>
<td>Chronobiology of the immune response</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Science session</td>
<td></td>
<td>Learning objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• To learn about the mediators that regulate the immune and</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>inflammatory response chronobiology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• To better understand the circadian rhythms of clinical symptoms of</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>rheumatic diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chairperson(s):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Maurizio Cutolo (Italy)</td>
<td>17:05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rainer H. Straub (Germany)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tanja Lange (Germany)</td>
<td>17:05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstract N° SP0046</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sleep as a modulator and adjuvant in immunity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rainer H. Straub (Germany)</td>
<td>17:25</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The neuroendocrine circadian modulators of the immune response</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Julie Gibbs (United Kingdom)</td>
<td>17:45</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Abstract N° SP0047</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Circadian clocks and inflammation: the clock as a pharmacological</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>target for inflammatory disease</td>
<td></td>
</tr>
</tbody>
</table>
Basic and Translational Science session

Nanomedicine in rheumatology

Learning objectives:

- To get a feeling what nanomedicine is and nanoparticles are
- To understand the interactions of nanoparticles with the immune system
- To recognise possibilities of nanoparticles in treatment of arthritis

Chairperson(s):
Sander W. Tas (Netherlands)
Johannes W. J. Bijlsma (Netherlands)

Ankooor Shah (United States) 17:05
Abstract N° SP0048
What are nanoparticles: physics for medical doctors

Cindy Strehl (Germany) 17:25
Abstract N° SP0049
Nanoparticles and the immune system

Bruno Sarmento (Portugal) 17:45
Abstract N° SP0050
Nanoparticles: a breakthrough in the treatment of arthritis?

V. Codullo (Italy) 18:05
E. Cova, S. Inghilleri, M. Colombo, D. Prosperi, F. Meloni, C. Montecucco
Abstract N° OP0022
Targeting fibroblastoid-like cells by drug loaded engineered gold nanoparticles as a novel approach for ILD-SSc treatment

F. Colomb (Italy) 18:15
Abstract N° OP0023
Targeted polymeric nanoparticles as diagnostic and therapeutic tool for rheumatoid arthritis

How to Treat/Manage (HOT) session 2

Ernest Choy (United Kingdom) 17:05
Abstract N° SP0051
Pain management

David Williams (United States) 17:45
Abstract N° SP0052
Fibromyalgia

The Young Rheumatologist

Beyond EMEUNET: development of a European-wide network of young clinicians from different specialties focusing on inflammatory diseases

Learning objectives:

- To develop solid future interactions between rheumatology and other specialties, such as nephrology, dermatology and gastroenterology
- To promote the development of a European-wide network of young clinicians from different specialties with the goal of improving the management of our patients and harnessing our combined resources to promote better and faster translational research on diseases shared by our specialties

Chairperson(s):
Laure Gossec (France)
Christophe Richez (France)

Anna Moltó (France) 17:05
Abstract N° SP0053
Experiences from young rheumatologists into EMEUNET

Pieter Hindryckx (Canada) 17:25
Abstract N° SP0054
Experiences from young gastroenterologists into Y-ECCO

Eve Smith (United Kingdom) 17:45
Abstract N° SP0055
Experiences from young representative of Paediatric Rheumatology European Society

Ana C. da Costa Ferreira (Portugal) 18:05
Abstract N° SP0056
Experiences from the Young Nephrologists’ platform
Practical skills session*  
Data visualisation: tables and graphs for publication and presentation I

Maarten Boers (Netherlands)  17:05  
Abstract N° SP0057  
Data visualisation: tables and graphs for publication and presentation

Practical skills session*  
Ultrasound basic I

Chairperson(s):  
Hilde Berner Hammer (Norway)  
Petra Hanova (Czech Republic)

Maria-Antonietta d’Agostino (France)  17:05  
Abstract N° SP0058  
Composite scoring system for RA synovitis + demo

Ingrid Möller (Spain)  17:25  
Abstract N° SP0059  
Scoring OA + demo

Andreas Diamantopoulos (Norway)  17:45  
Abstract N° SP0060  
Scoring large vessel vasculitis

Giorgio Tamborrini (Switzerland)  18:05  
Abstract N° SP0061  
Impact on scoring - machine and experience

Tutor(s):  
Lykke Oernbjerg (Denmark)

PARE session  
Patient organisations in action

Learning objectives:  
- Health democracy - patient participation in policy and decision-making  
- Skilling your organisation for tomorrow's challenges

Chairperson(s):  
Maria Ekroth (Finland)  
Codruta Zabalan (Romania)

Athanassia Pappa (Greece)  17:05  
Abstract N° SP0062  
How a change to a user-led concept of a patient organisation is leading to success?

Eirini Agapidaki (Greece) tbc  17:25  
Abstract N° OP0024-PARE  
Informative and preventive campaigns at the city councils in the Galician region

Karen Facey (United Kingdom)  17:45  
Abstract N° SP0061  
The role of patient organisations in health technology assessment

D. P. Richards (Canada)  18:05  
Abstract N° OP0025-PARE  
Development and use of a Canadian arthritis patient charter

A. I. Vázquez Lojo (Spain)  18:15  
Abstract N° OP0026-PARE  
Informative and preventive campaigns at the city councils in the Galician region

EULAR projects in Paediatric Rheumatology  
Hot topics in paediatric rheumatology

Learning objectives:  
To present the European recommendations on management of paediatric rheumatic diseases and emerging issues of design of clinical trials in paediatric rheumatology

Chairperson(s):  
Alberto Martini (Italy)  
Michael Hofer (Switzerland)

Sebastian Vastert (Netherlands)  17:05  
SHARE recommendations on JIA

Michael Beresford (United Kingdom)  17:30  
SHARE recommendations on connective tissue diseases

Nicola Ruperto (Italy)  17:55  
Clinical trial design in paediatric rheumatology

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11
**Scientific Programme**

**08:15 - 09:45**

**Basic and Translational Science session**

**Plasma cells as key players and therapeutic target in rheumatic diseases**

**Learning objectives:**
- To understand how plasma cells differentiate and survive
- To understand mechanisms how plasmablasts can regulate inflammatory responses
- To learn how antibody glycosylation modulates antibody-mediated effector functions

**Chairperson(s):**
David S. Pisetsky (United States)
Bimba F. Hoyer (Germany)
Andreas Radbruch (Germany)
Rene Toes (Netherlands)
Simon Fillatreau (Germany)

**Abstracts:**

- **H. U. Scherer (Netherlands)** 09:40
  - **Plasma cells as key players and therapeutic target in rheumatic diseases**
  - Synovial fluid mononuclear cells provide an environment for long-term survival of antibody secreting cells and promote the spontaneous production of anti-citrullinated protein antibodies

- **M. Torigoe (Japan)** 09:50
  - **Plasmablasts regulate inflammation**
  - Abnormal B cell activation through cellular metabolic reprogramming and its relevance to the pathogenesis of SLE

- **S. Iwata, K. Sakata, S. Nakayamada, Y. Tanaka**
  - **Abstract N° OP0027**
  - Abnormal B cell activation through cellular metabolic reprogramming and its relevance to the pathogenesis of SLE

**09:45 - 10:15**

**Exhibition (S5-S9)**

**Coffee break**

---

**08:15 - 09:45**

**Global year against joint pain**

**Learning objectives:**
- To review mechanisms of chronic pain
- To describe pain and signs of sensitization in osteoarthritis
- To identify peripheral mechanisms of arthritic pain

**Chairperson(s):**
Theodore Pincus (United States)
Tonia Vincent (United Kingdom)
Shafaq Sikandar (United Kingdom)

**Abstracts:**

- **Tuhina Neogi (United States)** 08:40
  - **Abstract N° SP0066**
  - Pain

- **David Walsh (United Kingdom)** 09:00
  - **Abstract N° SP0068**
  - Angiogenesis and joint pain

- **A. Blom (Netherlands)** 09:20
  - **Abstract N° OP0028**
  - Association of differential synovial expression patterns in early osteoarthritis with pain and progression of joint damage

- **H. O’Leary (Ireland)** 09:30
  - **Abstract N° OP0029**
  - Pain sensitization and response to physiotherapy treatment in people with moderate to severe osteoarthritis of the knee

---

07:45 - 19:15  Registration area S11

Registration
10:15 - 11:45  ICC Auditorium

What is New (WIN)

WIN session 2

Josef S. Smolen (Austria) 10:20
RA therapy

Alexander So (Switzerland) 11:00
Gout and crystal diseases

10:15 - 11:45  Hall B

Abstract session

Prognosis and outcome in RA

Chairperson(s):
Ingemar Petersson (Sweden)
Ronald van Volkenhoven (Netherlands)

C. Bouman (Netherlands) 10:20
A. A. den Broeder, A. van der Maas,
F. H. van den Hoogen, R. Landewe, N. van Herwaarden
Abstract N° OP0175
Radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors is primarily driven by mean disease activity over time, not so much by flaring or lower TNF inhibitor exposition

G. Akdemir (Netherlands) 10:30
L. Heimans, R. J. Goekoop, M. van Oosterhout,
J. B. Harbers, C. Bijkerk, G. M. Steup-Beekman, L. Lard,
P. B. J. de Sonnaville, B. A. M. Grillet, T. W. J. Huizinga,
C. F. Allaart
Abstract N° OP0176
Five year outcomes of remission steered treatment including drug tapering strategies in early arthritis patients

E. A. Haavardsholm (Norway) 10:40
A.-B. Aga, I. C. Olsen, S. Lillegraven, H. B. Hammer,
T. Uhlig, H. Fremstad, T. M. Madland, Å. S. Lexberg,
H. Haukeland, E. Rodevand, C. Hoili, H. Stray,
A. N. Bendvold, I. J. W. Hansen, G. Bakland,
L. B. Nordberg, D. V. D. Heijde, T. K. Kvien
Abstract N° OP0177
Ultrasound in the management of rheumatoid arthritis: results from the randomized controlled ARCTIC trial

L. R. Harrold (United States) 10:50
H. J. Litman, S. E. Connolly, S. Kelly, W. Hua, E. Alemao,
L. Rosenblatt, S. Rebello, J. M. Kremer
Abstract N° OP0178
Impact of anti-cyclic citrullinated peptide and rheumatoid factor status on response to abatacept therapy: findings from a US observational cohort

S. Gottheil (Canada) 11:00
C. Barnabe, G. Boire, C. Hitchon, C. Thorne, V. Bykerk,
D. Tin, P. Harauvi on behalf of CATCH Investigators
Abstract N° OP0179
Comparing initial treatment strategies with methotrexate on first use of biologic therapy: results from the Canadian early arthritis cohort

K. Forslind (Sweden) 11:10
K. Eberhardt, B. Svensson
Abstract N° OP0180
Occurrence of repair of erosions during eight years in a large inception cohort of patients with rheumatoid arthritis - a BARFOT-study

F. B. G. Lamers-Karnebeek (Netherlands) 11:20
J. Luime, P. van Riel, J. Jacobs, T. Jansen
Abstract N° OP0181
Prediction of flare after stopping TNF-inhibitor by baseline ultrasonography and patient characteristics in rheumatoid arthritis patients with low disease activity: 12-month results

D. Gerlag (Netherlands) 11:30
M. Safy, K. Maijer, M. de Hair, S. Tas, M. Starman-Kool,
A. van Tubergen, M. Janssen, P.-P. Tak
Abstract N° OP0182
Prevention of rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease: the PRAIRI study

10:15 - 11:45  Hall D

Abstract session

Advances in SLE therapeutics

Chairperson(s):
David Isenberg (United Kingdom)
Raphael Seror (France)

M. Stott-Miller (United Kingdom) 10:20
P. Egger, A. Eudy, J. Maskell, Q. Fu, H. Kan,
R. Alfonso-Cristancho, K. Costenbader
Abstract N° OP0039
Impact of belimumab use on flares among patients diagnosed with systemic lupus erythematosus (SLE) in a US commercially insured database: 2010-2014

G. Johnston (United Kingdom) 10:30
A. Ranger, N. Allaire, P. Colman, C. Wager, H. Li,
A. Thai, P. Cullen, C. Otolu, J. Czerkowicz, C. Roberts,
C. Chamberlain, L. Burkly
Abstract N° OP0040
Peripheral blood transcriptional changes elicited by treatment of systemic lupus erythematosus (SLE) patients with dapirolizumab pegol (a pegylated anti-CD40L fab’)

G. Akdemir (Netherlands) 10:30
L. Heimans, R. J. Goekoop, M. van Oosterhout,
J. B. Harbers, C. Bijkerk, G. M. Steup-Beekman, L. Lard,
P. B. J. de Sonnaville, B. A. M. Grillet, T. W. J. Huizinga,
C. F. Allaart
Abstract N° OP0176
Five year outcomes of remission steered treatment including drug tapering strategies in early arthritis patients

E. A. Haavardsholm (Norway) 10:40
A.-B. Aga, I. C. Olsen, S. Lillegraven, H. B. Hammer,
T. Uhlig, H. Fremstad, T. M. Madland, Å. S. Lexberg,
H. Haukeland, E. Rodevand, C. Hoili, H. Stray,
A. N. Bendvold, I. J. W. Hansen, G. Bakland,
L. B. Nordberg, D. V. D. Heijde, T. K. Kvien
Abstract N° OP0177
Ultrasound in the management of rheumatoid arthritis: results from the randomized controlled ARCTIC trial

L. R. Harrold (United States) 10:50
H. J. Litman, S. E. Connolly, S. Kelly, W. Hua, E. Alemao,
L. Rosenblatt, S. Rebello, J. M. Kremer
Abstract N° OP0178
Impact of anti-cyclic citrullinated peptide and rheumatoid factor status on response to abatacept therapy: findings from a US observational cohort
K. A. Monaghan (Australia) 10:40
T. Y. Tai, J. Benson, B. Linggi, S. Oon, M. Ng, A. Hoi, E. Morand, N. J. Wilson
Abstract N° OP0041
JNJ-473 potently and specifically depletes PDCS in SLE patient blood in vitro and ablates TLR9-induced interferon alpha responses

M. Y. Md Yusof (United Kingdom) 10:50
Abstract N° OP0042
Humanised anti-CD20 antibodies improve depletion and response in SLE patients with resistance to rituximab: results from the first 100 patients at a single centre

J. Little (United Kingdom) 11:00
M. Lunt, B. Parker, I. N. Bruce on behalf of the Systemic Lupus International Collaborating Clinics Group
Abstract N° OP0043
Corticosteroid use over time in the systemic lupus international collaborating clinics (SLICC) inception cohort - a descriptive analysis

R. Furie (United States) 11:10
L. Wang, J. Drappa, G. Illei
Abstract N° OP0044
Systemic lupus erythematosus (SLE) responder index [SRI(4)] response is associated with global benefit in patients with moderate to severe SLE

A. Doria (Italy) 11:20
Abstract N° LB0001
Efficacy and safety of subcutaneous belimumab plus standard care in patients with systemic lupus erythematosus (SLE) with low complement and positive anti-dsDNA

10:15 - 11:45  Hall E

How to Treat/Manage (HOT)

Nicolò Ruperto (Italy) 10:20
Abstract N° SP0069
JIA and other paediatric rheumatic diseases

John H. Stone (United States) 11:00
Abstract N° SP0070
IgG4 associated diseases

10:15 - 11:45  Hall C

Abstract session

Diagnosis and management of SSc

Chairperson(s):
Jörg Distler (Germany)
Cristina Ponte (Portugal)

M. Elhai (France) 10:20
C. Meune, E. Hachulla, A. Balbir-Gurman, G. Riemekasten, P. Airò, P. Carreira, Y. Allano
Abstract N° OP0030
Associated factors with mortality and derivation of a simple 5-factors to predict mortality in SSc-patients in the EUSTAR cohort

M. G. Lazzaroni (Italy) 10:30
Abstract N° OP0031
Risk factors for malignancies synchronous to the onset of systemic sclerosis in patients positive for anti-RNA polymerase III antibodies: a EUSTAR multicentre study

M. M. Luchetti (Italy) 10:40
Abstract N° OP0032
Gastrointestinal disease and microbial translocation in patients with systemic sclerosis: an observational study on the effect of nutritional intervention and implications for the role of the microbiota in the pathogenesis of the disease

T. Nevskaya (Canada) 10:50
M. Baron, J. E. Pope on behalf of the Canadian Scleroderma Research Group
Abstract N° OP0033
European scleroderma study group activity index captures variations in disease activity over time and predicts organ damage in early systemic sclerosis: data from the Canadian scleroderma research group

O. Distler (Switzerland) 11:00
Abstract N° OP0034
The serotonin receptor 2 inhibitor terguride has beneficial effects on skin fibrosis: results from a phase 2 proof of concept study
A. Berti (Italy) 11:10
C. Canevari, F. Gallivanone, M. Lanzillotta, E. Bozzalla Cassione, C. Campochiaro, G. A. Ramirez, M. G. Sabbadini, E. Della Torre
Abstract N° OP0035
Circulating plasmablasts levels reflect inflammatory activity in IgG4-related disease lesions as assessed by quantitative positron emission tomography

A. Young (United States) 11:20
V. Nagaraja, S. Visovatti, V. McLaughlin, D. Khanna
Abstract N° OP0036
Screening for pulmonary arterial hypertension in systemic sclerosis: comparison of the predictive accuracy of various algorithms

L.-A. Bissell (United Kingdom) 11:30
Abstract N° OP0037
First pilot study of an implantable loop recorder (ILR) in systemic sclerosis detects significant cardiac arrhythmias with CMR abnormalities

L. Li (Canada) 11:40
L. M. Belvedere, E. C. Sayre, J. A. Avina-Zubieta
Abstract N° OP0038
Improved survival in dermatomyositis and polymyositis: a general population-base study

Abstract session
Vasculitis

Chairperson(s):
Miguel Angel Gonzalez-Gay (Spain)
Francesco Ciccia (Italy)

M. Yates (United Kingdom) 10:20
Abstract N° OP0053
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

P. C. Grayson (United States) 10:30
Abstract N° OP0054
Neuroimmunomodulation of neutrophils as a novel mechanism of levamisole-induced vasculitis

A. Floris (United Kingdom) 10:40
Abstract N° OP0055
Using the Birmingham vasculitis activity score as a screening tool in patients with suspected vasculitis

T. Nakajima (Japan) 10:50
Abstract N° OP0056
Association of IL-12p40 and IL-12p70 with pathophysiology of takayasu arteritis

N. Bulanov (Russian Federation) 11:00
A. Serova, E. Kuznetsova, P. Novikov, S. Moiseev
Abstract N° OP0057
Urinary and serum KIM-1, MCP-1 and type IV collagen levels in the assessment of ANCA-associated nephritis activity

D. Cornec (France) 11:10
Abstract N° OP0058
Using mass spectrometry to quantify rituximab and perform individualized immunoglobulin phenotyping in ANCA-associated vasculitis

S. J. Lee (Republic of Korea) 11:20
Abstract N° OP0059
Serum CXCL10 levels are associated with clinical manifestations and disease activity in Behcet’s disease

X. Puéchal (France) 11:30
Abstract N° LB0002
Does adding azathioprine to glucocorticoid induction increase the remission rate and prevent relapses in patients with systemic necrotizing vasculitides without poor-prognosis factors? A multicenter, double-blind randomized controlled trial
HPR Abstract session

Developing evidence-based non-pharmacological care

Chairperson(s):
Tanja Stamm (Austria)
Francoise Alliot (France)

M. Ndosi (United Kingdom) 10:20

Abstract N° OP0060-HPR
Cross-cultural validation of the systemic sclerosis quality of life questionnaire in six European countries: a tool validation study

C. Hendricks (South Africa) 10:30
R. Parker, J. Jelsma

Abstract N° OP0061-HPR
The effect of a contextually relevant non-pharmacological intervention on the functioning of South African women with osteoarthritis: a randomized controlled trial

M. De Rooij (Netherlands) 10:40

Abstract N° OP0062-HPR
Efficacy of tailored exercise therapy in patients with knee osteoarthritis and comorbidity: a randomized controlled trial

M. van der Esch (Netherlands) 10:50
P. Juch, M. van der Leeden, M. Jansen, W. Wirth, L. Roorda, W. F. Lems, J. Dekker

Abstract N° OP0063-HPR
High proportion of non-contractile tissue in the vastus medialis muscle is associated with muscle weakness in patients with knee osteoarthritis; results from the AMS-OA cohort

B. Alcacer-Pitarch (United Kingdom) 11:00
A. Redmond, F. Del Galdo, M. Buch, A.-M. Keenan

Abstract N° OP0064-HPR
A model including foot-related factors impacting on quality of life (QoL) in systemic sclerosis

SpA and PsA clinical

Chairperson(s):
Martin Rudwaleit (Germany)
Anna Moltó (France)

U. Kiltz (Germany) 10:20
D. van der Heijde, A. Boonen, J. Braun on behalf of the ASAS HI international validation study

Abstract N° OP0084
Validation of the ASAS health index: results of a multicenter international study in 23 countries

Z. Ez-Zaitouni (Netherlands) 10:30
P. Bakker, M. van Lunteren, M. Reijnierse, I. J. Berg, R. Landewé, M. van Oosterhout, M. Lorenzin, D. van der Heijde, E. van Gaalen

Abstract N° OP0085
Does the presence of multiple SpA-features in patients with chronic back pain always lead to diagnosis of axial spondyloarthritis?

X. Baraliakos (Germany) 10:40
H. Boehm, A. Samir, G. Schett, J. Braun

Abstract N° OP0086
Which cells correspond to the typical signals for fatty and inflammatory lesions seen in magnetic resonance imaging in ankylosing spondylitis? A prospective study using biopsy material obtained during spinal surgery

G. Varkas (Belgium) 10:50
H. Cypers, N. Vastesaeger, L. van Praet, P. Carron, F. van den Bosch, D. Elewaut on behalf of the Be-Giant Consortium

Abstract N° OP0087
The association of extra-articular manifestations with disease duration in axial SpA: results from the (Be-)Giant cohort and the aspect study
V. Navarro-Compán (Netherlands) 11:00
S. Ramiro, R. Landewé, M. Dougados, C. Miceli-Richard, P. Richette, D. van der Heijde
Abstract N° OP0088
Inflammation on MRI of the spine is longitudinally related to disease activity in smokers but not in non-smokers in axial spondyloarthritis: 2-year data from the DESIR cohort

P. Putrik (Netherlands) 11:10
S. Ramiro, A. Moltó, A. Keszei, M. Dougados, D. van der Heijde, R. Landewé, A. Boonen
Abstract N° OP0089
Are individual or country level socio-economic determinants related to disease activity and self-reported physical function in patients with spondyloarthritis? Results from multi-national cross-sectional study ASAS-COMOSpa

M. de Hooge (Netherlands) 11:20
F. de Bruin, L. de Beer, P. Bakker, R. van den Berg, S. Ramiro, F. van Gaalen, K. Fagerli, R. Landewé, M. van Oosterhout, R. Ramonda, T. Huizinga, J. L. Bloom, M. Reijnierse, D. van der Heijde
Abstract N° OP0090
MRI lesions originating from either axSpA or degeneration are related to site of pain in patients with chronic back pain included in the SpACE-cohort

Y. El Miedany (United Kingdom) 11:30
M. El Gaafary, S. Youssef, S. Bahlas, I. Ahmed, M. Hegazi
Abstract N° OP0091
Psoriatic arthritis comorbidity index: development and validation of a new specific tool for classifying prognostic comorbidity in psoriatic arthritis patients

I. Castrejon (United States) 10:40
J. Chua, J. A. Block, T. Pincus
Abstract N° OP0094
Physician and patient estimates of global status are more likely to be discordant in osteoarthrosis than in rheumatoid arthritis

M. Kloppenburg (Netherlands) 10:50
Abstract N° OP0095
Randomized, placebo-controlled trial to evaluate clinical efficacy and structure modifying properties of subcutaneous etanercept (ETN) in patients with erosive inflammatory hand osteoarthritis (OA)

J. Martel-Pelletier (Canada) 11:00
A. J. Teichtahl, F. M. Cicuttini, F. Abram, Y. Wang, J.-P. Pelletier
Abstract N° OP0096
Meniscal extrusion and bone marrow lesions are independently associated with incident and progressive knee osteoarthritis

R. Wittoek (Belgium) 11:10
P. Carron, B. Lambert, P. Meersseman, A. Verbruggen, F. van den Bosch, D. Elewaut
Abstract N° OP0097
Immunoscintigraphic detection of TNF by radiolabeled certolizumab pegol in patients with erosive hand osteoarthritis in relation to disease activity and structural progression: a proof of concept study

F. P. Kroon (Netherlands) 11:20
R. Wittoek, G. Verbruggen, I. K. Haugen, T. W. Huizinga, M. Kloppenburg
Abstract N° OP0098
Effect of etanercept on synovitis and bone marrow lesions in erosive hand osteoarthritis

I. S. Burkov (United Kingdom) 11:30
G. Treece, A. Gee, T. Turmezei, E. Johannesdottir, S. Sigurdsson, T. Aspelund, H. Jónsson, V. Gudnason, K. Poole
Abstract N° OP0099
3D cortical bone mapping of the proximal femur in a large prospective population-based study supports the ganz hypothesis of hip osteoarthritis causation: the ages-Reykjavik study

Abstract session
New horizons in osteoarthritis
Chairperson(s):
Francesco dell’Accio (United Kingdom)
Ida Kristin Haugen (Norway)
A. R. Bihlet (Denmark) 10:20
M. Karsdal, I. Byrjalsen, A.-C. Bay-Jensen, C. Christiansen, J. R. Andersen, H. Gühring, C. Ladel, M. Michaelis, B. Riis, I. Valter
Abstract N° OP0092
Identification of pain subtypes associated with placebo-response: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis

F. Pan (Australia) 10:30
D. Aitken, J. Tian, F. Cicuttini, T. Winzenberg, C. Ding, G. Jones
Abstract N° OP0093
Does “pain elsewhere” influence the association between knee structural pathology and knee pain?

Abstract session
Clinical osteoporosis: new insights
Chairperson(s):
Glenn Haugeberg (Norway)
Hennie G. Raterman (Netherlands)
Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy: results of the phase 3 open-label STRUCTURE study

B. Langdahl (Denmark)

Abstract N° OP0100

Bisphosphonates during pregnancy: a prospective study

C. A. Inderjeeth (Australia)

Abstract N° OP0101

Bone quality, as measured by trabecular bone score, in female postmenopausal patients with systemic sclerosis and rheumatoid arthritis

Y. Hirano (Japan)

Abstract N° OP0104

The predictors for 12 months efficacy of denosumab, an anti-RANKL antibody, on osteoporosis in patients with rheumatoid arthritis from multicenter study (TBCR-BONE)

L. Rasch (Netherlands)

Abstract N° OP0105

Change in bone mineral density with high-dose prednisone in patients with rheumatoid arthritis

A. Fassio (Italy)

Abstract N° OP0106

Genetic effects on trabecular and cortical volumetric bone mineral densities and bone microstructure measured by HRpQCT

F. Pan (Australia)

Abstract N° OP0102

Abstract session

SpA and PsA basic and translational research

Chairperson(s):
Paul Wordsworth (United Kingdom)
Denis Podubnyy (Germany)

E. Schweikhard (Germany)

Abstract N° OP0107

Autoantibodies against CD74 - a new diagnostic marker for spondyloarthritis (SpA)

T. W. Kragstrup (Denmark)

Abstract N° OP0076

Autoantibodies against CD74 - a new diagnostic marker for spondyloarthritis (SpA)

L. D. Heffdal (Denmark)

Abstract N° OP0077

Increased frequencies of IL-23R positive T cells and IL-22 and IL-17 producing mait cells in the peripheral blood of patients with ankylosing spondylitis: preliminary results

D. Poddubnyy (Germany)

Abstract N° OP0078

Higher serum level of leptin might be responsible for less structural damage in the spine in female patients with ankylosing spondylitis

F. Ciccia (Italy)

Abstract N° OP0079

Tissue deficiency of the atypical chemokine receptor D6 is associated with the selective increase of gut-derived pro-inflammatory CXCR1highly6highTL1A+IL-23+CCR7+ cells in the peripheral blood, synovial fluids and bone marrow of as patients

U. Lindström (Sweden)

Abstract N° OP0080

Infections of the gut, urogenital and respiratory tract and appendicitis during childhood, and the risk of developing ankylosing spondylitis


Abstract N° OP0081

Synovial myofibroblasts from spondyloarthritis patients produce IL-26 spontaneously and the production is enhanced upon IL-1, TNF-α and LPS stimulation

L. D. Heftdal (Denmark)

Abstract N° OP0078

The predictors for 12 months efficacy of denosumab, an anti-RANKL antibody, on osteoporosis in patients with rheumatoid arthritis from multicenter study (TBCR-BONE)

L. van Tuyl, M. Kremer, I. Bultink, M. Boers, W. Lems

Abstract N° OP0105

The predictors for 12 months efficacy of denosumab, an anti-RANKL antibody, on osteoporosis in patients with rheumatoid arthritis from multicenter study (TBCR-BONE)

R. Alessandro, G. Triolo

Abstract N° OP0081

Tissue deficiency of the atypical chemokine receptor D6 is associated with the selective increase of gut-derived pro-inflammatory CXCR1highly6highTL1A+IL-23+CCR7+ cells in the peripheral blood, synovial fluids and bone marrow of as patients
S. Wade (Ireland) 11:30
M. Connelly, S. Cregan, C. Orr, D. Veale, U. Fearon
Abstract N° OP0083
MiR-125a decreased in PsA synovium and peripheral blood CD14+ monocytes and correlates to joint angiogenesis

C.-H. Lee (Republic of Korea) 11:20
J. M. Baek, J.-Y. Kim, K.-H. Yoon, J. Oh, M. S. Lee
Abstract N° OP0074
Ebselen is a potential anti-osteoporosis agent by suppressing receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation in vitro and lipopolysaccharide-induced inflammatory bone destruction in vivo

D. M. Roeleveld (Netherlands) 11:30
Abstract N° OP0075
Sensitive SPECT/CT imaging of synovial fap expression after anti-IL-22 treatment in experimental arthritis

10:15 - 11:45  Capital Suite 06

Abstract session
Cartilage, bone, synovium

Chairperson(s):
Tonia Vincent (United Kingdom)
Marie Kostine (France)

M. van den Bosch (Netherlands) 10:20
A. Blom, A. Maeda, T. Kilts, W. van den Berg, P. van Lent, M. Young, P. van der Kraan
Abstract N° OP0068
WISP1 induces pathology in experimental osteoarthritis and predicts disease progression in early osteoarthritis patients

J. Hood (United States) 10:30
C. Barroga, Y. Hu, V. Deshmukh
Abstract N° OP0069
Discovery of a small molecule inhibitor of the WNT pathway (SM04690) as a potential disease modifying treatment for knee osteoarthritis

S. R. Greisen (Denmark) 10:40
A. H. Sharpe, T. W. Kragstrup, E.-M. Hauge, W. Qiu, M. Hvid, B. Deleuran
Abstract N° OP0070
PD-L2 - a new link between inflammation and bone modulation in rheumatoid arthritis

L. Tsiklauri (Germany) 10:50
Abstract N° OP0071
Adipokine effects on differentiation of osteoporosis and osteoarthritis spongiosa-derived mesenchymal stromal cells

N. Y. Lin (Germany) 11:00
Abstract N° OP0072
Inhibition of NOTCH1 promotes hedgehog signaling in a HES1-dependent manner and exacerbates experimental osteoarthritis

C. Schoenfeld (Germany) 11:10
Abstract N° OP0073
RNA-seq based identification of factors involved in knee joint regeneration after induced osteoarthritis in notophthalmus viridescens

10:15 - 11:45  Capital Suite 13

Abstract session
New pathways to treatment

Chairperson(s):
David S. Pisetsky (United States)
Antigoni Triantafyllopoulou (Germany)

V. Reddy (United Kingdom) 10:20
C. Klein, D. Isenberg, G. Cambridge, M. Cragg, M. Leandro
Abstract N° OP0159
Improving B cell depletion in rheumatoid arthritis and systemic lupus erythematosus: resistance to rituximab and the potential of obinutuzumab

H. Idborg (Sweden) 10:30
Abstract N° OP0160
Characterization of systemic lupus erythematosus subgroups with features of antiphospholipid or Sjögren's syndrome utilizing affinity proteomics

N. A. Young (United States) 10:40
J. Hampton, A. Kalyanasundaram, A. Bratasz, J. Pyles, S. Aqel, W. Jarjour, S. Ardoin
Abstract N° OP0161
Cardiac magnetic resonance imaging of lupus nephritis-induced cardiovascular disease correlates with myocarditis, fibrosis, and enhanced pro-inflammatory cytokine expression in a mouse model

K. Sakata (Japan) 10:50
S. Nakayamada, Y. Miyazaki, S. Kubo, K. Nakano, Y. Tanaka
Abstract N° OP0162
Toll-like receptor 7-, but not toll-like receptor 9-, mediated interferon-α production from plasmacytoid dendritic cells in systemic lupus erythematosus

9 June 2016
Z. Zhang (China) 11:00
Abstract N° OP0163
Mesenchymal stem cells prevent podocyte injury in lupus prone mice via educating macrophage into an anti-inflammatory phenotype

S. A. Chalmers (United States) 11:10
C. Putterman
Abstract N° OP0164
Blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of Bruton's tyrosine kinase

X. Guo (United States) 11:20
L. Wang, G. Illei, P. Brohawn, B. W. Higgs, W. I. White
Abstract N° OP0165
Beneficial effects of an anti-IFNAR1 monoclonal antibody on immune cell dysregulation and complement system abnormalities of systemic lupus erythematosus: an exploratory analysis of phase IIB clinical trial of anifrolumab

J. Qi (China) 11:30
B. Shi, Z. Zhang, R. Feng, W. Chen, G. Yao, Y. Hou, L. Sun
Abstract N° OP0166
Il-27 participates in Sjögren's syndrome by regulating lymphocyte subsets

W. Olsder (Netherlands) 11:20
L. van Nieuwkoop, R. van Boerdonk, N. des Bouvrie
Abstract N° OP0116-PARE
Development of the guide for national online youth platforms including implementation in three countries

M. Ekrøth (Finland) 11:30
M. Ekrøth, T. Pakkala
Abstract N° OP0117-PARE
Floa elämää - peer support and networking event for children, youth and families with MSD disease

10:15 - 11:45  Room S19
PARE session
Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease

Learning objectives:
Help to equip and inspire young people to become empowered, involved in shared decision-making and involved in healthcare decisions

Chairperson(s):
Linda van Nieuwkoop (Netherlands)
Sofia Ramiro (Netherlands)

Petra Balazova (Slovakia) 10:20
Abstract N° SP0071
The role of Young PARE in getting organised: the Virtual Knowledge Centre

Alessia Alunno (Italy) 10:40
Abstract N° SP0072
The role of health professionals in improving shared decision-making with young people with RMDs

Irene Murphy (Ireland) 11:00
Abstract N° SP0073
Empowering young people with RMDs to find their voice and claim their space

10:15 - 11:45  Room S20
Abstract session
New insights into imaging

Chairperson(s):
Susanne Juhl Pedersen (Denmark)
Iustina Janta (Romania)

G. Sakellariou (Italy) 10:20
P. G. Conaghan, W. Zhang, J. W. J. Bijlsma,
P. Boyesen, M. A. D’Agostino, M. Doherty, D. Fodor,
M. Kloppenburg, J. Maeder, F. Miese, E. Naredo,
M. Porcheret, A. Iagnocco
Abstract N° OP0118
Development of the EULAR recommendations for the use of imaging in the clinical management of osteoarthritis

N. P. Sundlisater (Norway) 10:30
S. Lillegraeven, I. C. Olsen, A.-B. Aga, H. B. Hammer,
T. Uhlig, D. van der Heijde, T. K. Kvien,
E. A. Haavardsholm on behalf of the ARCTIC study group
Abstract N° OP0119
Predictors of radiographic progression in early rheumatoid arthritis patients treated by an aggressive tight control regime

I. Leineman (Russian Federation) 10:40
R. Faizenberg, T. Golimbievskaya, M. Shostak,
V. Mazurov
Abstract N° OP0120
Post-processing techniques for enhanced visualization of pulmonary vasculitis and pulmonary thrombosis by multislice spiral computed tomography in patients with systemic lupus erythematosus and antiphospholipid syndrome

L. Meric de Bellefon (Belgium) 10:50
P. Durez, C. Galant, A. Avramovska, A. Nzeusseu,
B. Lauwerys, F. A. Houssiau, M. S. Stoenoiu
Abstract N° OP0121
Safety, tolerability and feasibility of minimally invasive ultrasound-guided synovial biopsy of wrist and metacarpophalangeal joints - an ultrasound follow-up study
Poster tour

T2: Cartilage, bone, synovium
Chairperson(s): Anne-Marie Malfait (United States)  
Stephan Blüml (Austria)
Abstract N° THU0001 - THU0010

Poster tour

T3: Prognosis and outcome in RA
Chairperson(s): Ingemar Petersson (Sweden)  
Paola de Pablo (United Kingdom)
Abstract N° THU0029 - THU0036

Poster tour

T4: Comorbidities update 2016, part I
Chairperson(s): Johannes W.J. Bijlsma (Netherlands)  
Nicole Konijn (Netherlands)
Abstract N° THU0073 - THU0082

PRes Poster tour

T6: Arthritis in childhood
Chairperson(s): Tadej Avcin (Slovenia)  
Sebastian Vastert (Netherlands)
Abstract N° THU0213 - THU0222

Poster tour

T7: Walk through new pathways, biomarkers and potential treatments in SLE and Sjögren's
Chairperson(s): Reinhard E. Voll (Germany)  
Nils Venhoff (Germany)
Abstract N° THU0240 - THU0251

Poster tour

T8: SpA and PsA basic and translational research
Chairperson(s): Maxime Breban (France)  
Peggy Jacques (Belgium)
Abstract N° THU0363 - THU0372

Poster tour

T9: Axial SpA - clinical aspects
Chairperson(s): Robert B. M. Landewé (Netherlands)  
Victoria Navarro-Compán (Spain)
Abstract N° THU0374 - THU0383
Poster tour

**T10: Psoriatic arthritis**

Chairperson(s): Rik Lories (Belgium)
Elsa Sousa (Portugal)
Abstract N° THU0418 - THU0427

**T11: How to treat osteoporosis in patients with elevated disease**

Chairperson(s): Willem F. Lems (Netherlands)
Hennie G. Raterman (Netherlands)
Abstract N° THU0456 - THU0465

**T12: Crystal and metabolic bone diseases; bone diseases other than osteoporosis**

Chairperson(s): Eliseo Pascual (Spain)
Hang-Korng Ea (France)
Abstract N° THU0490 - THU0499

**T13: Clinical aspects of fibromyalgia**

Chairperson(s): Stefan Bergman (Sweden)
Serge Perrot (France)
Abstract N° THU0541 - THU0550

**T14: Outcome measures of RMDs**

Chairperson(s): Annelies Boonen (Netherlands)
Delphine Courvoisier (Switzerland)
Abstract N° THU0593 - THU0602

**PARE Poster tour**

**T15: PARE - Poster tour I**

Chairperson(s): Diana Skingle (United Kingdom)
Maarten de Wit (Netherlands)
Abstract N° PARE0001 - PARE0008

---

13:30 - 15:00  ICC Auditorium

**What is New (WIN)**

**WIN session 3**

Karim Raza (United Kingdom) 13:35
Abstract N° SP0074
Early arthritis

Cem Gabay (Switzerland) 14:15
Clinical aspects of RA

---

13:30 - 15:00  Hall B

**Challenges in Clinical Practice session**

**Combined cases: Sjögren's and a paediatric case**

Learning objectives:
- Two fascinating cases from both adult and paediatric rheumatology
- An unusual case of Sjögren's disease with massive selling of the parotid glands raising the question how to proceed: just biopsies, surgical removal or B cell depleting therapy? The potential consequences will be discussed with the audience
- The second case will be a child with a systemic autoimmune disease. How to proceed here?

Chairperson(s):
Salvatore de Vita (Italy)
Clarissa Pilkington (United Kingdom)

Tobias Alexander (Germany) 13:35
Case 1 presentation: An unusual case of Sjögren's syndrome

Simon Bowman (United Kingdom) 13:45
Case 1 discussion: An unusual case of Sjögren's syndrome

Eve Smith (United Kingdom) 14:15
Case 2 presentation:
A child with systemic autoimmune disease

Sylvia Kamphuis (Netherlands) 14:25
Case 2 discussion:
A child with systemic autoimmune disease

---

13:30 - 15:00  Hall D

**Clinical Science session**

**Advancements in the imaging of PsA**

Learning objectives:
- To update the role of imaging in PsA management
- To have insights into the value of imaging in understanding the pathophysiology of PsA

Chairperson(s):
Violetta Vlad (Romania)
Christian Dejaco (Austria)

Emilio Filippucci (Italy) 13:35
Abstract N° SP0075
Linking histology and imaging in the pathogenesis of PsA

Maria-Antonietta d'Agostino (France) 13:55
Imaging in monitoring therapy response in PsA: why, what and when?

Mikkel Østergaard (Denmark) 14:15
Abstract N° SP0076
Prognostic value of imaging markers in PsA
T. Fukuda (Japan) 14:35
Y. Umezawa, S. Tojo, T. Yonenaga, A. Asahina, H. Nakagawa, K. Fukuda
Abstract N° OP0126
Dual energy CT with iodine map is promising new imaging modality in the evaluation of hand psoriatic arthritis

M. Merashli (United Kingdom) 14:45
Abstract N° OP0127
Low frequency of us determined erosions in early psoriatic arthritis: results from the Leeds SPARRO cohort

13:30 - 15:00  Hall E
How to Treat/Manage (HOT)
HOT session 5

Frederic Houssiau (Belgium) 13:35
SLE

Francesca Barone (United Kingdom) 14:15
Sjögren’s syndrome

13:30 - 15:00  Hall C
Clinical Science session
When and how to treat Raynaud's phenomenon and related complications

Learning objectives:
- To learn how to make the differential diagnosis between primary and secondary Raynaud’s phenomenon
- To be updated on the most actual approaches to manage and to treat both conditions

Chairperson(s):
Alberto Sulli (Italy)
Luc Mouthon (France)

Vanessa Smith (Belgium) 13:35
Abstract N° SP0077
Differential diagnosis between primary and secondary Raynaud’s phenomenon

Jean-Luc Cracowski (France) 13:55
Abstract N° SP0078
When and how to manage the primary Raynaud’s phenomenon

Ariane L. Herrick (United Kingdom) 14:15
Abstract N° SP0079
When and how to manage the secondary Raynaud’s phenomenon and related conditions

B. Ruoaro (Italy) 14:35
C. Pizzorni, A. C. Trombetta, S. Paolino, E. Bernero, M. Cutolo, A. Sulli
Abstract N° OP0128
Evaluation of peripheral blood perfusion by laser speckle contrast analysis in systemic sclerosis patients treated with aminaphtone

L. C. Teixeira (Portugal) 14:45
I. Cordeiro, J. Canas da Silva, M. J. Santos, A. Cordeiro
Abstract N° OP0129
Nailfold capillaroscopy in rheumatology practice - a single center experience

13:30 - 15:00 Hall A
Outcome Science session
Role of new imaging techniques as RMD outcomes

Learning objectives:
- To address the validity of imaging as outcome in rheumatic diseases
- To understand the role of new imaging modalities in managing rheumatic diseases

Chairperson(s):
Ingemar Petersson (Sweden)
Sarah Ohrndorf (Germany)
Stephanie Finzel (Germany) 13:35
Abstract N° SP0080
Imaging in early detection of RA joint damage. What technique and how to use?

Philip Conaghan (United Kingdom) 13:55
Imaging in predicting outcomes in OA. What’s new?

Nicola Dalbeth (New Zealand) 14:15
Abstract N° SP0081
Imaging in the management of gout. Clinical tool or endpoint?

B. S. Eathakkattu Antony (Australia) 14:35
X. Jin, X. Wang, W. Han, Z. Zhu, F. Cicuttini, C. Ding, G. Jones
Abstract N° OP0130
Radiographic and magnetic resonance imaging markers predict cartilage volume loss and knee symptoms over 10.7 years in older adults

K. K. Keller (Denmark) 14:45
J. S. Thomsen, K. Stengaard-Pedersen, A. W. Nielsen, B. Schiotz-Christensen, S. G. Kjær, I. Svendsen, M. Graakjær, P. M. Petersen, B. Unger, B. Langdahl, E.-M. Hauge
Abstract N° OP0131
Trabecular thinning in metacarpophalangeal joints of anticitrullinated peptide antibody positive patients with arthralgia
HPR/PARE joint session
"Fewer words - more action" - tailored care for men with rheumatic diseases?

Learning objectives:
• To highlight how men with a rheumatic disease experience life
• To discuss the use of different coping strategies and if they are different from women
• To learn and spark ideas, across different disciplines and countries, on how we could look at gender differences to optimise the management for men with rheumatic diseases

Chairperson(s):
Milena Gobbo Montoya (Spain)
Dieter Wiek (Germany)

Mathilda Björk (Sweden) 13:35
Abstract N° SP0082
Disability in men and women with RA. Does it differ and does it matter?

Frank Demtröder (Germany) 13:53
Abstract N° SP0083
Balancing work and life: "when is a man a man?"

Bente Appel Esbensen (Denmark) 14:11
Abstract N° SP0084
"Being physically active is a salvation" - men's preferences for physical activity

Caroline Flurey (United Kingdom) 14:29
Abstract N° SP0085
Design of a self-management intervention for men with RA

M. Martin (United Kingdom) 14:47
H. Fiddler
Abstract N° OP0132-HPR
Axial spondyloarthritis know-how: what are the benefits of a brief exercise and self-management education group programme? A qualitative investigation

Basic and Translational Science session
Recent advances in our understanding of macrophage biology

Learning objectives:
• To obtain detailed insight into recent developments in the field of macrophage biology
• To understand how these may inform knowledge and treatment of inflammatory arthritis

Chairperson(s):
Florence Apparailly (France)
Tanya Shaw (United Kingdom)

Allan Mowat (United Kingdom) 13:35
Abstract N° SP0086
Macrophages in intestinal homeostasis and inflammation

Irina Udalova (United Kingdom) 13:55
Regulation of macrophage function

Harris Perlman (United States) 14:15
Macrophages in experimental and clinical arthritis

E. Karouzakis (Switzerland) 14:35
DNA demethylation pathway analysis in rheumatoid arthritis synovial fibroblasts and macrophages

E. R. Dorris (Ireland) 14:45
K. Creevey, C. Moran, M. Muthana, A. G. Wilson
The rheumatoid arthritis susceptibility gene C5ORF30 acts as an immunomodulator in macrophages

Basic and Translational Science session
Lubricants: potential as osteoarthritis treatment?

Learning objectives:
• To understand which lubricants are involved in joint homeostasis and function, whether lubricants can be a potential treatment for osteoarthritis
• To know what the status of current treatments are that are considered as viscosupplementation

Chairperson(s):
Francis Berenbaum (France)
Andreea Ioan-Facsinay (Netherlands)

Jacob Klein (Israel) 13:35
Abstract N° SP0087
Natural occurring lubricants to maintain joint homeostasis

Stephanie J. Bryant (United States) 14:05
Abstract N° SP0088
Hydrogels for osteoarthritis treatment
Peter Jüni (Canada) 14:25
Efficacy of hyaluronic acid as lubrication of the osteoarthritis joint

T. Conrozier (France) 14:45
F. Eymard, X. Chevalier
Abstract N° OP0135
Predictive factors of failure of viscosupplementation in patients with knee osteoarthritis. Results of a post-hoc analysis of a double blind, controlled non inferiority trial

13:30 - 15:00  Capital Suite 02
PReS session

Extra-articular complications of JIA

Learning objectives:
To study common extra-articular manifestations that can develop in patients with JIA

Chairperson(s):
Francesco Zulian (Italy)
Carine Wouters (Belgium)

Angelo Ravelli (Italy) 13:35
Macrophage activation syndrome

Athimalaipe Ramanan (United Kingdom) 13:55
Management and outcome of chronic uveitis

Rolando Cimaz (Italy) 14:15
Abstract N° SP0089
Osteoporosis in JIA

L. Galstian (Russian Federation) 14:35
E. Zholobova, O. Loskutova, M. Nikolaeva
Abstract N° OP0136
Abatacept treatment during 1 year period in juvenile idiopathic arthritis associated uveitis without previous biologics therapy

K. Minden (Germany) 14:45
S. Schenck, R. W. Holl, M. Niewerth, J. Klotsche, J. Rosenbauer, A. Thon
Abstract N° OP0137
Diabetes prevalence in patients with juvenile idiopathic arthritis (JIA)

13:30 - 15:00  Capital Suite 06
Practical skills session*

Crystals II

Chairperson(s):
Anne K. Tausche (Germany)
Eliseo Pascual (Spain)

Tutor(s):
Eleonora Norkuviene (Lithuania)
Francisca Sivera (Spain)
José Pimentao (Portugal)
Francesca Oliviero (Italy)

13:30 - 15:00  Capital Suite 01
The Young Rheumatologist

The elephant in the room: how to avoid biases in research?

Learning objectives:
• To increase familiarity of the audience with different types of biases and remind that they may occur at every stage
• To guide the young researchers on how to avoid biases before, during and after trials

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11
PARE session
Digital applications for the benefit of the patient

Learning objectives:
How e-health and m-health solutions can improve health care provision

Chairperson(s):
Kirsten Lerstroem (United Kingdom)
Dora Papastavrou (Greece)
Sofia Ernestam (Sweden)

13:35
Abstract N° SP0091
Can individual patients benefit from registries?
Elizabeth Murray (United Kingdom)

13:55
Abstract N° SP0092
Digital interventions to improve self-care
Simon Stones (United Kingdom)

14:15
Abstract N° SP0093
How innovative technologies can support individuals to better self-manage their conditions
L. Grange (France)

14:35
Abstract N° OP0139-PARE
The first serious game EduBioT: a modern therapeutic educational tool for adult patients with chronic inflammatory rheumatic disease, treated with biotherapy
G. O’Leary (Ireland)

14:45
Abstract N° OP0140-PARE
Self-management online: from concept to delivery, living well with arthritis online

EULAR projects in Clinical Affairs

Chairperson(s):
Ronald van Vollenhoven (Netherlands)
Ulf Müller-Ladner (Germany)
Gary J. Macfarlane (United Kingdom)

13:35
Revised EULAR recommendations for the management of fibromyalgia
Gulen Hatemi (Turkey)

13:55
Update of the EULAR recommendations for the management of Behcet’s disease
Willem F. Lems (Netherlands)

14:15
Abstract N° SP0094
EULAR/EFORT recommendations for prevention and management of osteoporotic fractures

Chetan Mukhtyar (United Kingdom)

14:35
Abstract N° SP0095
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

15:00 - 15:30
Exhibition (S5-S9)
Coffee break

15:30 - 17:00
ICC Auditorium
What is New (WIN)
WIN session 4
José A. P. da Silva (Portugal)

15:35
Rheumatic manifestations arising from endocrine/metabolic disorders
Berent J. Prakken (Netherlands)

16:15
Paediatric rheumatology

15:30 - 17:00
Hall B
Challenges in Clinical Practice session
Difficult vasculitis (pulmonary/renal & CNS)

Learning objectives:
- Recognise the histopathological spectrum of large vessel vasculitis and the related clinical profile
- Recognise mimics of central nervous system vasculitis and learn how to distinguish central nervous system vasculitis from mimics
Chairperson(s):
Carlo Salvarani (Italy)
Dimitrios Vasilopoulos (Greece)
Nicolo Pipitone (Italy)

15:35
Case 1 presentation: A case of temporal arteritis with uninflamed temporal artery
Alberto Cavazza (Italy)

15:45
Case 1 discussion: The role of the pathologist in the diagnosis of large vessel vasculitis
Cassandra Calabrese (United States)

16:15
Case 2 presentation: A case mimicking CNS-vasculitis
Leonard Calabrese (United States)

16:25
Case 2 discussion: How to recognize CNS-vasculitis mimics

15:30 - 17:00
Hall D
Clinical Science session
Optimization of MTX in RA treatment

Learning objectives:
How to optimize and use MTX in RA
Chairperson(s):
Michael Weinblatt (United States)
Gerd R. Burmester (Germany)

Michael Schiff (United States) 15:35
Abstract N° SP0096
MTX pharmacokinetics - oral vs SQ or genetics

Robert de Jonge (Netherlands) 15:55
Abstract N° SP0097
MTX polyglutamate and clinical response

Gerd R. Burmester (Germany) 16:15
Best dose of MTX in combination with biologics

R.-M. Flipo (France) 16:35
C. Gaujoux-Viala, C. Hudry, E. Zinovieva, E. Leutenegger, H. Herman-Demars
Abstract N° OP0141
Which strategies in rheumatoid arthritis patient with inadequate response to methotrexate monotherapy: the STRATEGE study

K. Michaud (United States) 16:45
S. Pedro
Abstract N° OP0142
Methotrexate use in RA: what 17 years and 22 621 patients can teach us

15:30 - 17:00 Hall E
How to Treat/Manage (HOT)

HOT session 6

Iain B. McInnes (United Kingdom) 15:35
Psoriatic arthritis

Filip van den Bosch (Belgium) 16:15
Spondyloarthritis/ankylosing spondylitis

15:30 - 17:00 Hall C
Clinical Science session
Joint replacement in OA: friend or foe?

Learning objectives:
• To understand the efficacy of joint replacements, but also their limitations
• For which patient groups joint replacements are especially successful
• Whether specific types of prosthesis are required for certain patient groups

Chairperson(s):
François Rannou (France)
W. Erwin van Spil (Netherlands)

Jan Victor (Belgium) 15:35
Joint replacement for end stage osteoarthritis: the holy grail?

Lisa Mandl (United States) 15:55
Abstract N° SP0098
For which patient a joint replacement is most successful?

Huub J. L. van der Heide (Netherlands) 16:15
Joint prosthesis: one size fits all?

D. Aitken (Australia) 16:35
I. Munugoda, F. Cicuttini, M. Callisaya, G. Jones
Abstract N° OP0143
The effect of physical activity on the risk of total joint replacement for severe knee or hip osteoarthritis: a population-based prospective cohort study

B. S. Eathakkattu Antony (Australia) 16:45
X. Jin, X. Wang, W. Han, F. Cicuttini, C. Ding, G. Jones
Abstract N° OP0144
Infra patellar fat pad signal intensity alterations and effusion-synovitis predict knee pain, cartilage volume loss and total knee replacement over 10.7 years in older adults

15:30 - 17:00 Hall A
Outcome Science session
How to identify and follow patients with inflammatory back pain?

Learning objectives:
To get an update on evidence base for the concept of inflammatory back pain

Chairperson(s):
Stefan Bergman (Sweden)
Sam Hider (United Kingdom)

Christian D. Mallen (United Kingdom) 15:35
Is the concept of inflammatory back pain relevant in primary care?

Ingemar Petersson (Sweden) 15:55
How to identify the right back pain patients for rheumatological care?

Robert B. M. Landewé (Netherlands) 16:15
How can modern imaging modalities facilitate the identification of patients with spondyloarthritis?

A. Moorthy (United Kingdom) 16:35
G. M. Crawford, A. G. Wade, A. Goyal
Abstract N° OP0145
An evaluation of inflammatory back pain in the community - a novel way of using social media (facebook)

M. van Onna (Netherlands) 16:45
S. Gorter, B. Maiburg, G. Waagenaar, A. van Tubergen
Abstract N° OP0146
Patterns of clinical assessment of general practitioners when facing a patient suspected for spondyloarthritis; a study with unannounced standardized patients in daily practice
15:30 - 17:00  Capital Suite 07

Health Professionals session
Physical activity assessment - what do we know, what do we do, how does it work?

Learning objectives:
• To gain knowledge on awareness and use of physical activity assessment among health care professionals
• To gain knowledge on awareness and use of physical activity assessments among patients with RMDs
• To gain knowledge on measurement properties of some physical activity assessments available for use in RMDs

Chairperson(s):
Nina Brodin (Sweden)
Norelee Kennedy (Ireland)
Birgitta Nordgren (Sweden) 15:35

Bente Appel Esbensen (Denmark) 15:53
Awareness and use among patients with inflammatory rheumatic disease of objective and subjective assessments of physical activity

Thijs Swinnen (Belgium) 16:11
When to use objective and subjective assessment of physical activity - issues of reliability, validity and usability

Claire Kinneavy (Ireland) 16:29
Perspectives from patients with arthritis

K. Hörnberg (Sweden) 16:47
B. Sundström, S. Wällberg Jonsson
Aerobic capacity over 16 years in patients with rheumatoid arthritis; relations to risk factors for cardiovascular disease

15:30 - 17:00  Capital Suite 11

Basic and Translational Science session
How cell death shapes immunity and tolerance

Learning objectives:
• To learn about the different ways of cell death and their specific effects on the immune system
• To understand the mechanisms how NETosis and apoptosis can limit inflammation

Chairperson(s):
Joachim R. Kalden (Germany)
Patrizia Rovere-Querini (Italy)
Sanja Arandjelovic (United States) 15:35

Mariana Kaplan (United States) 15:55
NETosis in SLE

Peter Vandenabeele (Belgium) 16:15
New insights into necroptosis

Martin Herrmann (Germany) 16:35
NETosis in the control of inflammation

R. G. Chirivi (Netherlands) 16:50
J. W. van Rosmalen, G. Schmets, H. van Es, J. M. Raats
First in class therapeutic ACPA reduces inflammation by inhibition of NETosis

15:30 - 17:00  Capital Suite 14

Basic and Translational Science session
"Smoke a joint to protect the joint". Cannabinoids & neuropeptides in pain and inflammation

Learning objectives:
• To learn the effects of endocannabinoids in suppression of pain and inflammation
• Their role in inflammatory diseases
• Neuropeptides (PACAP, tachykinins, galanin) in arthritis and pain
• Therapeutic targeting

Chairperson(s):
Fransiska Malfait (Belgium)
Serge Perrot (France)
Mauro Maccarrone (Italy) 15:35

Sue Brain (United Kingdom) 15:55
Biochemistry and pharmacology of the endocannabinoid system

Tamas Biro (Hungary) 16:15
Cannabinoids and inflammation: focus on the joint

Dopamine pathway and bone metabolism in rheumatoid arthritis

T. Okano (Japan) 16:45
J. Saegusa, K. Nishimura, S. Takahashi, S. Sendo, Y. Ueda, A. Onishi, A. Morinobu
3-bromopyruvate ameliorates autoimmune arthritis by exerting a dual effect on both TH17 and Treg cell differentiation and dendritic cell activation
15:30 - 17:00  Capital Suite 02

Clinical Science session
EULAR - EMA session

Learning objectives:
• Inform the participants about the approval processes of drugs regulated by the European Medicines Agency (EMA) and the American Food and Drug Administration (FDA)
• Outline parallel and differing procedures
• Address specific aspects of drug approval in special indications (e.g. axial SpA)
• Special aspects for biosimilars

Chairperson(s):
Richard Vesely (United Kingdom)
Ferdinand C. Breedveld (Netherlands)

Richard Vesely (United Kingdom) 15:35
How are new drugs approved in Europe by EMA?

Sandra Kweder (United States) 15:50
The drug approval process in the United States

Joachim Sieper (Germany) 16:05
Abstract N° SP0108
Different approaches to drug approval by EMA and FDA - the example of non-radiographic axial spondyloarthritis

Ferdinand C. Breedveld (Netherlands) 16:20
The approval process of biosimilars in Europe - what should the rheumatologist know?

Faculty
Discussion and Q&A with the faculty

15:30 - 17:00  Capital Suite 01

The Young Rheumatologist
Teaching clinical skills

Learning objectives:
• To teach how to perform a history and physical examination
• To teach how to read plain joint X-Rays
• Tips in teaching trainees in rheumatology in clinical practice

Chairperson(s):
Michael Doherty (United Kingdom)
Vasco C. Romao (Portugal)

Michael Doherty (United Kingdom) 15:35
Abstract N° SP0109
How to perform clinical history and physical examination?

Roberto Caporali (Italy) 15:55
How to read a plain joint X-Ray?

Janet Hafler (United States) 16:15
Abstract N° SP0110
The art of teaching rheumatology: tips and tricks

Alexandra Kosevoi (Romania) 16:35
Relationship between ultrasound-detected synovitis, quality of life and work productivity in patients with rheumatoid of working age

A. Sukhdeo (Australia) 16:45
F. Joshua, A. Damodaran, B. Shulruf
Abstract N° OP0151
A study on medical students learning ultrasound in rheumatoid arthritis (ASMSLURA)

15:30 - 17:00  Capital Suite 06

Practical skills session*
Local procedures including aspirations, injections and biopsies I

Chairperson(s):
Pedro Machado (Portugal)
Nemanja Damjanov (Serbia)

Nemanja Damjanov (Serbia) 15:35
Abstract N° SP0111
Sonographic-guided joint and periarticular aspirations and injections

Carlo A. Scirè (Italy) 15:50
Abstract N° SP0112
Minimally invasive ultrasound-guided synovial biopsy

Antonio Bouffard (United States) 16:05
Interventional radiology: minimally invasive image-guided procedures to diagnose and treat musculoskeletal diseases

Claudio Ungari (Italy) 16:20
Abstract N° SP0113
Minimally invasive biopsy of salivary glands

Faculty
Q&A and discussion

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11

15:30 - 17:00  Capital Suite 13

Practical skills session*
MRI I

Chairperson(s):
Mikkel Østergaard (Denmark)
Kay-Geert Hermann (Germany)

Mikkel Østergaard (Denmark) 15:35
Abstract N° SP0114
How to define and assess inflammatory and destructive changes in RA and PsA - including quiz cases

Iris Eshed (Israel) 15:55
Abstract N° SP0115
MRI of inflammatory diseases of vessels and muscles - how to apply, including case stories

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11
Torsten Diekhoff (Germany) 16:15
Abstract N° SP0116
How to use MRI to differentiate SpA from its differential diagnoses - including quiz cases

Kay-Geert Hermann (Germany) 16:35
Abstract N° SP0117
When and how to use MRI in clinical practice - including quiz cases

15:30 - 17:00  Room S19
PARE session
What is done for people with rare diseases? Can we do more?

Learning objectives:
To address the value and challenges of international collaboration between researchers and patient organisations in rare diseases:
• Raising funds
• Initiating research
• Developing new successful drugs

Chairperson(s):
Loreto Carmona (Spain)
Joep Welling (Netherlands)

Leona Wagner (United Kingdom) 15:35
Living with alkaptonuria and my activities for the alkaptonuria society

Christos Sotirelis (United Kingdom) 15:55
Rare disease patients’ perspective on improving access to orphan drugs and opportunities for better collaboration

Peter N. Robinson (Germany) 16:15
Phenomizer: The ultimate app to diagnose rare diseases

J. Andersen (Switzerland) 16:35
Abstract N° OP0152-PARE
Starting a disease specific youth group on a national level

A. Marchal (Belgium) 16:45
I. De Keyser on behalf of ReumaNet vzw - ORKA
Abstract N° OP0153-PARE
ReumaMama’s en - Papa’s: info sessions for (future) parents with RMDs and for parents with children with juvenile arthritis

15:30 - 17:00  Room S20
EULAR projects in Health Professionals
The Health Professionals’ approach to pain management in inflammatory arthritis and osteoarthritis

Learning objectives:
• To learn about changes in the physiotherapeutic approach to pain management
• To understand methods of systematic literature reviews and meta-analysis
• To learn about the work on EULAR recommendations on HPRs’ approach to pain management and the scientific evidence underpinning them

Chairperson(s):
Susan Oliver (United Kingdom)
Nola Kamala (United States)

Pernilla Asenløf (Sweden) 15:35
Abstract N° SP0118
The ongoing shift of paradigms within physiotherapy and pain management

Robin Christensen (Denmark) 15:53
Systematic reviews and meta-analyses for dummies: a tutorial on how, when, and why to get started

Rinie Geenen (Netherlands) 16:11
Abstract N° SP0120
Recommendations for prompt pain management in inflammatory arthritis and osteoarthritis

Cécile Overman (Netherlands) 16:29
Abstract N° SP0121
The benefits of prompt pain management in inflammatory arthritis and osteoarthritis. A systematic literature review and meta-analysis

C. Fongen (Norway) 16:47
H. Dafinrud, I. J. Berg, S. Ramiro, F. van Gaalen, R. Landewé, R. Ramonda, M. van Oosterhout, D. van der Heijde, K. M. Fagerli
Abstract N° OP0154-HPR
Spinal mobility is impaired in patients with chronic back pain of short duration, but does not discriminate between patients with axial spondyloarthritis and other forms of CBP
Guided Poster Tours

Thursday, 9 June 2016  11:50 - 13:30

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area, on a “first-come-first-served” basis on the day of the poster tour.

Poster tour T1: Immunity in rheumatic diseases

Chairperson(s): Leonie Taams (United Kingdom), Leendert Trouw (Netherlands)


THU0003  MOUSE B CELL CYTOKINE PRODUCTION REQUIRES OXIDATIVE PHOSPHORYLATION MEDIATED BY GLYCOLYSIS AND FATTY ACID OXIDATION / D. Wu - M. Dunlap - D. Huang - E. Pearce - A. H. Kim*

THU0004  ACTIVATED PLASMACYTOID DENDRITIC CELLS (PDCS) ALTER THE COMPOSITION OF THE BLOOD B CELL SUBSETS / O. Berggren - L. Rönnblom - M.-L. Eloranta*


THU0006  NOVEL CHANGES IN B AND T-CELL PHENOTYPES WITH BELIMUMAB IN AN AUTOANTIBODY MEDIATED DISEASE / C. Barrett* - R. B. Henderson - N. Galwey - S. Flint - A. Gibson - C. Savage


THU0009  ADIPONECTIN-ADIPOR1-STAT3 DEPENDENT PATHWAY IS A CRITICAL REGULATOR OF TH17 CELL DIFFERENTIATION IN COLLAGEN-INDUCED ARTHRITIS / M. Zhang*


Poster tour T2: Cartilage, bone, synovium

Chairperson(s): Anne-Marie Malfait (United States), Stephan Bluëml (Austria)


THU0017  DEFEROXAMINE SUPPRESSES COLLAGEN CLEAVAGE IN CULTURED HUMAN OSTEOARTHRITIC ARTICULAR CARTILAGE VIA A PROCESS INVOLVING DOWNREGULATION OF PROTEASE ACTIVITY, PROINFLAMMATORY CYTOKINES AND TYPE X COLLAGEN EXPRESSION AND UPREGULATION OF AMPK AND CITRIC ACID CYCLE GENES / E. V. Tchetina* - G. A. Markova - A. R. Poole

* Presenting author


### Poster tour T3: Prognosis and outcome in RA

**Chairperson(s):** Ingemar Petersson (Sweden), Paola de Pablo (United Kingdom)

**THU0029**  PREDICTING DAS28-CRP <2.6 AND LOW DISEASE ACTIVITY STATUS AT 6 MONTHS BASED ON EARLY CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS / I. S. Smolen* - X. Wang - I. Sainsbury - A. Kavanaugh

**THU0030**  ULTRASOUND INFLAMMATION IN ARTHRALGIA PATIENTS PREDICTS THE DEVELOPMENT OF ARTHRITIS M. van der Ven* - M. van der Veer-Meerkerk - D. Ten Cate - N. Rasappa - M. Kok - D. Csakvari - M. Hazes - A. Gerards - J. Luime


**THU0033**  EFFECTS OF EARLY REMISSION ON WORK ABILITY AND ABSENTEEISM IN EARLY RHEUMATOID ARTHRITIS T. H. Cheng* - K. Y. Kwok - L. S. TAM on behalf of the CRYSTAL study group


**THU0036**  IDENTIFYING CLINICAL FACTORS ASSOCIATED WITH LOWER DISEASE ACTIVITY DURING PREGNANCY IN PATIENTS WITH RHEUMATOID ARTHRITIS TO SELECT THOSE PATIENTS IN WHOM MEDICATION CAN BE SAFELY TAPERED / H. Ince-Askani - J. M. Hazes - R. J. Dolhain*

### Poster tour T4: Comorbidities update 2016, part 1

**Chairperson(s):** Johannes W.J. Bijlsma (Netherlands), Nicole Konijn (Netherlands)


**THU0074**  IMPACT OF THE DISCORDANCE BETWEEN C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION RATE ON CLINICAL RESPONSE TO COMBINATION ETANERCEPT-METHOTREXATE THERAPY IN RHEUMATOID ARTHRITIS / R. M. Fleischmann* - A. Szumski - H. Jones


**THU0076**  ASSOCIATION BETWEEN BODY MASS INDEX AND QUALITY OF LIFE AT ONE AND THREE YEARS POST DIAGNOSIS OF RHEUMATOID ARTHRITIS: RESULTS FROM AN INCEPTION COHORT / H. Helliwell* - S. Norton - E. Nikiphorou - D. Walsh - P. Kiely - A. Young


* Presenting author
PReS Poster tour T6: Arthritis in childhood

Chairperson(s): Tadej Avcin (Slovenia), Sebastian Vastert (Netherlands)


THU0218 COW’S MILK ALLERGY IN INFANCY AND LATER DEVELOPMENT OF JUVENILE IDIOPATHIC ARTHRITIS: A REGISTER-BASED CASE-CONTROL STUDY / P. Văhăsalo* - M. Arvonen - T. Pokka - L. Kröger - L. Virta

* Presenting author

GUIDED POSTER TOURS / THURSDAY 9 JUNE 2016 / 49
THU0219  PROSPECTIVE ANALYSIS OF THE IMMUNOGENIC RESPONSE IN JIA PATIENTS (PAEDIATRIC AND ADULT) ON ANTI-TNF TREATMENT / E. Quesada-Masachs* - D. Alvarez-de la Sierra - M. Garcia Prat - R. Pujol-Borrell - M. Martínez Gallo - C. Modesto Caballero - A. M. Martín Sánchez

THU0220  RETROSPECTIVE STUDY EVALUATING TREATMENT DECISION AND OUTCOME OF NON-JUVENILE IDIOPATHIC ARTHRITIS (JIA)-ASSOCIATED CHILDHOOD UVEITIS / E. Sardar* - P. Dusser - M. Labetoulle - E. Barreau - B. Bodaghi - I. Kone-Paut


THU0222  THE DIAGNOSIS OF FAMILIAL MEDITERRANEAN FEVER FOLLOWING THE INITIAL PRESENTATION OF MONOAARTHRITIS / O. Tanoues* - Y. Horovitz - S. Shalev - M. Khayat - R. Spiegel

Poster tour T7: Walk through new pathways, biomarkers and potential treatments in SLE and Sjögren's

**Chairperson(s):** Reinhard E. Voll (Germany), Nils Venhoff (Germany)

**THU0240**  DYSREGULATIONS IN THE SPHINGOLIPID PATHWAY IN SLE PATIENTS / A. Checa - H. Idborg* - D. G. Sar - P.-J. Jakobsson - C. E. Wheelock - I. Gunnarsson


**THU0244**  NONINVASIVE ASSESSMENT OF MACROPHAGE ACTIVATION IN EXPERIMENTAL GLOMERULONEPHRITIS USING OPTICAL IMAGING WITH NEAR-INFRARED LIGHT SERVICES AS A SURROGATE OF DISEASE ONSET / S. Braeherl - M. D. Cheung - D. Huang - W. J. Akers - A. H. Kim*

**THU0245**  INDIVIDUAL VERSUS COMBINED BLYS OR/AND APRIL NEUTRALIZATION REVEALS DEVELOPMENTAL PLASTICITY FOR PLASMA CELL SURVIVAL FACTOR REQUIREMENTS / P. Haselmayer* - M. Vigo - J. Nys - M. Schneider - H. Hess


**THU0250**  DYSREGULATION OF AUTOPHAGY IN SYSTEMIC LUPUS ERYTHEMATOSUS IS CORRELATED TO TRANSCRIPTIONAL INTERFERON SIGNATURES AND PROVIDES CANDIDATE BIOMARKERS / L. Chiche* - G. Penaranda - P. Savori - N. Jourde-Chiche - P. Halfon - C. Camus


Poster tour T8: SpA and PsA basic and translational research

**Chairperson(s):** Maxime Breban (France), Peggy Jacques (Belgium)

**THU0363**  POSITION 97 (P97) OF HLA-B, A RESIDUE IMPLICATED IN ANKYLOSING SPONDYLITIS PATHOGENESIS, PLAYS A KEY ROLE IN CELL SURFACE FREE HEAVY CHAIN EXPRESSION VIA INTERACTIONS WITH B2-MICROGLOBULIN / L. Chen - H. Shi - J. Yuan - P. Bowens*

**THU0364**  RARE ERAPI ALLOTYPE COMBINATIONS DO NOT EXPLAIN THE ERAPI ASSOCIATION WITH ANKYLOSING SPONDYLITIS / L. H. Appleton* - A. R. Roberts - M. Vecellio - B. P. Wordsworth

**THU0365**  LIGHT RS1077667 G>A GENE POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO ANKYLOSING SPONDYLITIS / L. H. Appletone* - A. R. Roberts - M. Vecellio - B. P. Wordsworth


**THU0367**  IDENTIFICATION OF DIFFERENTIALLY METHYLATED GENES IN PURIFIED DISEASE-RELEVANT BLOOD CELL POPULATIONS IN PATIENTS WITH SPONDYLOARTHRITIS / J. Tost* - A. Bugge Tinggaard - S.-F. Wang-Renault - F. Busato - M. Dougdas - C. Miceli-Richard


* Presenting author

**THU0370** DISEASE ACTIVITY, NOT DRUG EXPOSURE, AFFECTS PREGNANCY OUTCOMES IN INFLAMMATORY ARTHRITIS / E. Fishman* - J. Cusk - K. Dao


**Poster tour T9: Axial SpA - clinical aspects**

**Chairperson(s):** Robert B. M. Landewé (Netherlands), Victoria Navarro-Compán (Spain)


**THU0375** ASDAS-BASED REMISSION WAS LESS FREQUENT THAN BASDAI-BASED REMISSION, AND BOTH WERE RELATED TO CRP AND SMOKING IN EARLY AXIAL SPONDYLOARTHRITIS: THE DESIR COHORT / D. Wendling* - X. Guillot - L. Gosses - C. Prati - A. Saura - M. Dougados


**THU0379** CLINICAL DISEASE ACTIVITY MEASURES ARE ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN EARLY AXIAL SPONDYLOARTHRITIS / D. Poddubnyy* - M. Protopopov - H. Habel - J. Braun - M. Rudwaleit - J. Sieper

**THU0380** A SINGLE DETERMINATION OF C-REACTIVE PROTEIN DOES NOT SUFFICE TO DECLARE A PATIENT WITH A DIAGNOSIS OF AXIAL SPA CRP-NEGATIVE / R. Landewé* - T. Nurminen - O. Davies - M. Turina - D. Baeten


**THU0382** DEVELOPMENT OF SPA-FEATURES IN PATIENTS WITH CHRONIC BACK PAIN OVER A ONE-YEAR COURSE: DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY (SPACE)-COHORT / Z. Ez-Zaitouni* - M. van Lunteren - O. Davies - M. Turina - D. Baeten


**Poster tour T10: Psoriatic arthritis**

**Chairperson(s):** Rik Lories (Belgium), Elsa Sousa (Portugal)

**THU0418** OBESITY IMPAIRS THE RESPONSE TO TUMOUR NECROSIS FACTOR-ALPHA INHIBITORS IN PSORIATIC ARTHRITIS: RESULTS FROM THE DANBIO AND ICEBIO REGISTRIES / P. Hojgaard* - B. Glintborg - L. E. Kristensen - T. J. Love - B. Gudbjornsson - L. Dreyer


**THU0420** APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN BASDAI IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS / P. Mease* - H. Marzo-Ortega - A. Poder - F. van den Bosch - J. Wollenhaupt - E. Leespessailles - M. McIlraith - L. Teng - S. Hall

**THU0421** SERUM-BASED SOULABLE MARKERS MAY DIFFERENTIATE PSORIATIC ARTHRITIS FROM OSTEOARTHRITIS / V. Chandran* - A. V. Perruccio - S. Li - F. Abji - R. Gandhi - D. D. Gladman


**THU0423** TIME TO REBOUND IN JOINT SYMPTOMS FOLLOWING DISCONTINUATION OF TNFI THERAPY AFTER ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN PSORIATIC ARTHRITIS PATIENTS ENROLLED IN THE US CORRONA REGISTRY / L. R. Harrold* - B. Stolshek - S. Rebello - D. Collier - A. Mutebi - S. W. Wade - W. Malley - J. D. Greenberg - C. J. Etzel

**THU0424** TREATMENT WITH TNF ALPHA BLOCKERS IS ASSOCIATED WITH REDUCED PROGRESSION OF Atherosclerotic PLAQUES IN PATIENTS WITH PSORIATIC DISEASE - A PROSPECTIVE STUDY / L. Eder* - V. Chandran - R. Cook - D. D. Gladman

* Presenting author
THU0456

THU0457
COMPREHENSIVE DISEASE CONTROL WITH LESS RELAPSE AND RADIOGRAPHIC PROGRESSION AT ONE YEAR BY INTENSIVE THERAPY WITH ADDITIONAL SHORT-COURSE OF TOCILIZUMAB: A REAL-WORLD, PROSPECTIVE COHORT STUDY IN CHINESE PATIENTS WITH RHEUMATOID ARTHRITIS / X-Y. Wang - Y-Q. Mo - J-D. Ma - L-F. Chen - J. Jing - D-H. Zheng - L. Dai*

THU0458
INFLUENCE OF ORAL PREDNISOLONO ONE EFFECT OF DENOSUMAB ON OSTEOPOROSIS IN PATIENTS WITH JAPANESE RHEUMATOID ARTHRITIS; 12 MONTHS OF FOLLOW-UP - A MULTICENTER REGISTRY STUDY / Y. Kanayama* - Y. Hirano - N. Takahashi - S. Asai - N. Ishiguro - T. Kojima on behalf of TBCR-BONE study group

THU0459

THU0460
WHAT IS THE BEST LUMBAR SPINE VERTEBRAE COMBINATION TO PREDICT MAJOR OSTEOPOROTIC FRACTURE? THE OSTEOLASUS COHORT STUDY / H. Mrahi* - O. Lamy - M. Metzger - S. Soares - B. Aubry-Rozer - D. Stoll - D. Hans on behalf of Osteolasa cohort

THU0461

THU0462
THE PREDICTORS OF FRACTURE IN PATIENTS WITH COELIAC DISEASE: AN OBSERVATIONAL STUDY / R. Sinha - M. Bukhari*

THU0463
VIEWPOINTS OF DENTAL SURGEONS ON THE USE OF BISPHOSPHONATES IN RHEUMATOLOGY PATIENTS / C.aron - C. Deschaumes - M. Soubrier - S. Mathieu*

THU0464

THU0465

Poster tour T12: Crystal and metabolic bone diseases; bone diseases other than osteoporosis

Chairperson(s): Eliseo Pascual (Spain), Hang-Korng Ea (France)

THU0490

THU0491
A NOVEL METHOD OF ESTIMATING EXTRA-RENAL CLEARANCE OF URIC ACID / D. Hyndman* - S. Liu - J. Hall - J. N. Miner

THU0492
URIC ACID TRANSPORT KINETICS IN THE KIDNEY: DETECTION OF RENAL SECRETION AND THE MECHANISM OF LOW FEUA / S. Liu* - D. Hyndman - J. N. Miner

THU0493

THU0494
SKIN EVENTS WITH FEBUXOSTAT IN GOUT PATIENTS WITH PREVIOUS SKIN REACTIONS TO ALLOPURINOL. A RETROSPECTIVE REVIEW / N. Quilis* - M. Andres - P. Vela - E. Pascual

THU0495
EXAMINATION OF URIC ACID (SUA) LOWERING AND SAFETY WITH EXTENDED TREATMENT WITH LESINURAD AND ALLOPURINOL IN SUBJECTS WITH GOUT / K. G. Saag* - M. A. Becker - C. Storgard - M. Fung - N. Bhakta - S. Adler - J. Hu - T. Bardin

THU0496
ASSOCIATIONS OF PLASMA URIC ACID AND PURINE METABOLITES WITH BLOOD PRESSURE IN CHILDREN: THE KOALA BIRTH COHORT STUDY / L. E. Scheepers* - A. Boonen - W. D. Pijnenburg - J. Bierau - J. A. Staessen - Y. Mountain

THU0497

THU0498

THU0499

* Presenting author
**Poster tour T13: Clinical aspects of fibromyalgia**

**Chairperson(s):** Stefan Bergman (Sweden), Serge Perrot (France)

**THU0541**

PAIN FROM STRUCTURAL PATHOLOGY IS A RISK FACTOR FOR LATER GENERALIZED PAIN: A POPULATION BASED COHORT STUDY / E. Bondesson* - F. Larossa Pardo - M. E. Sandberg - A. Joud

**THU0542**


**THU0543**

EVALUATION OF THE FIBROMYALGIA RAPID SCREENING TOOL (FIRST) QUESTIONNAIRE TO SCREEN FIBROMYALGIA ASSOCIATED WITH INFLAMMATORY RHEUMATIC DISEASE / A. Fan - B. Pereira - A. Tournadre - Z. Tatar - S. Malochet-Guinanand - M. Soubrier - J.-J. Dubost*

**THU0544**

IMPAIRED PULMONARY DIFFUSING CAPACITY IN PATIENTS WITH FIBROMYALGIA / M. Rizzi - E. Atzeni* - A. Andrea Airoldi - I. F. Masala - F. Francesca Frassanito - C. Macaluso - E. Salaffi - P. Sarzi-Puttini

**THU0545**


**THU0546**


**THU0547**

IS PAIN CATASTROPHIZING ASSOCIATED WITH IMPAIRED CONDITIONED PAIN MODULATION IN PEOPLE WITH CHRONIC WIDESPREAD PAIN? / D. Rice - R. Parker* - G. Lewis - P. McNair

**THU0548**

SLEEP ARCHITECTURE AND CLINICAL PARAMETERS IN FIBROMYALGIA AND OSTEOARTHRITIS / W. K. Yeung* - K. Morgan - F. McKenna

**THU0549**


**THU0550**

EARLY MULTIDISCIPLINARY INTERVENTIONS TO PROMOTE WORK PARTICIPATION IN PEOPLE WITH REGIONAL MUSCULOSKELETAL PAIN: A SYSTEMATIC REVIEW / A. Cochrane* - N. M. Higgins - O. FitzGerald - P. Gallagher - J. Ashton - R. Breen - A. Brennan - O. Corcoran - D. Desmond

---

**Poster tour T14: Outcome measures of RMDs**

**Chairperson(s):** Annelies Boonen (Netherlands), Delphine Courvoisier (Switzerland)

**THU0593**


**THU0594**


**THU0595**

IMPACT OF PHYSICIAN-PATIENT INTERACTIONS ON DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. Drenkard* - G. Bao - H. Kan - B. Pobiner - P. Julie - W. Eastman - S. S. Lim

**THU0596**

PHYSICIAN'S GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS, REFLECTS SOLELY OBJECTIVE MEASURES AND DISREGARDS PATIENT REPORTED OUTCOMES / G. Eugenio* - R. Ferreira - C. Duarte - J. A. P. Silva

**THU0597**

COMPARAISON DE SELF ASSESSMENT OF DISEASE ACTIVITY TO DAS28 IN RHEUMATOID ARTHRITIS: DATA FROM THE RANDOMIZED “ROC” TRIAL / C. Sordet* - E. Chatelus - P. Ravaud - J.-E. Gottenberg on behalf of the ROC trial investigators

**THU0598**


**THU0599**

KEY DRIVERS IN BIOSIMILAR PRESCRIPTION IN INFLAMMATORY AUTOIMMUNE DISEASES INDICATIONS IN GERMANY / E. Sullivan - J. Piercy - J. Waller - C. Black - S. Kachroo* - E. A. Haavardsholm on behalf of the ARCTIC study group

**THU0600**


**THU0601**


**THU0602**


* Presenting author
### PARE Poster tour T15: PARE Poster tour I

Chairperson(s): Diana Skingle (United Kingdom), Maarten de Wit (Netherlands)

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Presenting Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARE0001</td>
<td>THE &quot;SWEDISH YOUNG RHEUMATICS&quot; PARTNERED UP WITH ANOTHER YOUNG IMID ASSOCIATION AND ABBVIE TO PRODUCE AN INFORMATIVE AND HOPE GIVING BOOK ON &quot;STARTING A FAMILY&quot;. THE COLLABORATION RESULTED A HIGHLY INFORMATIVE BOOK THAT PROVIDES A WEALTH OF INFORMATION ON FAMILY PLANNING / M. Beermann*</td>
<td></td>
</tr>
<tr>
<td>PARE0002</td>
<td>A PHOTO-PROJECT ABOUT YOUNG PEOPLE SUFFERING FROM JUVENILE ARTHRITIS / B. Ziegler*</td>
<td></td>
</tr>
<tr>
<td>PARE0003</td>
<td>WHAT DO I WANT TO TALK ABOUT? / T. Bellerby* - D. Stevens - L. Williamson</td>
<td></td>
</tr>
<tr>
<td>PARE0004</td>
<td>TOOLS FOR A CUSTOMIZED HEALTHCARE PLAN FOR DUTCH PEOPLE WITH RHEUMATIC DISEASES / R. van den Brink* - E. Schouws</td>
<td></td>
</tr>
<tr>
<td>PARE0005</td>
<td>BRIEF OVERVIEW OF ENCA (EUROPEAN NETWORK FOR CHILDREN WITH ARTHRITIS) / Y. Egert* - W. Costello - M. Kepic</td>
<td></td>
</tr>
<tr>
<td>PARE0006</td>
<td>IDENTIFICATION AND PRIORITIZATION OF RESOURCES FOR RHEUMATIC PATIENTS (REUMAPPA) / M. Gobbo* - L. Carmona</td>
<td></td>
</tr>
<tr>
<td>PARE0007</td>
<td>A SUCCESSFUL CAPS RECYCLING PROJECT &quot;NOT SATIATE CAPS&quot; / A. Phoka Charalambous*</td>
<td></td>
</tr>
<tr>
<td>PARE0008</td>
<td>SETTING UP A YOUTH GROUP: A CHALLENGE WORTH TACKLING ANMAR'S STEP ZERO PROJECT / U. G. Viora - S. Ostuzzi* - S. Rosi - S. Severoni</td>
<td></td>
</tr>
</tbody>
</table>

* Presenting author
Scientific Poster Session 1

Thursday, 9 June 2016  
11:45 - 13:30

Adaptive immunity (T cells and B cells) in rheumatic diseases


THU0003  MOUSE B CELL CYTOKINE PRODUCTION REQUIRES OXIDATIVE PHOSPHORYLATION MEDIATED BY GLYCOLYSIS AND FATTY ACID OXIDATION / D. Wu - M. Dunlap - D. Huang - E. Pearce - A. H. Kim*

THU0004  ACTIVATED PLASMACYTOID DENDRITIC CELLS (PDCS) ALTER THE COMPOSITION OF THE BLOOD B CELL SUBSETS / O. Berggren - L. Rönnblom - M.-L. Eloranta*

THU0005  DRUG RE-PURPOSING WITH A COMMERCIAL CHEMICAL LIBRARY IDENTIFIES NOVEL B CELL INHIBITORY COMPOUNDS / K. Matsumoto* - K. Bieber - S. Ghorbanalipoor - S. Ibrahim - D. Zillikens - R. Ludwig

THU0006  MOUSE B CELL CYTOKINE PRODUCTION REQUIRES OXIDATIVE PHOSPHORYLATION MEDIATED BY GLYCOLYSIS AND FATTY ACID OXIDATION / D. Wu - M. Dunlap - D. Huang - E. Pearce - A. H. Kim*


THU0009  ADIPONECTIN-ADIPOR1-STAT3 DEPENDENT PATHWAY IS A CRITICAL REGULATOR OF TH17 CELL DIFFERENTIATION IN COLLAGEN-INDUCED ARTHRITIS / M. Zhang*


THU0011  CD32+ B LYMPHOCYTES AND IL21R+ T LYMPHOCYTES ARE ASSOCIATED WITH DISEASE ACTIVITY AND INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS / A. Sućur* - Z. Jajić - M. Artuković - D. Flegar - D. Grciev


THU0014  THE IMPACT OF BIOLOGIC THERAPIES ON CD4+ AND CD8+ CELL SUBSETS IN RHEUMATOID ARTHRITIS: A LONG-TERM FOLLOW-UP STUDY / S. Dulic* - G. Toldi - Z. Vásárhelyi - A. Balog

* Presenting author
Cartilage, synovium and osteoimmunology


THU0017  DEFEROXAMINE SUPPRESS COLLAGEN CLEAVAGE IN CULTURED HUMAN OSTEOARTHRITIS ARTICULAR CARILLAGE VIA A PROCESS INVOLVING DOWNREGULATION OF PROTEASE ACTIVITY, PROINFLAMMATORY CYTOKINES AND TYPE X COLLAGEN EXPRESSION AND UPREGULATION OF AMPK AND CITRIC ACID CYCLE GENES / E. V. Tchetina* - G. A. Markova - A. R. Poole  


THU0024  ANTI-INFLAMMATORY INHIBITORS TARGETING JAK AND IKK HAVE AN ANABOLIC EFFECT ON TYPE II COLLAGEN TURNOVER EX VIVO / C. F. Kjeldgaard-Petersen* - A.-C. Bay-Jensen - M. A. Karsdal - P. Hägglund - C. S. Thudum  

THU0025  OVER-EXRESSED PGC-1B IN CD14+ MONOCYTES OF RHEUMATOID ARTHRITIS PATIENTS AND ITS DOWN-REGULATION CAN SUPPRESS OSTEOCLASTOGENESIS AND BONE RESORPTION THROUGH INHIBITION OF CATHEPSIN K AND TRAP / J. Inging - J.-D. Ma - Y.-Q. Mo - D.-H. Zheng - D. Lie*  


Rheumatoid arthritis - prognosis, predictors and outcome

THU0029  PREDICTING DAS28-CRP <2.6 AND LOW DISEASE ACTIVITY STATUS AT 6 MONTHS BASED ON EARLY CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS / I. S. Smolen - X. Wang - I. Sainsbury - A. Kavanagh  

THU0030  ULTRASOUND INFLAMMATION IN ARTHRALGIA PATIENTS PREDICTS THE DEVELOPMENT OF ARTHRITIS / M. van der Ven* - M. van der Veer-Meerkerk - D. Ten Cate - N. Rasappu - M. Kok - D. Cakvari - M. Hazes - A. Gerards - J. Luime  


THU0033  EFFECTS OF EARLY REMISSION ON WORK ABILITY AND ABSENTEEISM IN EARLY RHEUMATOID ARTHRITIS / T. H. Cheng* - K. Y. Kwock - L.-S. TAM on behalf of the CRYSTAL study group  

THU0034  USE OF RITUXIMAB COMPARED TO ANTI-TNF AGENTS AS SECOND AND THIRD-LINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: A 6-YEAR FOLLOW-UP REPORT FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY / J.-P. Pelletier - J.-D. Mathieu - D. Sauvageau - É. Villeneuve - D. Choquette  


THU0036  IDENTIFYING CLINICAL FACTORS ASSOCIATED WITH LOWER DISEASE ACTIVITY DURING PREGNANCY IN PATIENTS WITH RHEUMATOID ARTHRITIS TO SELECT THOSE PATIENTS IN WHOM MEDICATION CAN BE SAFELY TAPERED / A. Krishnamurthy - M. H. Hazes - R. J. Dolhain*  

THU0037  PERSONALITY TRAITS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN UNRECOGNIZED PREDICTOR OF MORTALITY / A. D. Crowson* - R. C. Colligan - E. L. Matteson - J. M. Davis III - C. S. Crowson  

THU0039
MORE THAN ONE IN THEIR THREE PATIENTS ARE MISCLASSIFIED AS BEING IN REMISSION BY THEIR CLINICIANS: RESULTS FROM A LARGE COHORT STUDY / A. Gill* - S. Nihiyano - S. Hussain - P. Sivakumar - J. Manson - C. Ciurtin

THU0040

THU0041
LARGE COUNTRY DIFFERENCES IN WORK OUTCOMES IN PATIENTS WITH RA - AN ANALYSIS IN THE MULTINATIONAL STUDY COMORA / A. van der Zee - Neuen* - P. Putrik - S. Ramiro - A. Keszei - I. Hmamouchi - M. Dougados - A. Boonen

THU0042
EVALUATION OF SYNOVITIS AT THE LARGE JOINT USING ULTRASONOGRAPHY AND HISTOLOGICAL FINDINGS FOR RA PATIENTS / A. Abe* - H. Ishikawa - K. Wakaki - A. Murasawa

THU0043
MINIMAL IMPORTANT DIFFERENCE IN QA: A VALIDATION FROM HEALTH ECONOMIC PERSPECTIVES IN PATIENT WITH RHEUMATOID ARTHRITIS USING REAL-WORLD DATA FROM ADELPHI DATABASE / C. Han* - N. Li - S. Peterson

THU0044
EFFICACY OF TREAT-TO-TARGET BIOLOGIC THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARED TO DELAYED INITIATION OF BIOLOGICS: A REAL WORLD STUDY / C. E. Lampropoulos* - P. Orfanos - M. Manoussakis - A. Tzioufas - H. M. Moutsopoulos - P. Glavocijannopoulos

THU0045
14-3-3 ETA POSITIVITY IS ASSOCIATED WITH RADIOGRAPHIC PROGRESSION DESPITE PATIENTS ACHIEVING CLINICAL REMISSION / D. van Schaardenburg* - S. Turk - W. P. Maksymowycz - A. Marotta

THU0046

THU0047
ARTHROSCOPIC MACRO-ASSESSMENT OF SYNOVIA IN RHEUMATOID ARTHRITIS PATIENTS HIGH ANTI-CCP / E. B. Komarova* - B. A. Rebrov - A. Blagodarenko - I. Pokryshka

THU0048

THU0049

THU0050

THU0051
THE LEVELS OF SERUM PENTRAOXIN 3, IL 6, FETUIN A AND INSULIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND TREATMENT / J. Huang* - S. Cui - J. Jiang - Y. Xie - L. Zhang - Y.-B. Park - S.-K. Lee - S.-W. Lee

THU0052
ASSOCIATION BETWEEN ANTIPHOSPHOLIPID ANTIBODIES AND ARTERIAL THROMBOTIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS / K.-J. Kim - J.-W. Baek* - Y.-J. Park - K.-S. Park - C.-S. Cho

THU0053

THU0054
GLYCATED ALBUMIN INCREASES WITH DISEASE ACTIVITY IN RHEUMATOID FACTOR POSITIVE RHEUMATOID ARTHRITIS PATIENTS WITH NORMAL FASTING GLUCOSE AND HBA1C / J.-S. Park* - C.-H. Lee - J. J. Song - Y.-B. Park - S.-K. Lee - S.-W. Lee

THU0055
BONE RESORPTION WAS CORRELATED WITH RADIOLOGIC PROGRESSION IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS / J. Huang* - S. Cui - J. Jiang - Y. Xie - L. Zhang

THU0056

THU0057

THU0058
PREDICTION OF SUCCESSFUL DOSE REDUCTION OR DISCONTINUATION OF BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW / L. Tweehuysen* - C. van den Ende - F. Beeren - E. Been - P. van den Hoogen - A. den Broeder

THU0059

THU0060

THU0061
PATIENTS' PERCEPTIONS OF RISK, RISK COMMUNICATION AND PREDICTIVE TESTING FOR RHEUMATOID ARTHRITIS / L. Tweehuysen* - C. van den Ende - F. Beeren - E. Been - P. van den Hoogen - A. den Broeder

THU0062

THU0063

* Presenting author
Rheumatoid arthritis - comorbidity and clinical aspects


THU0074 IMPACT OF THE DISCORDANCE BETWEEN C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION RATE ON CLINICAL RESPONSE TO COMBINATION ETANERCEPT-METHOTREXATE THERAPY IN RHEUMATOID ARTHRITIS / R. M. Fleischmann* - A. Szumski - H. Jones

THU0075 EFFICIENT SCREENING SYSTEM FOR EARLY ARTHRITIS - A PROJECT OF THE T2T INITIATIVE IN GERMANY / C. Jacobsen - T. Leipold - S. M. Proudman

THU0076 ASSOCIATION BETWEEN BODY MASS INDEX AND QUALITY OF LIFE AT ONE AND THREE YEARS POST DIAGNOSIS OF RHEUMATOID ARTHRITIS: RESULTS FROM AN INCEPTION COHORT / C. Jacobsen - T. Leipold - S. M. Proudman


THU0079 HDL, IGG ANTI-HDL ANTIBODIES AND PON1 AXIS IN RHEUMATOID ARTHRITIS: A NOVEL DOSE REDUCTION THERAPY USING BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS COMPARED TO MIXED OUTPATIENT CLINIC / T. H. Hansen* - K. M. Carlsen - P. Johansen

THU0080 RISK FACTORS FOR INCIDENT DIABETES MELLITUS IN PATIENTS WITH RHEUMATOID ARTHRITIS: HYDROXYCHLOROQUINE AND ABATACEPT PROTECT WHILE GLUCOCORTICOIDS AND STATINS BUT NOT STABLE RADIOGRAPHIC OUTCOME IN EARLY RHEUMATOID ARTHRITIS / M. Á. González-Gay - A. Suárez

THU0081 MEDICATION IMPACT ON THE RISK OF INCIDENT DIABETES MELLITUS IN PATIENTS WITH RHEUMATOID ARTHRITIS: HYDROXYCHLOROQUINE AND ABATACEPT PROTECT WHILE GLUCOCORTICOIDS AND STATINS WORSEN / G. Ozen - S. Pedro - M. Holmqvist - K. Michaud*
THU0085 LEVEL OF CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS WITH SUBCLINICAL HYPOTHYROID DYSFUNCTION / A. Knazyazev* - R. Rebrow - E. Komarova - A. Blagodarenko

THU0086 AN AUDIT ON RHEUMATOID ARTHRITIS PATIENTS WITH LUNG DISEASE ON METHOTREXATE AT A DISTRICT GENERAL HOSPITAL / A. Nugaliyadda* - G. Kasavkar - M. A. Yusuf - A. Nandagudi


THU0089 RHEUMATOID ARTHRITIS AND PERIODONTAL DISEASE IN ALGERIAN PEOPLE / C. Dahou* - F. Mechid - S. Salah - M. Meddad - S. Merad


THU0091 TREATMENT PATTERN AND DISEASE ACTIVITY SCORES IN RHEUMATOID ARTHRITIS PATIENTS; DATA TAKEN FROM QATAR RHEUMATOID ARTHRITIS REGISTRY / F. Alam* - M. Hammadouch - P. Chandra - S. Al Emadi

THU0092 EFFECT OF DISEASE MODIFYING ANTI RHEUMATIC DRUG METHOTREXATE ON THE LIPID PROFILE OF PATIENTS WITH RHEUMATOID ARTHRITIS / G. S. Sidhu*

THU0093 EFFICIENCY OF NON-BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS (RA) PATIENTS WITH COMORBIDITY / G. Mykytenko* - O. Iaremenko


THU0095 CLINICAL CHARACTERISTICS OF ELDERLY ONSET RHEUMATOID ARTHRITIS (EORA) COMPARED TO YOUNG ONSET RHEUMATOID ARTHRITIS (YORA) IN YOUNG AND OLD / I. Yoshii* - T. Chijiwa


THU0097 DESCRIPTIVE ANALYSIS OF LARGE SINGLE CENTER EXPERIENCE OF PATIENTS WITH INTERSTITIAL LUNG DISEASE AND RHEUMATOID ARTHRITIS / J. A. Zamora-Legodo* - C. S. Crosstown - M. L. Krause - E. L. Matteson


THU0101 THE PREDICTORS OF FRAGILITY FRACTURE IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY / R. Sinha - M. Bukhari*

THU0102 PLATELET ASSOCIATED IGG IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. Nishikawa* - S. Kaneshiro - H. Owaki - T. Fuji

THU0103 IS INTERLEUKIN 17 IMPLICATED IN OSTEOPOIESIS PATHOGENESIS IN RHEUMATOID ARTHRITIS? RELATION BETWEEN IL-17 LEVEL AND FRAX INDEX IN PREMENOPAUSAL RHEUMATOID ARTHRITIS PATIENTS / N. A. Aboeladl* - H. K. Koryem - M. A. Rezk - M. M. Hassan - S. S. Eltawab


THU0105 FRAX 10-YEAR FRACTURE RISK IN RHEUMATOID ARTHRITIS - ASSESSMENTS WITH AND WITHOUT BONE MINERAL DENSITY MAY LEAD TO VERY DIFFERENT RESULTS IN THE INDIVIDUAL PATIENT / K. D. Elde - O. Rintek Madsen* - M. Nurmohamed - W. Lems


THU0107 PREVALENCE OF POSITIVE QUANTIFERON-GOLD TEST IN ADULT PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND ITS SIGNIFICANCE IN DEVELOPING COUNTRIES / R. Cama* - C. Manakta


THU0109 VACCINATION RATES IN ADULTS WITH AUTOIMMUNE INFLAMMATORY DISEASES AND THE PATIENTS' PERSPECTIVE ON THEIR INFECTION RISK / R. Magro* - M. Rogers - F. Camilleri


THU0111 BIOLOGICS DISCONTINUATION AND BMI PREDICT RA FLARE RISK AFTER HIP AND KNEE ARTHROPLASTY / A. Piggie - V. P. Bykerk * Presenting author
Rheumatoid arthritis - anti-TNF therapy


THU0121  LOW DISEASE ACTIVITY AND ACR70-RESPONSE IS ASSOCIATED WITH THE INHIBITION OF PERIARTICULAR BONE LOSS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL PLUS METHOTREXATE / A. Pfeil* - A. Nussbaum - C. Jung - L. Reinhardt - P. Oelzner - A. Malich - J. Böttcher - G. Wolf

THU0122  ETANERCEPT TREATMENT DOES NOT ADVERSELY AFFECT TRADITIONAL CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS / A. Desodhar* - B. Bitman - Y. Yang - D. Collier


THU0127  INTRAVENOUS GOLIMUMAB THERAPY IMPROVES HEMOGLOBIN, RESULTING IN REDUCED ANEMIA, IMPROVED PHYSICAL FUNCTION AND FATIGUE IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS: RESULTS FROM GO-FURTHER PHASE III CLINICAL TRIAL / C. Ancuta* - C. Pomirleanu - C. Belibou - R. Maxim - L. Petaru - G. Strugaru - R. Chiriac

THU0128  MAINTENANCE OF IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND PHYSICAL FUNCTION AT 2 YEARS IN EARLY RA PATIENTS WITH SEVERE PROGRESSIVE DISEASE WHO ACHIEVED SUSTAINED LOW DISEASE ACTIVITY FOLLOWING 1 YEAR OF INITIAL THERAPY, WITH TWO DOSING FREQUENCIES OF CERTOLIZUMAB PEGOL / C. Bingham* - M. Weinblatt - G.-R. Burmester - P. V. Bykerk

THU0129  CLINICAL OUTCOMES OF IMMUNOCENICITY IN RHEUMATOID ARTHRITIS PATIENTS UNDER ANTI-TNF BIOLOGICS: RESULTS FROM AN OBSERVATIONAL STUDY / C. Ancuta* - C. Pomirleanu - C. Belibou - R. Maxim - L. Petaru - G. Strugaru - R. Chiriac


THU0133  STATISTICAL ASSESSMENT ACROSS MULTIPLE EARLY TIME POINTS VALIDATES BIOSIMILARITY OF BOW015 TO REFERENCE INFliximab IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON STABLE METHOTREXATE DOSES / G. Castañeda-Hernández* - M. Wyand - C. Lassen - L. Shneyer - J. Kay

* Presenting author
THU0134 GOOD RESPONSE ON ADALIMUMAB TREATMENT FOR PATIENTS WITH RHEUMATOID ARTHRITIS PERSISTS FOR UP TO 9 YEARS / J. M. Visman* - G.-J. Wolbink - M. Nurmonohaed on behalf of Amsterdam Rheumatology and Immunology Center (ARC)

THU0135 THE IMPACT OF EARLY TREATMENT WITH ADALIMUMAB ON RHEUMATOID FACTOR AND ANTI-CITRULLINATED PEPTIDE ANTIBODY LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE OPTIMA TRIAL / J. S. Smolen* - A. Kavanaugh - D. Aletaha - S. Florentinus - Y. Li - I. Lagunes

THU0136 USE OF A GLOBAL RISK SCORE TO IDENTIFY PATIENTS WITH RHEUMATOID ARTHRITIS AT RISK OF SERIOUS INFECTIOUS EVENTS DURING CERTOLIZUMAB PEGOL TREATMENT / J. R. Curtis* - K. Winthrop - M. de Longueville - C. O'Brien - M. N. Ndlovu - B. Harauki


THU0138 SECONDARY EFFICACY RESULTS UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY / J. Kay* - M. Weinblatt - E. Keystone - M. C. Genovese - A. Baranauskaitė - S. Y. Cheong - J. Ghil

THU0139 COMPARISON OF THE EFFICACY AND TOLERANCE OF THE "TRIPLE ORAL THERAPY" VERSUS "ANTI-TNF PLUS METHOTREXATE" IN RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: A SYSTEMATIC LITERATURE REVIEW / J. Mary* - M. Debandt - C. Lukas - J. Morel - B. Combe

THU0140 EFFICACY AND SAFETY ANALYSIS BY OVERALL ANTI-DRUG ANTIBODY RESULTS UP TO WEEK 30 IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SB2 (AN INFLIXIMAB BIOSIMILAR) OR INFLIXIMAB REFERENCE PRODUCT IN PHASE III STUDY / J.-Y. Choe* - J. S. Smolen - E. Keystone - M. C. Genovese - J. Choi - Y. H. Rho

THU0141 A NON-INTERVENTIONAL CLINICAL STUDY EVALUATING THE USE OF GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA), AND ANKYLOSING SPONDYLITIS (AS) IN A REAL-LIFE SETTING IN GERMANY / K. Krüger* - G. R. Burmester - S. Wassenberg - M. Bohl-Bühler - M. H. Thomas

THU0142 HIGH SIMILARITY BETWEEN EX-VIVO INHIBITED CYTOKINE PROFILING BY GOLIMUMAB AND ADALUMUMAB AS A PUTATIVE EXPLANATION FOR INFERIOR TREATMENT RESPONSE TO GOLIMUMAB AFTER ADALUMUMAB FAILURE IN RHEUMATOLOGY ARTHRITIS / L. Tweehuisen* - K. Schraa - M. Netea - F. van den Hoogen - L. Joosten - A. den Broeder

THU0143 SINGLE-ARM STUDY OF ETANERCEPT (ETN) IN ADULT PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) WHO FAILED ADALUMUMAB (ADA) TREATMENT / L. Bessette* - M. Khrasha - A. J. krivit - A. Kalyaperumal - R. Grantab - M. Poulin-Costello - D. Collier

THU0144 PHARMACOKINETICS AND SAFETY OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR, ADMINISTERED SUBCUTANEOUSLY BY AN AUTOINJECTOR OR PREFILLED SYRINGE IN HEALTHY MALE SUBJECTS / M. Afonso* - D. Kollins - L. Macke - H. Woehling - G. Wuerth

THU0145 PHARMACOKINETICS AND SAFETY OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR, AND ETANERCEPT ORIGINATOR PRODUCT IN HEALTHY MALE SUBJECTS: A RANDOMISED TWO-WAY CROSSOVER STUDY / M. Afonso* - S. Sanguino Heinrich - J. Pothel - H. Woehling

THU0146 IMPACT OF ANTI-DRUG ANTIBODIES ON EFFICACY AND SAFETY UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH ADALUMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY / M. C. Genovese* - M. Weinblatt - E. Keystone - A. Baranauskaitė - S. Y. Cheong - J. Ghil


THU0149 THE 54-WEEK RESULTS OF INTERFERON-T RELEASE ASSAY IN A PHASE III STUDY COMPARING SB2, AN INFLIXIMAB BIOSIMILAR, TO INFLIXIMAB REFERENCE PRODUCT IN PATIENTS WITH RHEUMATOID ARTHRITIS / P. Durez* - E. Mysler - J. S. Smolen - J.-Y. Choe - J. Choi - Y. H. Rho


THU0151 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PREDICTABILITY OF DISEASE CONTROL AT WEEK 52 BASED ON EARLY RESPONSE TO CERTOLIZUMAB PEGOL (IN COMBINATION WITH METHOTREXATE) IN ITALIAN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS: THE CZP-SPEED STUDY / P. Sarzi-Puttini* - E. Filippucci - S. Adam - P. L. Meroni - P. Talavera - T. Kumke - W. Grassi


THU0153 HEMOGLOBIN IS A BETTER PREDICTOR FOR RADIOGRAPHIC PROGRESSION THAN DAS28 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS-ANALYSIS FROM INTRAVENOUSLY ADMINISTERED GOLIMUMAB GO-FURTHER STUDY / R. Westhovens* - C. Han - M. E. Weinblatt - L. Kim - E. C. Hsia - D. Parenti - S. Kafka - C. O. Bingham III

* Presenting author
THU0154 EFFECTS OF ETAENERCEPT BIOMIMICS ON LIPID PROFILES IN PATIENTS WITH RHEUMATOID ARTHRITIS


THU0159 A LARGE-SCALE PROSPECTIVE SINGLE COHORT OBSERVATIONAL STUDY OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB: THE FINAL ANALYSIS OF 48-WEEK DATA FROM THE ANOUEAU STUDY / T. Takeuchi* - R. Nakajima - N. Agata - Y. Tanaka


THU0162 COMPARABLE TIME TO RETREATMENT WITH CT-P10 AND INNOVATOR RITUXIMAB UP TO 2 YEARS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS / W. Park* - D. H. Yoo - C. H. Suh - S. C. Shim - S. J. Lee - S. Y. Lee - T. S. Kwon - S. M. Kim


THU0164 EFFICACY OF INFlixIMAB FOR SUPPRESSING RADIOGRAPHIC PROGRESSION OF CERVICAL LESIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARISON WITH METHOTREXATE: TWO YEARS OF FOLLOW-UP - A MULTICENTER REGISTRY STUDY / Y. Kanayama* - T. Kojima - Y. Hirano - N. Takahashi - Y. Yabe - N. Ishiguro on behalf of TBCR study group

Rheumatoid arthritis - non biologic treatment and small molecules


THU0167 THE EFFECT OF FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR ON PATIENT-REPORTED OUTCOMES: RESULTS FROM TWO 24-WEEK PHASE 2B DOSE RANGING STUDIES / M. Genovese* - R. Westhovens - A. Kannava - L. Meuleners - A. van der Aa - P. Harrison - C. Tasset


THU0173 FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE AS MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY / A. Kannava* - L. Ponce - R. Cseuz - O. Reshetko - M. Stanislavchuk - M. Greenwald - A. van der Aa - F. Vanhouette - C. Tasset - P. Harrison

* Presenting author
A SAFETY ANALYSIS OF TOFACITINIB 5 MG TWICE DAILY ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BACKGROUND CONVENTIONAL SYNTHETIC DMARDS IN A PHASE 3 RHEUMATOID ARTHRITIS POPULATION / A. Krivitz - R. Harauzi - J. Kaine - V. Castellano - E. Bananis - C. A. Connell - H. Fan - L. Takiya

COMPARISON OF TWO COMMONLY USED INTRA-ARTICULAR STEROID PREPARATIONS IN ACUTELY SWOLLEN KNEE JOINT IN PATIENTS WITH CHRONIC ARTHRITIS - A RANDOMIZED CONTROLLED TRIAL / A. Kumar* - V. Dhir - S. Singh - A. Sharma - S. S. Khanna


NEED TO ADVANCE THERAPY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TRIPLE NDMARD VS BIOLOGIC COMBINATION THERAPY: RESULTS FROM THE CORRONA REGISTRY / D. A. Pappas* - C. Karki - H. Litman - J. D. Greenberg - J. M. Kremer - V. Garg


TREATMENT WITH TOFACITINIB INHIBITS HUMAN NAIVE B LYMPHOCYTE DEVELOPMENT AND FUNCTION IN VITRO / J. Thiel* - K. Fischer - R. E. Voll - R. Lorenzetti - B. Bannert - N. Venhoff - M. Rizzi


INCREASED EXPRESSION OF THE COLLAGEN INTERNALIZATION RECEPTOR ENDO180 IN FIBROBLAST-LIKE SYNOVIOCYTES OF PATIENTS WITH RHEUMATOID ARTHRITIS / L. Y. Hua


EFFICIENCY OF COMPLEX THERAPY OF RHEUMATOID ARTHRITIS USING RAMIPRIL / R. Zuckerman - P. Wong - E. K. Li - T. Y. Zhu - L. Qin - L. S. Tam

A SAFETY ANALYSIS OF TOFACITINIB 5 MG TWICE DAILY ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BACKGROUND CONVENTIONAL SYNTHETIC DMARDS IN A PHASE 3 RHEUMATOID ARTHRITIS POPULATION / A. Krivitz - R. Harauzi - J. Kaine - V. Castellano - E. Bananis - C. A. Connell - H. Fan - L. Takiya


A NOVEL REVERSIBLE BRUTON’S TYROSINE KINASE (BTK) INHIBITOR (BMS-986142) PROVIDES FAVORABLE SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC PROFILES IN HEALTHY SUBJECTS / S. K. Lee - J. Xing - I. Callet - R. Adamczyk - A. Grifilies - A. Liu - B. Murphy - M. Nowak*

PREFERRED INHIBITION OF IL-6 RELATIVE TO IL-7 SIGNALING PATHWAYS BY ABT-494: EXPOSURE-RESPONSE ANALYSIS OF EX-VIVO DATA FROM TWO PHASE 1 CLINICAL TRIALS AND COMPARISON TO TOFACITINIB / M.-E. Mohamed* - D. Koenig - H. S. Camp - S. Jungerwirth - A. A. Othman


* Presenting author
THU0197

THU0198

THU0199

THU0200

THU0201

THU0202

THU0203

THU0204
RETESTING OF BIOLGIC AGENTS AFTER REMISSION INDUCED WITH AND WITHOUT CONCOMITANT GLUCOCORTICOID TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROPENSITY SCORE MATCHED ANALYSIS / S. Asai* - T. Kojima - N. Takahashi - F. Funahashi - N. Ishiguro on behalf of TBCR study group

THU0205

THU0206
POST-MARKETING SURVEILLANCE OF EFFICACY AND SAFETY OF TACROLIMUS ADD-ON THERAPY IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS WITHOUT AN ADEQUATE RESPONSE TO BIOLOGICAL DMARDS / T. Takeuchi* - K. Ishida - K. Shiraki - T. Yoshiyasu

THU0207
DIACERIN IN COMBINATION WITH METHOTREXATE VERSUS METHOTREXATE ALONE IN THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS / W. Loutheeno* - S. Nilgunwong - R. Nanagara - B. Siripaitoon

THU0208
EFFECT OF DOUBLE FILTRATION PLASMAPHERESIS ON MRI-BONE EROSION IN RA / X. Yu* - L. Zhang - L. Wang

THU0209

THU0210

THU0211
THE COMBINATION OF CHINESE HERBAL PREPARATION ZHENG QING FENG TONG NING WITH METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS / Z. Feng* - M. Cao - L. Duan - Z. Wu

Paediatric rheumatology

THU0212
MODEL OF ARTHRITIS WITH THE TYPICAL SYSTEMIC MANIFESTATIONS IN WISTAR RATS / P. F. Litvintsky* - V. N. Sakhroev - E. I. Alexeeva - N. A. Mayansky

THU0213

THU0214

THU0215

THU0216

THU0217

THU0218
COW’S MILK ALLERGY IN INFANCY AND LATER DEVELOPMENT OF JUVENILE IDIOPATHIC ARTHRITIS: A REGISTER-BASED CASE-CONTROL STUDY / P. Váhásalo* - M. Arvonen - T. Pokka - L. Kröger - L. Virta

* Presenting author
THU0219 PROSPECTIVE ANALYSIS OF THE IMMUNOGENIC RESPONSE IN JIA PATIENTS (PAEDIATRIC AND ADULT) ON ANTI-TNF TREATMENT / E. Quesada-Masach* - D. Álvarez-de la Sierra - M. García Parat - R. Pujol-Borrell - M. Martínez Gallo - C. Modesto Caballero - A. M. Martín Sánchez

THU0220 RETROSPECTIVE STUDY EVALUATING TREATMENT DECISION AND OUTCOME OF NON-JUVENILE IDIOPATHIC ARTHRITIS (JIA)-ASSOCIATED CHILDHOOD UVEITIS / E. Sardar* - P. Dusser - M. Labetouille - E. Barreau - B. Bodaghi - I. Kone-Paut


THU0222 THE DIAGNOSIS OF FAMILIAR MEDITERRANEAN FEVER FOLLOWING THE INITIAL PRESENTATION OF MONOARTHRITIS / O. Tanou* - Y. Horovitz - S. Shalev - M. Khayat - R. Spiegel


THU0225 HYPOGONADOTROPIC HYPOGONADISM IN SYSTEMIC ARTHRITIS - AN INTERESTING CASE SERIES FROM A TERTIARY CARE CENTRE / B. Chiilikuri* - R. Sankaralingam - S. Sankar - R. Ramamoorthy - B. Mahendran


THU0227 ADOLESCENT AND YOUNG ADULT CARE IN ADULT RHEUMATOLOGY CLINICS / E. Bruce* - J. Fox - P. Watson - J. McDonagh


THU0231 BELIMUMAB IN PAEDIATRIC SLE (THE PLUTO STUDY) - STUDY DESIGN AND PARTICIPATION / J. Fettiplace* - B. Ji - D. Roth


THU0234 CLINICAL EXPERIENCE AND Decision-making in RELATION TO THE USE OF BIOLOGICS IN ADULT JIA / N. Smith* - T. Rapley - F. McErlane - L. Kearsley-Fleet - K. L. Hyrich - H. E. Foster


THU0236 BONE METABOLIC INDEX AND CLINICAL PHENOTYPE IN JUVENILE-ONSET ANKYLOSING SPONDYLITIS (JAS) / P. Zhang - Z. Hu - J. Qi - Y. Mou - Y. Jiang - J. Gu

THU0237 DISEASE ACTIVITY IN PATIENTS WITH JUVENILE SPODNOLARTHROPATHY ON ANTI-TNF THERAPY AS MEASURED BY THE JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE (JADAS)-10 AND THE JUVENILE SPODNOLARTHROPATHIS DISEASE ACTIVITY INDEX (JSPADA) / R. A. Russo* - M. M. Katsikas

THU0238 HOW TO DIAGNOSE AND PREVENT THE EPISODES OF PFAPA SYNDROME / M. Gunes - S. Cekic - S. S. Kilic

THU0239 PERFORMANCE OF DISEASE ACTIVITY MEASURES IN JUVENILE SPODNOLARTHROPATHIS IN A PLACEBO CONTROLLED TRIAL WITH INFLIXIMAB / S. Ramiro* - J. C. Casasola-Vargas - D. Van der Heijde - R. Landewé - R. Burgos-Vargas

SLE, Sjögren's and APS - etiology, pathogenesis and animal models

THU0240 DYSREGULATIONS IN THE SPHINGOLIPID PATHWAY IN SLE PATIENTS / A. Checa - H. Idborg* - D. G. Sar - P.-J. Jakobsen - C. E. Wheelock - I. Gunnarsson


* Presenting author
THU0244 NONINVASIVE ASSESSMENT OF MACROPHAGE ACTIVATION IN EXPERIMENTAL GLOMERULONEPHRITIS USING OPTICAL IMAGING WITH NEAR-INFRARED LIGHT SERVES AS A SURROGATE OF DISEASE ONSET S. Brechler - M. D. Cheung - D. Huang - W. J. Akers - A. H. Kim*

THU0245 INDIVIDUAL VERSUS COMBINED BLYS OR/AND APRI neutralization reveals developmental plasticity for plasma cell survival factor requirements / P. Haselmayer* - M. Vigolo - J. Nys - P. Schneider - H. Hess


THU0250 DYSREGULATION OF AUTOAFFHY IN SYSTEMIC LUPUS ERYTHEMATOSUS IS CORRELATED TO TRANSCRIPTIONAL INTERFERON SIGNATURES AND PROVIDES CANDIDATE BIOMARKERS / L. Chiche* - G. Penaranda - P. Savori - N. Jourde-Chiche - P. Halfon - C. Camus

THU0251 ABSENCE OF CAPSAE-ACTIVATED DNASE AFFECTS NETOSIS AND ITS MODULATION OF DENDRITIC CELL ACTIVATION IN A SEX-DEPENDENT MANNER / A. Del Mastro* - R. Caricchio

THU0252 DECREASED EXPRESSION OF IMMUNOREGULATORY PROTEIN PROGRAMMED DEATH LIGAND-1 (PD-L1) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PLACENTA / A. M. Stevens* - M. Yuasa - G. Deutsch


THU0256 COMPLEMENT C3 exacerbates TLR7-mediated skin inflammation but not systemic Autoimmunity / C. Giacomassi* - G. S. Ling - N. Buang - J. Strid - M. Botto


THU0258 DRVVT and APTT ratios for laboratory detection of lupus anticoagulant - to normalize or not to normalize that is the question / E. C. Hannson* - E.-M. Norberg - M. Berndtsson - J. P. Antovic - T. Panafidina - N. Serevdikina - T. Popkova - N. Ayzina - E. Nasonov

THU0259 DECREASED EXPRESSION of IMMUNOREGULATORY PROTEIN PROGRAMMED DEATH LIGAND-1 (PD-L1) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PLACENTA / A. M. Stevens* - M. Yuasa - G. Deutsch


THU0266 CGAMP and CGAS are expressed in a subset of patients with systemic lupus erythematosus and associate with disease activity / J. An - L. Durcan* - R. M. Karr - J. J. Woodward - K. Elkon

THU0267 THE OXIDATIVE STRESS MARKERS AS RISK FACTOR for ENDOTHELIAL DYSFUNCTION IN PRIMARY AND SECONDARY ANTIPHOSPHOLIPID SYNDROME / L. Stojanovich* - N. Stanisavljevic - D. Marisavljevic - V. Dopsaj - B. Todic

* Presenting author


THU0275  PHARMACODYNAMIC MODELING OF BTK OCCUPANCY VERSUS EFFICACY IN RA AND SLE MODELS USING THE NOVEL SPECIFIC BTK INHIBITOR M2951 / P. Haselmayer - M. Camps - L. Bruns - A. Bender - P. Schroeder - R. Genninbogleh*

THU0276  INCREASED OXIDATIVE DNA DAMAGE AND IMPAIRED GENE REPAIRING PATHWAY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / S. Donmez* - G. E. Pamuk - O. Doganlar - O. N. Pamuk


THU0278  INCREASED PLATELET AGGREGATION BY VON WILLEBRAND FACTOR ACTIVITY CORRELATES WITH ANTI-DSDNA ANTIBODY LEVELS AND ACUTE PHASE REACTANTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / J. Nossent - W. Raymond* - G. O. Eilertsen

THU0279  MSCS ALLEVIATE CLINICAL AND EXPERIMENTAL SJÖGREN’S SYNDROME BY INHIBITING IL-12 PRODUCTION OF APCS / B. Shi - J. Qi - R. Feng - Z. Zhang - W. Chen* - W. Li - X. Tang - G. Yao - L. Sun

THU0280  IL-12 EXACERBATES SJÖGREN’S SYNDROME THROUGH INDUCING LYMPHOCYTE INFLTRATIONS INTO SALIVARY GLANDS AND IMBALANCE OF LYMPHOCYTE SUBSETS / B. Shi - J. Qi - R. Feng - Z. Zhang - W. Chen* - W. Li - X. Tang - G. Yao - L. Sun

THU0281  ARTESANATE INHIBITS TYPE 1 INTERFERON INDUCTED PRODUCTION OF MACROPHAGE MIGRATION INHIBITORY FACTOR IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / X. Feng* - W. Chen - L. Sun

SLE, SJÖGREN’S AND APS - treatment


THU0283  ANTICOAGULATION AND LONG-TERM OUTCOMES IN PATIENTS WITH RENAL ARTERY STENOSIS AND ANTIPHOSPHOLIPID SYNDROME / A. Casian* - S. Sangle - S. ManouStathopoulou - N. Jordan - D. D’Cruz

THU0284  DYNAMICS OF B LYMPHOCYTE SUBSETS IN SLE PATIENTS TREATED WITH RITUXIMAB / A. A. Kruize - C. E. Hackx - M. Rossato - T. R. Radstake - J. A. van Roon - M. Mosca

THU0285  DALAZATIDINE, AN INHIBITOR OF THE KV1.3 CHANNEL ON ACTIVATED EFFCTOR MEMORY T CELLS, HAS IMMUNOTHERAPY POTENTIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS / A. M. Stevens* - M. Yuasa - D. Peckham - C. Olsen - S. P. Iadonato - P. Probst


THU0288  IMMUNE RESPONSES TO SUBCUTANEOUS (SC) ADMINISTRATION: A PHASE IB STUDY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / D. J. Wallace* - M. H. Weisman - T. E. Nasonov - E. L. Nasonov


THU0292 C-PEPTIDE AND MODIFIED HOMA-INDEX IN DIFFERENT CARBOHYDRATE METABOLISM DISTURBANCES DURING GLUCOCORTICOID THERAPY / G. Nurullina* - F. Valeeva

THU0293 SAFETY, PHARMACOKINETICS, ENZYME ACTIVITY, AND IMMUNOGENICITY OF RSVL-132, A NOVEL RNA-ASE FUSION PROTEIN: DEVELOPED TO REDUCE RNA-CONTAINING IMMUNE COMPLEXES IN SYSTEMIC LUPUS ERYTHEMATOSUS / D. Burge - J. Doedens - J. Eisenman - K. Elkon - C. Gabel - J. Posada* 

THU0294 AN INTERNATIONAL CONSENSUS EXERCISE TO CLASSIFY SLE DAMAGE ITEMS ACCORDING TO THEIR LIKELY ASSOCIATION WITH STEROIDS / J. Little* - M. Lunt - B. Parker - I. N. Bruce on behalf of the Systemic Lupus International Collaborating Clinics (SLICC)

THU0295 ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / J. T. Merrill* - R. Furie - V. P. Werth - M. Khamashita - J. Drappa - L. Wang - G. Illei


THU0297 PHYSICAL ACTIVITY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: EFFECTS ON FATIGUE AND DEPRESSIVE BEHAVIOR FOR IMPROVED QUALITY OF LIFE / L. Stojanovic* - G. Bogdanovic - A. Djokovic

THU0298 TYPE I INTERFERON PREDICTS BIOLOGICAL EFFECT OF BELIMUMAB ON RHEUMATOID FACTOR POSITIVE B CELLS IN SJÖGREN’S SYNDROME: RESULTS FROM THE BELISS TRIAL / L. Quartuccio* - C. P. Mavragani - A. Nezos - S. A. Gandolfi - A. Tincani - S. De Vita


THU0301 A PHASE II TRIAL OF RETINOIDS ON LUPUS NEPHRITIS IN A SINGLE CENTER / M. Funauchi* - Y. Nozaki - K. Kinoshita

THU0302 A RATIONALE FOR MORE INTENSIVE TREATMENT TO IMPROVE CLINICAL OUTCOMES / M. Y. Md Yusof* - D. Shaw - A. Rawstron - P. Emery - E. M. Vital

THU0303 LONGITUDINAL PATTERNS IN SLE RESPONSE TO STANDARD OF CARE THERAPY: IMPLICATIONS FOR SLE CLINICAL TRIAL DESIGN / M. Kim* - J. T. Merrill - K. C. Kalunian - B. H. Hahn - A. Roach - P. M. Izmirly on behalf of the Lupus Foundation of America Collective Data Analysis Initiative group


THU0305 PHARMACOKINETICS OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS BELIMUMAB FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / S. Z. Sheikh - N. L. Fox* - A. E. Hammer - H. Strucmper - J. Groark - D. Roth - D. Gordon


THU0307 REPOSITORY CORTICOTROPIN INJECTION (RCI) ATTENUATES DISEASE ACTIVITY IN PATIENTS WITH PERSISTENTLY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) REQUIRING CORTICOSTEROIDS: RESULTS FROM A 44-WEEK OPEN-LABEL EXTENSION STUDY / P. Becker - R. Furie* - M. Mitrane - E. Zhao

THU0308 HYDROXYCHLOROQUINE IMPROVES PREGNANCY OUTCOME IN WOMEN WITH ANTIPHOSPHOLIPID ANTIBODIES WITHOUT OTHER UNDERLYING CONNECTIVE TISSUE DISEASE / S. Sciascia* - S. Baldovino - E. M. Vital


THU0312 PHYSICAL FATIGUE IS VERY IMPORTANT AS CLINICAL OUTCOME FOR IMPROVEMENT BY TREATMENT ACCORDING TO PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME / S. A. Gandolfi - A. Nezos - S. A. Gandolfi - A. Tincani - S. De Vita


THU0314 CLINICAL AND IMMUNOLOGICAL CONSEQUENCES OF TOTAL GLUCOSIDES OF PEOASY TREATMENT IN SJÖGREN’S SYNDROME: A RANDOMIZED CONTROLLED TRIAL / Y. Zhou* - L. Jin - F. Kong - H. Zhang - Z. Chen - G. Wang - X. Li - X. Li

* Presenting author
SLE, Sjögren’s and APS - clinical aspects (other than treatment)


THU0317  TUBOLOINSTERIAL DAMAGE IS AN INDEPENDENT PREDICTOR OF END STAGE RENAL DISEASE IN LUPUS NEPHRITIS PATIENTS WITH MILD TO MODERATE RENAL IMPAIRMENT / B. Jovanovic - H. N. Khan - W. Mowrey - P. Izmirly - D. Schwartz - J. Buyon - C. Putterman - B. Gollav - A. Broder*

THU0318  THE PREGNANCY EXPERIENCE OF 85 WOMEN WITH SLE FOLLOWED IN A SPECIALIST LUPUS CLINIC COMPARED TO THE GENERAL POPULATION / C.-L. M. Murphy* - S. Croa - A. Rahman - I. Giles

THU0319  SUBOPTIMAL VITAMIN D LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. Ramos* - J. L. Andreu - M. Bascuas - M. Cuadros - M. Espinosa - B. J. Flores - J. Campos - J. Sanz

THU0320  CARDIOVASCULAR RISK PROFILES IN A LUPUS COHORT: THOSE THAT ARE MISSED / D. Boulou* - R. Koelmeyer - E. Morand - A. Hoi

THU0321  THE ASSOCIATION BETWEEN ECHOCARDIOGRAPHIC PARAMETERS AND MORTALITY IN PATIENTS WITH LUPUS NEPHRITIS / D. V. Monova* - S. Monov - K. Kirillov - E. Peneva


THU0323  PREDICTORS OF DISEASE SEVERITY, LYMHPOMA AND DEATH: PREVALENCE IN PATIENTS REGISTERED ON THE UNITED KINGDOM PRIMARY SJÖGREN’S SYNDROME REGISTRY / E. Lea* - B. Hargreaves - D. Lendrem - S. Mitchell - V. Hindmarsh - S. Bowman - B. Griffiths - W. F. Ng on behalf of UK primary Sjögren's syndrome registry (UKPSSR)


THU0326  BRAIN MRI IN PATIENTS WITH ACUTE CONFUSIONAL STATE OF DIFFUSE PSYCHIATRIC/ NEUROPSYCHOLOGICAL SYNDROMES IN SYSTEMIC LUPUS ERYTHEMATOSUS / G. Abe* - Y. Arinuma - Y. Sakuma - H. Kikuchi - S. Hirohata

THU0327  COMPARISON OF IMMUNOENZYMATIC ASSAY AND CRITHIDIA IMMUNOFLUORESCENCE TEST FOR THE DETECTION OF ANTI-DOUBLE STRAND DNA ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / G. Orsolini* - M. R. Snyder - C. S. Crowson - J. L. Frinack - M. G. Kevin


THU0330  VALIDITY OF PROTEIN-TO-CREATINE RATIO IN AN UNTIMED URINE SPECIMEN AND ESTIMATED GLOMERULAR FILTRATION RATE AS MEASURES OF PROTEINURIA AND RENAL FUNCTION IN PATIENTS WITH LUPUS NEPHRITIS / H. Nishina* - Y. Katsumata - M. Hanaoka - Y. Kawaguchi - H. Yamanaka

THU0331  OUTCOME OF PREGNANCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, PREVALENCE OF MATERNAL, OBSTETRIC, AND FETAL COMPLICATIONS / H. Alkoky* - N. Baghdadi - J. Al Saleh

THU0332  THE PREDICTIVE RISK FACTORS AND PROGNOSIS OF THROMBOTIC MICROANGIOPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS / D. V. Monova* - S. Monov - K. Kirillov - E. Peneva

THU0333  THE ASSOCIATION BETWEEN ECHOCARDIOGRAPHIC PARAMETERS AND MORTALITY IN PATIENTS WITH LUPUS NEPHRITIS / D. V. Monova* - S. Monov - K. Kirillov - E. Peneva

THU0334  A LONGITUDINAL ANALYSIS OF CHANGE IN LUPUS NEPHRITIS IN AN INTERNATIONAL INCEPTION COHORT USING A MULTISTATE MARKOV MODEL APPROACH / J. G. Hanly* on behalf of Systemic Lupus International Collaborating Clinics (SLICC)


THU0337  SUBOPTIMAL VITAMIN D LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. Ramos* - J. L. Andreu - M. Bascuas - M. Cuadros - M. Espinosa - B. J. Flores - J. Campos - J. Sanz

THU0338  OUTCOMES IN PATIENTS WITH ISCHEMIC STROKE REGARDING TITTER AND PERSISTENCE OF ANTIPHOSPHOLIPID ANTIBODIES / J. Y. Pyo* - S. W. Lee - J. J. Song - S.-K. Lee - Y.-B. Park


* Presenting author

THU0339  NON-CALCIFIED CORONARY ARTERY PLAQUE ASSOCIATES WITH ADVERSE LIPOPROTEIN PROFILES IN SYSTEMIC LUPUS ERYTHEMATOSUS / I. Durcan* - A. Arbah-Zadeh - M. Connelly - J. Otvos - L. S. Magder - M. Petri


THU0344  OSTEOPOROSIS AND VERTEBRAL FRACTURES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND META-ANALYSIS / M. García-Carrasco* - A. Rojas-Villarraga - N. Molano-González - P. Soto-Santillán - C. Mendoza-Pinto

THU0345  PRESENCE OF IMMUNOGLOBULIN (IG) A ANTIBODIES AGAINST CARDIOLIPIN AND BETAZ-GLYCOPROTEIN-1 IN THE ABSENCE OF IGG AND IGM IN SYSTEMIC LUPUS ERYTHEMATOSUS / M. Frodlund* - J. Wetterö - T. Skogh - C. Sjöwall

THU0346  FURTHER VALIDATION OF SIMPLE INDEX AS A SIMPLIFIED DISEASE ACTIVITY ASSESSMENT TOOL FOR SLE / N. Rabini - J. Moly* - A. Neves - W. Sequeira

THU0347  IS BALANCE AFFECTED IN PATIENTS WITH SIMPLE DISEASE ACTIVITY IN SINUS? / M. Alkan Melikoglu* - F. Bagci

THU0348  ASSESSMENT OF SUBMANDIBULAR GLAND ULTRASONOGRAPHY IN EARLY-STAGE SJÖGREN’S SYNDROME / N. Hashimoto* - S. Uchiyama - M. Kitano - T. Nakazawa - T. Iwasaki - T. Hashimoto

THU0349  EARLY SYMPTOMS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECALLED BY 337 SLE PATIENTS / N. Leuchten* - B. Milke - B. Winkler-Rohling - D. Daikh - T. Dörner - S. Johnson - M. Aringer on behalf of the SLE Classification Criteria Steering Committee


THU0351  VITAMIN D INSUFFICIENCY IS ASSOCIATED TO FATIGUE IN NON-SUPPLEMENTED WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN A MEDITERRANEAN REGION / T. C. Salman-Monte - P. Corzo* - F. Castro - L. Polino - V. Torrette-Segarra - J. Carbonell-Abello


THU0353  SERUM TWEAK LEVELS IN PATIENTS WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / V. Torrente-Segarra - J. Carbonell-Abello

THU0354  VITAMIN D INSUFFICIENCY IS ASSOCIATED TO FATIGUE IN NON-SUPPLEMENTED WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND META-ANALYSIS / M. García-Carrasco* - A. Rojas-Villarraga - N. Molano-González - P. Soto-Santillán - C. Mendoza-Pinto

THU0355  FURTHER VALIDATION OF SIMPLE INDEX AS A SIMPLIFIED DISEASE ACTIVITY ASSESSMENT TOOL FOR SLE / N. Rabini - J. Moly* - A. Neves - W. Sequeira

THU0356  COMPARISON BETWEEN JUVENILE-, ADULT-, AND LATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS TRIALS IN AFRICAN-AMERICANS / S. S. Lim* - D. McKinnell - C. Sjöwall

THU0357  ASSESSMENT OF SUBMANDIBULAR GLAND ULTRASONOGRAPHY IN EARLY-STAGE SJÖGREN’S SYNDROME / N. Hashimoto* - S. Uchiyama - M. Kitano - T. Nakazawa - T. Iwasaki - T. Hashimoto

THU0358  EARLY SYMPTOMS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECALLED BY 337 SLE PATIENTS / N. Leuchten* - B. Milke - B. Winkler-Rohling - D. Daikh - T. Dörner - S. Johnson - M. Aringer on behalf of the SLE Classification Criteria Steering Committee


THU0360  SERUM TWEAK LEVELS IN PATIENTS WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / V. Torrente-Segarra - J. Carbonell-Abello


THU0362  CLINICAL TRIAL SIMULATION IDENTIFIES FACTORS FOR PATIENT ENGAGEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS TRIALS IN AFRICAN-AMERICANS / S. S. Lim* - D. McKinnell - M. E. Pierson - I. O'Brien


THU0364  DIFFUSE ALVEOLAR NECROSIS IN A MULTI-ETHNIC SYSTEMIC LUPUS ERYTHEMATOSUS COHORT / S. S. Shaharir* - R. Mohd - R. Mustafar - N. S. Shahril

THU0365  HIP JOINT AVASCULAR NECROSIS IN A MULTI-ETHNIC SYSTEMIC LUPUS ERYTHEMATOSUS COHORT / S. S. Shaharir* - R. Mohd - R. Mustafar - N. S. Shahril

THU0366  ADVERSE PREGNANCY OUTCOMES AND ASSOCIATED FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / Z. Zhan* - D. Chen - Y. Yang - L. Liang

* Presenting author
Spondyloarthritis - etiology, pathogenesis and animal models

THU0363  POSITION 97 (P97) OF HLA-B, A RESIDUE IMPLICATED IN ANKYLOSING SPONDYLYTIS PATHOGENESIS, PLAYS A KEY ROLE IN CAL SURFACE FREE HEAVY CHAIN EXPRESSION VIA INTERACTIONS WITH B2-MICROGLOBULIN / L. Chen - H. Shi - J. Yuan - P. Bowness*

THU0364  RARE ERAP1 ALLOTYPE COMBINATIONS DO NOT EXPLAIN THE ERAP1 ASSOCIATION WITH ANKYLOSING SPONDYLYTIS / L. H. Appleton* - A. R. Roberts - M. Vecellio - B. P. Wordsworth

THU0365  LIGHT RS107667 G>A GENE POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO ANKYLOSING SPONDYLYTIS IN A CHINESE HAN POPULATION / B. Yang* - L. Wang


THU0370  DISEASE ACTIVITY, NOT DRUG EXPOSURE, AFFECTS PREGNANCY OUTCOMES IN INFLAMMATORY ARTHRITIS / E. Fishman* - J. Cush - K. Dao


THU0373  DEGRADATION FRAGMENTS OF COLLAGEN I AND V ARE EARLY DISEASE MARKERS IN B-GLUCAN TRIGGERED SPONDYLYTORSIS IN SKG MICE / N. S. Gudmann* - N. Fox - M. Karsdal - A. C. Bay-Jensen - J. Schmitz - A. S. Siebuhr

Spondyloarthritis - clinical aspects (other than treatment)


THU0375  ASDAS-BASED REMISSION WAS LESS FREQUENT THAN BASDAI-BASED REMISSION, AND BOTH WERE RELATED TO CRP AND SMOKING IN EARLY AXIAL SPONDYLYTORSIS. THE DESIR COHORT / D. Wendling* - X. Guillot - L. Gossec - C. Prati - A. Saras - M. Dougados


THU0379  CLINICAL DISEASE ACTIVITY MEASURES ARE ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN EARLY AXIAL SPONDYLYTORSIS / D. Poddubnyy* - M. Protopopov - H. Habel - J. Braun - M. Rudwaleit - J. Sieper

THU0380  A SINGLE DETERMINATION OF C-REACTIVE PROTEIN DOES NOT SUFFICE TO DECLARE A PATIENT WITH A DIAGNOSIS OF AXIAL SPA CRP-NEGATIVE / R. Landewé* - T. Numminen - O. Davies - M. Turina - D. Baeten


THU0382  DEVELOPMENT OF SPA-FEATURES IN PATIENTS WITH CHRONIC BACK PAIN OVER A ONE-YEAR COURSE: DATA FROM THE SPONDYLYTORSIS CAUGHT EARLY (SPACE)-COHORT / T. Baboolal - M. van Oosterhout - R. Ramonda - F. van Gaalen


THU0385  PATIENT AND PHYSICIAN AGREEMENT IN ALL BATH ANKYLOSING SPONDYLYTORSIS DISEASE ACTIVITY INDEX QUESTIONS IS EXCELLENT EXCEPT FOR ENTHESISIS / L. Ghukasyan - A. Mollo* - A. Etcheto - M. Dougados

* Presenting author
THU0386 THE ASSOCIATION OF SERUM TRAIL LEVELS AND METABOLIC PARAMETERS IN PATIENTS WITH AS AND PSA

THU0387 SERUM LEVELS OF TNF ALPHA AND VEGF AS MARKERS OF DISEASE ACTIVITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / B. Mahendran* - R. Sankalingam - K. Mohanasundaram - S. Sankaran - M. Mani - B. Chilukuri

THU0388 THE ASSOCIATIONS BETWEEN AGE WITH THE CLINICAL AND RADIOLOGICAL ACTIVITY IN SPONDYLOARTHRITIS / P. H. Li - C. Ho* - H. Y. Chung - C. S. Lau

THU0389 COMPARING DIFFUSION WEIGHTED IMAGING (DWI) WITH CLINICAL PARAMETERS AND SHORT TAU INVERSION RECOVERY (STIR) SEQUENCE IN DETECTING SPINAL AND SACROILIAC (SI) JOINTS INFLAMMATION IN SPONDYLOARTHRITIS (SPA) / H. Y. Chung - C. S. Lau* - P. Li


THU0395 THE PREVALENCE OF INFLAMMATORY AND STRUCTURAL LESIONS ON MRI OF THE SACROILIAC JOINTS IN PATIENTS WITH VERY EARLY PERIPHERAL SPONDYLOARTHRITIS / G. Varks* - P. Carron - H. Cypers - L. van Praet - D. Elewaut - L. Jans - F. van den Bosch


THU0401 SEVERE BONE MARROW EDEMA ON SACROILIAC JOINT MRI INCREASES THE RISK OF LOW BMD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / K. Y. Kang* - Y. S. Hong

THU0402 RADIOGRAPHIC PROGRESSION IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / K. Y. Kang* - S. Bakh


THU0405 ABILITY OF GENERAL PRACTITIONERS TO DISTINGUISH BETWEEN INFLAMMATORY AND NON-INFLAMMATORY SYMPTOMS IN PATIENTS AT RISK OF SPONDYLOARTHRITIS: THE APPSQA STUDY / M. C. Karreman* - J. M. Hazes - A. E. Weel

THU0406 LACK OF INFORMATION FOR PATIENTS AT RISK FOR SPONDYLOARTHRITIS: THE APPSQA STUDY / M. C. Karreman* - J. M. Hazes - A. E. Weel

THU0407 BASELINE RESULTS FROM PROOF - A 5-YEAR OBSERVATIONAL STUDY OF LONG-TERM DISEASE OUTCOME IN AXIAL SPONDYLOARTHRITIS / R. D. Inman - J. Sieper - D. Podubelsky - S. Akar - S. Munoz-Fernandez - M. Hojnik*

THU0408 PREVALENCE OF RENAL IMPAIRMENT IN PATIENTS WITH SPONDYLOARTHRITIS: RESULTS FROM THE INTERNATIONAL COMOSPA STUDY / M. Coulard* - M. Soubrier - B. Pereira - A. Molto - M. Dougados


* Presenting author
**Psoriatic arthritis**


**THU0413** UTILITY OF THE SPADE TOOL TO IDENTIFY AXIAL SPONDYLOARTHRITIS IN PATIENTS WITH CHRONIC BACKPAIN / S. Habibi* - S. Doshi - R. Sengupta


---

**Psoriatic arthritis**

**THU0418** OBESITY IMPAIRS THE RESPONSE TO TUMOUR NECROSIS FACTOR-ALPHA INHIBITORS IN PSORIATIC ARTHRITIS: RESULTS FROM THE DANBIO AND ICEBIO REGISTRIES / P. Højgaard* - B. Glintborg - L. E. Kristensen - T. J. Love - B. Gudbjornsson - L. Dreyer


**THU0420** APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN BASDAI IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS / P. Mease* - H. Marzo-Ortega - A. Poder - F. van den Bosch - J. Wollenhaupt - E. Lеспessailles - M. McIlraith - L. Teng - S. Hall

**THU0421** SERUM-BASED SOLUBLE MARKERS MAY DIFFERENTIATE PSORIATIC ARTHRITIS FROM OSTEOARTHRITIS / V. Chandran* - A. V. Perruccio - S. Li - F. Abji - R. Gandhi - D. D. Gladman


**THU0424** TREATMENT WITH TNF ALPHA BLOCKERS IS ASSOCIATED WITH REDUCED PROGRESSION OF ATHEROESCLEROTIC PLAQUES IN PATIENTS WITH PSORIATIC DISEASE: A PROSPECTIVE STUDY / L. Eder* - T. J. Love - B. Gudbjornsson - L. Dreyer

**THU0425** THE EARLY DIAGNOSIS OF PSORIATIC ARTHRITIS: STANDARDIZED EVALUATION OF SPECIFIC ENTIUSES, TENDONS AND CAPILLARIES IN PATIENTS WITH FRESH DIAGNOSED PSORIASIS / D. Becker-Capeller* - S. El-Nawab-Becker - C. Iking-Konert


**THU0427** ACHILLES ENThESITIS DEFINED BY ULTRASOUND IS NOT ASSOCIATED TO CLINICAL ENThESITIS IN PATIENTS WITH FRESH DIAGNOSED PSORIASIS / D. Becker-Capeller* - S. El-Nawab-Becker - C. Iking-Konert


**THU0429** APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN BASDAI IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS / P. Mease* - H. Marzo-Ortega - A. Poder - F. van den Bosch - J. Wollenhaupt - E. Lеспessailles - M. McIlraith - L. Teng - S. Hall

**THU0430** SERUM-BASED SOLUBLE MARKERS MAY DIFFERENTIATE PSORIATIC ARTHRITIS FROM OSTEOARTHRITIS / V. Chandran* - A. V. Perruccio - S. Li - F. Abji - R. Gandhi - D. D. Gladman

**THU0431** THE EARLY DIAGNOSIS OF PSORIATIC ARTHRITIS: STANDARDIZED EVALUATION OF SPECIFIC ENTIUSES, TENDONS AND CAPILLARIES IN PATIENTS WITH FRESH DIAGNOSED PSORIASIS / D. Becker-Capeller* - S. El-Nawab-Becker - C. Iking-Konert

**THU0432** TREATMENT WITH TNF ALPHA BLOCKERS IS ASSOCIATED WITH REDUCED PROGRESSION OF ATHEROESCLEROTIC PLAQUES IN PATIENTS WITH PSORIATIC DISEASE: A PROSPECTIVE STUDY / L. Eder* - T. J. Love - B. Gudbjornsson - L. Dreyer

**THU0433** TREATMENT WITH TNF ALPHA BLOCKERS IS ASSOCIATED WITH REDUCED PROGRESSION OF ATHEROESCLEROTIC PLAQUES IN PATIENTS WITH PSORIATIC DISEASE: A PROSPECTIVE STUDY / L. Eder* - T. J. Love - B. Gudbjornsson - L. Dreyer

* Presenting author


THU0438  ENTHESIS IN PSORIATIC ARTHRITIS AND NEED FOR BIOLOGICAL THERAPY / M. Bascuas - J. L. Andreu* - I. Millan - M. Cuadros - C. Ramos - M. Espinosa - B. J. Flores - J. Campos - J. Sanz


THU0443  UNMET NEEDS IN PSORIATIC ARTHRITIS: ONE THIRD OF THE PATIENTS WITH QUIESCENT DISEASE ACCORDING TO THE RHEUMATOLOGIST'S OPINION DO NOT ACHIEVE MINIMAL DISEASE ACTIVITY / J. L. van Mens* - A. W. van Kuijk - D. L. Baeten

THU0444  SUBCLINICAL ULTRASONOGRAPHIC ENTHESITIS IN PATIENTS WITH PSORIASIS IS ASSOCIATED WITH RISK MARKERS FOR PSORIATIC ARTHRITIS / L. Eder* - A. Polachek - C. F. Rosen - V. Chandran - D. D. Gladman

THU0445  VALIDATION OF THE CONTEST QUESTIONNAIRES TO SCREEN FOR PSORIATIC ARTHRITIS IN PRIMARY CARE PSORIASIS PATIENTS / M. C. Karreman* - J. M. Hazes - J. J. Luime


THU0447  MEASURING OUTCOME IN PSORIATIC ARTHRITIS: CORRELATION BETWEEN DIFFERENT SKIN SCORES M. Elmanoun* - C. Loftus - A. Szentpetery - P. Gallagher - L. Barnes - O. FitzGerald


THU0452  PSORIATIC ARTHRITIS AND PSORIASIS: THE ONGOING NEED FOR A MULTIDISCIPLINARY APPROACH TO MANAGEMENT / S. McCusker* - J. Leman - S. Bawa - M.-M. Gordon

THU0453  HIGH PREVALENCE OF PSORIATIC ARTHRITIS MISDIAGNOSES IN PSORIASIS PATIENTS IN RUSSIAN DERMATOLOGICAL CLINICS BASED ON PSORIASIS EPIDEMIOLOGY SCREENING TOOL (PEST), RHEUMATOLOGICAL EVALUATION AND THE CASPAR CRITERIA / M. Chamurlieva - T. Korotaeva* - E. Logina


* Presenting author
Osteoporosis

THU046

THU047
COMPREHENSIVE DISEASE CONTROL WITH LESS RELAPSE AND RADIOGRAPHIC PROGRESSION AT ONE YEAR BY INTENSIVE THERAPY WITH ADDITIONAL SHORT-COURSE OF TOCILIZUMAB: A REAL-WORLD, PROSPECTIVE COHORT STUDY IN CHINESE PATIENTS WITH RHEUMATOID ARTHRITIS / X.-Y. Wang - Y.-Q. Mo - J.-D. Ma - L.-F. Chen - J. Jing - D.-H. Zheng - L. Dai*

THU048
INFLUENCE OF ORAL PREDNISOLONE ON EFFECT OF DENOSUMAB ON OSTEOPOROSIS IN PATIENTS WITH JAPANESE RHEUMATOID ARTHRITIS; 12 MONTHS OF FOLLOW-UP / A MULTICENTER REGISTRY STUDY / Y. Kanayama* - Y. Hirano - N. Takahashi - S. Asai - N. Ishiguro - T. Kojima on behalf of TBCR-BONE study group

THU049

THU050
WHAT IS THE BEST LUMBAR SPINE VERTEBRAE COMBINATION TO PREDICT MAJOR OSTEOPOROTIC FRACTURE? THE OSTEOLASUS COHORT STUDY / H. Mraihi* - O. Lamy - M. Metzger - S. Soares - B. Aubry-Roziere - D. Stoll - D. Hans on behalf of Osteolasus cohort

THU051

THU052
THE PREDICTORS OF FRACTURE IN PATIENTS WITH COELIA DISEASE: AN OBSERVATIONAL STUDY / R. Sinha - M. Bukhari*-

THU053
VIEWPOINTS OF DENTAL SURGEONS ON THE USE OF BISPHOSPHONATES IN RHEUMATOLOGY PATIENTS / C. Daron - C. Deschaumes - M. Soubrier - S. Mathieu*

THU054

THU055

THU056

THU057
OSTEOPOROSIS AND CELIAC DISEASE IN PATIENTS WITH DISTAL RADIUS AND ANKLE FRACTURES / A. M. Hjelle* - G. Tell - E. Apalset - P. Mielnik - J. Bollerslev

THU058
OSTEOPOROSIS AND OSTEOCALCIN LEVELS IN PATIENTS WITH GOUT / A. Dogru* - A. Balkarlı - C. C. Karatay - M. Mugerza - A. Boteanu

THU059
COMPARISON BETWEEN THE AMERICAN RECOMMENDATIONS AND THE JAPANESE GUIDELINES FOR OSTEOARTHRITIS IN JAPANESE RHEUMATOID ARTHRITIS; 12 MONTHS OF FOLLOW-UP / Y. Kanayama* - Y. Hirano - N. Ishiguro - T. Kojima on behalf of TBCR-BONE study group

THU060
COMPARISON OF DORSAL AND LUMBAR PAIN IN PATIENTS WITH AND WITHOUT NON-ACUTE VERTEBRAL FRACTURES IN TERMS OF THERAPEUTIC APPROACH AND URGENT CARE BURDEN / C. A. Inderjeeth* - G. Tell - E. Apalset - P. Mielnik - J. Bollerslev

THU061

THU062

THU063
EVALUATION OF TRABECULAR BONE SCORE IN PATIENTS WITH A DISTAL RADIUS FRACTURE / H. S. Gong* - Y. H. Shin

THU064

THU065
THE INFLUENCE OF ORAL PREDNISOLONE ON EFFECT OF DENOSUMAB ON OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS - A MULTICENTER REGISTRY STUDY / Y. Kojima on behalf of TBCR-BONE study group

THU066

THU067
NARF: A NEW TOOL FOR THE IDENTIFICATION OF PATIENTS WITH OSTEOPOROSIS / A. E. Deschaumes - M. Soubrier - S. Mathieu*

THU068

THU069
PREVALENCE OF ASYMPATOMIC MORPHOMETRIC VERTEBRAL DEFORMITIES IN HIV-INFECTED PATIENTS / M. Llop Villatella* - W. A. Sifuentes Giraldo - M. Vázquez Díaz - C. Medina Quiliones - C. C. Macía Villa - S. Bañón-Escandell - J. L. Casado Osorio

* Presenting author
Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis

THU0482 PREDICTORS OF FRACTURES IN PATIENTS WITH UNTREATED EARLY MENOPAUSE: AN OBSERVATIONAL STUDY M. H. Dobrzynska* - R. Sinha - M. Bukhari

THU0483 INCREASED INFECTION RISK WITH CONCOMITANT USE OF RANKL-INHIBITOR, DENOSUMAB AND TNF-INHIBITORS OR OTHER BIOLOGICS: FACT OR FICTION? / F S. Chhibar* - G. Ehrensman

THU0484 Zoledronic Acid Infusion and Effect on Renal Function and Calcium in Osteoporosis R. Laxminarayan* - N. Sayed - M. Nisar - G. Swamy - H. Rachael


THU0487 Teriparatide Improved Bone Loss and Hyperalgesia in a Mouse Model of Osteoporosis S. Kato - H. Wakabayashi - Y. Naito - G. Miyamura* - A. Sudo

THU0488 New Zoledronate Database Significantly Improves Pre-assessments and Waiting Times to Repeat Infusions - Results from a Quality Improvement Project / S. Vasireddy* - C. Allman - J. Farrant - M. Ammiri - N. Khan - L. Bromilow

THU0489 Daily Teriparatide Treatment after Bisphosphonate Therapy in Osteoporosis of Patients with Rheumatoid Arthritis / Y. Hirano* - M. Isono - J. Fukui - J. Hasegawa - N. Ishiguro - T. Kojima

* Presenting author

Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis


THU0491 A Novel Method of Estimating Extra-renal Clearance of Uric Acid / D. Hyndman* - S. Liu - J. Hall - J. N. Miner

THU0492 Uric Acid Transport Kinetics in the Kidney: Detection of Renal Secretion and the Mechanism of Low Feua / S. Liu* - D. Hyndman - J. N. Miner


THU0494 Skin Events with Febuxostat in Gout Patients with Previous Skin Reactions to Allopurinol. A Retrospective Review / N. Quilis* - M. Andrés - P. Vela - E. Pascual

THU0495 Examination of Serum Uric Acid (SUA) Lowering and Safety with Extended Treatment with Lutisinrad and Allopurinol in Subjects with Gout / K. G. Saag* - M. A. Becker - C. Storgard - M. Fung - N. Bhakta - S. Adler - J. Hu - T. Bardin


THU0497 Ultrasound in Gout: Which Joints Should be Evaluated Concerning Differences Between the Early and Late Gout? / E. Norkuviene* - M. Petrulis - I. Apanavičienė - D. Virviciute - A. Baranauskaitė


THU0502 Comparison of Low Doses of Systemic Corticosteroids Therapy in Diabetic Patients with Oligoarticular or Polyarticular Gout Flares: An Observational Retrospective Study C. A. Guillet-Astete* - A. Boteau - M. Villarejo-Bojta

THU0503 Major Cardiovascular Events in Patients with Recurrent Gout, Cardiovascular and Chronic Kidney Disease, Initiating on Allopurinol or Febuxostat / J. Foody - R. Turpin - B. A. Tidwell - D. F. Eisenberg Lawrence* - K. L. Schulman

THU0504 Comorbidities and the Effectiveness of Corticosteroids in Patients with Gouty Arthritis E. Mikhnevich* - T. Pavlovich - J. Shishko

THU0505 The Development of a New European Regulatory Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Gout / E. Rook* on behalf of Rheumatology/Immunology Working Party, European Medicine Agency


THU0507 Evidence of the Use of Colchicine are More Numerous in Cardiology and Hepato-Gastroenterology than in Rheumatology: A Systematic Literature Review of Clinical Trials / F. Kmenta Lekpa* - A. F. Kwimatouso Lekpa

THU0508 Improvement in Treat to Target Serum Urate Levels: Results from a Comparison Between the Gema and the Gema-II Audits / F. Perez-Ruiz* - M. Andres - C. Diaz-Torne - E. de Miguel - C. Moragues - F. Sivera - M. Jimenez-Palop - C. Sanchez-Piedra

* Presenting author
THU0509  OPTICAL COHERENCE TOMOGRAPHY DESCRIPTION OF TOPHI IN GOUT SHOWS THAT IRREGULAR TOPHUS MORPHOLOGY, OEDema AND ABsENCE OF CAPSULE ARE ASSOCIATED WITH SYMPTOMATIC DISEASE
G. Ahiogruno* - E. Del Galdo - D. McGonagle


THU0511  FACTORS ASSOCIATED WITH PRECLINICAL AtherosclEROTIC CHANGES IN CAROTID ARTERY IN MEN WITH GOUT / H. Tag* - G. Kim - E. Park - D. Koo - J. Lee - S. Kim


THU0513  DETECTION OF SUBCLINICAL TOPHI IN PATIENTS WITH GOUTY ARTHRITIS: A DUAL-ENERGY COMPUTED TOMOGRAPHY STUDY / J. Kim* - J. Y. Lee


THU0515  INCREASED CAROTID INTIMA-MEDIA THICKNESS WAS RELATED WITH ELEVATED SERUM HomocystEINE LEVEL IN PATIENTS WITH HOMOCystEINA / J. H. Park* - S. T. Choi - J.-S. Song


THU0517  WOMEN WITH GOUT SHOW A POORER CARDIOVASCULAR PROFILE AFTER STRUCTURED ASSESSMENT J. A. Bernal* - M. André - F. Sivera - L. Carmona - P. Vela - E. Pascual

THU0518  NEW CARDIOVASCULAR RISK FACTORS SCREENING IN PATIENTS WITH GOUT / J. C. Ordonez* - M. Andres - J. A. Bernal - F. Sivera - L. Carmona - P. Vela - E. Pascual


THU0521  PREVALENCE OF GOUT AND ULT TREATMENT IN WESTERN SWEDEN - A REGISTER STUDY / M. I. Dehlin* - P. Drivelegka - V. Sigurdardottir - A. Svård - L. Jacobsson


THU0525  COUNTING SYNOVIAL FLUID MONOSODIUM URATE CRYSTALS MAY BE USEFUL IN THE MANAGEMENT OF PATIENTS WITH GOUT / P. Montagna* - R. Brizzolara - C. Ferrone - S. Soldano - M. Cutolo - M. A. Cimmino


THU0527  NEW CARDIOVASCULAR RISK FACTORS SCREENING IN PATIENTS WITH GOUT - FACTORS AFFECTING INITIATION AND PERSISTENCE OF URATE LOWERING THERAPY / M. I. Dehlin* - E. Hoaxa Ekström - M. Petzold - U. Strömberg - G. Telg - L. Jacobsson


THU0529  COUNTING SYNOVIAL FLUID MONOSODIUM URATE CRYSTALS MAY BE USEFUL IN THE MANAGEMENT OF PATIENTS WITH GOUT / P. Montagna* - R. Brizzolara - C. Ferrone - S. Soldano - M. Cutolo - M. A. Cimmino

THU0530  SPATIOTEMPORAL GAIT PARAMETERS AND PLANTAR PRESSURE DISTRIBUTION DURING BAREFOOT WALKING IN PEOPLE WITH GOUT AND ASYMPTOMATIC HOMOCystEINA: A CROSS-SECTIONAL OBSERVATIONAL STUDY / S. Stewart* - N. Dalboth - A. C. Vandal - K. Rome


THU0533  COMPARATIVE EFFICACY OF METHOTREXATE AND COLCHICINE IN CPPD AND CHRONIC ARTHRITIS PATIENTS / S. Vladimirov* - M. Eliseev - O. Zheylabina - E. Nasonov

THU0534  SKIPPING BREAKFAST INCREASES SERUM URIC ACID LEVELS / S. Liu* - J. N. Miner

THU0535  QUALITY OF LIFE IN PATIENTS WITH GOUT IN WESTERN SYDNEY / S.-N. Luong* - V. Thakkar - G. Hassett - H. Mannan - K. Pile


* Presenting author
THU0537  CLINICAL RESPONSE OF TOPHUS AND FLARES TO EXTENDED USE OF LESINURAD IN COMBINATION WITH A XANTHINE OXIDASE INHIBITOR IN PATIENTS WITH GOUT / T. Bardin* - N. Dalbeth - R. Terkeltaub - C. Storgard - M. Fung - J. Hui - E. Perez-Ruiz

THU0538  DECREASING URIC ACID LEVEL IS ASSOCIATED WITH IMPROVING GLOMERULAR FILTRATION RATE IN CHRONIC KIDNEY DISEASE PATIENTS WITH/WITHOUT GOUT / T.-S. Lin* - C.-Y. Huang - S.-C. Hsieh


Fibromyalgia

THU0541  PAIN FROM STRUCTURAL PATHOLOGY IS A RISK FACTOR FOR LATER GENERALIZED PAIN: A POPULATION BASED COHORT STUDY / E. Bondesson* - F. Larossa Pardo - M. E. Sandberg - A. Löwd


THU0543  EVALUATION OF THE FIBROMYALGIA RAPID SCREENING TOOL (FIRST) QUESTIONNAIRE TO SCREEN FIBROMYALGIA ASSOCIATED WITH INFLAMMATORY RHEUMATIC DISEASE / A. Fan - B. Pereira - A. Tournadre - Z. Tatar - S. Malochet-Guainand - M. Soubrier - J.-J. Dubost*

THU0544  IMPAIRED PULMONARY DIFFUSING CAPACITY IN PATIENTS WITH FIBROMYALGIA / M. Rizzi - F. Atzeni* - A. Andrea Arioldi - I. F. Masala - F. Francesca Frassanito - C. Macaluso - F. Salafi - P. Sarsi-Putinti


THU0547  IS PAIN CATASTROPHISING ASSOCIATED WITH IMPAIRED CONDITIONED PAIN MODULATION IN PEOPLE WITH CHRONIC WIDESPREAD PAIN? / D. Rice - R. Parker* - G. Lewis - P. McNair

THU0548  SLEEP ARCHITECTURE AND CLINICAL PARAMETERS IN FIBROMYALGIA AND OSTEARTHROPSIS / W. K. Yeung* - K. Morgan - F. McKenna


THU0551  NOVEL SJOGREN'S AUTOANTIBODIES FOUND IN FIBROMYALGIA PATIENTS WITH SICCA AND/OR XEROSTOMIA / A. Lichtbroun*


THU0555  IMPAIRED PULMONARY DIFFUSING CAPACITY IN PATIENTS WITH FIBROMYALGIA / M. Rizzi - F. Atzeni* - A. Andrea Arioldi - I. F. Masala - F. Francesca Frassanito - C. Macaluso - F. Salafi - P. Sarsi-Putinti


THU0559  FIBROMYALGIA SYMPTOMS IN A SAMPLE OF LEBANESE NURSES: PREVALENCE AND PREDICTIVE FACTORS / M. Zateri - M. Birtane


* Presenting author
Other orphan diseases


THU0562 A SURVEY OF RESISTANCE TO COLCHICINE TREATMENT IN FRENCH PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER / A. Corsia* - S. Georgin-Lavialle - G. Grateau - V. Hentgen - A. Faye - P. Quartier - I. Koné-Paut on behalf of French FGM working group


THU0564 TREATMENT OF FAMILIAL MEDITERRANEAN FEVER WITH ANAKINRA IN PATIENTS UNRESPONSIVE TO COLCHICINE / A.-C. Pecher* - A. Igney-Oertel - L. Kanz - J. Henes


THU0568 ULRASONOGRAPHY OF SALIVARY GLANDS FOR DIAGNOSE OF IGG4-RELATED MIKULICZ’S DISEASE D. F. Lin* - W. Q. Yang - M. J. Zhao - J. Y. Cao - Z. T. Liao


THU0573 SEMEN ANALYSIS IN ADOLESCENT WITH FAMILIAL MEDITERRANEAN FEVER / G. K. Aksoy* - M. F. Usta - Y. Ozguler - S. N. Esatoglu - G. Karatemiz - H. Ozdogan - S. Yurdakul - E. Seyahi


THU0575 MUSCULOSKELETAL SARCOIDOSIS- DEMOGRAPHICS, DIAGNOSTIC, TREATMENT CHARACTERISTICS, AND TREATMENT EXPERIENCE FROM A TERTIARY CARE CENTER IN THE UNITED STATES / M. Arakane* - S. Vogelgesang - Z. Ballas - N. Singh


THU0577 MUSCULOSKELETAL SARCOIDOSIS- DEMOGRAPHICS, DIAGNOSTIC, TREATMENT CHARACTERISTICS, AND TREATMENT EXPERIENCE FROM A TERTIARY CARE CENTER IN THE UNITED STATES / M. Arakane* - S. Vogelgesang - Z. Ballas - N. Singh


THU0590  RISK FACTORS FOR CYTOMEGALOVIRUS REACTIVATION IN PATIENTS WITH CONNECTIVE-TISSUE DISEASES Y. Ota* - Y. Kaneko - T. Takeuchi

THU0591  CLINICAL FEATURES OF ERYTHEMA NODOSUM IN SARCOIDOSIS / Y. Karpova* - B. Belov - O. Egorova - S. Radenska-Lopovok

Epidemiology, health services and outcome research


THU0595  IMPACT OF PHYSICIAN-PATIENT INTERACTIONS ON DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. Drenkard* - G. Bao - H. Kan - B. Pobiner - P. Julie - W. Eastman - S. S. Lim

THU0596  PHYSICIAN’S GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS, REFLECTS SOLELY OBJECTIVE MEASURES AND DISREGARDS PATIENT REPORTED OUTCOMES / G. Eugenio* - R. Ferreira - C. Silva - C. Duarte - J. A. P. Silva

THU0597  COMPARISON OF SELF ASSESSMENT OF DISEASE ACTIVITY TO DAS28 IN RHEUMATOID ARTHRITIS: DATA FROM THE RANDOMIZED “ROC” TRIAL / C. Sordet* - E. Chatelus - P. Ravaud - J. Sibilia - J.-E. Gottenberg on behalf of the ROC trial investigators


THU0599  KEY DRIVERS IN BIOSIMILAR PRESCRIPTION IN INFLAMMATORY AUTOIMMUNE DISEASES INDICATIONS IN GERMANY / E. Sullivan - J. Piercy - J. Waller - C. Black - S. Kachroo* - J. Aquilina

THU0600  PATIENTS’ PERCEPTION AND SATISFACTION OF WAITING TIME AT MEDICAL OUTPATIENTS / R. Magro* - J. Aquilina


THU0602  PATIENT GLOBAL ASSESSMENT IN RHEUMATOID ARTHRITIS CONVEYS A VARIABLE BLEND OF DISEASE ACTIVITY AND DISEASE IMPACT: A CROSS-SECTIONAL STUDY WITH 311 PATIENTS / A. Molto - I. Petersson - M. Redondo - G. Schett - L. Gossec


THU0605  OMEGA-3 FATTY ACIDS ASSOCIATED WITH DECREASED PAIN, INDEPENDENT OF INFLAMMATION, IN MTX TREATED EARLY RA PATIENTS / C. Lourdudos* - A. Wolk - D. Di Giuseppe - H. Westerlind - L. Klarenkog - L. Alfredsson - R. van Vollenhoven - J. Lampia

THU0606  INCIDENCE AND PREVALENCE OF CARDIOVASCULAR RISK FACTORS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIASIS, OR PSORIATIC ARTHRITIS / D. H. Solomon* - T. Lesperance - H. Radner - N. Accort

THU0607  EFFECTIVENESS AND PERSISTENCE OF GOLIMUMAB ACROSS RHEUMATIC DISEASE INDICATIONS IN CLINICAL PRACTICE: RESULTS FROM THE NATIONAL SWEDISH REGISTRY / D. Di Giuseppe* - T. Frissell - J. Askling


* Presenting author


THU0612  DEVELOPMENT AND VALIDATION OF AN ACCURATE AND PRECISE NATURAL LANGUAGE PROCESSING SYSTEM TO CAPTURE RHEUMATOID ARTHRITIS DISEASE ACTIVITY MEASURES / G. W. Cannon* - S. Mijoribra - B. R. South - J. Leng - C.-C. Lu - B. C. Sauer

THU0613  PAIN CATASTROPHIZING HAS A MAJOR IMPACT ON BOTH SUBJECTIVE AND COMPOSITE OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS; RESULTS FROM A LONGITUDINAL STUDY OF PATIENTS STARTING BDMARDS / H. B. Hammer* - J. Lampa


THU0617  WORK PRODUCTIVITY AND DAILY ACTIVITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN FOUR PHASE III RANDOMIZED CLINICAL TRIALS OF BARICITINIB / J. S. Smolen* - A. M. DeLozier - S. de Bono - L. Yang - C. Gaich

THU0618  DISEASE ACTIVITY DURING AND AFTER PREGNANCY IN WOMEN WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM A PROSPECTIVE MULTICENTER STUDY / K. Ursin* - S. Lydersen - J. Skomsvoll - M. Wallenius


THU0622  EPIDEMIOLOGY AND OUTCOME OF DERMATOMYOSITIS IN NORTHWESTERN THRACE REGION IN TURKEY M. A. Balec* - F. Saritas - S. Donmez - O. N. Pamuk


THU0626  DRUG ADHERENCE IMPACT ON SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS HEALTH / N. O. El-Azizi - A. A. M. Elhefny* - M. A. Abd El-Rahman - M. A. Abou-Sheaasha


THU0629  THE COST-EFFECTIVENESS OF GOLIMUMAB AS AN ADD-ON TO CONVENTIONAL CARE COMPARED TO CC FOR THE TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN SCOTLAND / R. H. Borse* - E. McCann - O. McGill - C. Black - S. Radioghoor - R. Insinga

* Presenting author


THU0632  RETROSPECTIVE ANALYSIS OF THE ASSOCIATION BETWEEN ANTI-CYCLIC CITRULLINATED PEPTIDE POSITIVITY AND HEALTHCARE COSTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS / S. Johnston* - C. Patel - K. Wilson - D. Spencer - L. Rosenblatt


THU0634  SEX DIFFERENCES IN CARDIOVASCULAR RISK FACTORS AND EVENT RATES IN PATIENTS WITH RHEUMATOID ARTHRITIS - DATA FROM 13 RHEUMATOLOGY CENTERS / S. Rollefstad* - E. Ikdahl - C. S. Crowson - S. E. Gabriel - G. D. Kitas - P. L. van Riel - A. G. Semb on behalf of A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA)


THU0638  LEG LENGTH INEQUALITY AS A RISK FACTOR FOR DISABILITY IN A COMMUNITY-BASED LONGITUDINAL STUDY / Y. M. Golightly* - C. Alvarez - J. Cantrell - J. B. Renner - C. G. Helmick - J. M. Jordan

* Presenting author
Scientific Programme

Development of a JAK3 specific inhibitor clinical candidate: functional differentiation of JAK3 selective inhibition over pan-JAK or JAK1 selective inhibition

A. Hammitzsch (United Kingdom) 09:30
L. Chen, H. Al-Mossawi, D. Simone, A. Ridley, P. Bowness
Abstract N° OP0156
Deciphering the in vitro therapeutic potential of JAK inhibitors in ankylosing spondylitis

08:15 - 09:45  Capital Suite 14

Basic and Translational Science session

Crystal arthritis

Chairperson(s):
Frederic Lioté (France)
Terence Gibson (United Kingdom)
Robert Terkeltaub (United States) 08:20
Abstract N° SP0123
Gout: a variable inflammatory disease

Abhishek Abhishek (United Kingdom) 08:40
Abstract N° SP0124
Systemic predisposition to CPPD and interaction with osteoarthritis

Hans J. Anders (Germany) 09:00
Abstract N° SP0125
Renal handling of urate and gout

S. Kob (Turkey) 09:20
Abstract N° SP0126
Prevalence and significance of MEFV gene mutations in patients with gouty arthritis

T. R. Merriman (New Zealand) 09:30
Abstract N° OP0157
Mitochondrial genetic variation and susceptibility to gout in polynesians

Educational session

The Lancet - meet the editor

Learning objectives:
The participants will learn about the approach of a leading medical journal how the papers submitted are managed and about future perspectives of medical publications

Chairperson(s):
Gerd R. Burmester (Germany)
Tore K. Kvien (Norway)
Bernard Combe (France)
Gerd R. Burmester (Germany) 08:20
Introduction

Jennifer Sargent (United States) 08:30
The Lancet: a publishing overview

Faculty 08:45
Panel discussion

Faculty 09:15
Q&A with the audience

09:45 - 10:15 Exhibition (S5-S9)
Coffee break

10:15 - 11:45 ICC Auditorium

What is New (WIN)
WIN session 5
Maxime Breban (France) 10:20
Axial and peripheral spondyloarthritis
Douglas Veale (Ireland) 11:00
Psoriatic arthritis

10:15 - 11:45 Hall B
Abstract session
Expanding therapeutic options in spondyloarthritis

Chairperson(s):
Maxime Dougados (France)
M. G. van de Sande (Netherlands)
S. Schreiber (Germany)
B. E. Sands, A. Deodhar, D. Baeten, J. Huang,
K. Gandhi, C. Karyekar, T. Fox, C. Gaillez
Abstract N° OP0113
No increased incidence of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies

D. Baeten (Netherlands)
S. Glatt, F. Strimenopoulou, P. Vajjah, S. Shaw,
L. Ionescu, S. Popa
Abstract N° OP0108
Bimekizumab, a monoclonal antibody that inhibits both IL-17A and IL-17F, produces a profound response in both skin and joints: results of an early-phase, proof-of-concept study in psoriatic arthritis

P. J. Mease (United States) 10:40
M. Okada, M. Kishimoto, C. L. Shuler, H. Carlier,
Abstract N° OP0109
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52 week results from a phase 3 study (SPIRIT-P1)

L. Rogge (France) 10:50
S. Menegatti, E. Latis, H. Yahia, C. Leloup, N. Ménaigé,
A. Moltó, C. Miceli-Richard, M. Dougdas, E. Bianchi
Abstract N° OP0111
Anti-TNF therapy in axial spondyloarthritis: prediction of therapeutic responses using immunological signatures

A. Sepriano (Portugal) 11:00
S. Ramiro, D. van der Heijde, P. Ávila-Ribeiro,
R. Fonseca, J. Borges, L. Teixeira, P. Carvalho,
M. Cerqueira, J. Neves, T. Meirinhos, A. Barcelos,
G. Sequeira, M. J. Salvador, J. A. Canas da Silva,
H. Santos, M. Bernardez, E. Vieira-Sousa, H. Canhão,
J. Branco, F. Pimentel-Santos, S. Landewé
Abstract N° OP0112
Effect of comedication with conventional synthetic DMARDs on TNF inhibitors-retention in patients with spondyloarthritis: a prospective cohort

W. Maksymowycz (Canada) 11:10
V. Strand, D. Baeten, P. Nash, H. Thom, S. Cure,
E. Palaka, K. Gandhi, H. Richards, S. Jugl
Abstract N° OP0114
Secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus adalimumab using a matching-adjusted indirect comparison

A. Joshi (United States) 11:20
K. A. Betts, M. Mittal, J. Song, S. Skup
Abstract N° OP0115
Relative efficacy of adalimumab versus secukinumab in active ankylosing spondylitis: a matching-adjusted indirect comparison

10:15 - 11:45 Hall D

Abstract session
Developments in the treatment of RA

Chairperson(s):
Peter C. Taylor (United Kingdom)
Paul Studenic (Austria)
M. C. Genovese (United States) 10:20
J. S. Smolen, M. E. Weinblatt, S. Meerwein, H. S. Camp,
L. Wang, A. A. Othman, N. Khan, S. Jungerwirth
Abstract N° OP0223
Safety and efficacy of ABT-494, a novel selective JAK1 inhibitor, in patients with active rheumatoid arthritis with an inadequate response to methotrexate

R. Westhovens (Belgium) 10:30
R. Alten, D. Pavlova, F. E. Enriquez Sosa, M. Mazur,
M. Greenwald, A. van der Ae, F. Vanhoutte, C. Tasset,
P. Harrison
Abstract N° OP0224
Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a 24-week phase 2B dose ranging study

10 June 2016
B. Glintborg (Denmark)  
I. Juul Sørensen, D. Vendelbo Jensen, N. S. Krogh,  
A. G. Loft, A. Colic, J. Espesen, J. Olsen, O. Hendricks,  
J. Grydehøj, I. M. J. Hansen, M. V. Sørensen, S. Chrysidis,  
N. Manilo, M. V. Sørensen, S. Chrysidis,  
N. Kristensen, M. L. Hetland

Abstract N° OP0225
Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Results from the Danbio registry

J. O’Dell (United States)  
T. Takeuchi, Y. Tanaka, I. Louw, T. Tiabut, M. Kai,  
M. Oribe, S. Nakashima, B. Finck on behalf of RApsody study group

Abstract N° OP0226
Randomized, double-blind study comparing CHS-0214 with etanercept in patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) therapy

P. Emery (United Kingdom)  
C. Bingham, G.-R. Burmester, V. P. Bykerk, D. Furst,  
X. Mariette, D. van der Heijde, R. van Vollenhoven,  
B. VanLunen, C. Ecoffet, C. Cioffi, M. Weinblatt

Abstract N° OP0227
A randomized double-blind treatment strategy study evaluating continuation or reduced-frequency dosing of certolizumab pegol versus withdrawal to maintain low disease activity in early RA patients (C-early period 2)

T. Takeuchi (Japan)  
M. Genovese, L. Xie, M. Issa, A. L. Pinto Correia,  
T. Rooney, K. Emoto, J. Smolen

Abstract N° OP0228
Baricitinib dose step-down following disease control in patients with rheumatoid arthritis

T. Takeuchi (Japan)  
N. Miyasaka, T. Inui, T. Yano, T. Yoshinari, T. Abe,  
T. Koike

Abstract N° OP0229
Both high titer of RF/ACPA at baseline is closely linked with high level of baseline plasma TNF level which resulted in low drug level and low clinical response in infliximab treatment in RA patients: post-hoc analysis of a double-blind clinical study (RISING study)

Z. Szekanecz (Hungary)  
S. Szántó, G. Szücs, S. Szamosi, Á. Horváth, A. Domján,  
H. P. Bhattoa, J. Kappelmayer, G. Toldi, P. Szeremly,  
A. Ajpok

Abstract N° OP0230
Multi drug resistance (MDR) protein activity of activated T lymphocytes is a predictor of biological treatment response in rheumatoid arthritis

10:15 - 11:45  Hall E

How to Treat/Manage (HOT)

HOT session 7

Ingrid Lundberg (Sweden)  
Abstract N° SP0126
Myositis

Loic Guillevin (France)  
11:00
Vasculitis

10:15 - 11:45  Hall C

Abstract session

Epidemiology of RMDs

Chairperson(s):  
Merete Hetland (Denmark)  
Delphine Courvoisier (Switzerland)

1. Pelaez-Ballestas (Mexico)  
Y. Granados, A. Silvestre, F. Julian-Santiago, N. Santana,  
C. Rosillo, J. Alvarez-Nemegyei, A. Loyola-Sanchez,  
R. Quintana, M. V. Goycoocha-Robles, C. Pacheco-Tena,  
M. Goñi, C. García-García, L. Cedeño, B. Pons-Estel on behalf of GLADERPO

Abstract N° OP0167
Prevalence of rheumatic disease in Latin American indigenous population: a community based study

A. Strangfeld (Germany)  
C. Bungartz, J. Richter, A. Zink, M. Schneider,  
J. Listing, R. Fischer-Betz

Abstract N° OP0168
First results from the prospective German pregnancy register Rhekiss

H.-H. Chen (Taiwan)  

Abstract N° OP0169
Association between use of disease-modifying anti-rheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: nationwide, population-based cohort study of 84989 patients

J. Callhoff (Germany)  
K. Albrecht, F. Hoffmann, A. Luque Ramos, A. Zink

Abstract N° OP0170
Low income is associated with lower functional capacity and higher disease burden in RA patients younger than 65

M. Rossides (Sweden)  
J. F. Simard, E. Svenungsson, M. von Euler, E. V. Arkema

Abstract N° OP0171
Prognosis of stroke patients with systemic lupus erythematosus: a population-based cohort study
D. De Cock (Belgium) 11:10
A. De Saedeleer, K. van der Elst, V. Stouten, J. Joly, R. Westhooven, P. Verschuere
Abstract N° OP0172
A cost-effectiveness analysis of different intensive combination therapies for early rheumatoid arthritis: 1 year results of the careRA trial

S. J. Bartlett (United States) 11:20
Abstract N° OP0173
How much of a barrier is excess weight and smoking for achieving sustained remission in early RA? Results from the Canadian early arthritis cohort

P. D. H. Hamann (United Kingdom) 11:30
K. Hyrich, A. Jobling, N. McHugh, G. Shaddick, J. Pauling
Abstract N° OP0174
The development of the modified DAS28-CRP to improve agreement with DAS28-ESR and ensure appropriate disease activity stratification in RA

10:15 - 11:45  Hall A

Abstract session
SLE, Sjögren’s and APS: clinical aspects (other than treatment)

Chairperson(s):
Dimitrios Boumpas (Greece)
Christophe Richez (France)

E. V. Arkema (Sweden) 10:20
H. Wadström, C. Sjöwall, J. Askling, J. F. Simard
Abstract N° OP0189
Rate of cervical neoplasia in systemic lupus erythematosus: a nationwide cohort-study

L. Durcan (United States) 10:30
W. Fu, M. Petri
Abstract N° OP0183
Hypocomplementemia associates with thrombosis in SLE patients with antiphospholipid antibodies

P.-E. Gavand (France) 10:40
Abstract N° OP0184
Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome. Data from a French nationwide study of 81 episodes in 67 adult patients

H. Zhang (China) 10:50
C. Liu, G. Yao, W. Chen, L. Sun
Abstract N° OP0185
Characteristics of primary Sjögren’s syndrome patients with IgG4-positive plasma cells in labial salivary glands

K. Elkon (United States) 11:10
Abstract N° OP0186
Immune complex bound U1 and Y1 RNA correlates with interferon-stimulated gene expression and disease activity: an observational study of systemic lupus erythematosus patients

A. Souto (Spain) 11:10
A. Castelo, J. R. Maneiro, E. Cervantes, A. Mera, J. Gomez-Reino
Abstract N° OP0187
All-cause and specified causes of mortality in systemic lupus erythematosus: systematic review and meta-analysis of clinical trials

F. A. Houssiau (Belgium) 11:20
A. El Mourad, S. Nieuwland-Husson, G. Depresseux
Abstract N° OP0188
The dose of glucocorticoids taken at one year, but not the initial dose prescribed, is an independent predictor of damage accrual in lupus nephritis

V. Oke (Sweden) 11:30
S. Brauner, A. Larsson, J. Gustafsson, A. Zickert, I. Gunnarsson, E. Venungsson
Abstract N° OP0190
Increased serum levels of IFN-α correlate with TH17 axis cytokines and independently to IFN-α identify patient group with higher organ damage

10:15 - 11:45  Capital Suite 07

HPR Abstract session
Shared decision-making

Chairperson(s):
Annette de Thurah (Denmark)
Bente Appel Ebensen (Denmark)

C. Hudry (France) 10:20
A. Lebrun, B. Moura, O. Backers, H. Herman-Demars
Abstract N° OP0191-HPR
Usability study of a new autoinjector in the management of rheumatoid arthritis

R. Rawat (India) 10:30
S. S. Baghel, R. Thakran, C. Messi, S. Kapoor, S. Garg, A. N. Malaviya
Abstract N° OP0192-HPR
Teaching methotrexate self-injection technique to the patients in a routine rheumatology out-patient clinic: factors favouring or countering acceptability
10:40
E. Moholt (Norway)
Abstract N° OP0193-HPR
Aiming for remission in early RA: impact on pain during the first 2 years of treatment

10:50
G. Piemonte (Italy)
K. El Aoufi, F. Braschi, M. Poli, S. Guiducci, S. Bellando Randone, L. Rasero, M. Matsuic Cerinic
Abstract N° OP0194-HPR
Nursing triage in rheumatology: three months experience in an outpatient clinic of the University of Florence (Italy)

11:00
F. Fayet (France)
M. Rodere, C. Savel, B. Pereira, M. Soubrier, M. Couderc
Abstract N° OP0195-HPR
Comparison of educational models for maintaining optimal safety in the self-management of biotherapy amongst rheumatoid arthritis and spondyloarthritis patients

11:10
L. van Rossen (United Kingdom)
C. Harris, R. Witherington, A. Keat
Abstract N° OP0196-HPR
Dose reduction of biologic drugs in axial spondyloarthritis in clinical practice

11:20
J. M. Hazes (Netherlands)
Abstract N° OP0197-HPR
Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis

11:30
S. Gavan (United Kingdom)
G. Daker-White, A. Barton, K. Payne
Abstract N° OP0198-HPR
Exploring factors which influence anti-TNF treatment decisions for rheumatoid arthritis in England - a qualitative analysis

10:15 - 11:45  Capital Suite 11

Abstract session

Comorbidities

Chairperson(s):
Johannes W. J. Bijlsma (Netherlands)
Annette van der Helm (Netherlands)

N. Konijn (Netherlands)
Abstract N° OP0262
Similar clinical and radiological outcome in the COBRA and COBRA-light treatment group 4 years after initiation of the COBRA-light trial

Y. El Miedany (United Kingdom)
M. El Gaafary, S. Youssef, S. Bahlas, I. Ahmed, M. Hegazi
Abstract N° OP0255
Rheumatoid arthritis comorbidity index: development and validation of a new specific tool for classifying prognostic comorbidity in rheumatoid arthritis patients

H. Kokkonen (Sweden)
S. Rantapää-Dahlqvist
Abstract N° OP0256
Presence of risk factors for cardiovascular disease predate the onset of symptoms of rheumatoid arthritis

C. S. Crowson (United States)
M. Maha El Gaafary, S. Youssef, D. Palmer, A. Nasr
Abstract N° OP0258
Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping DMARDs/biologic agents by ultrasonographic assessment in rheumatoid arthritis patients who achieved clinical remission

J. R. Curtis (United States)
M. Liu, S. Rebello, M. Trivedi, T. Lesperance, Y. Li, N. Accortt
Abstract N° OP0259
Impact of sustained remission on risk for infection in patients with rheumatoid arthritis enrolled in a US registry

A. Strangfeld (Germany)
A. Richter, B. Siegmund, P. Herzer, K. Rockwitz, W. Demary, M. Aringer, A. Zink, J. Listing
Abstract N° OP0260
Lower intestinal perforations are more frequent and present untypically in patients treated with tocilizumab compared to other biologic or conventional synthetic DMARDs

B. Combe (France)
C. Roubille, N. Rincheval, M. Dougados, R.-M. Flipo, J.-P. Daures
Abstract N° OP0261
7-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort
Abstract session
An inflammatory update!

Chairperson(s):
Reinhard E. Voll (Germany)
Stefan Siebert (United Kingdom)
Z. Szondy (Hungary)

10:20
A. Pallai, B. Kiss, G. Vereb, M. Armaka, G. Kollias, Z. Szekanecz
Abstract N° OP0207
Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by anti-TNF-alpha targeting molecules

S. Yu (China)  
10:30
C.-H. Huang, W.-H. Huang, C.-H. Huang, Y. Huo, Y. Tao
Abstract N° OP0208
Emerging role of IL-33/ST2 axis in endothelial cell injury of lupus nephritis

Y. Gan (China)  
10:40
X. Sun, L. Li, J. He, Z. Li
Abstract N° OP0209
Elevated GITRL is associated with multi-organ involvement and increased disease activity of primary Sjögren's syndrome and promotes pathogenic TH17 differentiation

G. Ascone (Netherlands)  
10:50
I. Di Ceglie, W. de Munter, B. Walgreen, A. Sloetjes, P. van Lent, P. van der Kraan
Abstract N° OP0210
Apolipoprotein E aggravates inflammation and joint destruction in murine antigen-induced arthritis

T. McGarry (Ireland)  
11:00
M. Biniecka, D. Veale, U. Fearon
Abstract N° OP0211
Reprogramming of metabolic pathways inhibits TLR2-induced inflammation in RA

R. Audo (France)  
11:10
Abstract N° OP0212
Phospholipid transfer protein (PLTP): a link between inflammation and lipids in rheumatoid arthritis?

S. Tas (Netherlands)  
11:20
L. Huitema, B. Helder, A.-R. Noort, C. Lebre
Abstract N° OP0213
Personal exposure to air pollution influenced disease activity and exhaled breath biomarkers: a prospective study in a childhood-onset systemic lupus erythematosus population

Abstract session
Advances in paediatric rheumatology

Chairperson(s):
Rolando Cimaz (Italy)
Helen E. Foster (United Kingdom)
N. Ruperto (Italy)

10:20
Abstract N° OP0215
Subcutaneous abatacept in patients with polyarticular juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs: pharmacokinetics, efficacy and safety

G. Horneff (Germany)  
10:30
A. C. Schultz, A. Hospach, G. Ganser, I. Foeldvari, A. Thon, R. Trauzeddel, E. Weller, K. Minden, J. P. Haas
Abstract N° OP0216
Safety of tocilizumab, interleukin-1 inhibitors and etanercept in 262 systemic juvenile idiopathic arthritis patients

J. Swart (Italy)  
10:40
Abstract N° OP0217
Adjudication of infections in the pharmacovigilance in juvenile idiopathic arthritis patients (PHARMACHILD) treated with biologic agents and/or methotrexate

H. Lythgoe (United Kingdom)  
10:50
T. Morgan, E. Heaf, O. Lloyd, M. W. Beresford on behalf of UK JSLE study group
Abstract N° OP0218
Evaluation of the ACR and SLICC classification criteria in juvenile systemic lupus erythematosus: a longitudinal analysis

G. Horneff (Germany)  
11:00
A. Klein, A. Hospach, P. Oommen, I. Foeldvari, J. Kuemmerle-Deschner, I. Feddersen, K. Minden
Abstract N° OP0219
Update on malignancies in children with juvenile idiopathic arthritis in the German BiKeR registry

M. F. G. Goulart (Brazil)  
11:10
Abstract N° OP0220
Personal exposure to air pollution influenced disease activity and exhaled breath biomarkers: a prospective study in a childhood-onset systemic lupus erythematosus population
R. Campanilho-Marques (United Kingdom) 11:20
C. Deakin, S. Simou, L. R. Wedderburn, C. Pilkington
Abstract N° OP0221
Efficacy and safety of tumour necrosis factor-α antagonists
in a large cohort of juvenile dermatomyositis patients

I. Pontikaki (Italy) 11:30
M. Gerosa, L. M. Argolini, I. Trespidi, P. L. Meroni
Abstract N° OP0222
Pregnancy outcome in patients affected by juvenile
idiopathic arthritis (JIA) exposed to biological agents:
a monocentric experience in a tertiary centre of Milan

10:15 - 11:45  Capital Suite 01

Abstract session
Scleroderma, myositis and related conditions

Chairperson(s):
László Czirják (Hungary)
Mike O. Becker (Switzerland)

J. Schniering (Switzerland) 10:20
S. Haller, Z. Guo, C. Feghali-Bostwick, R. Schibli,
O. Distler, C. Müller, B. Maurer
Abstract N° OP0045
Early detection of lung involvement in systemic sclerosis
using molecular targeted imaging

M.-E. Truchetet (France) 10:30
P. Laurent, P. Manicki, I. Douchet, E. Lazaro, P. Duffau,
C. Richez, J. Séneschal, J. Constans, T. Pradeu, P. Blanco,
C. Contin-Bordes
Abstract N° OP0046
Decreased circulating ILC2 levels correlate with skin
fibrosis in human systemic sclerosis and are associated
with a skewing of the ILC1/ILC2 balance in the skin

M. Tomcik (Czech Republic) 10:40
H. Storkanová, O. Krystufkova, M. Klein, H. Mann,
L. Vernerova, M. Spiritovic, J. Zamecnik, P. Perniola,
L. Senolt, J. Zamecnik
Abstract N° OP0047
Expression of heat shock protein 90 in muscle tissue
and plasma is increased in idiopathic inflammatory
myopathies and correlates with disease activity, skeletal
muscle, heart and lung involvement

R. Stratton (United Kingdom) 10:50
N. Arumallam, S. Zafar, H. Rosario, B. Ahmed Abdi,
Z. Taki, C. Denton, D. Abraham, N. Mazumder, O. Etohi,
A. Mohamed, F. Xing
Abstract N° OP0048
IL-31 is an inflammatory pro-fibrotic factor elevated in a
subset of scleroderma patients with severe pruritus

M. Stellato (Switzerland) 11:00
M. Rudnik, F. Renoux, E. Pachera, K. Sotlar, K. Klingel,
J. Henes, B. Bllyszczyk, O. Distler, G. Kania
Abstract N° OP0049
Myocardial fibrogenesis in systemic sclerosis: involvement
of a novel stromal sub-population

E. Praino (Italy) 11:10
C. Rotondo, C. Scioscia, M. G. Anelli, A. Chialà,
L. Coladonato, S. Perniola, D. Natuzzi, C. Bruni,
S. Guiducci, M. Mattucci-Cerinic, G. Lapadula,
F. Iannone
Abstract N° OP0050
Serum levels of adipokines in the categories of body mass
index (BMI) in patients with systemic sclerosis

A. M. Soare (Germany) 11:20
C. Dees, Y. Zhang, R. Liang, T. Wohlfahrt, S. Rauber,
N. Lin, C.-W. Chen, A. Ramming, O. Distler, C. Mihai,
G. Schett, J. Distler
Abstract N° OP0051
Dipeptidyl-peptidase-4 (DPP4) characterizes a
subpopulation of fibrosis-promoting fibroblasts and is a
molecular target for the treatment of fibrosis

K. R. Costa Pereira (Brazil) 11:30
J. Elias, D. Moraes, A. L. Guimarães, J. Garcia,
E. Cardoso, V. Leopoldo, A. Zombrilli, E. Gonçalves,
T. Costa, A. B. Stracieri, B. Simões, M. C. Oliveira
Abstract N° OP0052
Autologous hematopoietic stem cell transplantation
improves functional evaluation of systemic sclerosis patients

10:15 - 11:45  Capital Suite 06

Abstract session
Emerging concepts in genomics & genetics

Chairperson(s):
Stephen Eyre (United Kingdom)
Leonid Padyukov (Sweden)

A. R. Roberts (United Kingdom) 10:20
M. Vecellio, L. Chen, C. J. Cohen, B. P. Wordsworth
Abstract N° OP0231
Differential transcription factor binding could explain
the genetic association of ankylosing spondylitis with
polymorphisms in the IL23R-IL12RB2 intergenic region

D. Mauro (United Kingdom) 10:30
M. J. Lewis, V. Pullabhatla, S. Vyas, M. Simpson,
D. Cunningham-Graham, A. C. Syvanen, C. Pitzalis,
E. de Rinaldis, T. J. Vyse
Abstract N° OP0232
C1QTNF4 mutation identified by exome sequencing
is associated with systemic lupus erythematosus and
dysregulation of TNF-induced apoptosis

A. Julià (Spain) 10:40
P. Carreira, R. Blanco, V. Martinne Taboada,
L. Carreño Pérez, J. Pérez-Venegas, A. Olivé,
J. L. Andreu, M. Aguirre Zamarone, P. Vela, J. M. Nolla,
J. L. Marenco de la Fuente, A. Zea, J. M. Pego, M. Freire,
E. Diez, A. Aterido, A. Alonso, M. López-Lasanta,
M. López-Corbeto, R. Tortosa, S. Marsal,
A. Fernández-Nebro
Abstract N° OP0233
Genome-wide pathway analysis reveals that VEGF genetic
pathway is associated with oral ulcers in systemic lupus
erythematosus
B. Brynedal (Sweden) 10:50
Abstract N° OP0234
Rheumatoid arthritis subsets defined by sub-specificities of anti-citrullinated antibodies (ACPAS) have unique HLA associations

A. G. Pratt (United Kingdom) 11:00
J. Massey, A. E. Anderson, N. Nair, J. Diboll, A. Skelton, D. Lendrem, L. N. Reynard, H. J. Cordell, S. Eyre, A. Barton, J. D. Isaacs
Abstract N° OP0235
Identification of novel CD4+ lymphocyte expression quantitative trait loci in untreated early arthritis patients

J. Oliver (United Kingdom) 11:10
D. Plant, G. Orozco, K. L. Hyrich, A. W. Morgan, A. G. Wilson, J. D. Isaacs, A. Barton
Abstract N° OP0236
Whole transcriptome investigation of response to anti-TNF treatment in rheumatoid arthritis

P.-A. Juge (France) 11:20
Abstract N° OP0237
Polymorphisms of gene implicated in type 1 interferon pathway are associated with the clinical response of rituximab at 24 weeks in rheumatoid arthritis

C. Terao (Japan) 11:30
Abstract N° OP0238
FCGR2B and multiple HLA loci are associated with susceptibility to IgG4-related disease

X. Guo (United States) 11:10
Abstract N° OP0244
Sustained suppression of rheumatoid arthritis disease markers by mavrilimumab but not golimumab in anti-tumor necrosis factor-inadequate responders: an exploratory analysis in the phase IIB earth explorer 2 clinical trial

C. T. Prendergast (United Kingdom) 10:20
R. A. Benson, L. B. McInnes, J. M. Brewer, P. Garside
Abstract N° OP0239
Dissecting the molecular basis of immune cell accumulation in the inflamed joint using a murine model of rheumatoid arthritis

F. Humby (United Kingdom) 10:30
Abstract N° OP0240
Synovial lymphocytic aggregates associate with highly active RA and predict erosive disease progression at 12 months: results from the pathobiology of early arthritis cohort

P. Zeng (Sweden) 10:40
L. Klareskog, L. Alfredsson, C. Bengtsson
Abstract N° OP0241
Repetitive prolonged physical workload is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA-study

A. P. Croft (United Kingdom) 10:50
Abstract N° OP0242
Selective deletion of FAP expressing cells attenuates synovial inflammation and protects against inflammatory bone changes

G. Sauvageau (Canada) 11:00
N. Carrier, A. J. de Brum-Fernandes, P. Liang, A. Masetto, C. Daniel, G. Boire
Abstract N° OP0243
Single nucleotide polymorphisms (SNP) in the IL-4 receptor, IL-4, and CD40 loci and outcome prediction in patients with early immune-mediated inflammatory polyarthritis

K. Mankia (United Kingdom) 11:30
L. Hunt, E. Hensor, J. Nam, V. Clercugh, A. Speirs, A. Tugnait, T. Do, D. Devine, P. Emery
Abstract N° OP0246
Increased prevalence of periodontal disease in anti-CCP positive individuals at risk of progression to inflammatory arthritis: a target for prevention?
Abstract session

PARE Abstract session

Chairperson(s):
Kate Betteridge (United Kingdom)
Jolanta Grygielska (Poland)

N. Caeyers (Belgium) 10:20
on behalf of ReumaNet vzw
Abstract N° OP0247-PARE
Survey: what do patients think about their care, caretakers and the role of patient organisations?

C. Koehn (Canada) 10:30
Abstract N° OP0248-PARE
Understanding the importance of a patient’s role in the management of RA: results from a patient-based survey developed by the RA narrative global advisory panel

K. Mace (Australia) 10:40
Abstract N° OP0249-PARE
25 years of camp freedom - a 6 day camp for children 7-17 years old with arthritis

E. Kritza (Greece) 10:50
Abstract N° OP0250-PARE
Shared decision-making in rheumatoid arthritis - patients/doctors workshop

Z. Paskins (United Kingdom) 11:00
Abstract N° OP0249-PARE
Patient and public involvement in design, analysis and reporting of a public priority setting exercise for research in osteoporosis

K. Blidberg (Sweden) 11:10
Abstract N° OP0252-PARE
Increasing the interest in research in rheumatology

N. Lopuhaä (Netherlands) 11:20
Abstract N° OP0253-PARE
“Samen reuma” - a closed group on facebook for people with rheumatic diseases

W. B. Nowell (United States) 11:30
Abstract N° OP0254-PARE
Rheumatoid arthritis patient characteristics and willingness to participate in research among members of the creakyjoints arthritis patient community: results from a patient survey

Abstract session

Novel insights into B and T cell immunity in rheumatic disease

Chairperson(s):
Leendert Trouw (Netherlands)
Claudia Mauri (United Kingdom)

A. Pianta (United States) 10:20
Abstract N° OP0200
Immune responses to prevotella copri in patients with rheumatoid arthritis

H. U. Scherer (Netherlands) 10:30
Abstract N° OP0201
Circulating, auto-reactive B cells specific for citrullinated antigens in patients with rheumatoid arthritis display an activated, proliferative phenotype

N. Pandya (United States) 10:40
Abstract N° OP0202
Long-lived CD19-negative human plasma cells are generated at the plasmablast to plasma cell transition

A. Musters (Netherlands) 11:00
Abstract N° OP0203
In rheumatoid arthritis synovitis is not dominated by polymorphic local, but rather by uniform systemic T cell responses

E. Della Torre (Italy) 11:10
Abstract N° OP0204
Clonal expansion of CD4+ cytotoxic T lymphocytes in IgG4-related disease
G. G. Kinney (United States) 11:20
Abstract N° OP0205
Clinical and preclinical assessment of the anti-MCAM monoclonal antibody PRX003, a potential novel treatment for TH17-mediated inflammatory diseases

F. Renoux (Switzerland) 11:30
M. Stellato, E. Pachera, D. Impellizzieri, C. Dees, J. Distler, G. Kania, O. Boyman, O. Distler
Abstract N° OP0206
FRA2 is playing a key role in the control of treg development and autoimmunity

11:45 - 13:30  Exhibition (S5-S9)
Poster viewing & lunch

11:50 - 13:30  Poster area

Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area, on a “first-come-first-served” basis the day of the poster tour. For full details regarding the guided poster tours on Friday, please refer to pages 101 to 108.

Poster tour
F1: Time for some fun with molecules
Chairperson(s): Iain B. McInnes (United Kingdom)
Carl Goodyear (United Kingdom)
Abstract N° FRI0001 - FRI0007

Poster tour
F2: Biology of RA I
Chairperson(s): Zoltán Szekanecz (Hungary)
Agnes Szentpetery (Ireland)
Abstract N° FRI0042 - FRI0051

Poster tour
F3: Comorbidities update 2016, part II
Chairperson(s): Johannes W.J. Bijlsma (Netherlands)
Natalia Kuchuk (Netherlands)
Abstract N° FRI0106 - FRI0114

Poster tour
F4: RA treatment: predictors, tapering and biosimilars
Chairperson(s): Maya Buch (United Kingdom), Elena Nikphorou (United Kingdom)
Abstract N° FRI0154 - FRI0163

Poster tour
F5: Safety and efficacy of non-TNFα blockers in the treatment of RA - I
Chairperson(s): Lene Terslev (Denmark)
Lene Dreyer (Denmark)
Abstract N° FRI0198 - FRI0207

Poster tour
F6: From research to biomarkers and targeting SSc
Chairperson(s): Gabriela Riemekasten (Germany)
Janine Schniering (Switzerland)
Abstract N° FRI0238 - FRI0246

Poster tour
F7: Scleroderma, myositis and related syndromes I
Chairperson(s): Maurizio Cutolo (Italy)
Alberto Sulli (Italy)
Abstract N° FRI0305 - FRI0314

Poster tour
F8: SLE and APS - clinical aspects
Chairperson(s): Dimitrios Vassilopoulos (Greece)
Christos Koutsianas (United Kingdom)
Abstract N° FRI0354 - FRI0362

Poster tour
F9: Vasculitis I
Chairperson(s): Carlo Salvarani (Italy)
Alessandra Soriano (Italy)
Abstract N° FRI0354 - FRI0362

Poster tour
F10: SpA - clinical
Chairperson(s): Robert B. M. Landewé (Netherlands)
Sofia Ramiro (Netherlands)
Abstract N° FRI0394 - FRI0404

Poster tour
F11: Imaging in RMD - adding value
Chairperson(s): Esperanza Naredo (Spain)
Alexandra Kosevoi (Romania)
Abstract N° FRI0513 - FRI0522

Poster tour
F12: Epidemiology of RMDs
Chairperson(s): Axel Finckh (Switzerland), Deborah Symmons (United Kingdom)
Abstract N° FRI0550 - FRI0560
Poster tour
F13: Education
Chairperson(s): Annamaria Iagnocco (Italy)
Peter Mandl (Austria)
Abstract N° FRI0599 - FRI0608

HPR Poster tour
F14: Focus on rehabilitation
Chairperson(s): Anthony Redmond (United Kingdom)
Rikke H. Moe (Norway)
Abstract N° FRI0643-HPR - FRI0652-HPR

PARE Poster tour
F15: PARE - Poster tour II
Chairperson(s): Dieter Wiek (Germany)
Petra Balazova (Slovakia)
Abstract N° PARE0009 - PARE0017

13:30 - 15:00  ICC Auditorium
What is New (WIN)
WIN session 6
Serge Ferrari (Switzerland)  13:35
Osteoporosis/bone diseases
Michael Doherty (United Kingdom)  14:15
Abstract N° SP0127
Osteoarthritis

13:30 - 15:00  Hall B
Challenges in Clinical Practice session
Difficult to treat rheumatoid arthritis
Learning objectives:
To understand and to manage difficult RA patients that
do not respond to all our therapies or that are unable to
tolerate all our therapies
Chairperson(s):
Francisca Sivera (Spain)
Ferdinand C. Breedveld (Netherlands)
J. Leonard M. Schoneveld (Netherlands)  13:35
Abstract N° SP0128
Case 1 presentation: A case of difficult to manage
rheumatoid arthritis
Jacobb M. van Laar (Netherlands)  13:45
Case 1 discussion: "Nothing worked"
Faye Cooles (United Kingdom)  14:15
Case 2 presentation:
A tale of too many side effects or all’s well that ends well
John D. Isaacs (United Kingdom)  14:25
Case 2 discussion: "Adverse events make treatment impossible"

13:30 - 15:00  Hall D
Clinical Science session
Biomarkers: powerful or powderpuff?
Learning objectives:
• To be appraised of the advances possible in the
  management of complex medical syndromes by the use
  of biomarkers using cancer as an example
• To understand the strengths and limitations of current
  biomarkers in the rheumatic diseases
• To understand the future possibilities in biomarker
  research and precision medicine in rheumatology
Chairperson(s):
Gary S. Firestein (United States)
Jagtar Nijjar (United Kingdom)
Timothy Yap (United Kingdom)  13:35
Can biomarkers enhance medical care?
Lessons from cancer
Josef S. Smolen (Austria)  13:55
New biomarkers are of little added value
Ronald van Vollenhoven (Netherlands)  14:15
Biomarkers are critical for our future
A. Mahto (United Kingdom)  14:35
F. Humby, S. Gregoriadou, N. Ng, K. Blighe, L. Zou,
M. Lewis, M. Bombardieri, S. Kelly, C. Pitzalis
Abstract N° OP0263
Synovial B cell gene signature predicts response to
rituximab therapy
A. J. Macdonald (United States)  14:45
K. Cerosaletti, J. Chen, T.-S. Nguyen, S. Posso,
G. Marchesini, M. Abashian, A. P. Martin, D. De Rosa,
T. Samanta, J. Poorbaugh, R. J. Benschop, J. Buckner
Abstract N° OP0264
Relative frequencies of circulating T follicular helper
and T follicular regulatory cells in autoimmune patients
and healthy control donors and the effect of disease
modulating therapy

13:30 - 15:00  Hall E
How to Treat/Manage (HOT)
HOT session 8
Christopher Denton (United Kingdom)  13:35
Raynaud’s phenomenon/systemic sclerosis
Dan Solomon (United States)  14:15
Abstract N° SP0130
Comorbidity within RA
Clinical Science session

The role of nuclear medicine in rheumatology

Learning objectives:
• Session organised in collaboration with EANM
• To review the role of nuclear medicine in the diagnosis and treatment of rheumatic diseases
• To have insights into novel applications of nuclear medicine in joint inflammation

Chairperson(s):
Jacqueline Uson (Spain)
Willm U. Kampen (Germany)
Mohan Krishnarmurthy (United Kingdom)

13:35 Role of bone scintigraphy in the management of rheumatoid arthritis/inflammatory joint disease
Conny van der Laken (Netherlands)

13:55 FDG-PET for imaging joint inflammation in chronic joint disease
Willm U. Kampen (Germany)

14:15 60 years of radiosynoviorthesis: state of the art
G. Schett (Germany)

14:35 Fever of unknown origin (FUO) and inflammation of unknown origin (IUO): is 18F-FDG-PET/CT a useful first line diagnostic strategy?
S. T. G. Bruijnen (Netherlands)

14:45 Patient’s perceptions of remission and the art of conciliation
D. Homer (United Kingdom)
on behalf of the West Midlands Rheumatology Nurse Specialist Network

Health Professionals session

Collaboration for success.
User-centred design for improvement of health services

Learning objectives:
• To understand the concept and characteristics of participatory design and, in particular, experienced based co-design
• To understand how user involvement can improve healthcare services
• To recognise different approaches for user involvement in the development of healthcare services

Chairperson(s):
Ingemar Petersson (Sweden)
Suzanne Verstappen (United Kingdom)
Sarah Hewlett (United Kingdom)

13:35 Using experience-based co-design to improve the quality of healthcare services
Asa Revenäs (Sweden)

13:53 Co-designing a mobile internet service for self-management of physical activity in RA
Karin Hakansson (Sweden)

14:11 Using experience-based co-design to improve the quality of healthcare services
Sanne van der Weegen (Netherlands)

14:29 A user’s experience of co-design
Karina Goodrich (United Kingdom)

14:47 Patient participation in multidisciplinary team care: views of patients and health care professionals
E. Kuijpers (Netherlands)

13:35 Do we need new PROMs or can we reuse?
Sarah Hewlett (United Kingdom)

13:55 Psychometric properties of clinical relevance for commonly used PROs in rheumatological care
Mart van de Laar (Netherlands)

14:15 Patient’s perceptions of remission and the art of conciliation
Maarten de Wit (Netherlands)

14:35 A survey of patient reported experience, patient reported outcome and work in patients with inflammatory arthritis seen in nurse led rheumatology clinics in the UK
D. Homer (United Kingdom)
on behalf of the West Midlands Rheumatology Nurse Specialist Network

14:45 The EULAR outcome measure library, an evolutional database of validated patient-reported outcomes: use and dissemination in the first two years
I. Castrejon (United States)
13:30 - 15:00  Capital Suite 11

Basic and Translational Science session

ER stress & rheumatic disease

Learning objectives:
• To learn about the complexity of ER stress and autophagy pathways
• To understand how those pathways are implicated in immune/inflammatory responses

Chairperson(s):
Francesco Ciccia (Italy)
Peggy Jacques (Belgium)

Bart Lambrecht (Belgium) 13:35
Overview of ER stress and immune system

Sebastien Gaumer (France) 13:55
Abstract N° SP0138
The fruit fly, as a tool to study ER stress

Arthur Kaser (United Kingdom) 14:15
ER stress, autophagy and inflammatory bowel disease

S. Jo (Republic of Korea) 14:35
Abstract N° OP0270
Targeting IL-23 can attenuate progression of spinal ankylosis in ankylosing spondylitis

S. Aguilera (Chile) 14:45
Abstract N° OP0271
Perk pathway characterization in labial salivary glands of Sjögren’s syndrome’s patients: could it be an adaptive response?

13:30 - 15:00  Capital Suite 14

Basic and Translational Science session

Joint EULAR - EFIS session: Do stromal cells house and cure immune cells?

Learning objectives:
• To understand interactions between stromal cell and immune cell populations
• To get insights into the therapeutic potential of stromal cells
• To learn about the importance of stromal cells in the development of an inflammatory reaction

Chairperson(s):
Christophe Richez (France)
Cosimo de Bari (United Kingdom)

Anja Hauser (Germany) 13:35
Organisation of protective and pathogenic immunological memory by mesenchymal stromal cells

Chris Buckley (United Kingdom) 13:55
The role of fibroblast subsets in the persistence of inflammation

Francesca Barone (United Kingdom) 14:15
Stromal cells and lymphoid neogenesis

C. X. Maracle (Netherlands) 14:35
P. Kucharzewska, B. Helder, H. Olsson, S. W. Tas
Abstract N° OP0272
Identification of new inhibitors of angiogenesis in a novel 3D model of rheumatoid arthritis synovial angiogenesis

Z. Vereb (Hungary) 14:45
A. Váncsa, M. Pilling, G. Petrovski, Z. Szekanecz
Abstract N° OP0273
Effects of tumor necrosis factor alpha on cytokine secretion of synovial fluid-derived mesenchymal stem-like cells

13:30 - 15:00  Capital Suite 02

PReS session

Role of imaging in childhood-onset rheumatic diseases

Learning objectives:
To provide an update on the role of imaging in childhood rheumatic disease

Chairperson(s):
Miroslav Harjacek (Croatia)
Paz Collado (Spain)
Jelena Vojinovic (Serbia) 13:35

Abstract N° SP0139
The role of ultrasound in JIA

Abstract N° SP0139
The role of ultrasound in JIA

Abstract N° SP0139
The role of ultrasound in JIA

Abstract N° OP0274
Quantification of dynamic MRI examinations in juvenile idiopathic arthritis

Abstract N° OP0275
Prevalence of ultrasound-detected findings in foot in juvenile idiopathic arthritis versus healthy children: association to paediatric foot posture
**The Young Rheumatologist**

**Physician-patient relationship in the era of interactive media**

**Learning objectives:**
- To discuss how physicians and patients perceive the use of interactive media for medical issues
- To understand how the use of interactive media can worsen or improve physician-patient relationship

**Chairperson(s):**
Diana Skingle (United Kingdom)
Alessia Alunno (Italy)

Elena Nikiphorou (United Kingdom) 13:35
Abstract N° SP0141
The point of view of physician. Social media: PROs and CONs of sharing patient and physician personal experience

Linda van Nieuwkoop (Netherlands) 13:55
The point of view of patients. Role of interactive media in accessing medical information and in building patient-physician relationship

**Faculty**
14:15
Interactive open discussion

**T. P. Vliet Vlieland (Netherlands) 14:25**
C. van den Ende on behalf of Educational Subcommittee of the EULAR Standing Committee of Health Professionals in Rheumatology
Abstract N° OP0276
Postgraduate rheumatology education for health professionals in rheumatology: availability, needs and barriers

J. Clausen (Germany) 14:35
P. Böhm, E. Farin-Glattacker, A. Thyrolf
Abstract N° OP0277-PARE
Patient research partners involved in a project to enhance disease-associated communications skills of rheumatoid patients

---

**Practical skills session**

**Capillaroscopy II**

**Chairperson(s):**
Alberto Sulli (Italy)
Vanessa Smith (Belgium)

Vanessa Smith (Belgium) 13:35
Abstract N° SP0028
How to differentiate normal from abnormal capillaroscopic patterns: role of in early diagnosis

Alberto Sulli (Italy) 13:50
Abstract N° SP0029
Counting and scoring the capillaries: manual versus (semi)automatic systems

---

**Practical skills session**

**Ultrasound advanced I**

**Chairperson(s):**
Sandrine Jousse-Joulin (France)
Giorgio Tamborrini (Switzerland)
Heidi Siddle (United Kingdom) 13:35
Abstract N° SP0143
US for diagnosing inflammatory versus mechanical midfoot pain and relevant guided interventions + demo

Justina Janta (Romania) 13:55
Abstract N° SP0144
Ultrasound of the nail; Why use it in rheumatology? + demo

Stephanie Finzel (Germany) 14:15
Abstract N° SP0145
How to differentiate erosions and vessel channels + demo

Mads Ammitzboll (Denmark) 14:35
Abstract N° SP0146
How to distinguish tenosynovitis from normal vessel artefacts in wrists and fingers + demo

**Tutor(s):**
Lykke Oernbjerg (Denmark)

---

**PARE session**

**It's in your hands**

**Learning objectives:**
- To empower patients to acquire knowledge
- To identify strategic actions
- To develop skills to act on that knowledge

**Chairperson(s):**
Jenny de la Torre-Aboki (Spain)
Boryana Boteva (Bulgaria)
### 10 June 2016

#### SCIENTIFIC PROGRAMME / FRIDAY 10 JUNE 2016 / 97

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 13:35         | Room S20    | Wilfried Mau (Germany)  
Abstract N° SP0147  
A self-determined life with a rheumatic disease - how can social participation be preserved or obtained and how can barriers be overcome |
| 13:55         |             | Margarida Fonseca Santos (Portugal)  
Abstract N° SP0148  
Learning to control - when knowledge becomes power over the day-to-day setbacks |
| 14:15         |             | Peter Tugwell (Canada)  
Does enhancing health literacy improve equity and empowerment? |
| 14:35         |             | Simon Stones (United Kingdom)  
Stene Prize essay: Living with a rheumatic or musculoskeletal disease (RMD): how I take action to enjoy life to the full |
| 14:45         |             | E. S. Rösch (Switzerland)  
Abstract N° OP0278-PARE  
Patient empowerment: national action week with informative lectures in Layman’s terms for those who are affected by rheumatism |
| 13:30 - 15:00 | Room S20    | **EULAR projects in Education and Training**  
**The EULAR School of Rheumatology - a new era of education**  
Chairperson(s):  
Annamaria Iagnocco (Italy)  
Anna Moltó (France)  
Johannes W. J. Bijlsma (Netherlands)  
13:35  
EULAR education in 2016. Where are we now?  
Gerd R. Burmester (Germany)  
14:00  
EULAR education: Where do we want to go?  
Annamaria Iagnocco (Italy)  
14:25  
Abstract N° SP0149  
EULAR education: What is it for you?  
A. Sabanathan (United Kingdom)  
14:50  
G. Fent, M. Purva  
Abstract N° OP0279  
Developing and running a rheumatology emergency simulation course |
| 15:30 - 17:00 | ICC Auditorium | **What is New (WIN)**  
**WIN session 7**  
Reinhard E. Voll (Germany)  
15:35  
Systemic lupus and APS  
Frank O. Nestle (United Kingdom)  
16:15  
New developments in psoriasis: what rheumatologists should know |
| 15:30 - 17:00 | Hall B      | **Challenges in Clinical Practice session**  
**Vaccination in rheumatic patients: a two-edged sword**  
Learning objectives:  
- Vaccination in rheumatic diseases and in biologic-treated patients  
- Does vaccination cause autoimmunity?  
- Safety of vaccination; adjuvant induced autoimmunity  
- Current recommendations  
Chairperson(s):  
Howard Amital (Israel)  
Nico Wulffraat (Netherlands)  
Carlo Perricone (Italy)  
15:35  
Case 1 presentation: HPV vaccine and autoimmune rheumatological disease  
Yehuda Shoenfeld (Israel)  
15:45  
Abstract N° SP0150  
Case 1 discussion: Adjuvants, vaccines and the role of immune stimulation in the genetically prone person for autoimmunity  
Natasa Toplak (Slovenia)  
16:15  
Case 2 presentation: Vaccination in biologic-treated juvenile idiopathic arthritis  
Marc Bijl (Netherlands)  
16:25  
Case 2 discussion: Vaccination management in rheumatic diseases, current recommendations |
| 15:30 - 17:00 | Hall D      | **Clinical Science session**  
**Advances in large vessel vasculitis**  
Learning objectives:  
- To recognise the clinical spectrum of large vessel vasculitis  
- To identify the role of imaging in the diagnosis and follow-up of patients with large vessel vasculitis  
- To review advances in the use of emerging therapies for the treatment of large vessel vasculitis  
Chairperson(s):  
Eric Matteson (United States)  
Francesco Muratore (Italy)  
15:30  
Eric Matteson (United States)  
15:35  
Nico Wulffraat (Netherlands)  
15:45  
Carlo Perricone (Italy)  
15:50  
Case 1 presentation: HPV vaccine and autoimmune rheumatological disease  
Yehuda Shoenfeld (Israel)  
16:15  
Case 2 presentation: Vaccination in biologic-treated juvenile idiopathic arthritis  
Marc Bijl (Netherlands)  
16:25  
Case 2 discussion: Vaccination management in rheumatic diseases, current recommendations |
Marco A. Cimmino (Italy) 15:35
Abstract N° SP0151
Clinical diagnosis of large vessel vasculitis

Torsten Bley (Germany) 15:55
Abstract N° SP0152
Role of imaging in the diagnosis and treatment of large vessel vasculitis

Kenneth Warrington (United States) 16:15
Abstract N° SP0153
Emerging therapies in large vessel vasculitis

L. M. Belvedere (Canada) 16:35
Abstract N° OP0280
Improved survival in giant cell arteritis: a population-based study

Abstract N° OP0281
Survival of biopsy-proven giant cell arteritis in Italy during a 26-year period: correlation with histological pattern

15:30 - 17:00   Hall E
How to Treat/Manage (HOT)

HOT session 9

Dafna D. Gladman (Canada) 15:35
Abstract N° SP0154
Comorbidities of PsA and other rheumatic conditions

Kevin Winthrop (United States) 16:15
Infection and rheumatic diseases

15:30 - 17:00   Hall C
Clinical Science session

When and how to diagnose and treat vitamin D deficiency?

Learning objectives:
To learn the evidences, reasons and methods to restore normal serum vitamin D levels in healthy subjects and rheumatic patients in presence of insufficiency

Chairperson(s):
Nemanja Damjanov (Serbia)
Angela Tincani (Italy)

Heike Bischoff-Ferrari (Switzerland) 15:35
Practical guidelines for the supplementation of vitamin D and the treatment of deficits

Laura Andreoli (Italy) 15:55
Abstract N° SP0155
Vitamin D and systemic lupus erythematosus: when and how to treat vitamin D insufficiency/deficiency

Maurizio Cutolo (Italy) 16:15
The circannual rhythms of vitamin D serum levels follows the seasons: links with the immune-inflammatory response

I. Oma (Norway) 16:35
J. K. Andersen, S. Holm, O. K. Olstad, I. Fostad, T. Lyberg, S. M. Almdahl, Ø. Molberg, I. Hollan
Abstract N° OP0282
Expression of vitamin D receptor associated genes in the aorta of coronary artery disease patients with and without rheumatoid arthritis

S. Chaiamnuay (Thailand) 16:45
W. Lomarat, R. Rattapol Pakchotanon, P. Narongroeknavin, P. Asavatanabodee
Abstract N° OP0283
A randomized double-blind comparative clinical trials to evaluate efficacy of vitamin D in systemic lupus erythematosus (SLE) patients

15:30 - 17:00   Hall A
Outcome Science session

Data harmonization across (rheumatoid arthritis) clinical cohorts and registers

Learning objectives:
- Collaborative projects including data from multiple sources is key to study rare outcomes or rare exposures
- To understand the limitations related to heterogeneity of data from various sources
- To learn about potential measures to limit the heterogeneity and allow combined analyses

Chairperson(s):
Helga Radner (Austria)
William G. Dixon (United Kingdom)

Helga Radner (Austria) 15:35
Heterogeneity of data collection in clinical RA cohorts and registers

Elena Nikiphorou (United Kingdom) 15:55
Abstract N° SP0156
How to collect comorbidities

Johan Askling (Sweden) 16:15
Towards a standardized data collection in RA?

S. Norton (United Kingdom) 16:35
M. Hifinger, S. Ramiro, P. Putrik, T. Sokka, A. Boonen
Abstract N° OP0284
Comparability of the health assessment questionnaire between countries: psychometric examination of cross-national measurement equivalence
K. Chatzidionysiou (Sweden) 16:45
E. Nikiphorou, L. Gossec, K. Hyrich, C. Filip, Y. van Eijk-Hustings, W. Dixon, J. Askling, H. Radner on behalf of the EULAR Task Force for standardising minimum data collection in Rheumatoid Arthritis observational research
Abstract N° OP0285
The EULAR task force for standardising minimum data collection in rheumatoid arthritis observational research: results of a hierarchical literature review

15:30 - 17:00 Capital Suite 07

HPR/Primary Care joint session
Telemedicine and e-health in community care

Learning objectives:
To explore the practical issues surrounding implementation of telehealth and the ethical implications

Chairperson(s):
Thijs Swinnen (Belgium)
Stefan Bergman (Sweden)

Trevor Russell (Australia) 15:35
Internet-based multidisciplinary assessment

Ruth Chambers (United Kingdom) 15:53
Abstract N° SP0157
E-health in general practice

Tom Dawson (United Kingdom) 16:11
Abstract N° SP0158
Internet-based multidisciplinary assessment

Maartje Niezen (Netherlands) 16:29
Abstract N° SP0159
Technological challenges in implementing e-health

Ethical implications of employing e-health solutions to promote healthy lifestyles

T. Thomsen (Denmark) 16:47
M. Aadahl, N. Beyer, M. L. Hetland, K. B. Loeppenthin, J. Midtgaard, R. Christensen, B. A. Esbensen
Abstract N° OP0286-HPR
The efficacy of motivational counselling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial

15:30 - 17:00 Capital Suite 14

Basic and Translational Science session
Potential targets in inflammatory fibrotic conditions in SSc

Learning objectives:
To understand inflammatory fibrosis, identify targets addressing fibrosis, characterise signalling in fibrosis

Chairperson(s):
Jörg Distler (Germany)
Mike O. Becker (Switzerland)

Christopher Denton (United Kingdom) 15:35
Cytokines as target in SSc

Oliver Distler (Switzerland) 15:55
Fibroblasts as target in SSc

Jacob M. van Laar (Netherlands) 16:15
Adaptive immune system as target in SSc

M. Rudnik (Switzerland) 16:35
M. Stellato, P. Blyszczuk, E. Pachera, R. Dobrota, B. Maurer, K. Klingel, J. Henes, K. Sotlar, O. Distler, G. Kania
Abstract N° OP0289
MicroRNAs as potential regulators of monocyte differentiation and function in heart fibrosis in systemic sclerosis

M. Elhai (France) 16:45
Abstract N° OP0290
OX40L blockade protects against skin and lung inflammation-driven fibrosis
The Young Rheumatologist
How to get into the international world of rheumatology

Learning objectives:
• To give young rheumatologists and young researchers a perspective and tips on how they can get international exposure and how they can get internationally involved
• To stimulate in young rheumatologists the wish to work in a European context and go beyond their country borders

Chairperson(s):
Francisca Sivera (Spain)
Sofia Ramiro (Netherlands)

Anna Moltó (France) 15:35
The role of EMEUNET

Pedro Machado (Portugal) 15:55
Opportunities abroad

Maxime Dougados (France) 16:15
Collaborative EU projects - how to get involved?

George E. Fragoulis (Greece) 16:35
Sicca symptoms in rheumatoid arthritis: real Sjögren’s or not?

Sandra Selickaja (Lithuania) 16:45
Anti-TIF1-gamma antibodies - markers of paraneoplastic myositis but not of paraneoplastic rheumatic syndromes or solid tumors

Practical skills session*
Data visualisation: tables and graphs for publication and presentation II

Maarten Boers (Netherlands) 15:35
Abstract N° SP0057
Data visualisation: tables and graphs for publication and presentation

Practical skills session*
Ultrasound basic II

Chairperson(s):
Petra Hanova (Czech Republic)
Hilde Berner Hammer (Norway)

Maria-Antonietta d’Agostino (France) 15:35
Composite scoring system for RA synovitis + demo

Ingrid Möller (Spain) 15:55
Abstract N° SP0058
Scoring OA + demo

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area S11
Guided Poster Tours

Friday, 10 June 2016 11:50 - 13:30

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area, on a “first-come-first-served” basis on the day of the poster tour.

**Poster tour F1: Time for some fun with molecules**

**Chairperson(s): Iain B. McInnes (United Kingdom), Carl Goodyear (United Kingdom)**

**FR10001**

**FR10002**
SPINAL MICROGLIAL ACTIVATION IN A MURINE SURGICAL MODEL OF KNEE OSTEOARTHRITIS / A.-M. Malfait* - P. B. Tran - R. E. Miller - S. Ishihara - R. J. Miller

**FR10003**

**FR10004**
INHIBITION OF PHOSPHODIESTERASE 4 (PDE4) REDUCES DERMAL FIBROSIS BY INTERFERING WITH THE RELEASE OF PRO-FIBROTIC CYTOKINES FROM M2-MACROPHAGES / C. Maier* - A. Ramming - G. Schett - J. H. Distler - C. Beyer

**FR10005**
A DISTINCT PROFILE OF SERUM FREE FATTY ACIDS IS ASSOCIATED WITH CLINICAL FEATURES AND SKewed TH1 RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS / J. Rodriguez-Carrio* - M. Alperi-López - P. López - F. J. Ballina-García - A. Suárez

**FR10006**

**FR10007**
EFFECT OF TYPE 1 AND 2 INTERFERONS ON NEUTROPHIL APOPTOSIS IN NAIVE AND TNF ALPHA PRIMED NEUTROPHILS / S. Irwin* - A. Midgley - R. Wright - M. Peak - M. Beresford

**Poster tour F2: Biology of RA I**

**Chairperson(s): Zoltán Szekanecz (Hungary), Agnes Szentpetery (Ireland)**

**FR10042**

**FR10043**

**FR10044**
SMOKING INDUCES IRREVERSIBLE DEREGULATION OF MICRORNA EXPRESSION IN RHEUMATOID ARTHRITIS / K. Andersson - M. Turkkila - S. Töyrä - M. Bokarewa*

**FR10045**

* Presenting author
POSTER TOURS / FRIDAY 10 JUNE 2016

**Poster tour F3: Comorbidities update 2016, part 2**

*Chairperson(s): Johannes W.J. Bijlsma (Netherlands), Natalia Kuchuk (Netherlands)*

**FRI1010**
The association of fatigue, comorbidities and anti rheumatic drugs in rheumatoid arthritis: results from the COMEDRA study / A. Tournadre* - B. Pereira - L. Gosses - M. Soubrier - M. Dougdos

**FRI1011**
Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer. Results from a large population based study of the Italian society for rheumatology / M. Caprioli* - G. Carrara - S. Pennetta - C. A. Sciriè on behalf of RECORD

**FRI1012**

**FRI1013**
Postoperative complications in patients with rheumatoid arthritis using a biological agent - a systematic review and meta-analysis / H. Io*^a^)

**FRI1014**

---

**Poster tour F4: RA treatment: predictors, tapering and biosimilars**

*Chairperson(s): Maya Buch (United Kingdom), Elena Nikiphorou (United Kingdom)*

**FRI1015**

**FRI1016**

**FRI1017**

**FRI1018**

**FRI1019**

* Presenting author
FR0159 PERSISTENCE WITH BIOLOGIC MONOTHERAPY IN COMPARISON WITH COMBINATION THERAPY WITH NON-LEUKOCYTE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM AN ONTARIO RHEUMATOID ARTHRITIS COHORT / A. N. Lau* - M. Movahedi - M. Tatangelo - C. Bombardier on behalf of Ontario Best Practices Research Initiative (OBRI) investigators

FR0160 ANTI-TNF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS DOES NOT ATTENUATE CUTANEOUS TNF ACTIVITY FOLLOWING A TUBERCULIN SKIN TEST / R. Byng-Maddick* - C. Haas - M. Ehrenstein - M. Noursadeghi


FR0163 EFFICACY OF THE BIOSIMILAR BOW015, COMPARED TO ORIGINATOR INFILXIMAB, INITIATED AT MODERATE AND SEVERE DISEASE ACTIVITY THRESHOLDS IN RHEUMATOID ARTHRITIS / P. Taylor* - M. Wyand - A. Knight - C. Costantino - C. Lassen

Poster tour F5: Safety and efficacy of non-TNFα blockers in the treatment of RA - I

Chairperson(s): Lene Terslev (Denmark), Lene Dreyer (Denmark)


FR0207 INCREASED SERUM FREE LIGHT CHAINS OF IMMUNOGLOBULINS IN SYSTEMIC SCLEROSIS PATIENTS: A COMPARATIVE SAFETY AND IMMUNOGENICITY STUDY OF ABATACEPT OR ANTI-TUMOUR NECROSIS FACTOR THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF PHASE III TRANSITION STUDY / S. Wassenberg - H. Burkhart on behalf of AMARA-study group

Poster tour F6: From research to biomarkers and targeting SSC

Chairperson(s): Gabriela Riemekasten (Germany), Janine Schniering (Switzerland)


FR0241 HMGB1 INDUCES REACTIVE OXYGEN SPECIES (ROS)-DEPENDENT ACTIVATION OF THE ER STRESS PATHWAY IN C2C12 MYOTUBES / A. P. Lightfoot* - R. S. Morgan - R. G. Cooper

FR0242 ROLE OF MITOCHONDRIA- AND NADPH OXIDASE-DERIVED ROS IN FIBROBLASTS ISOLATED FROM PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS / T. Spadoni* - S. Svegliati - A. Gabrielli

* Presenting author
**Poster tour F7: Scleroderma, myositis and related syndromes I**

Chairperson(s): Maurizio Cutolo (Italy), Alberto Sulli (Italy)

**FRI0248**
**PREDICTORS OF DISABILITY IN SYSTEMIC SCLEROSIS: A STUDY FROM THE DESCIPHER PROJECT**

**FRI0249**
**RISK FACTORS FOR DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION IN AUSTRALIAN SCLERODERMA PATIENTS**
K. Morris* - M. Huq - W. Stevens - C. Rabusa - S. P. Huxley - M. Nikpour on behalf of Australian Scleroderma Interest Group (ASIG)

**FRI0250**
**SELF REPORTED GASTROINTESTINAL TRACT SYMPTOMS IN SYSTEMIC SCLEROSIS: EXPERIENCE FROM A LARGE CONSECUTIVE COHORT**

**FRI0251**
**ANTI-MDA5 AUTO-ANTIBODY: EXPANDING THE CLINICAL SPECTRUM IN PATIENTS WITH DERMATOMYOSITIS IN NORTH AMERICA**
S. Moghadam-Kia* - C. V. Odds - S. Sato - M. Kuwana - R. Aggarwal

**FRI0252**
**EFFICACY OF MYCOPHENOLATE MOFETIL (MMF) VERSUS ORAL CYCLOPHOSPHAMIDE (CYC) ON SKIN THICKNESS IN THE SCLERODERMA LUNG STUDY II**

**FRI0253**
**A 18 OBSERVATION IN PATIENTS WITH PROGRESSIVE SYSTEMIC SCLEROSIS TREATED WITH AN INTENSIFIED B-LYMPHOCYTE DEPLETION**
D. Rossi - M. Saracco - S. Sciascia - R. Pellerito - V. Moderna - D. Roccatello

**FRI0254**
**THE EFFECT OF CYCLOPHOSPHAMIDE ON LUNG FUNCTION IN DIFFERENT STAGES OF INTERSTITIAL LUNG DISEASE ASSOCIATED TO SYSTEMIC SCLEROSIS**

**FRI0255**
**COMBINATION THERAPY WITH RITUXIMAB AND MYCOPHENOLATE MOFETIL IN SYSTEMIC SCLEROSIS. SAFETY AND EFFICACY FROM 12 MONTHS**
P. Fraticelli* - C. Fischetti - F. Salaffi - M. Carotti - P. Pontisso - F. Cozzi

**FRI0256**
**SIGNIFICANCE OF COGNITIVE IMPAIRMENT IN SYSTEMIC SCLEROSIS**

**FRI0257**
**AUGMENTED CONCENTRATIONS OF CX3CL1 ARE ASSOCIATED WITH PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS**

**Poster tour F8: SLE and APS - clinical aspects**

Chairperson(s): Dimitrios Vassilopoulos (Greece), Christos Koutsianas (United Kingdom)

**FRI0305**
**FACTORS DETERMINING HYDROXYCHLOROQUINE SERUM LEVELS IN A COHORT OF CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**
C. C. Mok* - K. L. Chan - P. Jannetto

**FRI0306**
**SERUM ANTI-MULLERIAN HORMONE LEVELS IN SLE PATIENTS: INFLUENCE OF DISEASE SEVERITY AND THERAPY ON THE OVARIAN RESERVE**
S. C. Mok - A. Barini - B. Tolusso - G. Ferraccioli - E. Gremese

**FRI0307**
**CHANGES IN URINARY BIOMARKER LEVELS CAN PREDICT TREATMENT RESPONSES IN LUPUS NEPHRITIS**

**FRI0308**
**SURFACE TETHERIN IS A NOVEL CELL-SPECIFIC BIOMARKER FOR INTERFERON RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS**

**FRI0309**
**TYPE I INTERFERON ACTIVITY IS ASSOCIATED WITH MUCOCUTANEOUS BUT NOT MUSCULOSKELETAL DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS**

**FRI0310**
**SERUM INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 (IGFBP2) AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL TREATMENT RESPONSE IN LUPUS NEPHRITIS**
I. Parodis* - H. Ding - A. Zickert - M. Cario-André

**FRI0311**
**NEUROPSYCHIATRIC LUPUS: COMBINING ADVANCED MORPHOMETRIC METHODS, DIFFUSION TENSOR IMAGING AND CONVENTIONAL MRI LEADS TO THE PATHWAYS OF BRAIN ABNORMALITIES. CORRELATION WITH CLINICAL AND LABORATORY DATA**

* Presenting author
**Poster tour F9: Vasculitis I**

**Chairperson(s): Carlo Salvarani (Italy), Alessandra Soriano (Italy)**

FRI0354 CARDIOPULMONARY INVOLVEMENT IN TAKAYASU ARTERITIS / D. Brennan* - K. J. Warrington - J. Schmidt - C. Crowson - M. J. Koster

FRI0355 COMPARISON OF RITUXIMAB WITH CYCLOPHOSPHAMIDE AS INDUCTION THERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-Strauss SYNDROME): A 24 MONTHS FOLLOW-UP ANALYSIS / N. Venhoff* - K. Halmischlag - M. Rizzi - R. Voll - J. Thiel


FRI0357 INCIDENCE AND PREDICTORS OF THORACIC AORTIC DAMAGE IN BILATERAL-PROVEN GIANT CELL ARTERITIS: A SINGLE-INSTITUTION COHORT STUDY / M. J. Koster* - C. Crowson - E. L. Matteson - K. J. Warrington

FRI0358 SHORT TERM PROGNOSIS OF A PROSPECTIVELY FOLLOWED COHORT OF UNSELECTED ADULT IGA VASCUITIS CASES - A SINGLE RHEUMATOLOGY CENTRE EXPERIENCE / J. Ostatovskin* - A. Hočevar - Ž. Rotar - M. Tomšič


**Poster tour F10: SpA - clinical**

**Chairperson(s): Robert B. M. Landewé (Netherlands), Sofia Ramiro (Netherlands)**


FRI0395 LOW-DOSE SEMI-CORONAL CT OF THE SACROILIAC JOINTS IN THE EARLY DIAGNOSIS OF ANKYLOSING SPONDYLITIS / D. Gao* - K. Li - Y. Wang - Q. Wen - J. Zhu - J. Zhang - F. Huang


FRI0398 PHARMACOLOGIC THERAPY AND RADIOGRAPHIC PROGRESSION IN ANKYLOSING SPONDYLITIS: A GROWING CONTROVERSY / L. Gensler* - J. D. Reveille - M. A. Brown - M. Rahbar - M. Lee - M. H. Weisman

FRI0399 BACKFILL IS MORE IMPORTANT THAN EROSION AND FAT DEPOSITION IN DIAGNOSING AXIAL SPONDYLOARTHRITIS AS SEEN ON MRI / Z. Hu - P. Zhang - M. Qiu - J. Qi - X. Guo - J. Gu*  


FRI0402 QUANTIFICATION OF FAT FRACTION OF VERTEBRAL BONE MARROW IN PATIENTS WITH ANKYLOSING SPONDYLITIS / S. Lee* - Y. Song - B. S. Koo - T.-H. Kim

* Presenting author
**Poster tour F11: Imaging in RMD - adding value**

**Chairperson(s):** Esperanza Naredo (Spain), Alexandra Kosevoi (Romania)

**FRI0513** VALIDATING MRI-DETECTED INFLAMMATION THRESHOLDS PREDICTIVE OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL

**FRI0514** ADDING MRI OF THE SPINE TO THE ASAS CLASSIFICATION CRITERIA FOR AXIAL Spondyloarthritis, REDUNDANT OR BENEFICIAL? DATA FROM THE Spondyloarthritis CAUGHT EARLY (SPACE)-COHORT

**FRI0515** QUANTITATION AND IMPACT OF SECONDARY OSTEOARTHRITIS IN PATIENTS WITH ANTI-CITRULLINATED PROTEIN ANTIBODIES POSITIVE RHEUMATOID ARTHRITIS

**FRI0516** ULTRASONOGRAPHIC ASSESSMENT OF NEWLY DEVELOPED ELDERLY-ONSET RHEUMATOID ARTHRITIS: A COMPARISON WITH YOUNGER-ONSET RHEUMATOID ARTHRITIS


**FRI0518** ULTRASONOGRAPHIC DEFINITIONS FOR VASCULITIS IN CRANIAL AND LARGE VESSEL GIANT CELL ARTERITIS: RESULTS OF A DELPHI SURVEY OF THE OMERACT ULTRASOUND LARGE VESSEL VASCULITIS GROUP

**FRI0519** ULTRASONOGRAPHIC DEFINITION OF CARTILAGE CHANGE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RELIABILITY STUDY BY THE OMERIC ULTRASONOGRAPHIC CRITERIA FOR ELEMENTARY LESIONS IN CALCIUM PYROPHOSPHATE DEPOSITION DISEASE


**FRI0521** RELIABILITY OF AN OMERIC RHEUMATOID ARTHRITIS TENOSYNOVITIS SCORING SYSTEM FOR WRIST AND HAND / D. Glinatsi* - P. Bird - F. Gandjbakhch - E. A. Haavardsholm - P. G. Conaghan - M. Östergaard on behalf of the OMERACT MRI in arthritis working group


**Poster tour F12: Epidemiology of RMDs**

**Chairperson(s):** Axel Finckh (Switzerland), Deborah Symmons (United Kingdom)

**FRI0550** REAL-WORLD TREATMENT PATTERNS AMONG RHEUMATOID ARTHRITIS PATIENTS WHO SWITCH FROM A TUMOR NECROSIS FACTOR INHIBITOR TO ANOTHER MEDICATION / B. Chastek* - J. R. Curtis - L. K. Becker - P. Mahajan - C. Chen

**FRI0551** EVALUATION OF CHANGE IN ANTI-CITRULLINATED PEPTIDE AUTOANTIBODY LEVELS IN CLINICAL PRACTICE AND ASSOCIATION WITH RESOURCE USE / E. Alemao* - Z. Guo - C. Iannaccone - M. Frits - N. Shadick - M. Weinblatt

**FRI0552** PATIENTS WITH RHEUMATOID ARTHRITIS ARE MORE OBESE THAN THE GENERAL POPULATION ALREADY AT DISEASE ONSET: A COLLABORATIVE ANALYSIS FROM THREE LARGE GERMAN RA DATABASES / A. Richter - J. Callhoff - D. Huscher - G. Schett - A. Zink


**FRI0555** LONG-TERM EFFECTIVENESS OF HERPES ZOSTER VACCINE AMONG PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASES / H. Yun - E. Xie - J. W. Baddley - K. Winthrop - L. Chen - J. R. Curtis*
FRI0556  DOES LEAVING POVERTY REDUCE NEWLY ACCUMULATED DAMAGE IN SLE? / E. Yelin* - L. Trupin - J. Yazdany


FRI0560  THE INCREASE IN THE NATIONWIDE INCIDENCE OF INFLAMMATORY RHEUMATIC DISEASES IN FINLAND DURING THIS MILLENNIUM / V. Rantalaiho* - H. Kautiainen - L. Virta - K. Puolakka

**Poster tour F13: Education**

**Chairperson(s): Annamaria Iagnocco (Italy), Peter Mandl (Austria)**

FRI0599  CLINICIAN TRAINING IN MOTIVATIONAL COMMUNICATION SKILLS: THE IMPACT OF THE LANGUAGE OF CHANGE PROGRAM AMONG RHEUMATOLOGISTS FROM ACROSS CANADA / K. Lavoie - M. Bell - T. Taylor - R. Arendse - M. Saum - D. Faucher - M. Shawi - M. Camerlain*


FRI0601  ROLE OF GROUP LEARNING TO IMPROVE REPRODUCIBILITY OF DAS-28 AMONGST HEALTHCARE PROFESSIONALS / S. S. Majed* - E. M. Clark on behalf of Rheumatology Dept, North Bristol NHS Trust


FRI0604  THE EFFECT OF AN EDUCATIONAL INTERVENTION BASED ON CLINICAL SIMULATION IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS DIAGNOSIS BY GENERAL PRACTITIONERS: A RANDOMIZED CLINICAL TRIAL S. A. Mora Alfonso* - D. G. Fernández - L. F. Sastre on behalf of Hospital Universitario de la Samaritana

FRI0605  EFFECT OF AN EDUCATIONAL INTERVENTION BASED ON CLINICAL SIMULATION IN THE DIAGNOSIS OF SPONDYLOARTHRITIS (SPA) FROM GENERAL PRACTITIONERS, A STUDY BEFORE AND AFTER S. A. Mora Alfonso* - D. G. Fernández Ávila - L. F. Sastre


FRI0607  RHEUMATOLOGY TRAINING IN INDIA - A REFLECTION AND COMPARISON WITH UNITED KINGDOM P. Das* - A. Moorthy - B. Dharmarand

FRI0608  SIMULATION FOR JOINT INJECTION AND ASPIRATION. COLLABORATING OUR EXPERIENCES, WHAT HAVE WE LEARNED? / S. Shabbir* - K. Shah - J. Mukherjee - M. Carby

**Poster tour F14: Focus on rehabilitation**

**Chairperson(s): Anthony Redmond (United Kingdom), Rikke H. Moe (Norway)**

FRI0643-HPR  A MULTICENTRE FOCUS GROUP STUDY ON IMPORTANT OUTCOMES FOR PATIENTS WITH PSORIATIC ARTHRITIS / E. Dures* - W. Tillett - J. Lord - C. Bowen - N. McHugh - S. Hewlett

FRI0644-HPR  PERCEIVED PHYSICAL ACTIVITY BENEFITS AND BARRIERS IN RHEUMATOID ARTHRITIS PATIENTS L. Sammut* - P. Clayton - J. Arnold - B. Davidson

FRI0645-HPR  FREQUENTLY ASKED QUESTIONS OF PATIENTS WITH OSTEOPOROSIS: A CONSENSUS EXERCISE A. Claassen* - S. Koëter - J. Botman - H. Schers - C. van den Ende on behalf of project group “Towards a regional approach of osteoporosis”

FRI0646-HPR  DOES PAINFUL HAND ARTHRITIS INFLUENCE MOTOR CORTEX EXCITABILITY AND MOTOR SKILL LEARNING? R. Parker* - G. Lewis - D. Rice - P. McNair

FRI0647-HPR  PHYSICAL ACTIVITY AND AEROBIC CAPACITY ASSESSMENT - A SURVEY AMONG PATIENTS WITH RHEUMATIC DISEASE IN SWEDEN, IRELAND AND DENMARK / N. Brodin* - N. Kennedy - T. Swinnen - B. Appel Ebsen - M. Saavedra Salinas - C. Arce Salinas on behalf of Mexican Accreditation Council for Rheumatology (MACR)


* Presenting author
PARE Poster tour F15: PARE Poster Tour II

Chairperson(s): Dieter Wiek (Germany), Petra Balazova (Slovakia)

PARE0009 ESTONIAN YOUTH AWARENESS OF INVISIBLE CHRONIC DISEASES / L. Kullamaa*

PARE0010 INFLUENCE OF RMDS ON SEXUALITY AND COUPLE’S RELATIONSHIP: A HARD PROBLEM FOR PATIENTS WHICH REMAINS UNSPOKEN / U. G. Viora* - M. G. Pisu - S. Tonolo - G. Voltan

PARE0011 LIGAFLASH, BEYOND AN IMAGE. A PHOTOGRAPHIC EXHIBITION / V. Romero Pazos* - F. J. Carreira Roca - A. I. Vázquez Lojo - C. van Biel on behalf of Liga Reumatolóxica Galega

PARE0012 REVMA CHALLENGE 2015 - GIVE A HELPING GLOVE AND SUPPORT A PATIENT WITH RHEUMATOID ARTHRITIS / H. Smucrova*

PARE0013 JUVENILE IDIOPATHIC ARTHRITIS: IT’S NOT JUST AN OLD PERSON’S DISEASE / S. R. Stones* on behalf of MyJIA Virtual Expert Advisory Group

PARE0014 PATIENT ADVOCACY FOR BETTER INFORMATION ON BIOSIMILARS AND SWITCHING / G. Korevaar*

PARE0015 PATIENT INVOLVEMENT IN THE DESIGN OF TECHNOLOGICALLY-ENHANCED CLOTHING TO HELP MANAGE MUSCULOSKELETAL CONDITIONS / S. de Souza* - A. Chan - C. Simpson - D. Atkinson - D. Williams - H. Lempp


**Cytokines and inflammatory mediators**

**FRI0001**  

**FRI0002**  
SPINAL MICROGLIAL ACTIVATION IN A MURINE SURGICAL MODEL OF KNEE OSTEOARTHRITIS A.-M. Malfait* - P. B. Tran - R. E. Miller - S. Ishihara - R. J. Miller

**FRI0003**  

**FRI0004**  
INHIBITION OF PHOSPHODIESTERASE 4 (PDE4) REDUCES DERMAL FIBROSIS BY INTERFERING WITH THE RELEASE OF PRO-FIBROTIC CYTOKINES FROM M2-MACROPHAGES / C. Maier* - A. Ramming - G. Schett - J. H. Distler - C. Beyer

**FRI0005**  

**FRI0006**  

**FRI0007**  
EFFECT OF TYPE 1 AND 2 INTERFERONS ON NEUTROPHIL APOPTOSIS IN NAÏVE AND TNF ALPHA PRIMED NEUTROPHILS / S. Irwin* - A. Midgley - R. Wright - M. Peak - M. Beresford

**FRI0008**  
MOBILIZATION OF LYMPHATIC ENDOTHELIAL PRECURSORS CELLS AND LYMPHATIC NEOVASCULARIZATION IN PRIMARY SJÖGREN’S SYNDROME / A. Alperi-López - P. J. Ballina-García - I. Rosa - S. Caterbi - R. Gerli

**FRI0009**  
SERUM 14-3-3 ETA IS AN RA SPECIFIC MECHANISTIC MARKER / B. Dasgupta* - Y. Cherkas - S. Lamberth - B. Hayden - C. Brodmerkel - A. Marotta - M. Curran

**FRI0010**  
PHARMACOKINETICS, SAFETY AND TOLERANCE OF BCD-085, A NOVEL IL-17 INHIBITOR, BASED ON THE RESULTS OF PHASE 1 CLINICAL STUDY IN HEALTHY VOLUNTEERS / B. Dasgupta* - Y. Cherkas - S. Lamberth - B. Hayden - C. Brodmerkel - A. Marotta - M. Curran

**FRI0011**  
MYCOPHENOLIC ACID SYNERGIZES WITH LIPOPOLYSACCHARIDE TO INDUCE INTERLEUKIN (IL)-1B RELEASE VIA ACTIVATION OF CASPASE-1 AND PROTECTS MRL/LPR MICE AGAINST MORTALITY INDUCED BY ENDOTOXEMIA / X. Huang - Y. He - J. Zhuang - E. Sun*

REGULATION OF OSTEOCLAST DIFFERENTIATION BY ARGINASE 1 / J. Brunner* - M. Hofmann - V. Saferding - K. Redlich - J.-S. Smolen - G. Schabauer - S. Blüml

PHARMACOLOGICAL BLOCKADE OF CCR3 REDUCES COLLAGEN-INDUCED ARTHRITIS SEVERITY / J. Hablot* - M. Koonfany - P. Reboul - J.-Y. Jouzeau - M. Doulin


BMP-2 AND TGF-B INHIBIT IL-34 EXPRESSION IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS / M. Chemel-Mary* - B. Legoff - Y. maugars - D. Heymann - F. Verrechia


INFLAMMATORY STATUS AND SERUM URIC ACID LEVELS DETERMINE HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVELS IN A NON-RHEUMATIC POPULATION / M. Andres* - M. A. Quintanilla - P. Morillas on behalf of FAPRES registry investigators


NO REACTIVATION OF DORMANT MYCOBACTERIUM TUBERCULOSIS IN HUMAN IN VITRO GRANULOMA MODEL AFTER ANTI-IL-17A TREATMENT, IN CONTRAST TO ANTI-TNFα TREATMENT / N. Kapoor - M. Kammüller* - P. E. Kolattukudy

A CYTOKINE-MEDIATED BIOLOGICAL BASIS FOR FATIGUE IN PRIMARY SJÖGREN'S SYNDROME / N. Howard Tripp* - J. Tarn - C. Gillespie - D. Lendrem - W.-F. Ng

THE INFLAMMATORY PATHOLOGY OF LUPUS NEPHRITIS IS SIGNIFICANTLY INFLUENCED WITH PSYCHOSOCIAL STRESS, SUPPRESSED WITH EXERCISE, AND CORRELATES WITH TNF-ALPHA AND MCP-1 EXPRESSION IN A MURINE MODEL / S. Aqel - J. Hampton - G. Valente - J. Sheridan - W. Jarjour - N. A. Young


RAGE ACTIVITY INFLUENCES CO-DEVELOPMENT OF JOINT AND VASCULAR DISEASE IN RA / S. Yu* - C.-K. Wong - E. K. Li - L.-S. Tam

JOINT INFLAMMATION AND CARTILAGE DESTRUCTION IN EXPERIMENTAL OSTEOARTHRITIS IS NOT MEDIATED BY INTERLEUKIN-1β / S. van Dalen* - A. Blom - L. Joosten - A. Sloetjes - M. Helsen - W. van den Berg - P. van Lent

META-IMMUNOLOGICAL PROFILING OF PATIENTS WITH BEHÇET’S DISEASE REVEALS NOVEL BIOMARKERS OF DISEASE ACTIVITY, PROGRESSION AND RESPONSE TO THERAPY / S. van Dalen* - A. Blom - L. Joosten - A. Sloetjes - M. Helsen - W. van den Berg - P. van Lent

BMP-2 AND TGF-B INHIBIT IL-34 EXPRESSION IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS / M. Chemel-Mary* - B. Legoff - Y. maugars - D. Heymann - F. Verrechia


TNF ALPHA PRODUCTION IN CULTURED HUMAN MACROPHAGES AFTER CTLA4-IG (ABATAcept) IN VITRO TREATMENT / R. Brizzolara* - P. Montagna - S. Soldano - A. C. Trombetta - S. Paolino - C. Pizzorni - A. Sulli - B. Ruaro - D. Camellino - V. Tomatis - M. Cutolo

RAGE ACTIVITY INFLUENCES CO-DEVELOPMENT OF JOINT AND VASCULAR DISEASE IN RA / S. Yu* - C.-K. Wong - E. K. Li - L.-S. Tam

JOINT INFLAMMATION AND CARTILAGE DESTRUCTION IN EXPERIMENTAL OSTEOARTHRITIS IS NOT MEDIATED BY INTERLEUKIN-1β / S. van Dalen* - A. Blom - L. Joosten - A. Sloetjes - M. Helsen - W. van den Berg - P. van Lent

META-IMMUNOLOGICAL PROFILING OF PATIENTS WITH BEHÇET’S DISEASE REVEALS NOVEL BIOMARKERS OF DISEASE ACTIVITY, PROGRESSION AND RESPONSE TO THERAPY / S. van Dalen* - A. Blom - L. Joosten - A. Sloetjes - M. Helsen - W. van den Berg - P. van Lent

CHONDROITIN SULPHATE INHIBITION OF NF-KB ACTIVITY: ATTENUATION OF HYALURONAN FRAGMENT INDUCED INFLAMMATORY RESPONSE IN MACROPHAGES BY CHONDROITIN SULPHATE IS MEDIATED BY REDUCTION IN NF-KB ACTIVITY / T. Stabler - E. Montell - J. Vergès - V. B. Kraus*

Rheumatoid arthritis - etiology, pathogenesis and animal models

**FR10042**

**FR10044**
SMOKING INDUCES IRREVERSIBLE DEREGLUATION OF MICRORNA EXPRESSION IN RHEUMATOID ARTHRITIS / K. Andersson - M. Turkkila - S. Töyrä - M. Bokarewa*

**FR10045**

**FR10047**

**FR10048**

**FR10049**

**FR10050**

**FR10051**
IN VIVO IMAGING TO CHARACTERIZE THE SPECIFICITY, FUNCTION AND BEHAVIOR OF THE CD4+ T CELLS INITIATING ARTICULAR INFLAMMATION / R. A. Benson* - C. T. Prendergast - I. B. McInnes - J. M. Brewer - P. Garside

**FR10052**
TARGETING TRISTETRAPROLIN TO TREAT INFLAMMATORY ARTHRITIS / E. Ross - A. Naylor - G. Kollias - A. Filer - J. Dean - C. Buckley - A. Clark*

**FR10053**

**FR10054**

**FR10055**

**FR10056**

**FR10057**

**FR10058**
PRODUCTION OF AN ANTI-TYPE II COLLAGEN IGG2B MONOCLONAL ANTIBODY CAPABLE OF INDUCING DESTRUCTIVE POLYARTHRITIS IN MICE / S. Yoshino* - N. Mizutani - T. Kobakokkruad

**FR10059**
COMPLEMENT-MEDIATED NEUTROPHIL LYSIS - A MECHANISM PROMOTING HYPERCITRULLINATION IN RHEUMATOID ARTHRITIS / T. Gazitt* - C. Lood - J. Ledbetter - K. B. Elkon

**FR10060**
EXTRACELLULAR MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IS ESSENTIAL FOR HYPOXIA-INDUCED ANGIOGENESIS IN A HIF-1-AND HIF-2-INDEPENDENT MANNER / M. Mursell - M. Hahne - P. Kunath - C. Strehl - F. Buttgereit - T. Gaber*

**FR10061**
IN VIVO IMAGING TO CHARACTERIZE THE SPECIFICITY, FUNCTION AND BEHAVIOR OF THE CD4+ T CELLS INITIATING ARTICULAR INFLAMMATION / R. A. Benson* - C. T. Prendergast - I. B. McInnes - J. M. Brewer - P. Garside

* Presenting author
Rheumatoid arthritis - prognosis, predictors and outcome

FRI0062
OBESITY IS ASSOCIATED WITH WORSE CLINICAL OUTCOMES YET LIMITED RADIOGRAPHIC PROGRESSION IN EARLY RHEUMATOID ARTHRITIS / A. Levitsky* - S. Saevardsdottir - K. Brismar - K. Hambardzumyan - C. Lourudoss - R. F. van Vollenhoven

FRI0063

FRI0064

FRI0065
PRESENCE, GRADE AND LOCATION OF POWER DOPPLER PREDICT PROGRESSION OF RADIOGRAPHIC DAMAGE IN TNFa BLOCKER INDUCED CLINICAL REMISSION IN RHEUMATOID ARTHRITIS PATIENTS B. Raffeiner* - E. Grisam - G. Rizzo - C. Botsios - A. Doria - F. Omoto - L. Punzi

FRI0066

FRI0067

FRI0068
CONTRIBUTIONS OF SOCIAL DETERMINANTS OF HEALTH ON REMISSION IN RHEUMATOID ARTHRITIS PATIENTS K. Cui - C. Bombardier* - G. Tomlinson on behalf of Ontario Best Practices Research Initiative (OBRI) Investigators

FRI0069
DISCORDANT CLASSES OF INFLAMMATION AND PAIN IN EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS. RESULTS FROM THE EARLY RHEUMATOID ARTHRITIS NETWORK AND THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTRY / D. F. Mcwilliams* - E. Ferguson - A. Young - P. D. Kiely - D. A. Walsh

FRI0070

FRI0071

FRI0072
EARLY DETECTION OF INFAMMATORY ARTHRITIS: THE ROLE OF MUSCULOSKELETAL SYMPTOMS, INFECTIONS AND RHEUMATOID ARTHRITIS-RELATED COMORBIDITIES IN PRIMARY CARE / M. H. V. Beers-Tas - M. M. Nielsen - J. C. Korevaar - D. V. Schaardeenburg*

FRI0073

FRI0074

FRI0075
EFFECTS OF DMARDS ON CITRULLINATED PEPTIDE AUTOANTIBODY LEVELS IN RA PATIENTS - A LONGITUDINAL ANALYSIS / G. Schett* - C. Wunderlich - C. Figueiredo - J. F. Cobre - A. J. Hueber - C. Allaart

FRI0076

FRI0077

FRI0078

FRI0079
THE EFFECTIVENESS OF INITIAL TIGHT DISEASE CONTROL AND PAIN CONTROL FOR ACHIEVING LONG STANDING COMPREHENSIVE DISEASE REMISSION (CDR) IN RHEUMATOID ARTHRITIS TREATMENT / L. Yoshii*

FRI0080

FRI0081
COMPARISON OF DISEASE BURDEN IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), RA WITH SECONDARY OSTEOARTHRITIS (OA), AND OA IN ROUTINE CARE / I. Castrejon* - J. Chuah - A. M. Malfait - J. A. Block - T. Pincus

FRI0082

FRI0083
FACTORS ASSOCIATED WITH THE NEED FOR BIOLOGICAL THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. Cuadros - J. L. Andreu* - I. Millan - M. Bascas - C. Ramos - M. Espinosa - B. J. Flores - J. Campos - J. Sanz

* Presenting author


PREDICTORS FOR ATTAINING REMISSION TO TWO CONSECUTIVE VISITS IN NEWLY DIAGNOSED EARLY RA PATIENTS / M. Kuijper* - J. Luime - P. de Jong - A. Gerards - J. van Zeven - I. Tchetverikov - P. de Sonnaville - M. van Krugten - B. Gillet - M. Hazes - A. Weel


DISABLEMENT IN EARLY RHEUMATOID ARTHRITIS MAY PERSIST DESPITE IMPROVEMENT IN DISEASE ACTIVITY: EVIDENCE FROM YORKSHIRE EARLY ARTHRITIS REGISTER / S. Twigg* - E. Hensor - P. Emery - A. Tennant - A. W. Morgan on behalf of YEAR consortium


BASELINE SERUM 14-3-3 ETA INDEPENDENTLY PREDICTS CLINICALLY IMPORTANT IMPROVEMENTS IN HAQ-DI IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB / S. Hirata* - K. Hanami - A. Marotta - Y. Tanaka


APOLIPOPROTEIN A1 IS PROTECTIVE FOR JOINT DAMAGE PROGRESSION IN ACRA-POSITIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / S. Ajeganova* - B. Svensson - I. Hafström

ASSESSMENT OF LARGE JOINT DESTRUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY USING FDG-PET/CT AND ARASHI SCORING METHOD / T. Suto* - Y. Yonemoto - K. Okamura - C. Okura - K. Takagiishi


ERYTHROCYTE METHOTREXATE POLYGLUTAMATE LEVELS DO NOT DETERMINE EFFICACY AND TOLERABILITY OF METHOTREXATE IN RHEUMATOID ARTHRITIS / V. Dhawan* - A. Sandhu - A. Bhattachar - V. Dhawan - J. Kaur - A. Sood - A. Sharma - S. Sharma


* Presenting author
**Rheumatoid arthritis - comorbidities and clinical aspects**

FRI106  THE ASSOCIATION OF FATIGUE, COMORBIDITIES AND ANTI RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COMEDRA STUDY / A. Tournade* - B. Pereira - L. Gossec - M. Soubrier - M. Dougados

FRI107  NO INCREASED RISK OF HIGH GRADE CERVICAL DYSPLASIA IN WOMEN WITH RHEUMATOID ARTHRITIS / L. Chauve* - L. Kearsley-Fleet - N. Brown - K. Watson - M. Lunt - D. Symmons - K. Hynich


FRI109  INFLUENCE OF AROMATASE INHIBITORS THERAPY ON THE OCCURRENCE OF RHEUMATOID ARTHRITIS IN WOMEN WITH BREAST CANCER. RESULTS FROM A LARGE POPULATION BASED STUDY OF THE ITALIAN SOCIETY FOR RHEUMATOLOGY / M. Caprioli* - G. Carrara - S. Pennetta - C. A. Scirià on behalf of RECORD


FRI113  POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING A BIOLOGICAL AGENT - A SYSTEMATIC REVIEW AND META-ANALYSIS / H. Ito*

FRI114  DEVELOPMENT OF THE PATIENT MOTIVATION QUESTIONNAIRE: CONCEPTUALIZING AND MEASURING MOTIVATION IN PATIENTS WITH INFLAMMATORY ARTHRITIS / Y. El Miedany* - M. Mahal El Gafary - S. Youssef - D. Palmer


FRI117  THE PREVALENCE OF DIABETES MELLITUS AMONG RHEUMATOID ARTHRITIS PATIENTS IS MORE THAN TWICE THE PREVALENCE IN THE DANISH POPULATION / A. Enamifar* - I. M. Hansen


FRI121  PROSPECTIVE ASSESSMENT OF CARDIOVASCULAR RISK FACTORS IN RELATION TO DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS / B. Targońska-Stępniak* - M. Piotrowski - R. Zwolak - M. Majdan


FRI127  PROSPECTIVE ASSESSMENT OF CARDIOVASCULAR RISK FACTORS IN RELATION TO DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS / B. Targońska-Stępniak* - M. Piotrowski - R. Zwolak - M. Majdan


* Presenting author

LIPID MANAGEMENT AMONG INDIVIDUALS WITH INFLAMMATORY ARTHRITIS IN THE NATIONAL REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE COHORT / I. Navarro-Millan* - C. Gamboa - J. R. Curtis - M. M. Safford


INTERLEUKIN-6 BLOCKADE RAISES LDL VIA REDUCED CATABOLISM RATHER THAN VIA INCREASED SYNTHESIS - A CYTOKINE-SPECIFIC MECHANISM FOR CHOLESTEROL CHANGES IN RHEUMATOID ARTHRITIS / J. Robertson* - D. Porter - N. Sattar - C. Packard - M. Caslake - I. B. McInnes - D. McCarey


RISK OF TYPE 2 DIABETES MELLITUS DEVELOPMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS / L. Kondratyeva* - T. Popkova - E. Nasonov


ANEMIA IS A MORE COMMON SYMPTOM IN LATE-ONSET RA COMPARED TO YOUNG-ONSET RA AND IS STRONGER RELATED TO IMPAIRED KIDNEY FUNCTION / P. Studenic* - D. Aletaha - H. Haslacher - M. Unger - J. Smolen - M. Köller

MANAGEMENT OF GOUT IN PRIMARY CARE: WHAT ARE THE FACTORS ASSOCIATED WITH ADHERENCE? / J. Smolen - M. Köller

HIGH PREVALENCE OF DEPRESSION IN RA PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE ADAGIO COHORT / R.-M. FLIPO* - L. Martinez - M. P. Paquet - G. Reach


RISK OF TYPE 2 DIABETES MELLITUS DEVELOPMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS / L. Kondratyeva* - T. Popkova - E. Nasonov


MANAGEMENT OF GOUT IN PRIMARY CARE: WHAT ARE THE FACTORS ASSOCIATED WITH ADHERENCE? / J. Smolen - M. Köller

HIGH PREVALENCE OF DEPRESSION IN RA PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE ADAGIO COHORT / R.-M. FLIPO* - L. Martinez - M. P. Paquet - G. Reach


RISK OF TYPE 2 DIABETES MELLITUS DEVELOPMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS / L. Kondratyeva* - T. Popkova - E. Nasonov


MANAGEMENT OF GOUT IN PRIMARY CARE: WHAT ARE THE FACTORS ASSOCIATED WITH ADHERENCE? / J. Smolen - M. Köller

HIGH PREVALENCE OF DEPRESSION IN RA PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE ADAGIO COHORT / R.-M. FLIPO* - L. Martinez - M. P. Paquet - G. Reach


MANAGEMENT OF GOUT IN PRIMARY CARE: WHAT ARE THE FACTORS ASSOCIATED WITH ADHERENCE? / J. Smolen - M. Köller

HIGH PREVALENCE OF DEPRESSION IN RA PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE ADAGIO COHORT / R.-M. FLIPO* - L. Martinez - M. P. Paquet - G. Reach

Rheumatoid arthritis - anti-TNF therapy


FRI0159  PERSISTENCE WITH BIOLOGIC MONOTHERAPY IN COMPARISON WITH COMBINATION THERAPY WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM AN ONTARIO RHEUMATOID ARTHRITIS COHORT / A. N. Lau* - M. Movahedi - T. Tanggelo - C. Bombardier on behalf of Ontario Best Practices Research Initiative (OBRI) investigators

FRI0160  ANTI-TNF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS DOES NOT ATTENUATE CUTANEOUS TNF ACTIVITY FOLLOWING A TUBERCULIN SKIN TEST / R. Byng-Maddick* - C. Haas - M. Ehrenstein - M. Noursadeghi


FRI0163  EFFICACY OF THE BIOSIMILAR BOW015, COMPARED TO ORIGINATOR INFliximab, INITIATED AT MODERATE AND SEVERE DISEASE ACTIVITY THRESHOLDS IN RHEUMATOID ARTHRITIS / P Taylor* - M. Wyand - A. Knight - C. Costantino - C. Lassen


FRI0171  EVALUATING TREATMENT EFFICACY IN RHEUMATOID ARTHRITIS: INTERRELATION DISEASE ACTIVITY - FUNCTIONAL STATUS - UTILITY / C. Codreanu* - C. Costantino - L. Enache - M. Parvu - S. Rednic - R. Ionescu


* Presenting author


FRI0179  ANTI-TNF THERAPY IS ASSOCIATED WITH AN IMPAIRED FUNCTION OF NK CELLS AND A DEFECTIVE IMMUNOSURVEILLANCE AGAINST B CELL LYMPHOMAS / G. Nocturne* - B. Ly - S. Bouidaoud - R. Seror - L. Zitvogel - X. Mariette

FRI0180  NO PREDICTION OF RELAPSE BY TNF BLOCKER CONCENTRATIONS OR DETECTION OF ANTIBODIES AGAINST ANTI-TNF: DATA FROM STRASS STUDY / H. Marotte* - M. Rinaudo - S. Paul - B. Fautrel

FRI0181  CHANGING USE OF METHOTREXATE (MTX) AND BIOLOGICS IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN THE UNITED STATES (US): RESULTS OF A COMPREHENSIVE PHARMACEUTICAL CLAIMS ANALYSIS / J. R. O’Dell* - S. Cohen - C. Thorne - T. R. Mikuls


FRI0183  PREGNANCY OUTCOMES IN WOMEN EXPOSED TO INFLIXIMAB (INNOVATOR) / J. Slater* - J. Phillips - C.-Y. Guo - M. Clark - A. Geldhof - N. Gearhart - R. Nissen

FRI0184  INCREASING TREND TO TIME ON INFILXIMAB IS PREDICTIVE OF INCREMENTALLY BETTER LONG-TERM RETENTION IN STABLE RHEUMATOLOGY PATIENTS IN CANADA / M. Khrash* - J. Foley - E. Stein


FRI0187  A RANDOMIZED CROSSOVER COMPARISON OF INJECTION SITE PAIN WITH 40 MG/0.8 ML AND 40 MG/0.4 ML FORMULATIONS OF ADAHMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS / P. Nash* - J. Vanhoof - S. Hall - R. Tarzynski-Potempa - K. Unnebrink - A. Cividino


FRI0189  THE USE OF INTERFERON GAMMA RELEASE ASSAYS IN SCREENING FOR LATENT TB PRIOR TO BIOLOGICS IN PATIENTS WITH RHEUMATIC DISORDERS; VALIDATION OF NICE GUIDANCE / S. Sacks* - N. Ahmad - A. Steuer - A. Zakari


FRI0191  BIOSIMILAR CANDIDATE ABP 501: ADDITIONAL EFFICACY ANALYSES FROM THE PHASE 3 STUDY / S. Cohen* - N. Zhang - P. Kaur


FRI0193  ETANERCEPT DOSE REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS - A PILOT STUDY IN SOUTH WALES / S. Duffill* - S. Kia - N. Amos - E. Thomas on behalf of Search Results Abertawe Bro Morgannwg University Health Board


* Presenting author
Rheumatoid arthritis - other biologic treatment

FRI0197 TIME LAG OF IMPROVEMENT IN SYNOVIAL HYPEROXYGEN COMPARISON TO RAPID RESPONSE IN POWER DOPPLER SYNOVIAL VASCULARITY IN POST-ADALIMUMAB RHEUMATOID ARTHRITIS / Y.-C. Chen* - J.-F. Chen - T.-T. Cheng

Rheumatoid arthritis - other biologic treatment

FRI0198 WHICH SERONEGATIVE RA PATIENTS RESPOND TO RITUXIMAB? / E. M. Vital* - E. M. Hensor - P. Emery


FRI0201 RITUXIMAB TREATED NON RESPONDER RHEUMATOID ARTHRITIS PATIENTS ARE GENERATING A NEW AUTOANTIBODY REPERTOIRE / Z. Konthur - M. M. Wiemkes - T. Häupl - G. R. Burmester - K. Skriner*


FRI0206 SERO-PERSISTIVENESS FOR RHEUMATOID FACTOR IS AN INDEPENDENT PREDICTOR FOR ACHIEVEMENT OF GOOD EULAR RESPONSE AT 24 WEEKS IN ACPA POSITIVE RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT: RESULTS FROM JAPANESE MULTICENTER REGISTRY / N. Takashashi* - T. Kojima - K. Funahashi - N. Ishiguro on behalf of TBCR study group


FRI0208 ABATACEPT THERAPY COMBINED WITH TACROLISUM FOR RHEUMATOID ARTHRITIS PATIENTS SHOWS SUPERIOR EFFICACY THAN ABATACEPT THERAPY WITHOUT TACROLISUM / A. Nampei* - Y. Nagayama - H. Tsuboi


FRI0215 SUBCUTANEOUS TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH A CSDMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM ANALYSIS OF A LARGE PHASE IV INTERNATIONAL UMBRELLA STUDY, "TOZURA" / E. Choy* - R. Caporali - R. Xavier - B. Fauteil - R. Sanmarti - C. Bernasconi - A. Petö-Schramm


SCIENTIFIC POSTER SESSION 2 / FRIDAY 10 JUNE 2016 / 119


FRI0220 PRESCRIPTION OF TOCILIZUMAB ALONE OR IN COMBINATION WITH DMARDS IN RHEUMATOID ARTHRITIS PATIENTS IN A REAL LIFE SETTING: THE ACT-SOLO STUDY 12 MONTHS RESULTS / J. Tebib* - I. Idier - M. Coudert - J.-F. Maillefer - R.-M. Flipo


FRI0224 COMPARISON OF EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR, BCD-020, AND INNOVATOR RITUXIMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO TNF-α INHIBITORS / A. Eremeeva - E. Chernyayeva - R. Ivanov - E. Nasonov - L. Knizeva*

FRI0225 SHORT COURSE OF TOCILIZUMAB INCREASES RISK OF HEPATITIS B VIRUS (HBV) REACTIVATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: A REAL-WORLD PROSPECTIVE COHORT STUDY / L.-F. Chen - Y.-Q. Mo - J. Jing - J.-D. Ma - D.-H. Zheng - L. Da*

FRI0226 TOCILIZUMAB IS SIMILARLY EFFECTIVE IN RA PATIENTS WITH NO OR UP TO TWO PRIOR BDMARD Failures: Results from the German Prospective Cohort Study Rabbit / L. Baganz* - A. Strangfeld - I. Kekow - A. Bussmann - A. Krause - C. Stille - I. Listing - A. Richter - A. Zink


FRI0229 RISK OF HOSPITALIZED INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING ABATACEPT AND OTHER BIOLOGICS: ANALYSIS OF A UNITED STATES CLAIMS DATABASE / N. Baker* - M. Boers - M. Hochberg - H. Kawabata - N. Ray - T. Simon

FRI0230 ASSESSMENT OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL ANTI-CD40 MONOCLONAL ANTIBODY, CFZ533, IN HEALTHY VOLUNTEERS AND IN RHEUMATOID ARTHRITIS PATIENTS / A. Slade - P. Koo - Y. He - P. Espie - A. Auger-Sarrazin - J. Rush - P. Gergely*


FRI0233 REAL-WORLD TREATMENT PERSISTENCE AND CLINICAL OUTCOMES OF TNFI CYCLING VS SWITCHING TO NEW MECHANISM-OF-ACTION DMARDS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN THE UNITED STATES / W. Wei - K. Knapp - L. Wang - C. Chen - G. Craig - K. Ferguson - S. Schwartzman*

FRI0234 PREDICTIVE FACTORS OF DISCONTINUATION OF THERAPY WITH ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. Piantoni* - E. Colombo - A. Tincani - P. Airò - M. Scarsi


FRI0237 TOCILIZUMAB IMPACT ON KINETICS OF TREATMENT TARGET PARAMETERS IN SYSEMIC NEPHROTIC TYPE AA-AMYLIOIDOSIS, SECONDARY TO RA / A. Alexeeva - Y. Muraviev* - S. Radenska-Lopovok - E. Aleksandrova - L. Kashnikova

* Presenting author
Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models


FRI0240  SIRT-1 REGULATES TGF-B INDUCED DERMAL FIBROBLAST MIGRATION VIA MODULATION OF CYR61 EXPRESSION / W. Jeong* - E.-J. Park - E.-J. Kwon - M. Cho - J. Kim

FRI0241  HMGBl INDUCES REACTIVE OXYGEN SPECIES (ROS)-DEPENDENT ACTIVATION OF THE ER STRESS PATHWAY IN C2C12 MYOTUBES / A. P. Lightfoot* - R. S. Morgan - R. G. Cooper

FRI0242  ROLE OF MITOCHONDRIA- AND NADPH OXIDASE-DERIVED ROS IN FIBROBLASTS ISOLATED FROM PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS / T. Spadoni* - S. Svegliati - A. Gabrielli

FRI0243  IS THE BMP ANTAGONIST GREMLIN-1 A TARGET IN SYSTEMIC SCLEROSIS? / S. O’Reilly*


FRI0246  DYSREGULATION OF CCN PROTEINS IN SYSTEMIC SCLEROSIS PATIENTS WITH PIGMENTARY DISORDERS / P. Henrot* - C. Pain - J. Seneschal - A. Taieb - M.-E. Truchetet - M. Cario-André


Scleroderma, myositis and related syndromes


FRI0249  RISK FACTORS FOR DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION IN AUSTRALIAN SCLERODERMA PATIENTS / K. Morrisroe* - M. Huq - W. Stevens - C. Rabusa - S. Proudman - M. Nikpour on behalf of Australian Scleroderma Interest Group (ASIG)


FRI0251  ANTI-MDA5 AUTO-ANTIBODY: EXPANDING THE CLINICAL SPECTRUM IN PATIENTS WITH DERMATOMYOSITIS IN NORTH AMERICA / S. Moghadam-Kia* - C. V. Oddis - S. Sato - M. Kuwana - R. Aggarwal


FRI0253  A 18 MONTH OBSERVATION IN PATIENTS WITH PROGRESSIVE SYSTEMIC SCLEROSIS TREATED WITH AN INTEGRATED B-LYMPHOCYTE DEPLETION - CLINICAL AND IMMUNOLOGICAL RESPONSE / D. Rossi* - A. Balbir-Gurman - A. Awisat - Z. Vadatz

FRI0254  THE EFFECT OF CYCLOPHOSPHAMIDE ON LUNG FUNCTION IN DIFFERENT STAGES OF INTERSTITIAL LUNG DISEASE ASSOCIATED TO SYSTEMIC SCLEROSIS / M. Saracco - S. Sciascia - R. Pellerito - V. Modena - D. Roccatello


* Presenting author


FRI0262 PERIPHERAL BLOOD PERFUSION IS LOWER IN PRIMARY RAYNAUD'S PHENOMENON PATIENTS THAN IN THOSE WITH SYSTEMIC SCLEROSIS SHOWING THE "EARLY" PATTERN OF NAILFOLD MICROANGIOPATHY B. Ruauro* - A. Sulli - V. Smith - A. C. Trombetta - C. Pizzorni - M. Cutolo


FRI0267 MYCOPHENOLATE MOFETIL VERSUS ORAL CYCLOPHOSHAMIDE IN SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE: SCLERODERMA LUNG STUDY II / D. Khanna* - M. Roth - P. Clements - D. Furst - C.-H. Tseng - R. Elashoff - E. Volkmann - S. Kafaja - J. Goldin - D. Tashkin on behalf of Scleroderma Lung Study II


FRI0270 PATIENT PERCEPTION OF DISEASE BURDEN IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) D. Khanna* - Y. Allanore - C. Denton - M. Matucci-Cerinic - J. Pope - B. Hinzmann - S. Briody - J. de Oliveira Pena - O. Distler

FRI0271 PERFORMANCE OF MODIFIED RODNAN SKIN SCORE IN EARLY DIFFUSE CUTANEOUS SCLERODERMIA - ANALYSIS FROM 4 COHORTS / D. Khanna* - S. Produman - T. Frech - S. Nithyanova - R. Domisc - V. Berrocal - W. Stevens - M. Nikpour - C. Denton on behalf of ASIG, GRASS and PRESS collaborators

FRI0272 EVALUATION OF BLEYMICYN INDUCED RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS VASCULOPATHY IN GERM CELL TUMOUR PATIENTS / D. Faulkner* - J. Britton - S. Eng - E. Del Galdo - D. Stark - M. Buch


FRI0275 CHANGE IN CXCL4 LEVELS MAY PREDICT TREATMENT RESPONSE IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (SSC-ILD) / E. Volkmann* - D. Tashkin - R. Elashoff - C.-H. Tseng - D. Khanna - M. Mayes - J. Charles - P. Clements - M. Roth - D. Furst - S. Assassi on behalf of EULAR working group

FRI0276 PERIPHERAL STRUCTURAL EVALUATION (RADIOGRAPHIC) AND AXIAL (SCAN) IN A POPULATION OF 77 PATIENTS WITH SYSTEMIC SCLEROSIS / E. Bauer* - D. Mandy - O. Huttin - I. Chary-Valkenaere - D. Loeuille


FRI0278 MACROVASCULAR DYSFUNCTION OF UPPER AND LOWER LIMBS CORRELATES WITH DIGITAL ULCERATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS / E. Moradkhani* - S. Ale-Saeidi - E. Gharibdoost

ARE PATIENTS WITH EXTENDED INTERSTITIAL LUNG DISEASE BETTER TARGET FOR THE TREATMENT IN SSC? A. Taker* - H. Yasuoka - K. Yamaoka - T. Takeuchi


SENSITIVITY TO CHANGE OF NAILFOLD VIDEOCAPILLAROSCOPY AND RELATIONSHIP WITH DISEASE PROGRESSION / J. Avouac* - E. Toinolo - G. Leprì - C. Hurabielle - A. Vallet - Y. Allanore


THE USE OF A DORSAL APPROACH FOR THE INJECTION OF BOTULINUM TOXIN A IN THE TREATMENT OF RAYNAUD'S PHENOMENON SECONDARY TO SCLERODERMA / K. Dhaluwal* - M. Griffin - S. Salinas - K. Howell - C. Denton - P. Butler


RISK FACTORS FOR RECURRENCE OF POLYMYSITIS/DERMAATOMYSITIS ASSOCIATED INTERSTITIAL LUNG DISEASE / M. Nakazawa* - Y. Kaneko - T. Takeuchi

SCREENING FOR MALIGNANCIES IN SYSTEMIC SCLEROSIS PATIENTS POSITIVE FOR ANTI-RNA POLYMERASE III ANTIBODIES: A DELPHI EXERCISE AMONG EUSTAR EXPERTS / M. G. Lazzaroni* - I. Cavazzana - P. Airo’ on behalf of EUSTAR co-authors

THE PROGNOSIS INTERVALS FOR PTS WITH SSC-ILD USING DISCRIMINANT ANALYSIS / O. B. Osvyannikova* - S. Glukhova - O. Koneva - V. Lesnyak - L. Ananieva


A QUANTITATIVE VIDEOCAPILLAROSCOPIC STUDY ABOUT THE MAIN CATEGORIES OF THE "SCLERODERMA PATTERN" AND THEIR CORRELATION WITH THE CLINICAL FEATURES OF SYSTEMIC SCLEROSIS (SSC) R. De Angelis* - E. Di Donato - W. Grassi


* Presenting author
FRI0305  FACTORS DETERMINING HYDROXYCHLOROQUINE SERUM LEVELS IN A COHORT OF CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. C. Mok* - K. L. Chan - P. Jannetto


FRI0310  SERUM INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 (IGFBP2) AS A BIOMARKER OF CLINICAL AND HISTOPATHOLOGICAL TREATMENT RESPONSE IN LUPUS NERVIUS / I. Paradisi* - H. Ding - A. Zickert - L. Arnaud - C. Mohan - I. Gunnarsson


FRI0312  PREDICTORS OF INCIDENT EPISODES OF PROTEINURIA AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / L. S. Magder - A. Duarte-Garcia - E. Barr - M. Petri*


FRI0314  ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CLINICAL DATABASE AND REPOSITORY ANALYSIS: THE IMPACT OF SYSTEMIC LUPUS ERYTHEMATOSUS ON THE CLINICAL PHENOTYPE OF ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PATIENTS S. Zauli* - D. Andrade - D. Erkan - M. Tektonidou on behalf of APS ACTION


FRI0318  SERUM ADIPOCYTE FATTY ACID-BINDING PROTEIN LEVEL IS ELEVATED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS BUT NOT ASSOCIATED WITH BIOPHYSICAL MARKERS OF CARDIOVASCULAR DISEASE / A. Mak* - H. Schwarz - N. Y. Kow - S. H. Tay - L. H. Ling


FRI0322  THERAPY ON THE OVARIAN RESERVE / C. C. Mok* - K. L. Chan - P. Jannetto

FRI0323  A “COMPOSITE-INDEX” APPROACH FOR DEFINING SALIVARY GLAND INFLAMMATION, DYSFUNCTION AND ITS IMPACT ON PATIENT-REPORTED OUTCOMES: A ROLE FOR SALIVARY GLAND ULTRASONOGRAPHY? C. Baldini* - N. Luciano - F. Ferro - S. Bombardieri - M. Mosca

FRI0324  WORK PRODUCTIVITY IN PRIMARY SJÖGREN’S SYNDROME: A CROSS-SECTIONAL MULTICENTER STUDY C. Baldini* - E. Bartoloni - R. Priori - E. Carubbi - A. Alunno - L. Quattrocchi on behalf of GRiSS group


* Presenting author
124 / SCIENTIFIC POSTER SESSION 2 / FRIDAY 10 JUNE 2016

FR10329 BONE EROSI VE DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS IS ASSOCIATED WITH LOCAL HYPERVASCULARIZATION INDEPENDENTLY FROM ACPA POSITIVITY / F. Ceccharelli - C. Perricone - E. Cipriano - L. Massoni - M. Pendolino - G. Capalbo - F. R. Spinelli - C. Alessandri - F. Conti - G. Valesini


FR10332 FACTORS AFFECTING THE ATTITUDES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS REGARDING POTENTIAL CLINICAL TRIAL PARTICIPATION / J. Braverman* - S. Lops - E. Felicione - C. Wagner


FR10334 ALTERED CUTANEOUS MICROVASCULAR FUNCTION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME K. Perdan Pirkmajer* - E. Blokar - M. Cepar - Z. Melik - A. Ambrozic - K. Kankar


FR10336 HYPOCOMPONEMENTIA IN SYSTEMIC LUPUS ERYTHEMATOSUS; ESTABLISHING THE IMPORTANCE OF LOW C3 AND C4 IN A LONGITUDINAL COHORT / L. Durcan* - W. Fu - M. Petri

FR10337 ANTI-C1Q AUTOANTIBODIES, C1Q CIRCULATING IMMUNE COMPLEXES AND COMPLEMENT LEVELS IN PATIENTS WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / C. Magro-Checa - R. A. Schaarenburg - H. J. L. Beart - T. W. Huizinga - G. M. Step-Beekman - L. A. Trouw*


FR10340 BREASTFEEDING IN SYSTEMIC LUPUS ERYTHEMATOSUS / M. Acevedo - J. Pretini - M. Micelli* - G. Sequeira - E. M. Kerzeberg


FR10342 VULVAR HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL CHANGES IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME / M. Orlandi* - A. De Magnis - S. Maddali Bongi

FR10343 SLEEP DISORDERS IN PATIENTS AFFECTED BY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH PROLONGED INACTIVE DISEASE / M. Iudici* - S. Pasano - I. Pantano - L. Pierro - G. Valentini


FR10346 EVALUATING DIFFERENCES IN THE ENROLLED POPULATIONS OF RANDOMIZED CLINICAL TRIALS OF SYSTEMIC LUPUS ERYTHEMATOSUS / N. Goel - B. Barrett - A. Duncan - M.-B. Gallagher - M. Mackey

FR10347 PHENOTYPIC CHANGES OF LYMPHOCYTES IN PATIENTS WITH SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH AN INTENSIFIED B CELL DEPLETION THERAPY WITH RITUXIMAB / E. M. Kerzberg - L. Solfitte - D. Di Simone - D. Rossi - D. Roccatello


FR10350 THE IFN BIOMARKER SIGLEC1 INDICATES EXTRAGLANDULAR MANIFESTATION IN PRIMARY SJÖGREN’S SYNDROME: PROPENSITY SCORE MATCHED LANDMARK ANALYSIS / T.-T. Chuang* - C.-E. Kuo

FR10352 SMALL FIBRE NEUROPATHY AND GANGLIONOPATHY IN PRIMARY SJÖGREN’S SYNDROME (PSS) / V. Gupta* - J. Peters - M. Bombardieri - A. Radunovic - N. Sutcliffe

FR10353 A LONGITUDINAL ANALYSIS OF CHANGE IN LUPUS DISEASE ACTIVITY PATTERN IN HOPKINS LUPUS COHORT USING A MULTISTATE MARKOV MODEL APPROACH / W. Fu* - M. Petri

* Presenting author
Vasculitis

FRI10354 CARDIOPULMONARY INVOLVEMENT IN TAKAYASU ARTERITIS / D. Brennan* - K. J. Warrington - J. Schmidt - C. Crowson - M. J. Koster

FRI10355 COMPARISON OF RITUXIMAB WITH CYCLOPHOSPHAMIDE AS INDUCTION THERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-TRAUSS SYNDROME): A 24 MONTHS FOLLOW-UP ANALYSIS N. Venhoff* - K. Halmeslag - M. Rizzi - R. Voll - J. Thiel


FRI10357 INCIDENCE AND PREDICTORS OF THORACIC AORTIC DAMAGE IN BIOPSY-PROVEN GIANT CELL ARTERITIS: A SINGLE-INSTITUTION COHORT STUDY / M. J. Koster* - C. Labarca - C. Crowson - E. L. Matteson - K. J. Warrington


FRI10365 LIMITED EVIDENCE OF ACTIVE VARICELLA ZOSTER VIRUS (VZV) INFECTION IN A COHORT OF ACUTE GIANT CELL ARTERITIS (GCA) PATIENTS / A. M. Sammel* - K. Rossettenstein - J. J. Post - J. V. Bertouch


FRI10369 PATTERN OF CLINICAL PRESENTATION AND DISEASE SEVERITY IN PATIENTS WITH POLYMyalGIA RHEUMATICA / D. Camellino* - A. Sobrero - V. Tomatis - S. Paolino - M. Cutolo - M. A. Cimmino

FRI10370 TWO SUBSETS OF GIANT CELL ARTERITIS CHARACTERIZED BY THE ABSENCE OR PRESENCE OF SPONDYLOARTHRITIS OR ITS ASSOCIATED DISEASES / D. Ernst* - N. Baerlecken - R. Schmidt - T. Witte


FRI10374 THE DIAGNOSTIC VALUE OF ALPHA-1-ANTITRYPSIN PHENOTYPE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S GRANULOMATOsis) / I. Belyaeva* - M. Pervakova - S. Lapin - V. Mazurov - A. Chudinov

FRI10375 CLINICAL IMPROVEMENT ACCORDING TO PATIENT REPORTED OUTCOMES IN PATIENTS WITH POLYMyalGIA RHEUMATICA: A LONGITUDINAL ANALYSIS FROM ROUTINE CARE / I. Castrejon* - S. L. Everakes - A. Nika - W. Sequeira - T. Pincus


FRI10378 NATIONAL AUDIT OF VASculITIS INPATIENT COMORBIDITIES AND MORTALITY FROM 2005-14 / L. Harty* - S. Burns - D. Jayne

FRI10379 SURVIVAL ANALYSIS IN ANTIINTERPHILIP CYTOPLYTIC ANTIBODY-ASSOCIATED VASculITIS / L. Petelytska* - O. Iaremenko

* Presenting author

FRI0381  PATTERN OF CLINICAL PRESENTATION AND OUTCOME OF POLYMYALGIA RHEUMATICA / A. Sobrero* - D. Camellino - C. Cosso - C. Pizzorni - M. Cutolo - M. A. Cimmino

FRI0382  LARGE VESSEL VASCULITIS AND PERIVASCULAR DISORDERS UNDERGOING IMMUNOSUPPRESSIVE THERAPY: THE USE OF PERFUSION-CT FOR RESPONSE MONITORING / M. S. Marius* - J. Henes - T. Xenitidis - K. Nikolaou - G. Bier

FRI0383  PREDICTORS OF FRAGILITY FRACTURES IN PATIENTS WITH POLYMYALGIA RHEUMATICA ON STEROIDS: AN OBSERVATIONAL STUDY / M. Bukhari*


FRI0385  CLINICAL CHARACTERISTIC OF VALVULAR INVOLVEMENT IN TAKAYASU'S ARTERITIS / N. Gao* - T. Wang - W. Ci - Z. Du - Z. Zhou


FRI0387  PERIPHERAL NEUROPATHY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA). INCAT DISABILITY SCORE TO EVALUATE DAMAGE AND TO PREDICT LONG-TERM OUTCOME IN 50 PATIENTS / R. Padoan* - M. Felicetti - M. Marconato - F. Cinetto - C. Agostini - L. Punzi - F. Schiavon


FRI0391  ANKLE BRACHIAL INDEX, PULSE WAVE VELOCITY AND ECHOCARDIOGRAPHIC STUDY IN 81 PATIENTS WITH BEHÇET'S DISEASE / S.-J. Yoo* - S. W. Kang - C. S. Shim - I. S. Yoo - Y. Kim

FRI0392  ULTRASONOGRAPHIC SCORING REVEALED THAT THE RATIO OF EXTRA-SYNOVIAL INFLAMMATION TO SYNOVIAL INFLAMMATION IN THE SHOULDER IS HIGHER IN PMR PATIENTS THAN THAT IN ELDERLY-ONSET RA PATIENTS WITH PMR-LIKE ONSET / T. Suzuki* - R. Yoshida - Y. Seri

FRI0393  CUT-OFF VALUES FOR INTIMA-MEDIA THICKNESS OF TEMPORAL, FACIAL AND AXILLARY ARTERIES IN PATIENTS WITH SPONDYLOARTHRITIS / A. Deminger* - E. Klingberg - M. Geijer - J. Göthlin - M. Hedberg - E. Rehnberg

Spondyloarthritis - clinical aspects (other than treatment)


FRI0395  LOW-DOSE SEMI-CORONAL CT OF THE SACROILIAC JOINTS IN THE EARLY DIAGNOSIS OF ANKYLOSING SPONDYLITIS / D. Gao* - K. Li - Y. Wang - Q. Wen - J. Zhu - J. Zhang - F. Huang


FRI0399  BACKFILL IS MORE IMPORTANT THAN EROSION AND FAT DEPOSITION IN DIAGNOSING AXIAL SPONDYLOARTHRITIS AS SEEN ON MRI / Z. Hu - P. Zhang - M. Qiu - J. Qi - X. Guo - J. Gu*


FRI0402  QUANTIFICATION OF FAT FRACTION OF VERTEBRAL BONE MARROW IN PATIENTS WITH ANKYLOSING SPONDYLITIS / S. Lee* - Y. Song - B. S. Koo - T.-H. Kim


* Presenting author


PREVALENCE AND SIGNIFICANCE OF RADIOGRAPHIC SACROILIITIS IN A LARGE INFLAMMATORY BOWEL DISEASE POPULATION / A. Nangit* - D. Scaramangas - G. Dejesus - D. Karayev - C. Williams - D. Li - X. Yan - S. Targan - T. Leach - D. McGovern - M. Weisman


EPIDEMIOLOGY OF ANKYLOSING SPONDYLITIS IN TAIWAN: A NATIONWIDE POPULATION STUDY / UVEITIS / M. Sykes* - L. Hamilton - C. Jones - K. Gaffney

THE PREVALENCE OF ANKYLOSING SPONDYLITIS AMONG PATIENTS PRESENTING WITH ACUTE ANTERIOR MEASURE FIBROMYALGIA SYMPTOMS? / M. N. Magrey* - M. A. Khan


EVALUATING THE IMPACT OF A LOCAL INFLAMMATORY BACK PAIN AWARENESS CAMPAIGN IN THE UNITED KINGDOM / G. Tracey* - J. McCaulder-Ojeda - R. Sengupta


ASSOCIATION BETWEEN OBJECTIVELY ASSESSED PHYSICAL ACTIVITY AND DISEASE PROGRESSION IN A POPULATION BASED SAMPLE OF ANKYLOSING SPONDYLITIS PATIENTS / H. I. Khan* - D. Atiken - P. Lewis - J. Zochling

PLASMA CALPROTECTIN IN SPA-PATIENTS, A BIOMARKER FOR PERIPHERAL ARTHRITIS / I. M. Hansen* - G. Bakland - Ø. Forre


THE PREVALENCE OF AXIAL SPONDYLOARTHROSIS IN PATIENTS PRESENTING WITH ACUTE ANTERIOR UVEITIS / M. Sykes* - L. Hamilton - C. Jones - K. Gaffney

EPIDEMOLOGY OF ANKYLOSING SPONDYLITIS IN TAIWAN: A NATIONWIDE POPULATION STUDY / M.-Y. Hsieh* - C.-F. Kuo


* Presenting author


FRI0443 DOES THE CYTOKINE PATTERN, INCLUDING THE IL23 - IL17 IMMUNE AXIS, CHANGE IN PREGNANT WOMEN WITH PSORIATIC ARTHRITIS? / A. Pluma Sanjurjo* - P. M. Villiger - F. Förger


FRI0445 TILDRIKIZUMAB TREATMENT IMPROVED MEASURES OF PSORIATIC ARTHRITIS IN ADULTS WITH CHRONIC PLAQUE PSORIASIS / R. G. Langley - D. Thaçi - K. Reich - K. Papp - A. Mehta* - Q. Li - C. La Rosa

FRI0446 TREATMENT WITH TILDRIKIZUMAB, AN ANTI-IL-23P19 MONOCLONAL ANTIBODY, IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS / D. Thaçi - K. Papp - K. Reich - R. G. Langley - A. Mehta* - Q. Li - C. La Rosa


FRI0439 EFFECTS OF DIFFERENT ANTI-TNF ALPHAS TREATMENTS ON LIPID AND CARBOHYDRATE METABOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS / R. Colia - A. Corrado* - N. Maruotti - A. Carriero - F. d’Onofrio - F. P. Cantatore


FRI0436 FATIGUE IS ASSOCIATED WITH WORK PRODUCTIVITY IMPAIRMENT IN UK PATIENTS WITH AXIAL SPONYLOARTHRITIS (AXSpA): A PROSPECTIVE CASE-CONTROL STUDY / R. Rejhsinghani* - K. M. Brown - N. B. Schiller - G. Yoon - E. Foster - L. S. Gensler


Psoriatic arthritis


FRI0433 FACTORS ASSOCIATED WITH ELEVATED ACUTE PHASE REACTANTS IN PATIENTS WITH INFLAMMATORY BACK PAIN; IMPACT OF C REACTIVE PROTEIN ON THE PHENOTYPE OF PATIENTS. DATA FROM THE PROSPECTIVE MULTICENTER FRENCH COHORT DESIR / P. Manick* - J. M. Morel - B. Combe - D. van der Heijde - G. Lukas


* Presenting author
**FR10452**
ARE GM-CSF-PRODUCING TH17 CELLS IMPORTANT IN THE PATHOGENESIS OF PSORIATIC ARTHRITIS?
C. Stober* - J. Goodall - H. Gaston

**FR10453**
THE INCREASED PREVALENCE OF NAFLD IS WORRISOME AMONG PATIENTS WITH PSORIATIC ARTHRITIS
C. Giapari - G. Carvalho - L. Anjos - P. Sampaio-Barros - J. Mores - C. Goñalves - C. Saad - C. Goldenstein-Schainberg*

**FR10454**
ENDOTHelial DYSfunction IN PSoriATIC arthritis: evaluation by ENDothelial-DEPENDent FLOW-MEDIATED Dilation and coronary FloW RESerVe / G. Murdaca* - G. Bezante - E. Penza - M. Balbi - S. Negri - E. Puppo

**FR10455**

**FR10456**

**FR10457**

**FR10458**

**FR10459**

**FR10460**

**FR10461**

**FR10462**

**FR10463**

**FR10464**

**FR10465**
DOES SKIN MATTER IN INCIDENT PSORIATIC ARTHRITIS? / M. Vis* - I. Tchetverikov - K. Wervers - A. Gerards - C. Appels - M. Kok - W. van der Graaff - J. Veris - J. van Groenendaal - L. Korswagen - J. Hazes - J. Luime on behalf of DEPAR study group

**FR10466**
INCREASED RISK OF CANCER IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION STUDY M.-J. Chiot* - Y.-F. Fang - C.-F. Kuo

**FR10467**

**FR10468**

**FR10469**
MEASURING OUTCOME IN PSORIATIC ARTHRITIS (MOPSA), A NEW WEB-BASED TOOL FOR ASSESSMENT OF PSORIATIC ARTHRITIS SHOWING INITIATION OF TREATMENT CHANGE IN PATIENTS ACHIEVING MINIMAL DISEASE ACTIVITY / M. Elamoun* - A. Szentpetery - P. Gallagher - O. FitzGerald

**FR10470**

**FR10471**


FR20481  No Change in Self-Reported Pain from Pre-Pregnancy to Six Months Postpartum in Women with Juvenile Idiopathic Arthritis / B. Jakobsen* - H. S. Koksik - K. Uris - M. Wallenius


Other orphan diseases


FR20474  Serum level of IL-23 and IL-23r polymorphisms in patients with psoriatic arthritis / R. Sokolik* - K. Gębura - L. Kornan - B. Wysoczanska - P. Wiland - K. Bogunia-Kubik


FR20477  A Modified Version of the Psoriatic Arthritis Disease Activity Score (MPASDAS) Using SF-12 As a Measure of Quality of Life May Be More Feasible in Clinical Practice / V. Chandran* - M. Got - S. Li - A. V. Perruccio - D. D. Gladman

Diagnostics and imaging procedures

FRI0513 VALIDATING MRI-DETECTED INFLAMMATION THRESHOLDS PREDICTIVE OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL / H. A. Ahmad* - J. F. Baker - M. Ostergaard - J. Ye - P. Emery - P. G. Conaghan


FRI0516 ULTRASONOGRAPHIC ASSESSMENT OF NEWLY DEVELOPED ELDERLY-ONSET RHEUMATOID ARTHRITIS: A COMPARISON WITH YOUNGER-ONSET RHEUMATOID ARTHRITIS / A. Suzuki* - T. Okai


* Presenting author


FR10521 RELIABILITY OF AN OMERACT RHEUMATOID ARTHRITIS TENOSYNOVITIS SCORING SYSTEM FOR WRIST AND HAND / D. Glinatsi* - P. Bird - F. Gandjbakhch - E. A. Haavardsholm - P. G. Conaghan - M. Østergaard on behalf of the OMERACT MRI in arthritis working group


FR10525 ELASTOGRAPHIC ULTRASOUND OF METACARPOPHALANGEAL (MCP) SYNOVITUM IN RHEUMATOID ARTHRITIS (RA) / A. M. Sammel* - M. C. Spies - R. DeCarle - M. Rayment - F. Joshua

FR10526 QUALITY OF ULTRASOUND-GUIDED SYNOBIOSIES PERFORMED IN CLINICAL PRACTICE / A. Najm* - G. Bart - M.-F. Heymann - Y. Maugars - B. Le Golf

FR10527 IMPACT OF ULTRASOUND IN TREATMENT DECISION OF RHEUMATOID ARTHRITIS ASSESSED IN ROUTINE CLINICAL PRACTICE / C. Sifuentes-Cantú* - L. Saldañariaga-Rivera - I. Contreras-Yáñez - M. Gutiérrez - V. Pascual-Ramos

FR10528 EPIDEMIOLOGICAL AND CLINICAL RELATIONSHIP OF ULTRASONOGRAPHIC FEATURES OF ACUTE ANSERINE SYNDROME / C. A. Guillen Astete* - G. Silvestre-Egea - A. Boteanu

FR10529 INITIAL VALIDATION OF THE SYMPTOMS IN PERSONS AT RISK OF RHEUMATOID ARTHRITIS (SPARRA) QUESTIONNAIRE / M. V. Beers-Tas - L. V. Tuyt - B. Maat - W. Hoogland - R. Stock - K. Raza - D. V. Schaubenburg* 


FR10534 STUDYING BONE MINERAL DENSITY LOSS IN CLINICALLY SUSPECT ARTHRALGIA, ASSOCIATIONS WITH SUBCLINICAL INFLAMMATION AND PROGRESSION TO CLINICAL ARTHRITIS / M. Glinat* - H. W. van Steenbergen - M. Reijnierse - J. Kjølvåg - A. H. M. van der Helm-van Mil


FR10537 AUTOMATED JOINT SPACE WIDTH MEASUREMENT AND DIGITAL X-RAY RADIOGRAMMETRY IN EARLY RA / M. Platten* - Y. Kisten - J. Kjølvåg - L. Arnaud - K. Forslund - R. van Vollenhoven

FR10538 VALIDATION OF A SEMI-AUTOMATIC ALGORITHM FOR DEFINING CORTICAL BREAKS IN FINGER JOINTS USING HIGH-RESOLUTION PERIPHERAL QUANTITATIVE CT / M. Peters* - A. Scharmga - A. van Tubergen - B. van Rietbergen - B. Weyers - D. Loefen - J. van den Bergh - P. Peusens


FR10540 EVALUATION OF NAILFOLD VIDEOCAPILLAROSCOPY IN CENTRAL SEROUS CHORIORETINOPATHY / M. K. Erol* - A. Balkarli - D. Toslak - D. Durmaz - B. Dogan - E. Baskan - S. Altun - M. Bulut - V. Cobankara

* Presenting author
Epidemiology, health services and outcome research

FRI0541
A CROSS-SECTIONAL, INTERNATIONAL SURVEY ON NON-INVASIVE TECHNIQUES TO ASSESS THE MICROCIRCULATION IN PATIENTS WITH RAYNAUD’S PHENOMENON (SUNSHINE SURVEY) / N. Ugur* - G. Dinsdale - Y. Smith - Y. Allanore - J. Petri - A. Sulli - M. Catteau - A. L. Henrik - F. Ingppolli on behalf of SUNSHINE study group on behalf of the EULAR study group on microcirculation in Rheumatic Diseases

FRI0542
BIOELECTRICAL IMPEDANCE ANALYSIS IS NOT A VALID METHOD FOR THE ASSESSMENT OF BODY COMPOSITION IN PATIENTS WITH RHEUMATOID ARTHRITIS / N. Konijn* - L. van Tuyl - B. Dijkstra - I. Baltink - M. van der Schueren - W. Lems

FRI0543

FRI0544

FRI0545

FRI0546
THE POWER DOPPLER RESULT IN RHEUMATOID ARTHRITIS DEPENDS ON THE POSITION OF HANDS DURING ULTRASOUND EXAMINATION / R. Husic* - A. Lackner - J. Hermann - M. H. Stradner - C. Dejaco

FRI0547

FRI0548

FRI0549
CONE-BEAM CT, A NEW LOW-DOSE 3 D IMAGING TECHNIQUE FOR ASSESSMENT OF BONE EROSIONS IN RHEUMATOID ARTHRITIS: RELIABILITY ASSESSMENT AND COMPARISON WITH CONVENTIONAL RADIOGRAPHY / Y. Aurell* - M. Malac - M. L. Andersson - K. Forslund

FRI0550
REAL-WORLD TREATMENT PATTERNS AMONG RHEUMATOID ARTHRITIS PATIENTS WHO SWITCH FROM A TUMOR NECROSIS FACTOR INHIBITOR TO ANOTHER MEDICATION / B. Chastek* - J. R. Curtis - L. K. Becker - P. Mahajan - C. Chen

FRI0551
EVALUATION OF CHANGE IN ANTI-CITRULLINATED PEPTIDE ANTIBODY LEVELS IN CLINICAL PRACTICE AND ASSOCIATION WITH RESOURCE USE / E. Alemao* - Z. Guo - C. Iannaccone - M. Friis - N. Shadick - M. Weinblatt

FRI0552
PATIENTS WITH RHEUMATOID ARTHRITIS ARE MORE OBESE THAN THE GENERAL POPULATION ALREADY AT DISEASE ONSET. A COLLABORATIVE ANALYSIS FROM THREE LARGE GERMAN RA DATABASES / K. Albrecht* - A. Richter - J. Calhoff - D. Huscher - G. Schett - A. Zink

FRI0553

FRI0554

FRI0555
LONG-TERM EFFECTIVENESS OF HERPES ZOSTER VACCINE AMONG PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASES / H. Yun - F. Xie - J. W. Baddley - K. Winthrop - L. Chen - J. R. Curtis*

FRI0556
DOES LEAVING POVERTY REDUCE NEWLY ACCUMULATED DAMAGE IN SLE? / E. Yelin* - L. Trupin - J. Yazdany

FRI0557
THE ASSOCIATION BETWEEN BODY MASS INDEX AND MRI-DETECTED INFLAMMATION; PARADOXICAL EFFECTS IN RHEUMATOID ARTHRITIS, OTHER ARTHRITIDES AND SYMPTOM-FREE CONTROLS / L. Mangnus* - M. Weinblatt

FRI0558

FRI0559

FRI0560
THE INCREASE IN THE NATIONWIDE INCIDENCE OF INFLAMMATORY DISEASES IN FINLAND DURING THIS MILLENNIUM / V. Rantalaiho* - H. Kautiainen - L. Virta - K. Puolakka

FRI0561
HEALTHCARE RESOURCE UTILIZATION AND INFECTION RISK IN RHEUMATOID ARTHRITIS PATIENTS WITH AND WITHOUT COMORBIDITIES / A. Teeple* - M. Ryan - L. Muirheid - L. Ellis

FRI0562
ATTITU AND PARTICIPANT CHARACTERISTICS IN A RHEUMATOID ARTHRITIS COHORT / A. Cesta* - X. Li - M. Tatangelo - C. Bombardier

FRI0563
IT’S MORE THAN DRYNESS AND FATIGUE: THE PATIENT PERSPECTIVE ON HEALTH-RELATED QUALITY OF LIFE IN PRIMARY SJÖGREN’S SYNDROME - A QUALITATIVE STUDY / A. Lackner* - A. Ficjan - J. Unger - W. Graninger - C. Dejaco

FRI0564

FRI0565
THE ASSOCIATION BETWEEN BODY MASS INDEX AND MRI-DETECTED INFLAMMATION; PARADOXICAL EFFECTS IN RHEUMATOID ARTHRITIS, OTHER ARTHRITIDES AND SYMPTOM-FREE CONTROLS / L. Mangnus* - M. Weinblatt

FRI0566
THE INCREASE IN THE NATIONWIDE INCIDENCE OF INFLAMMATORY DISEASES IN FINLAND DURING THIS MILLENNIUM / V. Rantalaiho* - H. Kautiainen - L. Virta - K. Puolakka

* Presenting author
FRI10565  INFLUENCE OF ROUTE OF ADMINISTRATION/DRUG FORMULATION AND OTHER FACTORS ON COMPLIANCE WITH TREATMENT IN RHEUMATOID ARTHRITIS AND DYSLIPIDEMIA / B. Faurett* - A. Balsa - P. van Riel - M. Casillas - J.-P. Capron - C. Cuéllar - I. De La Torre


FRI10568  DISEASE ACTIVITY STATES OF THE DAPSA, A PSORIATIC ARTHRITIS SPECIFIC INSTRUMENT, ARE VALID AGAINST THE CONSTRUCTS OF FUNCTIONAL STATUS AND STRUCTURAL PROGRESSION / D. Aletaha* - F. Alasti - J. Smolen


FRI10577  A NATIONAL ELECTRONIC HEALTH RECORD-ENABLED REGISTRY IN RHEUMATOLOGY: THE ACR'S RHEUMATOLOGY INFORMATICS SYSTEM FOR EFFECTIVENESS (RISE) / J. Yazdany* - S. Kazi on behalf of Research & Publications Subcommittee


FRI10581  THE VICTIOUS CIRCLE OF EDUCATIONAL LEVEL, RHEUMATOID ARTHRITIS, AND RISK OF POVERTY - RESULTS IN REAL-WORLD RHEUMATOID ARTHRITIS PATIENTS USING THE RASCH MEASUREMENT MODEL / L. M. Ørnbjerg* - K. Christensen - A. Tennant - M. Hetland

FRI10582  FLUCTUATING LEVELS OF RHEUMATOID FACTOR PREDICT PROGRESSION OF RHEUMATOID ARTHRITIS, BUT NOT INDEPENDENT OF DISEASE ACTIVITY / M. Unger* - F. Alasti - G. Supp - P. Studenic - J. Smolen - D. Aletaha

FRI10583  THE DECLINING BURDEN OF ABSENTEEISM DUE TO RHEUMATOID ARTHRITIS AND ANKYlosing SPONDYLITIS IN SLOVENIA / P. Došenović Bonča - I. Erzen - D. Marinski - M. Tomšič*


FRI10586  THE EFFECTS OF AN EDUCATIONAL MEETING AND SUBSEQUENT COMPUTER REMINDERS ON THE ORDERING OF LABORATORY TESTS BY RHEUMATOLOGISTS: AN INTERRUPTED TIME SERIES ANALYSIS / D. Aletaha* - F. Alasti - J. Smolen - M. Bernardes - L. Costa


HYPERURICEMIA AND THE RISK FOR CARDIOVASCULAR DISEASE: INDIVIDUAL PATIENT META-ANALYSIS OF 77,045 INDIVIDUALS ENROLLED IN 15 EPIDEMIOLOGIC STUDIES / S. Baumgartner* - R. Morlock

MAINTAINING MENTAL HEALTH IN OLDER PEOPLE WITH MUSCULOSENSORY PAIN: A LONGITUDINAL COHORT STUDY / S. Baker* - C. A. Chew-Graham - R. Wilkinson - J. McBeth


ASSOCIATION OF GOUT DIAGNOSIS WITH INCREASED RISK OF JOINT REPLACEMENT: A POPULATION-BASED COHORT STUDY OF OVER 250,000 PATIENTS / S. Perreault* - A. B. Klein - R. Morlock

RESPONSIVENESS AND TEST-RETEST RELIABILITY OF NEW DISEASE ASSESSMENT INSTRUMENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN RELATION TO SLEDAI-2K / W. W. Chatham* - C. E. Collins - N. Gaylis - H. Busch - E. Hautamaki - S. Narayanan

RHEUMATOID ARTHRITIS RISK ALLELES, HLA-DRB1 HAPLOTYPES, AND RESPONSE TO TNFI THERAPY - RESULTS FROM A SWEDISH COHORT STUDY / X. Jiang* - J. Asling - S. Sævardsdóttir - L. Padyukov - S. Viatte - T. Frisell

SYSTEMATIC REVIEW OF CONSUMER PERCEIVED HEALTH INFORMATION NEEDS REGARDING BACK PAIN Y. Z. Lim* - M. Senevickwama - F. M. Cicuttini - D. Uquhart - A. E. Wluka


ROLE OF GROUP LEARNING TO IMPROVE REPRODUCIBILITY OF DAS-28 AMONGST HEALTHCARE PROFESSIONALS / S. S. Majeed* - E. M. Clark on behalf of Rheumatology Dept, North Bristol NHS Trust


THE EFFECT OF AN EDUCATIONAL INTERVENTION BASED ON CLINICAL SIMULATION IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS DIAGNOSIS BY GENERAL PRACTITIONERS: A RANDOMIZED CLINICAL TRIAL / S. A. Mora Alfonso* - D. G. Fernández - L. F. Sastre on behalf of Hospital Universitario de la Samaritana

THE IMPACT OF GOUT FLARES ON PATIENT-REPORTED ASSESSMENTS OF PAIN AND DISABILITY / S. A. Mora Alfonso* - D. G. Fernández Ávila - L. F. Sastre


RHEUMATOLOGY TRAINING IN INDIA - A REFLECTION AND COMPARISON WITH UNITED KINGDOM F. Das* - A. Moorthy - B. Dharmanand

SIMULATION FOR JOINT INJECTION AND ASPIRATION. COLLABORATING OUR EXPERIENCES, WHAT HAVE WE LEARNT? / S. Shabbir* - K. Shah - J. Mukherjee - M. Carby

FIFTEEN-YEAR TREND IN INFORMATION ON THE INTERNET FOR PATIENTS WITH RHEUMATOID ARTHRITIS: EVOLVING, BUT WITH OPPORTUNITIES FOR IMPROVEMENT / J. D. Castillo-Ortiz* - J. D. J. Valdivia-Nuno - A. Ramírez-Gomez - J. J. Castaneda-Sanchez - J. M. Sanchez-Gonzalez - C. Ramos-Remus

* Presenting author
Scientific Programme

08:00 - 15:00 Registration area S11

Registration

08:30 - 10:00 ICC Auditorium

What is New (WIN)

WIN session 8

Xavier Mariette (France) 08:35
Sjögren's syndrome

Jiri Vencovsky (Czech Republic) 09:15
Abstract N° SP0163
Myositis

08:30 - 10:00 Hall B

Challenges in Clinical Practice session
The elderly patient with osteoarthritis

Learning objectives:
To learn how osteoarthritis and comorbidities mutually influence each other, and what the evidence is for alternative therapies for osteoarthritis in this patient group

Chairperson(s):
Jagtar Singh Nijjar (United Kingdom)
Dirkjan van Schaardenburg (Netherlands)

Wing-Yee Kwok (Netherlands) 08:35
Abstract N° SP0164
Case 1 presentation:
Problems in conventional therapy in osteoarthritis

Gillian Hawker (Canada) 08:45
Case 2 discussion: Mutual influence of osteoarthritis and comorbidities on symptoms and outcome

Gyorgy Nagy (Hungary) 09:15
Case 2 presentation:
Thermal water and osteoarthritis, a case report

Tamas Bender (Hungary) 09:25
Abstract N° SP0165
Case 2 discussion:
Balneotherapy: efficacy and safety in osteoarthritis

08:30 - 10:00 Hall D

Clinical Science session
SLE: What will it be and how will it be treated 5 years from now

Learning objectives:
Insights into future developments in SLE diagnosis and treatment

Chairperson(s):
Marta Alarcon-Riquelme (Spain)
Ruth Fritsch-Stork (Netherlands)
Lars Rönnblom (Sweden) 08:35
Abstract N° SP0166
The interferon pathway in SLE: from immunology to new insights and new treatment

Marta Alarcon-Riquelme (Spain) 08:53
From immunogenetics to a new taxonomy for connective tissue diseases

Rebecca Fischer-Betz (Germany) 09:11
Abstract N° SP0167
Outcome assessment in SLE
Alexandre E. Voskuyl (Netherlands)  09:29
Abstract N° SP0168
How new treatments in lupus are changing the landscape

R. Furie (United States)  09:47
J. T. Merrill, V. F. Werth, M. Khamashta, K. Kalunian, P. Brohawn, G. Illei, J. Drappa, L. Wang, S. Yoo
Abstract N° OP0291
Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE)

08:30 - 10:00  Hall E

How to Treat/Manage (HOT)
HOT session 10

Socrates Papapoulos (Netherlands)  08:35
Osteoporosis

Francis Berenbaum (France)  09:15
Osteoarthritis

08:30 - 10:00  Hall C

Clinical Science session
“Time Is Joint”: early recognition and treatment of arthritis

Learning objectives:
How to best identify and treat early arthritis

Chairperson(s):
David S. Pisetsky (United States)
Gerd R. Burmester (Germany)

Ailsa Bosworth (United Kingdom)  08:35
The patient’s perspective

Christian D. Mallen (United Kingdom)  08:55
The general practitioner’s perspective

Paul Kirwan (Ireland)  09:15
The health professional’s perspective

Annette van der Helm (Netherlands)  09:35
The doctor’s perspective

08:30 - 10:00  Hall A

Outcome Science session
Clinical outcomes for PMR/GCA

Learning objectives:
• To learn about the latest clinical guidance for managing PMR
• To recognise the complications of glucocorticoid treatment
• To appreciate the importance of patient relevant outcomes in PMR

Chairperson(s):
Sarah Mackie (United Kingdom)
Bhaskar Dasgupta (United Kingdom)

Christian Dejaco (Austria)  08:35
EULAR/ACR guidelines for PMR - the updated evidence

Frank Buttgereit (Germany)  08:50
Steroid complication in patients with PMR/GCA

Toby Helliwell (United Kingdom)  09:05
Improving outcomes for patients in primary care

Sarah Mackie (United Kingdom)  09:20
Patient relevant outcomes in PMR/GCA

K. Kume (Japan)  09:35
K. Amano, S. Yamada, T. Kanazawa, K. Hatta
Interspinous bursitis evaluation by ultrasound is very useful for diagnosis of polymyalgia rheumatica extension study

S. Hider (United Kingdom)  09:45
C. Morton, S. Muller, J. Belcher, K. Gilbert, M. Bucknall, C. Mallen
Patient priorities for PMR research: a primary care survey

08:30 - 10:00  Capital Suite 07

Health Professionals session
Getting active against rheumatoid arthritis fatigue

Learning objectives:
• Develop an understanding of the relationship between physical activity and fatigue in rheumatoid arthritis
• Consider barriers to, and practical facilitators of, physical activity in the presence of fatigue
• Identify practical methods for monitoring physical activity

Chairperson(s):
Yvonne van Eijk-Hustings (Netherlands)
Yeliz Prior (United Kingdom)

Keegan Knittle (Finland)  08:55
Health behaviour change techniques to effectively promote physical activity in people with rheumatoid arthritis

Norelee Kennedy (Ireland)  09:15
Activity monitoring to support patient goals and assess progress
S. G. McKenna (Ireland) 09:35
N. Kennedy
Abstract N° OP0294-HPR
Sleep quality, sleep disturbances and physical activity: a national survey of Irish people who have inflammatory arthritis

T. O’Dwyer (Ireland) 09:45
A. Monaghan, J. Moran, F. Wilson, F. O’Shea
Abstract N° OP0295-HPR
Increasing physical activity in ankylosing spondylitis (INPACT-AS): a randomised controlled trial

Basic and Translational Science session
Endothelial to mesenchymal transition and angiogenesis as driving mechanisms in systemic sclerosis

Learning objectives:
An update on the mechanisms supporting the progressive transition of the endothelial cells into myofibroblasts and the reactive neoangiogenesis in systemic sclerosis

Chairperson(s):
Oliver Distler (Switzerland)
Christopher Denton (United Kingdom)

Sergio Jimenez (United States) 08:35
Abstract N° SP0176
Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis

Oliver Distler (Switzerland) 08:55
Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis

Gabriela Riemekasten (Germany) 09:15
Possible pathogenetic effects from the interaction between endothelial cells and specific antibodies in systemic sclerosis

S. Soldano (Italy) 09:35
P. Montagna, A. C. Trombetta, R. Brizzolara, A. Sulli, C. Pizzorni, S. Paolino, M. Cutole
Abstract N° OP0296
Comparison of bosentan and macitentan effects on endothelial-to-mesenchymal transition process induced by ET-1 in cultured human microvascular endothelial cells

K. Akashi (Japan) 09:45
J. Saegusa, S. Sendo, K. Nishimura, K. Tsuda, I. Naka, T. Okano, S. Takahashi, M. Nishida, Y. Ueda, A. Morinobu
Abstract N° OP0297
Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice

Basic and Translational Science session
Cell-cell interaction in joint inflammation

Learning objectives:
- To learn direct and indirect cellular interactions defining inflammation and matrix remodelling
- To learn complex interaction networks leading to (chronic) inflammation
- To learn cell interactions of/with vascular cells influencing angiogenesis especially under inflammatory conditions

Chairperson(s):
Chris Buckley (United Kingdom)
Theresa Tretter (Germany)

Ernest Brah (United States) 08:35
Abstract N° SP0177
Inhibitory pathways of synovial angiogenesis

Alla Skapenko (Germany) 08:55
Cellular interactions of/with inflammatory cells

Chris Buckley (United Kingdom) 09:15
Cellular interactions with vascular cells and impact on angiogenesis

M. Sun (Sweden) 09:35
Abstract N° OP0298
Anti-citrullinated protein antibodies promote synovial fibroblasts migration and adhesion through a peptidylarginine deiminases (PAD) dependent pathway

M. L. Vecellio (United Kingdom) 09:45
A. R. Roberts, B. P. Wordsworth
Abstract N° OP0299
Susceptibility to ankylosing spondylitis is influenced independently by two closely adjacent RUNX3 SNPs that show strong functional effect in different cell types

PReS session
Transition of care

Learning objectives:
Learning from existing experiences how to organise the transition process and presentation of new EULAR/PReS recommendations

Chairperson(s):
Clarissa Pilkington (United Kingdom)
Pierre Quartier (France)

Kirsten Minden (Germany) 08:35
Abstract N° SP0178
Transition care programmes: a European perspective
The Young Rheumatologist
Career paths in research - how to start and where to go?

Learning objectives:
• To learn about concrete examples on how a research career was started and evolved, both from the basic/translational and clinical research perspectives
• An active discussion on needs and opportunities for fellows will follow

Chairperson(s):
Maya Buch (United Kingdom)
Sofia Ramiro (Netherlands)

Johan Askling (Sweden) 08:35
Testimonies of clinical research

Georg Schett (Germany) 08:50
Testimonies of basic/translational research

Désirée van der Heijde (Netherlands) 09:05
The view and advice of an expert

Silvia Fernandes (Portugal) 09:20
Vitamin deficiency and disease activity/severity in spondyloarthritis: results of the ASAS-COMOSpA intern. study

Enrico Tombetti (Italy) 09:30
Takayasu arteritis: clinimetry, progression and coronary involvement

**Practical skills session**
**Ultrasound advanced II**

Chairperson(s):
Mads Ammitzboll (Denmark)
Sandrine Jousse-Joulin (France)

Heidi Siddle (United Kingdom) 08:35
US for diagnosing inflammatory versus mechanical midfoot pain and relevant guided interventions + demo

Iustina Janta (Romania) 08:55
Ultrasound of the nail; Why use it in rheumatology? + demo

Stephanie Finzel (Germany) 09:15
How to differentiate erosions and vessel channels + demo

Mads Ammitzboll (Denmark) 09:35
How to distinguish tenosynovitis from normal vessel artefacts in wrists and fingers + demo

Tutor(s):
Lykke Oernbjerg (Denmark)
08:30 - 10:00  Room S20

EULAR projects in Epidemiology and Health Services

Benchmarking of healthcare quality indicators and standard of care for RA and OA

Learning objectives:
- To learn how standardised quality metrics can be integrated in routine rheumatology clinical practice
- To learn how these metrics can be used to facilitate national and international comparison (benchmarking)

Chairperson(s):
Ingemar Petersson (Sweden)
Anthony Woolf (United Kingdom)

Anthony Woolf (United Kingdom) 08:35
The EUMUSC.NET project in the national and international perspective of WHO burden of disease perspective

Ingemar Petersson (Sweden) 09:00
The importance of structured benchmarking for the development of health care services and research

Loreto Carmona (Spain) 09:25
The use of health care quality indicators and standards of care in rheumatological practice

Faculty 09:50
Q&A

10:15 - 11:45  Room S19

PARE session

New approaches to understanding and managing chronic musculoskeletal pain

Learning objectives:
To provide insights into the latest advances in pain research, new approaches to pain control and opportunities for self-management

Chairperson(s):
Elsa Mateus (Portugal)
Neil Betteridge (United Kingdom)

Frances Williams (United Kingdom) 10:20
Abstract N° SP0180
Advances in the genetics of chronic pain syndromes: how twin studies help

Pete Moore (United Kingdom) 10:40
Self-management of pain: the Pain Toolkit and its use in everyday life

Catarina Marques (Portugal) 11:00
Abstract N° SP0181
Chronic pain control: a Portuguese patient group initiative

11 June 2016
10:00 - 12:00  Exhibition (S5-S9)

Poster viewing & coffee break

10:05 - 12:00  Poster area

Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area, on a “first-come-first-served” basis the day of the poster tour.

For full details regarding the guided poster tours on Saturday, please refer to pages 146 to 153.

Poster tour

S1: Genetic basis and genomics of disease
Chairperson(s): Elena Neumann (Germany)
Caroline Ospelt (Switzerland)
Abstract N° SAT0001 - SAT0010

Poster tour

S2: Innate immune cells coming to play
Chairperson(s): Reinhard E. Voll (Germany)
Martin Herrmann (Germany)
Abstract N° SAT0021 - SAT0030

Poster tour

S3: Biology of RA II
Chairperson(s): Zoltán Szekanecz (Hungary)
Emese Balogh (Ireland)
Abstract N° SAT0042 - SAT0051

Poster tour

S4: Safety and efficacy of non TNFα blockers in the treatment of RA - II
Chairperson(s): Lene Terslev (Denmark)
Simon Krabbe (Denmark)
Abstract N° SAT0144 - SAT0153

Poster tour

S5: Basic research in systemic sclerosis
Chairperson(s): Gabriela Riemekasten (Germany)
Britta Maurer (Switzerland)
Abstract N° SAT0184 - SAT0194
Poster tour

S6: Scleroderma, myositis and related syndromes II
Chairperson(s): Maurizio Cutolo (Italy)
                Vanessa Smith (Belgium)
                Abstract No SAT0195 - SAT0204

PReS Poster tour

S7: Juvenile-onset connective tissue diseases
Chairperson(s): Özgür Kasapcopur (Turkey)
                Alexandre Belot (France)
                Abstract No SAT0253 - SAT0262

Poster tour

S8: SLE and Sjögren’s - clinical aspects
Chairperson(s): Ronald van Vollenhoven (Netherlands)
                Christina Tsalapaki (Greece)
                Abstract No SAT0281 - SAT0290

Poster tour

S9: Vasculitis II
Chairperson(s): Carlo Salvarani (Italy)
                Francesco Muratore (Italy)
                Abstract No SAT0330 - SAT0338

Poster tour

S10: Optimising treatment of axial SpA
Chairperson(s): Maxime Dougados (France)
                Denis Poddubny (Germany)
                Abstract No SAT0371 - SAT0380

Poster tour

S11: New insights in osteoarthritis
Chairperson(s): Margreet Kloppenburg (Netherlands)
                Alice Courties (France)
                Abstract No SAT0424 - SAT0433

Poster tour

S12: Infection related rheumatic diseases
Chairperson(s): Dimitrios Vassilopoulos (Greece)
                Konstantinos Thomas (Greece)
                Abstract No SAT0481 - SAT0490

Poster tour

S13: New approaches to back pain - soft tissue problems
Chairperson(s): Christian D. Mallen (United Kingdom)
                Sam Hider (United Kingdom)
                Abstract No SAT0502 - SAT0511

Poster tour

S14: Imaging RMD - what else?
Chairperson(s): Esperanza Naredo (Spain)
                Signe Moeller-Bisgaard (Denmark)
                Abstract No SAT0528 - SAT0537

HPR Poster tour

S15: Getting around rheumatic disease
Chairperson(s): Anthony Redmond (United Kingdom)
                Camilla Fongen (Norway)
                Abstract No SAT0637-HPR - SAT0644-HPR

12:00 - 13:30  ICC Auditorium

What is New (WIN)
WIN session 9
Piercarlo Sarzi-Puttini (Italy) 12:05
Pain and fibromyalgia
Maria-Antonietta d’Agostino (France) 12:45
New developments in imaging for rheumatic diseases

12:00 - 13:30  Hall B

Challenges in Clinical Practice session
Seronegative inflammatory arthritis: diagnostic and management challenges

Learning objectives:
To obtain insights into the pathogenesis, investigation, treatment and outcomes of seronegative arthritis

Chairperson(s): John D. Isaacs (United Kingdom)
                Elena Nikiphorou (United Kingdom)

Marine Gaudé (France) 12:05
Abstract No SP0182
Case 1 presentation: Is this really rheumatoid arthritis?

Xavier Puéchal (France) 12:15
Case 1 discussion: Non-rheumatic inflammatory arthritis

Elena Nikiphorou (United Kingdom) 12:45
Case 2 presentation: Challenging “seronegative” arthritis

Tom Huizinga (Netherlands) 12:55
Case 2 discussion: Beyond rheumatoid factor and anti-CCP
12:00 - 13:30  Hall D

**Clinical Science session**

**Picking knowledge from other medical disciplines for SSc**

**Learning objectives:**
- To increase interdisciplinary work and understanding
- To receive information about approaches in other disciplines

**Chairperson(s):**
Gabriele Valentini (Italy)
Yannick Allanore (France)

**Duska Dragun (Germany)**
Advances from nephrologists
12:05

**Gerry Coghlan (United Kingdom)**
Advances from PAH specialists
12:25

**Carsten Tschöpe (Germany)**
Advances from angiologists and cardiologists
12:45

**J. Avouac (France)**
13:05

**Abstract N° OP0304**
Estrogens inhibit the profibrotic effects of TGF-beta and protect from the development of experimental dermal fibrosis

**A. Smržová (Czech Republic)**
13:15

Abstract N° OP0305
Psychological profile of scleroderma patients described by multidimensional Minnesota multiphasic personality inventory (MMPI II) and beck depression inventory tests (BDI II)

12:00 - 13:30  Hall C

**Clinical Science session**

**Paget’s and other rare bone diseases**

**Learning objectives:**
- To get insight in clinical signs and symptoms, and treatment options in Paget’s diseases and in reflex-dystrophy
- To learn about modern thoughts around glucocorticoid induced osteoporosis
- To know about the long-term (10 years) data of denosumab in post-menopausal women

**Chairperson(s):**
Olga M. Lesnyak (Russian Federation)
Natalia Kuchuk (Netherlands)

**Frank Buttgerieit (Germany)**
12:05

**Abstract N° SP0186**
Glucocorticoid induced osteoporosis

**Andrea Giusti (Italy)**
12:30

**Abstract N° SP0185**
Reflex dystrophy: diagnosis and treatment

**Stuart H. Ralston (United Kingdom)**
12:55

**Abstract N° SP0184**
Paget’s disease: new developments

**E. Czerwinski (Poland)**
13:20

**H. Bone, M. Brandi, J. Brown, R. Chapurlat, S. Cummings, A. Fahrleitner-Pammer, D. Kendler, K. Lippuner, J.-Y. Reginster, E. Vittinghoff, N. Daizadeh, A. Wang, P. Dakin, R. Wagman, S. Papapoulos**
Abstract N° OP0306
Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial

12:00 - 13:30  Hall E

**How to Treat/Manage (HOT)**

**HOT session 11**

**Chairperson(s):**
Robert B. M. Landewé (Netherlands)
Ronald van Vollenhoven (Netherlands)

**Désirée van der Heijde (Netherlands)**
12:05
Update of the ASAS/EULAR recommendations for the management of axial SpA

**Annette van der Helm (Netherlands)**
12:25
EULAR classification criteria for clinically suspect arthralgia

**Bernard Combe (France)**
12:45
Abstract N° SP0183
Update of the EULAR recommendations for the management of early arthritis

**Josef S. Smolen (Austria)**
13:05
Abstract N° OP0303
Paget’s disease: new developments

**H. Bone, M. Brandi, J. Brown, R. Chapurlat, S. Cummings, A. Fahrleitner-Pammer, D. Kendler, K. Lippuner, J.-Y. Reginster, E. Vittinghoff, N. Daizadeh, A. Wang, P. Dakin, R. Wagman, S. Papapoulos**
Abstract N° OP0306
Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial

12:00 - 13:30  Hall A

**Outcome Science session**

**Analytical issues of complex databases**

**Learning objectives:**
To better be able to make an informed choice about important analytical issues in complex (longitudinal) databases

**Chairperson(s):**
Axel Finckh (Switzerland)
Suzanne Verstappen (United Kingdom)

**Thomas Frisell (Sweden)**
12:05
Abstract N° SP0187
Why missing data is a problem, and what you shouldn’t do to solve it

**Jamie Sergeant (United Kingdom)**
12:20
Abstract N° SP0188
Multiple imputation: a possible solution to the problem of missing data
Jos Twisk (Netherlands) 12:35
Why choosing marginal models for longitudinal datasets?

Sam Norton (United Kingdom) 12:55
Abstract N° SP0189
Why choose random effects models for longitudinal datasets?

M. E. Sandberg (Sweden) 13:15
H. Westerlund, S. Saevarsdottir I, P. Frumento, L. Klareskog, L. Alfredsson
Abstract N° OP0307
No long-term effect on disease activity and pain of physical activity found in prospective observational study of early rheumatoid arthritis

12:00 - 13:30 Capital Suite 07
Health Professionals session
**Intimate life and sexual relations in RA**

**Learning objectives:**
To increase knowledge on experiences, assessment and clinical implications regarding intimate life and sexual relations in RA

**Chairperson(s):**
Andrea Domjan (Hungary)
Hana Smucrová (Czech Republic)

Annette Sverker (Sweden) 12:05
Abstract N° SP0190
Lived experiences of intimate life in men and women with early RA

Kristina Areskoug (Sweden) 12:23
Abstract N° SP0191
Sexual health in rheumatoid arthritis - the role of the physiotherapist

Sarah Ryan (United Kingdom) 12:41
Abstract N° SP0192
Disease impact on sexuality and its management in rheumatology care

Codruta Zabalan (Romania) 12:59
Abstract N° SP0193
Nine years of marriage and three in bed - myself, my husband and my RA

P. Santos-Moreno (Colombia) 13:17
L. Villarreal, J. Bello, N. Palacio, C. Castro, D. Buitrago-Garcia
Abstract N° OP0308-HPR
Precipitating, predisposing and maintenance factors associated with sexual disorders in patients with rheumatoid arthritis

12:00 - 13:30 Capital Suite 11
Basic and Translational Science session
**Bone and heart: common molecular mechanisms in osteoporosis and atherosclerosis**

**Learning objectives:**
- Elucidate common mechanisms in bone metabolism and atherosclerosis
- The OPG/RANKL and Wnt/DKK systems in atherosclerosis and bone disease
- Occurrence of cardiovascular disease and bone loss in animal models and humans

**Chairperson(s):**
Yehuda Shoenfeld (Israel)
Peter Lakatos (Hungary)

Georg Schett (Germany) 12:05
Basic molecular mechanisms of bone turnover and atherosclerosis

Piet Geusens (Netherlands) 12:25
Abstract N° SP0194
Do bone erosions result from local synovitis or bone marrow edema?

Willem F. Lems (Netherlands) 12:45
Abstract N° SP0195
Osteoporosis and cardiovascular disease

V. Vasilkova (Belarus) 13:05
T. Mokhort, E. Naumenko
Abstract N° OP0309
Association of bone mineral density and carotid atherosclerosis in patients with diabetes type 2

Chary Lopez-Pedrera (Spain) 13:15
Abstract N° OP0310
Association of neutrophil extracellular traps with atherosclerosis in rheumatoid arthritis

12:00 - 13:30 Capital Suite 14
Basic and Translational Science session
**Adiposity as a driver of arthritis through inflammatory mechanisms**

**Learning objectives:**
- To review the role of adipokines in rheumatic diseases
- To define mechanisms by which obesity contributes to pathogenesis of osteoarthritis
- To describe therapeutic implications, including the effect of diet and exercise
11 June 2016
**PARE/HPR joint session**

There is more than drugs

**Learning objectives:**
- How to boost your vitality

**Chairperson(s):**
- Jürgen Clausen (Germany)
- Rikke H. Moe (Norway)
- Klaus Pfeifer (Germany)

- Christian Schubert (Austria)

- Diana J. Pedersen (Denmark)

- E. Löfberg (Sweden)

- F. van der Giesen (Netherlands)

Abstract N° SP0201
Sports and exercise for arthritis patients

Abstract N° SP0202
Psychoneuroimmunology: from psyche to immune activity and back

Abstract N° SP0203
How the Danish Rheumatism Association works with alternative and complementary treatment

Abstract N° OP0313-PARE
The Swedish Rheumatism Association's blog about training - a new way of learning

Abstract N° OP0314-PARE
Group exercise therapy in ankylosing spondylitis (AS): the patients' perspective

**Highlight session**

**Clinical Basic Translational Highlight session**

**Chairperson(s):**
- Dirk Elewaut (Belgium)
- João E. Fonseca (Portugal)

- Costantino Pitzalis (United Kingdom)

Abstract N° OP0313-PARE
Basic and translational highlights

Abstract N° OP0314-PARE
Clinical highlights

- Thjis Swinnen (Belgium)

**HPR Highlight session**

**Chairperson(s):**
- Els van den Ende (Netherlands)
- Pedro Munuera (Spain)

- Daniel Aletaha (Austria)

- Yeliz Prior (United Kingdom)

- Joep Welling (Netherlands)

**Highlight session**

**PARE Highlight session**

**Chairperson(s):**
- Marios Kouloumas (Cyprus)
- Dieter Wiek (Germany)
- Anna Moltó (France)

- Thijs Swinnen (Belgium)

**Highlight session**

**Clinical Basic Translational Highlight session**

**Chairperson(s):**
- Dirk Elewaut (Belgium)
- João E. Fonseca (Portugal)

- Costantino Pitzalis (United Kingdom)

Abstract N° OP0313-PARE
Basic and translational highlights

Abstract N° OP0314-PARE
Clinical highlights

- Thjis Swinnen (Belgium)
Guided Poster Tours

Saturday, 11 June 2016

10:05 - 12:00

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area, on a “first-come-first-served” basis on the day of the poster tour.

Poster tour S1: Genetic basis and genomics of disease

Chairperson(s): Elena Neumann (Germany), Caroline Ospelt (Switzerland)


SAT0004 GENOMIC STRATIFICATION BY HLA-DRB4 EXPRESSION IDENTIFIES INNATE AND ADAPTIVE IMMUNE PATTERNS AS DIFFERENTIAL PREDICTORS OF RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS / E. A. Stuhlmueller* on behalf of Transcriptomics & Bioinformatics


SAT0006 POLYMORPHISMS IN STAT4, IL10, PSORS1C1, PTPN2 AND MIR146A GENES ARE DIFFERENTLY ASSOCIATED WITH NEGATIVE PROGNOSTIC FACTORS IN ITALIAN PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS / P. Conigliaro* - C. Perricone - C. Ciccacci - S. Rufini - P. Triggianese - C. Politi - A. Latini - G. Novelli - P. Borgia - R. Perricone

SAT0007 GENETIC POLYMORPHISMS OF HLA-DRB1 ARE ASSOCIATED WITH DERMATOMYOSITIS AND ANTI-MDA5 ANTIbODIES IN CHINESE / Y. Wang - Z. Chen* - L. Sun


* Presenting author
Poster tour S2: Innate immune cells coming to play

**Chairperson(s):** Reinhard E. Voll (Germany), Martin Herrmann (Germany)

**SAT0021**
TYPE 2 INNATE LYMPHOCYVE CELLS ARE RAPIDLY AND PERSISTENTLY RECRUITED IN EXPERIMENTAL FIBROSIS AND THEIR COUNTS CORRELATE WITH THE SEVERITY OF SKIN AND LUNG FIBROSIS IN SYSTEMIC SCLEROSIS


**SAT0022**

**SAT0023**

**SAT0024**

**SAT0025**

**SAT0026**
PRO-RESOLVING AND CARTILAGE-PROTECTIVE ACTIONS OF RESOLVIN D1 IN INFLAMMATORY ARTHRITIS


**SAT0027**
INHIBITION OF TLR7 AND TLR8 SIGNALING BY ANTAGONIZING MICRO-RNA DERIVED FROM EXTRACELLULAR VELOCLES SUPPRESSES INFLAMMATION IN A NOVEL HUMAN-MOUSE CHIMERIC MODEL OF LUPUS / N. A. Young* - G. Valente - J. Hampton* - H. Steigelman - W. Jarjour

**SAT0028**

**SAT0029**
DECTIN-1 MEDIATES ABERRANT INNATE AND ADAPTIVE IMMUNE RESPONSE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / M. Y. Mok* - L. K. Lam - Y. Lo - D. Luk - W. C. Lau - W. K. Chan

**SAT0030**
ACTIVE PMR AND GCA IS ASSOCIATED WITH CHANGES IN MONOCYTE SUBSET COMPOSITION / Q. Wang* - K. van der Geest - Y. van Sleen - W. Abdulahad - J. Westra - A. Boots - E. Brouwer

---

Poster tour S3: Biology of RA II

**Chairperson(s):** Zoltán Szekanecz (Hungary), Emese Balogh (Ireland)

**SAT0042**

**SAT0043**

**SAT0044**

**SAT0045**
ANTIBODIES DIRECTED AGAINST ENDOGENOUS AND EXOGENOUS CITRULLINATED ANTIGENS PRE-DATE THE ONSET OF RHEUMATOID ARTHRITIS / L. Johansson - F. Pratesi - M. Brink - L. Ärlestig - C. D'Amato - D. Bartaloni - P. Migliorini - S. Rantapää-Dahlqvist*

**SAT0046**
REGULATION OF SIRT1 MAYBE A PIONEERING STRATEGY IN TREATMENT OF RHEUMATOID ARTHRITIS S. Y. Lee* - W. T. Chung - S. W. Lee - S. Y. Park

**SAT0047**
LOCAL CRYOTHERAPY DOWN-REGULATES LOCAL AND SYSTEMIC IL-6 AND IL-17 PATHWAYS IN ADJUVANT-INDUCED ARTHRITIS / X. Guillot* - H. Martin - K. Maguin-Gaté - S. Py - C. Demougeot - D. Wendling - N. Tordi

**SAT0048**

**SAT0049**

**SAT0050**

**SAT0051**
OVEREXPRESSION OF CCL18 PROMOTES RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST MIGRATION AND INVASION BY REGULATING MMP9 EXPRESSION VIA DOWNREGULATED MIR-15A/MIR-16 / W. Tan* - Y. Shi - X. Feng - W. Wang - W. Xuan - M. Zhang

* Presenting author
**Poster tour S4: Safety and efficacy of non-TNFα blockers in the treatment of RA - II**

**Chairperson(s): Lene Terslev (Denmark), Simon Krabbe (Denmark)**

**SAT0144**

SOLUBLE FORM OF GP130 MOLECULE, AN IL-6 INHIBITOR, CONTRIBUTES TO EFFICACY ON RA TO TOCILIZUMAB (AN ANTI-IL-6 RECEPTOR ANTIBODY) THERAPY / K. Yoshizaki* - S. N. J. Song - H. Itoh - M. Iwashashi - K. Uno

**SAT0145**


**SAT0146**


**SAT0147**


**SAT0148**


**SAT0149**

RADIOMATIC OUTGOES IN PATIENTS RECEIVING CLINICAL REMISSION OR LOW DISEASE ACTIVITY IN A PHASE 3 STUDY OF SARIUMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE, MODERATE-TO SEVERE RHEUMATOID ARTHRITIS / D. van der Heijde* - J. Simon - H. van Hoostraten - E. K. Manangan - J. Fay I. van Adelsberg - C. Fan - M. C. Genovesen

**SAT0150**

COMPARATIVE RISK OF MALIGNANCY WITH INITIATION OF ABATACEPT AND OTHER BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A COHORT ANALYSIS OF A UNITED STATES CLAIMS DATABASE S. Suisse* - N. Baker - H. Kawabata - N. Ray - T. Simon

**SAT0151**

IMAGING AND HISTOPATHOLOGICAL CHANGES TO TOCILIZUMAB IN PATIENTS WITH MODERATE TO SEVERE RA: A SINGLE CENTRE RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY / A. S. Zayat* - C. Wong - R. Cuthbert - Z. Ash - S. J. Bingham - P. Emery - M. H. Buch

**SAT0152**


**SAT0153**


**Poster tour S5: Basic research in systemic sclerosis**

**Chairperson(s): Gabriela Riemekasten (Germany), Britta Maurer (Switzerland)**

**SAT0184**


**SAT0185**


**SAT0186**


**SAT0187**


**SAT0188**


**SAT0189**


**SAT0190**

HISTOLOGICAL STUDY ON THE EXPRESSION OF TRANSCRIPTIONAL INTERMEDIARY FACTOR 1(TIF1) IN THE PATIENTs WITH INFLAMMATORY MYOPATHIES / Y. Kim* - J. Kim - S. W. Kang - S.-C. Shim - I. S. Yoo - S.-J. Yoo

**SAT0191**


**SAT0192**

DECREASED INTERLEUKIN-6/STAT3, BUT INCREASED INTERFERON/STAT1 SIGNALLING IN LYMPHOCYTES OF PATIENTs WITH SYSTEMIC SCLEROSIS (SSC) / C. Kittel - M. Skwarek - B. Heschel - J. Fantana - M. Aringer*


**Poster tour S6: Scleroderma, myositis and related syndromes II**

**Chairperson(s): Maurizio Cutolo (Italy), Vanessa Smith (Belgium)**


SAT0199  NMR-BASED METABOLOMIC ANALYSIS FOR THE DIAGNOSIS OF SYSTEMIC SCLEROSIS / K. H. Jung* - S. Oh - W. Park - M. J. Lim - S. Kwon - S. Park


SAT0202  NAILFOLD MICROANGIOPATHY EXTENT AND CHOROIDAL VASCULAR THICKNESS EVALUATED BY NAILFOLD VIDEOCAPILLAROSCOPY AND OPTICAL COHERENCE TOMOGRAPHY IN SYSTEMIC SCLEROSIS PATIENTS / E. Bernero* - A. Sulli - C. Pezzoni - S. Paolino - E. Alessandri - M. Nicoló - G. E. Traverso - C. A. Cutolo


**PRES Poster tour S7: Juvenile-onset connective tissue diseases**

**Chairperson(s): Özgür Kasapcopur (Turkey), Alexandre Belot (France)**


SAT0259  DERMATOLOGICAL FEATURES OF KAWASAKI DISEASE: DATA EXTRACTED FROM THE FRENCH KAWASAKI DISEASE COHORT (KAWANET) / C. Specht* - M. Darce - K. Brochard - P. Lechevalier - E. Launay - I. Kone Paut - M. Piram on behalf of the Kawanet study group

* Presenting author
SAT0260  A NOVEL MRI-BASED ANALYSIS WORKFLOW FOR CHRONIC RECURRENT MULTIFOCAL OSTEOMYEITIS (CRMO) / Y. Chu - D. Roetter - C. Trentin - M. Hinton* - O. Kubassova - R. Hargunani - M. Boesen - P. O'Donnell


**Poster tour S8: SLE and Sjögren's - clinical aspects**

**Chairperson(s): Ronald van Vollenhoven (Netherlands), Christina Tsalapakí (Greece)**

SAT0281  COMPENSATORY BRAIN MECHANISMS TO MAINTAIN COGNITIVE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS / M. Barraclough - I. N. Bruce* - S. McKie - B. Parker - R. Elliott


SAT0283  RELAPSES OF LUPUS NEPHRITIS - RISK FACTORS, INCIDENCE AND IMPACT ON OUTCOME / D. V. Monova* - S. Monov


SAT0286  RISK OF SEVERE HERPES SIMPLEX VIRUS INFECTION IN PATIENTS SLE: A NATIONWIDE POPULATION COHORT STUDY / T.-H. Li* - C.-C. Lai - Y.-S. Chang


SAT0288  CLINICAL PHENOTYPING IN 608 PATIENTS FROM THE UNITED KINGDOM PRIMARY SJÖGREN'S SYNDROME REGISTRY / N. Howard Tripp* - D. Lundrem - J. Tarn - K. Hackett - W.-F. Ng

SAT0289  SONOGRAPHIC ALTERATIONS DURING THE COURSE OF SJÖGREN'S SYNDROME - A FIVE-YEAR FOLLOW UP / B. Hofauer* - M. Bas - N. Mansour - D. Loeffelbein - A. Knopf


**Poster tour S9: Vasculitis II**

**Chairperson(s): Carlo Salvarani (Italy), Francesco Muratore (Italy)**

SAT0330  EFFECTIVE AND RAPID TREATMENT OF FLARES IN PATIENTS WITH BEHÇET'S DISEASE BY THE SINGLE CHAIN ANTI-TNF ANTIBODY DLX105 / T. Xenitidis* - C. Berger - T. Jung - J. Henes - I. Koetter


SAT0332  TAKAYASU ARTERITIS (TA): THE PATHOLOGICAL CHANGES IN THE CORONARY ARTERIES / O. Zimba*

SAT0333  HEMOSTATIC MECHANISMS MAY PLAY A ROLE IN THE DEVELOPMENT OF THROMBOSIS IN MALE PATIENTS WITH BEHÇET'S DISEASE: A THROMBOELASTOGRAPHIC ANALYSIS / B. Kara Kivanc - E. Gonullu - C. Bal - M. O. Akay - A. Erturk - D. Uskudar Cansu - T. Kasifoglu - C. Korkmaz*


* Presenting author
**Poster tour S10: Optimising treatment of axial SpA**

**Chairperson(s): Maxime Dougados (France), Denis Poddubny (Germany)**

**SAT0371**

**SAT0372**

**SAT0373**
Efficacy and safety of golimumab in patients with active, very early peripheral spondyloarthritis: first results from the CRESPA study, a monocentric, placebo-controlled randomized trial / P. Carron* - G. Varks - H. Cypers - I. van der Graaf - D. Elewaut - F. van den Bosch

**SAT0374**
Pregnancy outcome in couples with males exposed to long-term anti-TNF alpha blocker therapies / M. C. Micu* - V. Bojinca - M. Mihai - C. Suta - A. Ramazan - R. Micu

**SAT0375**

**SAT0376**
SERUM CRP LEVELS DEMONSTRATE PREDICTIVE VALUE FOR RADIOGRAPHIC AND MRI OUTCOMES IN PATIENTS WITH ANKYLOSING SPONDYLITIS AS TREATED WITH THE TNF-INHIBITOR GOLIMUMAB / J. Braun* - X. Baraliakos - K.-G. Hermann - S. Xu - B. Hsu

**SAT0377**

**SAT0378**

**SAT0379**

**SAT0380**
NSAIDs modify the effect of tumour necrosis factor inhibitors on new bone formation in ankylosing spondylitis / L. Gensler* - J. D. Revelle - M. M. Ward - M. A. Brown - M. Rahbar - M. Lee - M. H. Weisman

---

**Poster tour S11: New insights in osteoarthritis**

**Chairperson(s): Margreet Kloppenburg (Netherlands), Alice Courties (France)**

**SAT0424**

**SAT0425**
Does weight in the offspring of people with a total knee replacement for severe primary knee osteoarthritis have a detrimental effect on knee cartilage and pain? A 10-year prospective study / F. Pan* - L. Blizzard - J. Tian - F. Cicuttini - T. Winzenberg - C. Ding - G. Jones

**SAT0426**

**SAT0427**

**SAT0428**

**SAT0429**

**SAT0430**
Neither obesity, smoking and alcohol are associated with hand osteoarthritis (OA) - longitudinal data from osteoarthritis initiative (oai) / L. S. Lee - D. H. Kim - M. C. Paik - D. G. Jang - S. Y. Lee - H. A. Kim

**SAT0431**

**SAT0432**

**SAT0433**
Zoledronic acid does not slow spinal radiographic progression in those with radiographic osteoarthritis / H. I. Keen - L. V. Host* - L. L. Laslett - D. M. Black - G. Jones

* Presenting author
**Poster tour S12: Infection related rheumatic diseases**

Chairperson(s): Dimitrios Vassilopoulos (Greece), Konstantinos Thomas (Greece)

**SAT0481**

Clinical features associated with higher mortality in adults with septic arthritis - A 10-year retrospective study / A. Premkumar* - C. Pawa - M. Lahiri - A. Santosa

**SAT0482**


**SAT0483**

Ultrasonography changes during the course of septic arthritis are associated with functional outcome / E. Gaienneux* - G. Cormier - O. Merot - Y. Maugars - B. Le Goff

**SAT0484**


**SAT0485**


**SAT0486**


**SAT0487**

Screening for past infection with hepatitis B in patients receiving rituximab: an audit / M. Cates* - C. Gut

**SAT0488**


**SAT0489**


**SAT0490**

Poor long-term adherence to secondary penicillin prophylaxis among paediatric patients with rheumatic fever / G. Amariroyo* - G. Chodick - I. Somekh - J. Zalcman - L. Harel

**Poster tour S13: New approaches to back pain - soft tissue problems**

Chairperson(s): Christian D. Mallen (United Kingdom), Sam Hider (United Kingdom)

**SAT0502**

Tolerance and acceptability of US guided epidural injections via the sacral hiatus A. Colombey* - T. Garraud - G. Bart - C. Darriuert-Laffite - B. Le Goff

**SAT0503**


**SAT0504**

Prevalence and correlates of household work related musculoskeletal disorders in low back region among Sri Lankan housewives / P. D. Ranasineghe* - I. Atukorala - A. Samaranyake - N. S. Gunawardana

**SAT0505**

Severely-disabling chronic low back pain: combination treatment with glucosamine-chondroitin sulfate reduces disability, pain and NSAID consumption - Results from a large, community-based, pilot, open prospective interventional study / G. Singh* - L. Alexseeva - D. Gorlaichev - A. Barinov - E. Nasonov - A. Mithal - S. Pyanykh

**SAT0506**


**SAT0507**

Comparison of oral splinting and kinesiotaping in temporomandibular joint pain / K. Baldaci*

**SAT0508**

Manual therapy and exercise for rotator cuff disease: A Cochrane review / M. Page - S. Green

**SAT0509**

Feasibility of ultrasound-guided facet joint injections through a longitudinal approach C. Darriuert-Laffite* - A. Colombey - J. Glemarec - Y. Maugars - B. Le Goff

**SAT0510**

Painful shoulder: relevance of clinical and sonographic data on corticosteroid injection outcome / M. Cerqueira* - J. Sousa Neves - D. Santos Faria - F. Teixeira - M. C. Afonso - J. A. Costa

**SAT0511**

Management of adhesive capsulitis with landmark guided high volume steroid injections in the community based musculoskeletal clinic / S. Baltsezak

**Poster tour S14: Imaging RMD - what else?**

Chairperson(s): Esperanza Naredo (Spain), Signe Moeller-Bisgaard (Denmark)

**SAT0528**


* Presenting author
GUIDED POSTER TOURS / SATURDAY 11 JUNE 2016 / 153


SAT0530 DEEP CLINICAL REMISSION - AN OPTIMIZED TARGET IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS? EXPERIENCE FROM AN ULTRASONOGRAPHY STUDY / V. Y. Geng* - Z. Zhang


SAT0532 TIBIAL CORTICAL THICKNESS MEASURED BY HIGH-RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY DISCRIMINATES VERTEBRAL FRACTURES IN PATIENTS ON LONG-TERM GLUCOCORTICOIDS INDEPENDENT OF AREAL BONE MINERAL DENSITY / J. Shen* - L.-S. Tam on behalf of Hong Kong GIOP study group

SAT0533 KNEE SYNOVITIS: ULTRASONOGRAPHIC FINDINGS STRONGLY CORRELATE WITH SYNOVIAL MEMBRANE HISTOLOGY / A. Najm* - C. Orr - U. Fearon - D. Veale

SAT0534 HOW TO DEFINE SONOGRAPHIC SIGNS OF AXILLARY VASCULITIS IN GIANT CELL ARTERITIS? / M. Milchert* - M. Brzosko


SAT0536 UTILITY OF 18F-FDOPA-DEOXYGLUCOSE POSTRON EMISSION TOMOGRAPHY FOR THE DIAGNOSIS OF POLYMYALGIA RHEUMATICA: A CONTROLLED STUDY / M. Sondag - X. Guillot - F. Verhoeven - O. Blagosklonov - C. Prati - H. Boulahdour - D. Wendling*

SAT0537 SENSITIVITY AND SPECIFICITY OF ULTRASOUND SCORE FOR THE DIAGNOSIS OF GOUT / M. Basaric* - G. Radunovic - N. Damjanov - M. Perovic-Radak

HPR Poster tour S15: Getting around rheumatic disease


SAT0638-HPR DELAYS IN DIAGNOSING OF PATIENTS WITH RHEUMATIC DISEASES IN POLAND / J. Grygielska* - P. Samel-Kowalik - A. Klak - M. Matczak - E. Raciborski

SAT0639-HPR THE MOST FREQUENT INQUIRIES OF PATIENTS ON SUBCUTANEOUS ANTI-TNF ALPHA THERAPIES / M. Pavic Nikolic* - A. Hocevar


SAT0641-HPR REASONS TO STOP DRINKING ALCOHOL AMONG PATIENTS WITH RHEUMATOID ARTHRITIS - A MIXED METHOD STUDY / M. Andersson* - L. Larsson


SAT0644-HPR BELIEFS, KNOWLEDGES AND REPRESENTATIONS OF PATIENTS WITH GOUT DISEASE FOLLOWED BY GENERAL HEALTHCARE AND HOSPITAL RHEUMATOLOGY: FROM DIONYSUS TO THE SWORD OF DAMOCLES / C. Sarran* - C. Bougeois Sarran - C. Deprouw - M. Guignot - A. Frazier - L. Baumann Coblentz - E. Hang Kong

* Presenting author
Scientific Poster Session 3

Saturday, 11 June 2016
10:05 - 12:00

Genomics, genetic basis of disease and HLA/T cell recognition


SAT0004 GENOMIC STRATIFICATION BY HLA-DRB4 EXPRESSION IDENTIFIES INNATE AND ADAPTIVE IMMUNE PATTERNS AS DIFFERENTIAL PREDICTORS OF RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS B. A. Stuhlmüller* on behalf of Transcriptomics & Bioinformatics


SAT0006 POLYMORPHISMS IN STAT4, IL10, PSORS1C1, PTPN2 AND MIR146A GENES ARE DIFFERENTIALLY ASSOCIATED WITH NEGATIVE PROGNOSTIC FACTORS IN ITALIAN PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS P. Conigliaro* - C. Perricone - C. Ciccacci - S. Rufini - P. Triggianese - C. Politi - A. Latini - G. Novelli - P. Borgia - R. Perricone

SAT0007 GENETIC POLYMORPHISMS OF HLA-DRB1 ARE ASSOCIATED WITH DERMATOMYOSITIS AND ANTI-MDA5 ANTIBODIES IN CHINESE / Y. Wang - Z. Chen* - L. Sun


SAT0012 GENETIC ANALYSIS OF ABCG2 IN PRIMARY HYPERURICEMIA AND GOUT / B. Sibburkova* - P. Simek - P. Cepek - K. Pavelcova - K. Pavelka

* Presenting author
**Innate immunity in rheumatic diseases**

**SAT0021**

**SAT0022**

**SAT0023**

**SAT0024**

**SAT0025**

**Sat0026**
**Rheumatoid arthritis - etiology, pathogenesis and animal models**

**SAT0031**

**SAT0032**
CIRCULATING PLATELETS IS ACTIVATED AND ASSOCIATED WITH DISEASE ACTIVITY OF PATIENTS WITH PRO-RESOLVING MEDIATORS ISSUED FROM APOPTOTIC CELL EFFEROCYTOSIS (SUPERMAPO) MODULATE T. Colasanti - M. Pendolino - C. Barbati - R. Mancini - F. Conti - G. Valesini

**SAT0033**
LARGE COHORT OF ITALIAN RHEUMATOID ARTHRITIS PATIENTS / A. Pecani* - C. Alessandri - F. R. Robinson - J. Sokolove

**SAT0034**
DECTIN-1 MEDIATES ABERRANT INNATE AND ADAPTIVE IMMUNE RESPONSE IN PATIENTS WITH SYSTEMIC SCLEROSIS / U. Holmskov - P. Junker

**SAT0035**

**SAT0036**

**SAT0037**

**SAT0038**

**SAT0039**

**SAT0040**

**SAT0041**
CIRCULATING PLATELETS IS ACTIVATED AND ASSOCIATED WITH DISEASE ACTIVITY OF PATIENTS WITH PRO-RESOLVING MEDIATORS ISSUED FROM APOPTOTIC CELL EFFEROCYTOSIS (SUPERMAPO) MODULATE T. Colasanti - M. Pendolino - C. Barbati - R. Mancini - F. Conti - G. Valesini

**SAT0042**
LARGE COHORT OF ITALIAN RHEUMATOID ARTHRITIS PATIENTS / A. Pecani* - C. Alessandri - F. R. Robinson - J. Sokolove

**SAT0043**
DECTIN-1 MEDIATES ABERRANT INNATE AND ADAPTIVE IMMUNE RESPONSE IN PATIENTS WITH SYSTEMIC SCLEROSIS / U. Holmskov - P. Junker

**SAT0044**

**SAT0045**

**SAT0046**
PRO-RESOLVING AND CARTILAGE-PROTECTIVE ACTIONS OF RESOLVIN D1 IN INFLAMMATORY ARTHRITIS / C. van Kooten - O. Teng

**SAT0047**
INHIBITION OF TLR7 AND TLR8 SIGNALING BY ANTAGONIZING MICRO-RNA DERIVED FROM EXTRACELLULAR VESICLES SUPPRESSES INFLAMMATION IN A NOVEL HUMAN-MOUSE CHIMERIC MODEL OF LUPUS / N. A. Young* - G. Valiente - J. Hampton - H. Steigelman - W. Jairour

**SAT0048**

**SAT0049**

**SAT0050**
ACTIVE PM AND GCA IS ASSOCIATED WITH CHANGES IN MONOCYTE SUBSET COMPOSITION / Q. Wang* - K. van der Geest - Y. van Sleen - W. Abdulahad - J. Westra - A. Boots - E. Brouwer

**SAT0051**
ASSOCIATION OF HLA-DP/DQ AND STAT4 POLYMORPHISMS WITH ANKYLOSING SPONDYLITIS IN A CHINESE POPULATION / I. Xiu - W. Yang - B. Yang

* Presenting author
Rheumatoid arthritis - prognosis, predictors and outcome

SAT0040  THE ACTIVE METABOLITE OF LEFLUNOMIDE, A77 1726, ATTENUATES ARTHRITIS SEVERITY IN MICE WITH SPONTANEOUS ARTHRITIS VIA INDUCTION OF HEME OXYGENASE-1 / S.-J. Moon - H.-S. Kim*


SAT0042  DISENTANGLING THE ROLE OF HYPOXIA-INDUCIBLE FACTOR 1 AND 2 IN THE ADAPTATION PROCESS OF HUMAN MICROVASCULAR ENDOTHELIAL CELLS TO PATHOPHYSIOLOGICAL HYPOXIA / M. Hanhe - P. Kunath - M. Mursell - C. Strehl - G.-R. Burmester - F. Buttgeret - T. Gaber*


SAT0046  REGULATION OF sRIT1 MAYBE A PIONEERING STRATEGY IN TREATMENT OF RHEUMATOID ARTHRITIS S. Y. Lee* - W. T. Chung - S. W. Lee - S. Y. Park

SAT0047  LOCAL CRYOTHERAPY DOWN-REGULATES LOCAL AND SYSTEMIC IL-6 AND IL-17 PATHWAYS IN ADJUVANT-INDUCED ARTHRITIS / X. Guillot* - H. Martin - K. Maguin-Gaté - S. Py - C. Demougeot - D. Wendling - N. Tordi


SAT0051  TRANSCRIPTION FACTOR SOX5 PROMOTES RHEUMATOID ARTHRITIS SYNOVIAL FIBROCYTE MIGRATION AND INVASION BY REGULATING MMP9 EXPRESSION VIA DOWNREGULATED MIR-15A/MIR-16 / W. Tan* - Y. Shi - X. Feng - F. Wang - W. Xuan - M. Zhang

Rheumatoid arthritis - prognosis, predictors and outcome


SAT0054  LOCAL CRYOTHERAPY DOWN-REGULATES LOCAL AND SYSTEMIC IL-6 AND IL-17 PATHWAYS IN ADJUVANT-INDUCED ARTHRITIS / X. Guillot* - H. Martin - K. Maguin-Gaté - S. Py - C. Demougeot - D. Wendling - N. Tordi

SAT0055  TREATMENT RESPONSE TO CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs) AND BIOLOGICS IN SEROPOSITIVE AND SERONEGATIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RESULTS FROM CATCH (CANADIAN EARLY ARTHRITIS COHORT) / B. Aberumand* - V. Bykerk - O. Schieir - A. Finckh - D. Courvoisier - J. Richter - S. Vordenbaumen


SAT0057  LOW MORTALITY RATE IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS FROM SOUTH ITALY D. Iacono* - G. Cuomo - V. D’Aroscsa - I. Pantano - G. Valentini

* Presenting author
SAT0058 CONSISTENCY OF RADIOGRAPHIC RESPONSES WITH SARILUMAB PLUS METHOTREXATE ACROSS SUBPOPULATIONS OF PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 STUDY / D. van der Heijde* - C. Fan - H. van Hoogstraten - E. K. Mangan - J. van Adelsberg - P. C. Miranda - M. C. Genovese

SAT0059 CRITERIA FOR CHOICE BY CLINICIANS OF THE THERAPEUTIC STRATEGY IN PATIENTS WITH INSUFFICIENT RESPONSE TO A FIRST ANTI-TNF: DATA FROM THE RANDOMIZED "ROC" CRITERIA / E. Chatelus* - C. Sordet - P. Ravaud - J. Sibilia - J.-E. Gottenberg on behalf of the ROC trial investigators

SAT0060 ACHIEVEMENT OF INDIVIDUAL IMPORTANT RESPONSE MEASURED BY DAS28DCRIT IN ACTIVE RHEUMATOID ARTHRITIS WHEN TREATED WITH TOCILIZUMAB: DATA FROM A LARGE PROSPECTIVE OBSERVATIONAL STUDY / F. Behrens* - M. Köhm - M. Hofmann - G. Fliedner - C. Specker - H. Burkhardt


SAT0062 TEST FOR SERUM PROGRAMMED AUTOANTIBODIES CAN REDUCE THE SERONEGATIVE STATUS IN RHEUMATOID ARTHRITIS BY ONE THIRD / G. Assmann* - S. Zinke - M. Gerling - N. Fadle - D. Preuss - M. Pfeundschuh - L. Thurner


SAT0064 THERAPY ADHERENCE, PRESCRIBED MEDICATIONS, DISEASE ACTIVITY AND PSYCHOSOCIAL CONSEQUENCES IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. G. Kuipers* - M. Koller - F. Zeman - K. Müller - J. U. Röfler

SAT0065 EFFECTS OF DMARD TAPERING ON TREATMENT COSTS IN RHEUMATOID ARTHRITIS PATIENTS - AN ANALYSIS FROM THE PROSPECTIVE RANDOMIZED CONTROLLED REMI-6 STUDY / M. Hagen - C. Pfeuchtenberger - K. Haendle - H. Mann - K. Pavelka - J. Vencovský - L. Šenolt - M. Filková


SAT0067 NO NEED TO DETECT ANTI-DRUG ANTIBODIES IN PATIENTS TREATED WITH TNF INHIBITORS / M. Herold* - B. Rintelen - F. S. Singer - B. F. Leeb


SAT0070 PROGNOSTIC FACTORS FOR ABATACEPT RETENTION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A JAPANESE MULTICENTER REGISTRY / M. Hanabayashi* - N. Takahashi - Y. Yokota - H. Miyake - T. Kojima - N. Ishiguro on behalf of the CareRA study group


SAT0074 NUMBER OF AUTOANTIBODIES ASSOCIATED WITH ALL-CAUSE MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS / L. Vidal-Bracho* - A. Montes - R. Varella - M. D. Bóveda - E. Pérez-Pampín - J. J. Gómez-Reino - A. González


SAT0076 Good therapeutic response with biologics but patients' physicians' opinion are different: data from the austrian bioreg registry / M. Herold* - G. Eichbauer-Sturm - R. Puchner - B. Rintelen - F. S. Singer - B. F. Leeb

SAT0077 NO NEED TO DETECT ANTI-DRUG ANTIBODIES IN PATIENTS TREATED WITH TNF INHIBITORS / M. Herold* - L. Bosso - T. Haueis - W. Klötz - G. Zangerl

SAT0078 VALIDATION OF THE RHEUMATOID ARTHRITIS PREDICTION RULES FOR THE DISEASE DEVELOPMENT IN PATIENTS WITH JOINT PAIN FROM WEST SWEDEN / R. Pullerits - S. Bratt - M. Turkilla - M. Erlandsson - M. Bokarewa*

SAT0079 UTILITY OF SURVIVIN MEASUREMENTS FOR EARLY RECOGNITION OF CLINICALLY SUSPECT ARTHRALGIA AND DIAGNOSIS OF RHEUMATOID ARTHRITIS IN WEST SWEDEN / M. Bokarewa* - M. Turkkila - S. Bratt - M. Erlandsson - R. Pullerits

SAT0080 PROGNOSTIC FACTORS FOR ABATACEPT RETENTION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A JAPANESE MULTICENTER REGISTRY / M. Hanabayashi* - N. Takahashi - Y. Yokota - H. Miyake - T. Kojima - N. Ishiguro on behalf of TBCR

SAT0081 PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE USE OF MUSCULOSKELETAL ULTRASONOGRAPHY TO IMPROVE RHEUMATOID ARTHRITIS MANAGEMENT: CANADIAN EXPERIENCE (ECHO) / M. Stein* - E. Rampakakis - J. S. Sampalis - W. Bensen

SAT0082 CHARACTERIZATION OF RA PATIENTS WITH A DAS28 RESPONSE TO ADALIMUMAB THERAPY BY IMPROVEMENT IN PAIN: A GERMAN NONINTERVENTION STUDY / M. Köhm* - E. Scharbatke - E. Stemmler - G. Greger - F. Behrens - B. Wittig

* Presenting author
Rheumatoid arthritis - comorbidity and clinical aspects

SAT0096
INDICATORS AND FREQUENCY OF HIP SYNOVITIS DETECTED BY ULTRASOUND IN RA / A. A. Negm* - A.-S. Mohamed - A. Abonar - E. Abdulazim - S. Al Araby

SAT0097

SAT0098
RISK OF HOSPITALIZATION FOR SERIOUS BACTERIAL INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICS. ANALYSIS FROM THE RECORD STUDY OF THE ITALIAN SOCIETY FOR RHEUMATOLOGY / A. Bortoluzzi* - G. Sakelariou - G. Carrara - M. Govoni - C. A. Scirè

SAT0099

SAT1000
ASSOCIATION BETWEEN CHRONIC PERIODONTITIS AND CLINICAL PROFILE OF RHEUMATOID ARTHRITIS B. Rodríguez-Lozano* - J. L. Garnier Rodríguez - J. González Febles - S. Dadlani - B. Tejera Segura - I. Ferraz Amaro - J. F. Díaz González - S. Bustabad Reyes

SAT1001
COULD THE FUNCTIONAL DISABILITY OF RHEUMATOID ARTHRITIS PATIENTS INFLUENCE IN THE DEVELOPMENT OF PERIODONTITIS? / B. Rodríguez-Lozano* - S. Dadlani - J. L. Garnier Rodríguez - J. González Febles - L. Expósito Pérez - H. Sánchez Pérez - M. García González - S. Bustabad Reyes

* Presenting author

SAT0103  RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN A SWISS COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATRIC ARTHRITIS AND AXIAL SPONDYLYARTHRITIS / K. Lauper - P. Chevallier-Ruggeri - A. Finckh - C. Gabay*


SAT0108  METHOTREXATE AND ANTI-TNF TREATMENT IMPROVE ENDOTHELIAL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATRIC ARTHRITIS AND ANKYLOSING SPONDYLITIS / G. Rey* - I. Hofstad - M. C. Smästuen - S. Agewall - I. Hollan


SAT0110  PREVALENCE OF SELF-REPORTED COMORBIDITIES IN RHEUMATOID ARTHRITIS OUT-PATIENT CLINIC PATIENTS / G. Haugeberg* - B.-T. S. Fevang - D. M. Soldal - C. Gjedde

SAT0111  INCREASED INRILIN RESISTANCE AND IMPAIRED BETA-CELL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: COULD INFAMMATTION FULLY EXPLAIN THESE METABOLIC DISTURBANCES? / G. G. Ristic* - V. Subota - D. Stanisavljevic - B. Glicic - M. Petronjievic - D. Stefanovic

SAT0112  THE EFFECT OF CARDIAC REHABILITATION PROGRAM ON DISEASE ACTIVITY, FUNCTIONAL OUTCOME AND CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS / H. Peynirci Cersit - I. Yagci* - S. Cersit - N. Inanc


SAT0114  THE IMPACT OF EDUCATION ON ADHERENCE TO TREATMENT WITH DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTS / I. Holc* - A. Pahor - S. Gradinsnik - K. Dai - M. Koren Krajnc - V. Kovačič Grobelšek - M. Dobnik

SAT0115  CORRELATIONS BETWEEN RHEUMATOID ARTHRITIS ACTIVITY INDICES AND FACTORS AFFECTING ACUTE PHASE REACTANTS IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. H. Kim* - I. A. Choi

SAT0116  MORTALITY PROFILE OF PATIENTS WITH RHEUMATOID ARTHRITIS IN FRANCE AND ITS CHANGE IN 10 YEARS / J. L. Andreu* - M. A. Martín - J. Avouac* - F. Amrouche - G. Rey - Y. Allanore


SAT0118  DYSLIPIDEMIA IS UNDERTREATED IN PATIENTS WITH RHEUMATOID ARTHRITIS WITHOUT MAJOR CVD DISORDER / G. Haugeberg* - B.-T. S. Fevang - D. M. Soldal - C. Gjesdal


SAT0121  THE EFFECT OF TYPE 2 DIABETES ON DISEASE ACTIVITY IN MALE AND FEMALE RHEUMATOID ARTHRITIS PATIENTS / I. Nieuwenhuis* - V. Brown - C. Popa - J. Fransen


SAT0124  RISK FACTORS OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) / M. A. Satybaldeva* - N. S. Seredavkina - S. Glukhova - D. Karateev - T. Reshetnyak - E. Nasonov

SAT0125  TOCILIZUMAB ACHIEVES RAPID REDUCTION OF DISEASE ACTIVITY AND HAS BENEFICIAL EFFECTS ON BONE MINERAL DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS - RESULTS OF A PROSPECTIVE 5-YEAR STUDY / M. Höhle*
Rheumatoid arthritis - other biologic treatment

SAT1014
SOLUBLE FORM OF GP100 MOLECULE, AN IL-6 INHIBITOR, CONTRIBUTES THE EFFICACY ON RA TO TOCILIZUMAB (AN ANTI-IL-6 RECEPTOR ANTIBODY) THERAPY / K. Yoshizaki* - S. N. J. Song - H. Itoh - M. Iwashashi - K. Uno

SAT1015

SAT1016

* Presenting author
Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models

SAT0167 HEALTH-RELATED PHYSICAL AND EMOTIONAL WELL-BEING AND FATIGUE IMPROVE SIGNIFICANTLY WITH SIRUKUMAB TREATMENT: RESULTS OF A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS G. Karpouzas* - C. Thorne - T. Takeuchi - K. McQuarrie - S. Sheng - W. Xu - S. Peterson - R. Ganguy - C. Han - K. Fei - B. Hsu


SAT0169 SUCCESSFUL EXTENSION OF TOCILIZUMAB INFUSION INTERVALS FROM 4 WEEKS TO 6 OR 5 WEEKS IN 90% OF RA PATIENTS WITH GOOD RESPONSE TO 4 WEEKS INTERVALS / H. Uda* - O. Saiki

SAT0170 BDMAIDS MONO VS COMBO THERAPY IN RHEUMATOID ARTHRITIS. ANALYSIS OF A RHEUMATOLOGICAL SINGLE TERTIARY CENTER REAL-LIFE EXPERIENCE / J. Farina* - E. Galuppi - B. Abdel Hafith - A. Lo Monaco - M. Govoni


SAT0176 IL-6 BLOCKADE WITH TOCILIZUMAB DOES NOT SUPPRESS CD4+ T CELL ACTIVATION AT 48 WEEKS OF THE TREATMENT / M. Murakami* - T. Kuritani - N. Nishimoto

SAT0177 BARICITINIB FOR RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS / N. V. Zamora* - J. Tayar - M. A. Lopez-Olivo - R. Christensen - M. E. Suarez-Almazor


SAT0179 EXPERIENCES OF RITUXIMAB TREATMENT IN RF+ RHEUMATOID ARTHRITIS / P. Matt* - U. Lindqvist


SAT0181 CXCL14 IS NOT A BIOMARKER IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATAcept AND TOCILIZUMAB / V. D'abrosca* - S. Vettori - G. Cuomo - D. Iacono - G. Ferraciolli

SAT0182 CORRELATION BETWEEN POSITIVE BLOOD FLOW SIGNAL ON JOINT ULTRASONOGRAPHY AND PROGRESSION OF JOINT DESTRUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB FOR 4 YEARS / Y. Sugimura* - S. Miyamoto - T. Kashiwagura - M. Kobayashi - N. Miyakoshi - Y. Shimada


* Presenting author
SAT0190 
HISTOLOGICAL STUDY ON THE EXPRESSION OF TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 (TIF1) IN THE PATIENTS WITH INFLAMMATORY MYOPATHIES / Y. Kim* - J. Kim - S. W. Kang - S.-C. Shim - I.-S. Yoo - S.-J. Yoo

SAT0191 

SAT0192 
DECREASED INTERLEUKIN-6/STAT3, BUT INCREASED INTERFERON/STAT3 SIGNALLING IN LYMPHOCYTES OF PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) / C. Kittel - M. Skwarek - B. Heschel - J. Fantana - M. Aringer*

SAT0193 

SAT0194 

Scleroderma, myositis and related syndromes

SAT0195 

SAT0196 

SAT0197 

SAT0198 

SAT0199 
NMR-BASED METABOLIC ANALYSIS FOR THE DIAGNOSIS OF SYSTEMIC SCLEROSIS / K. H. Jung* - S. Oh - W. Park - M. J. Lim - S. Kwon - S. Park

SAT0200 

SAT0201 

SAT0202 
NAILFOLD MICROANGIOPATHY EXTENT AND CHOROIDAL VASCULAR THICKNESS EVALUATED BY NAILFOLD VIDEOCAPILLAROSCOPY AND OPTICAL COHERENCE TOMOGRAPHY IN SYSTEMIC SCLEROSIS PATIENTS / Y. Kim* - J. Kim - S. W. Kang - S.-C. Shim - I.-S. Yoo - S.-J. Yoo

SAT0203 

SAT0204 
The EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (SCLEROID) SCALE - A NEW PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH SYSTEMIC SCLEROSIS UNDER DEVELOPMENT / R. Dobrota* - Z. Zdrojewski - A. Paradowska-Gorycka - M. Oleśińska

SAT0205 

SAT0206 
SAT0207 
SAT0208 
SAT0209 
SAT0210 
SAT0211 
SAT0212

* Presenting author

11 June 2016

SAT0213 STUDY OF MUSCLE & SUBCUTANEOUS FAT MASS IN CHILDREN WITH JUVENILE DERMATOMYOSITIS / A. Kallesh* - A. K. Bhalla - S. Singh - S. V. Attri


SAT0215 TWELVE YEAR FOLLOW-UP ON PROGRESSION OF NAILFOLD MICROANGIOPATHY DETECTED THROUGH TRANSITION BETWEEN DIFFERENT CAPILLAROSCOPIC PATTERNS OF MICROVASCULAR DAMAGE IN SYSTEMIC SCLEROSIS / C. Pizzorni* - B. Ruaro - S. Paolino - D. Camellino - M. A. Cimmino - M. Cutolo - A. Sulli


SAT0220 RETROSPECTIVE AUDIT COMPARING BNF STANDARDS WITH DETECT CRITERIA FOR PAH-SCREENING IN SYSTEMIC SCLEROSIS PATIENTS AT A DGH / D. Hall* - L. Williamson


SAT0223 SOLUBLE SEMAPHORIN 3A AND NEUROPILIN-1: NEW MARKERS FOR DYSREGULATION OF ANGIOGENESIS IN SYSTEMIC SCLEROSIS / A. Olewicz-Gawlik - D. Sikorska* - W. Samborski


SAT0227 THE EFFICACY OF VASOACTIVE AND VASODILATING DRUGS ON DIGITAL ULCERS HEALING IN SYSTEMIC SCLEROSIS PATIENTS / C. Pizzorni* - B. Ruaro - S. Paolino - D. Camellino - M. A. Cimmino - M. Cutolo - A. Sulli


SAT0232 ANTI-CENTROMERE ANTIBODY POSITIVE DIFFUSE SCLERODERMA IS UNCOMMON BUT HAS A DISTINCT CLINICAL PHENOTYPE / J. Caetano* - S. Nihtyanova - J. Harvey - V. Ong - C. Denton


* Presenting author

SAT0235  SURVIVAL IN SYSTEMIC SCLEROSIS RELATED PULMONARY ARTERIAL HYPERTENSION IN THE MODERN TREATMENT ERA: RESULTS FROM A MULTICENTRE AUSTRALIAN COHORT STUDY / K. Morrisroe* - M. Huq - W. Stevens - C. Rabusa - S. Proudamon - M. Nikpour on behalf of Australian Scleroderma Interest Group (ASIG)

SAT0236  THE TRADITIONAL CARDIOVASCULAR RISK FACTORS AND THEIR RELATIONS TO HEART STRUCTURE IN PATIENTS WITH SYSTEMIC SCLEROSIS / L. Ananyeva* - E. Cheremukchina - D. Novikova - R. Alekperov


SAT0241  OBSERVATIONAL STUDY OF SEASONAL MONTHLY INFUSIONS OF ILOPROST - EXPERIENCE FROM A REGIONAL CENTRE IN UK / P. Joshi* - S. Venkatachalam - T. Sheeran

SAT0242  LUNG INVOLVEMENT IN UNDIFFERENTIATED CONNECTIVE TISSUE DISEASES (UCDT): RELATIONSHIP WITH CLINICAL AND CAPILLAROSCOPIC FEATURES / R. Irace* - A. Riccardi - S. Vettori - M. Iudici - G. Valentini


SAT0245  COMPARISON OF PAT CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY / G. Cengiz - K. Erol - K. Gok - S. Ozgocmen*

SAT0246  COMPARISON OF LEVEL OF FATIGUE AND DISEASE CORRELATES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS / K. Gok - K. Erol - G. Cengiz - S. Ozgocmen*

SAT0247  HIGHER FIBRINOGEN PLASMA LEVELS AT BASELINE ARE ASSOCIATED WITH A FASTER DEVELOPMENT OF NEW DIGITAL PITTING SCARS/ULCERS AT FOLLOW-UP IN SYSTEMIC SCLEROSIS PATIENTS / S. Vettori* - V. Giacco - D. Capocotta - B. Russo - G. Valentini


SAT0250  SCREENING FOR SUBCLINICAL PULMONARY VASCULAR DISEASE OF SYSTEMIC SCLEROSIS: THE BEST NON-INVASIVE TEST AND WHAT WE FOUND BY GENE EXPRESSION ANALYSIS OF PERIPHERAL BLOOD / Y. Koyama* - S. Fuke - Y. Sato - T. Higuchi


SAT0252  LONG-TERM SURVIVAL ANALYSIS AND PROGNOSTIC OUTCOME FACTORS IN IDIOPATHIC INFLAMMATORY MYOPATHY / Y. Zuò* - Y. An - C. Li - Z. Guo - Z. Li

Paediatric rheumatology


* Presenting author


SAT0286 RISK OF SEVERE HERPES SIMPLEX VIRUS INFECTION IN PATIENTS SLE: A NATIONWIDE POPULATION COHORT STUDY / T.-H. Li* - C.-C. Lai - Y.-S. Chang


SAT0288 CLINICAL PHENOTYPING IN 608 PATIENTS FROM THE UNITED KINGDOM PRIMARY SJÖGREN’S SYNDROME REGISTRY / N. Howard Tripp* - D. Lendrem - J. Tarn - K. Hackett - W.-F. Ng

SAT0290 SONOGRAPHIC ALTERATIONS DURING THE COURSE OF SJÖGREN’S SYNDROME - A FIVE-YEAR FOLLOW UP / B. Hofauer* - M. Bas - N. Mansour - D. Loeffelbein - A. Knopf


SAT0296 IS HYPERURICEMIA AN INDEPENDENT RISK FACTOR FOR ARTERIAL THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS? / C. Mok* - K. L. Chan - L. Y. Ho - C. H. To

SAT0297 PRIMARY SJÖGREN’S SYNDROME: CLINICAL AND BIOLOGICAL FEATURES ACCORDING TO THE PRESENCE OF ANTI-SSA ANTIBODIES FROM A COHORT OF 176 PATIENTS / S. Ismael - S. Lechtman - K. Champion - P. Cacoub - P. Cacoub - D. Sene*

SAT0298 RETROSPECTIVE EVALUATION OF BASEAL LEPTIN LEVELS IN SLE PATIENTS WHO DEVELOPED DISEASE FLARES AND DAMAGE ACCRUAL / D. P. E. Margiotta* - M. Vadacca - L. Navarini - F. Basta - M. Lo Vullo - A. A. Filletti


SAT0303 EFFECT OF HMG-COA REDUCTASE INHIBITOR DRUGS (STATINS) ON SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY: A SYSTEMATIC REVIEW AND META-ANALYSIS / G. M. Garcia* - A. Urbano - E. Salido

SAT0304 COAGULATION FACTOR XIII MIGHT BE A PROMISING MARKER FOR PREDICTING ATHEROSCLEROSIS IN SLE I. Matsuura* - E. Lourenco - J. Grossman - B. Skaggs - M. McMahon

SAT0305 NEUTROPHIL EXTRACELLULAR TRAPS MARKERS ARE ELEVATED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / L. Jeremic* - B. Bonaci Nikolic


* Presenting author


SAT0310  THE RELATIONSHIPS BETWEEN THE OCCURRENCE OF ANTIBODIES USED IN CLINICAL PRACTICE FOR DIAGNOSIS OF LUPUS AND CLINICAL CRITERIA USED IN THE SLICC CLASSIFICATION SYSTEM / M. Dryglew ska* - M. Majdan - D. Suszek - A. Majdan - Z. Kiebik - M. Grzywnowicz

SAT0311  THE COMPARABILITY OF PATIENT AND PHYSICIAN GLOBAL ASSESSMENT IN EARLY AND NON-EARLY SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / M. Pasali* - V. Sadovici-Bobeca - M. Cebanu - V. Salaru - L. Mazur-Nicorici - M. Mazur

SAT0312  WORK DISABILITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN MOLDAVIAN LUPUS STUDY GROUP / M. Cebanu* - V. Salaru - V. Sadovici - L. Mazur-Nicorici - M. Pasali - N. Loghin-Oprea - M. Mazur


SAT0314  CLINICAL AND IMMUNOLOGICAL FEATURES OF ANTI-CENTROMERE ANTIBODY POSITIVE SJÖGREN’S SYNDROME / M. Tsukamoto* - K. Suzuki - T. Takeuchi


SAT0317  THE ASSOCIATION BETWEEN ABO BLOOD TYPES AND VENOUS THROMBOEMBOLISM IN INDIVIDUALS WITH A POSITIVE ANTIPHOSPHOLIPID PROFILE IS VARIED BY SEX / M. Shusterman* - E. Golub - W. B. Mowrey - A. Broder

SAT0318  THE SIGNIFICANCE OF ANTI-PHOSPHOLIPID TESTING IN MULTIPLE SCLEROSIS: SYSTEMATIC REVIEW AND META ANALYSIS / M. Merashli* - P. Ames


SAT0320  JG3 AUTOANTIBODIES BINDING TO STATHMIN AS MARKER OF POLYNEUROPATHY IN PRIMARY SJÖGREN’S SYNDROME / S. Ross - T. Witte - M. Stangel - R. E. Schmidt - N. T. Baerlecken*

SAT0321  PREVALENCE AND MORTALITY FROM INFECTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN A TERTIARY LEVEL HOSPITAL / O. Vera Lastra - C. Camacho Guerra - M. A. Saavedra - M. D. P. Cruz Domínguez - G. Medina

SAT0322  PREVALENCE AND RISK FACTORS FOR COGNITIVE IMPAIRMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS / O. Vera-Lastra* - M. Castejon - J. Sepulveda-Delgado - M. D. P. Cuz-Domínguez - G. Medina - L. J. Jara

SAT0323  CLINICAL VARIANTS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDREN / P. K. Ishuova*

SAT0324  HEADACHES IN PATIENTS WITH SLE: CLINICAL CHARACTERISTICS / S. Monov - R. Shumnaliev* - D. Monova - E. Chamuriliiska - R. Rashkov

SAT0325  SMOKING IS ASSOCIATED WITH FUTURE LUPUS CUTANEOUS ACTIVITY IN PROSPECTIVE ANALYSES / S. G. Kvatra* - W. Fu - M. Petri


SAT0327  B CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS IN THE DIAGNOSIS AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS / J. Beckmann - N. Bartholomä - N. Venhoff - P. Henneke - A. Janda - U. Salzer*

SAT0328  THE COMPARABILITY OF PATIENT AND PHYSICIAN GLOBAL ASSESSMENT IN EARLY AND NON-EARLY SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / M. Pasali* - V. Sadovici - L. Mazur-Nicorici - M. Pasali - N. Loghin-Oprea - M. Mazur


SAT0330  EFFECTIVE AND RAPID TREATMENT FOR FLARES IN PATIENTS WITH BEHÇET’S DISEASE BY THE SINGLE CHAIN ANTI-TNF ANTIBODY DLX105 / T. Xentidis* - C. Berger - T. Jung - J. Henes - I. Koetter


SAT0332  TAKAYASU ARTERITIS (TA): THE PATHOLOGICAL CHANGES IN THE CORONARY ARTERIES / O. Zimba*

SAT0333  HEMOSTATIC MECHANISMS MAY PLAY A ROLE IN THE DEVELOPMENT OF THROMBOSIS IN MALE PATIENTS WITH BEHÇET’S DISEASE: A THROMBOELASTOGRAPHIC ANALYSIS / B. Kara Kivanc - E. Gomullu - C. Bal - M. O. Akay - A. Erturk - D. Uskudar Cansu - T. Kasifoglu - C. Korkmaz*

SAT0334  NATIONALWIDE TRENDS IN HOSPITALIZATION AND IN-HOSPITAL MORTALITY ASSOCIATED WITH ANCA-ASSOCIATED VASCLITIS (AAV) / Z. Wallace* - L. Lu - E. Miloslavsky - S. Unizony - J. Stone - H. Choi

* Presenting author
EVALUATION OF MEDICATION COMPLIANCE IN BEHÇET’S DISEASE / M. Cinar* - F. I. Cinar - S. Yilmaz - C. Acikel - M. Cakar - I. Simsek

HENOCH - SCHÖNLEIN PURPURA IN ADULTS: DATA FROM A REFERRAL CENTER IN SWEDEN / N. Marketos* - M. Segelmark

KIDNEY INVOLVEMENT IN MICROSCOPIC POLYANGITIS - RUSSIAN EXPERIENCE / N. Bulanov* - E. Shchegoleva - E. Kuznetsova - P. Novikov - S. Moiseev


PENTRAKIN 3 AS BIOMARKER IN ASSESSMENT OF DISEASE ACTIVITY IN TAKAYASU ARTERITIS P. K. Devarasetti - S. K. Appani - R. V. P. Irlapati* - L. Rajasekhar


IMPACT OF DOSE TAPERING OF TUMOUR NECROSIS FACTOR-BLOCKERS ON RADIOGRAPHIC PROGRESSION IN THE ANKYLosing Spondylitis - A 4- YEAR PROSPECTIVE FOLLOW UP FROM SINGLE-CENTRE COHORT J. W. Park* - H. M. Kwon - J. K. Park - E. B. Lee - Y. W. Song - E. Y. Lee

EFFECTICITY AND SAFETY OF GOLIMUBA IN PATIENTS WITH ACTIVE, VERY EARLY PERIPHERAL SPOndylitis: FIRST RESULTS FROM THE CRESA STUDY, A MONOCENTRIC, PLACEBO-CONTROLLED RANDOMIZED TRIAL / P. Carron* - G. Varkas - H. Cypers - L. van Praet - D. Elewaut - F. van den Bosch

PREGNANCY OUTCOME IN COUPLES WITH MALES EXPOSED TO LONG-TERM ANTI-TNF ALPHA BLOCKER THERAPIES / M. C. Micu* - V. Bojinca - M. Mihai - C. Suta - A. Ramazan - R. Micu


NSAIDS MODIFY THE EFFECT OF TUMOR NECROSIS FACTOR INHIBITORS ON NEW BONE FORMATION IN ANKYLosing Spondylitis / L. Gensler* - J. D. Reveille - M. W. Ward - M. A. Brown - M. Rahbar - M. Lee - M. H. Weissman

SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR TO BIOSIMILAR INFILXIMAB IN PATIENTS AFFECTED BY SPOndylarthritis. A 6-MONTH OBSERVATIONAL STUDY / A. Batticciotto* - S. Parisi - F. Li Gobbi - M. Antivelle - M. Benucci - E. Fusaro - P. Sarzi-Puttini

* Presenting author
SAT0382

SAT0383
EFFECTIVENESS OF TNF INHIBITORS IN AXIAL SPONDYLARTHROPATHIES ACCORDING TO THE PRESENCE OF OBJECTIVE SIGNS OF INFLAMMATION: A MULTICENTRIC RETROSPECTIVE STUDY / C. Vidal* - C. Lukas - B. Combe - F. Berenbaum - C. Jorgensen - J. Sellam - J. Morel

SAT0384

SAT0385

SAT0386

SAT0387
ANTI-TNF TREATMENT OF REACTIVE ARTHRITIS: A MONOCENTRIC EXPERIENCE / A. Brinster - X. Guillot - C. Prati - D. Wendling

SAT0388

SAT0389
LONG-TERM IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION OVER 4 YEARS OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH AXIAL SPONDYLARTHROPATHIES, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLARTHROPATHIES / D. van der Heijde* - J. Braun - M. Rudwaleit - R. Landewé - O. Purcaru - A. Kavanagh

SAT0390

SAT0391

SAT0392
THE DRUG SURVIVAL OF ANTI-TUMOUR NECROSIS FACTOR (TNF) TREATMENT IN A UK COHORT OF AXIAL SPONDYLARTHROPATHIES PATIENTS / E. Yahya* - C. Cavill - J. Berry-Jenkins - D. Bond - C. Boyle - R. Sengupta

SAT0393

SAT0394

SAT0395

SAT0396

SAT0397

SAT0398
APPLICATION OF DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS (DAPSA) IN A COHORT OF PATIENTS FOLLOWED IN THE INSTITUTE OF RHEUMATOLOGY PRAGUE / J. Stolfa* - L. Sedova

SAT0399

SAT0400

SAT0401

SAT0402
SAFETY OF ETANERCEPT THERAPY IN HBSAG CARRIERS WITH ANKYLOSING SPONDYLITIS: A PROSPECTIVE STUDY / L. Fang* - Z. Hu - Y. Pan - Z. Lin - Z. Liao - J. Gu

SAT0403

* Presenting author


SAT0406 EFFICACY AND SAFETY OF LOXOPROFEN HYDROGEL PATCH VERSUS LOXOPROFEN TABLET IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A RANDOMIZED CONTROLLED TRIAL / M. Fan* - S. Cao - L. Tu - Q. Wei - R. Yuan - J. Gu


SAT0409 IMPROVED CLINICAL OUTCOMES AND WORKABILITY IN SPONDYLOARTHRITIDES DURING REAL-LIFE ADMINISTRATION OF ADALIMUMAB IN CENTRAL AND EASTERN EUROPE / P. Géher* - S. Szántó - D. Öpriş - O. Iaremenko - O. Nagy - V. Chernyshov

SAT0410 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR DATA FROM MEASURE 1, A PHASE 3 RANDOMISED TRIAL / P. Emery* - D. Baeten - A. Deodhar - A. Wei - P. Geusens - Z. Tallozcy - Y. Gong - B. Porter


SAT0413 GENETIC ASPECT OF INTER-INDIVIDUAL VARIABILITY IN THE RESPONSE TO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN AXIAL SPONDYLOARTHRITIS / G. Kilic - C. Sakalar - B. Kurt - M. Cakir - E. Kilic - S. Ozgocmen*


SAT0417 EVOLUTION OF MRI INFLAMMATION AND STRUCTURAL LESIONS ON SERIAL SCANS OVER 5 YEARS IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TUMOR-NECROSIS-FACCTOR-ALPHA INHIBITORS / O. Iaremenko - O. Nagy - V. Chernyshov - O. R. Madsen - M. Østergaard


SAT0419 GENDER DIFFERENCES IN DISEASE ACTIVITY, PHYSICAL FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH TNF-A INHIBITORS / B. P. van der Sliek - S. Arends* - E. Brouwer - F. R. Wink - M. Elde - H. Bootsma - F. Maas - A. Spoorenberg

SAT0420 SMOKING RELATED WITH DISEASE RESPONSE AND AGE AT DIAGNOSIS IN ANKYLOSING SPONDYLITIS / T. Rusman* - M. Nurmmohamed - I. Visman - I. van der Horst-Bruinsma


**Osteoarthritis**


* Presenting author


SAT0430  NEITHER OBESITY, SMOKING AND ALCOHOL ARE ASSOCIATED WITH HAND OSTEOARTHRITIS (OA): LONGITUDINAL DATA FROM OSTEOARTHRITIS INITIATIVE (OAI) / I. K. Haugen - K. Magnusson* - A. Turkiewicz - M. Englund


SAT0432  BLENDED PHYSICAL ACTIVITY INTERVENTION WITH REDUCED FACE-TO-FACE CONTACT AND USUAL PHYSICAL THERAPY SHOW SIMILAR EFFECTIVENESS IN PATIENTS WITH KNEE AND HIP OSTEOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL / C. J. Kloeck* - D. Bossen - D. H. de Bakker - J. Dekker - C. Veenhof

SAT0433  ZOLEDRONIC ACID DOES NOT SLOW SPINAL RADIOGRAPHIC PROGRESSION IN THOSE WITH RADIOGRAPHIC OSTEOARTHRITIS / H. I. Keen - L. V. Host* - L. L. Laslett - D. M. Black - G. Jones

SAT0434  OSTEOARTHRITIS RELATED EFFUSION: FOLLOW UP OF PAIN AND FLUID THICKNESS AFTER TREATMENT WITH SPIRIONOLACTONE. A PROSPECTIVE STUDY / A. R. Radwan* - A. Elsamani - S. Ohrndorf


SAT0438  MAGNETIC RESONANCE IMAGING MARKERS AS PREDICTORS FOR TOTAL KNEE REPLACEMENT OVER 10.7 YEARS IN OLDER ADULTS / B. S. Eathakkatu Antony* - X. Jin - F. Cicuttini - J. Martel-Pelletier - J.-P. Pelletier - A. Pelletier - C. Ding - G. Jones


SAT0440  RADIOLOGIC PROGRESSION OF DISTAL INTERPHALANGEAL JOINT OSTEOARTHRITIS IN RHEUMATOID ARTHRITIS / C. Lechtenboehmer* - V. K. Jaeger - D. Kyburz - U. A. Walker - T. Hülge


SAT0442  WAIST CIRCUMFERENCE IS THE ANTHROPOMETRIC VARIABLE MORE RELATED TO CLINICAL SEVERITY OF RESULTS FROM A 24 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY OF OSTEOARTHRITIS OF THE KNEE: EXPLORATORY ANALYSIS / C. Dietrich - G. Jones

SAT0443  COMPARISON OF THERAPEUTIC RESPONSE RATES, USING VARIOUS RESPONSE DEFINITIONS IN A PROSPECTIVE RANDOMIZED NON-INFERIORITY TRIAL COMPARING TWO INTRA-ARTICULAR HYALURONIC ACID PREPARATIONS (1-IHA) IN SYMPTOMATIC KNEE OSTEOARTHRITIS (OA), AND PREDICTIVE FACTORS OF A BETTER RESPONSE / E. Maheu* - L. R. Dreiser - B. Avouac - T. Bardin

SAT0444  COMPARISON OF EFFICACY OF INTRAARTICULER STERIOD INJECTIONS IN THE PATIENTS WITH KNEE OSTEOARTHRITIS WITH OR WITHOUT SYNOVITIS / E. Capkin* - O. Yerligök - M. Karkucak

SAT0445  RACE AND SEX DIFFERENCES IN RADIOGRAPHIC PROGRESSION OF KNEE OSTEOARTHRITIS / E. R. Vina* - D. Ran - E. Ashbeck - C. K. Kwon

SAT0446  REFERENCE CURVES FOR THE AUSTRALIAN/CANADIAN HAND OSTEOARTHRITIS INDEX (AUSCAN) IN THE GENERAL POPULATION / F. Kroon* - S. Ramiro - P. Rosyn - S. Le Cessie - F. R. Rosendaal - M. Kloppenburg


SAT0448  A COMPARISON OF THE DIFFERENT QUANTITATIVE SENSORY TESTING MEASUREMENTS ADDRESSING PAIN MECHANISMS IN PEOPLE WITH OSTEOARTHRITIS / H. Hassan* - D. F. McWilliams - D. Wilson - N. Frowd - A. Raga - M. Acasuso

SAT0449  THE RELATIONSHIP BETWEEN THE ARTICULAR SURFACE PROJECTION AND RADIOLOGIC LAXITY OF THE TIBIALSPINEARCAPITAL JOINT - H. S. Gong*


SAT0451  THE ASSOCIATION OF PATELLA ALTA WITH THE SEVERITY OF RADIOLOGICAL TIBIOFEMORAL KNEE OSTEOARTHRITIS / L. Coskun Benilaydi* - N. Cuzdan Coskun - T. Sarpel

* Presenting author
SAT0452 DO TRADITIONAL RISK FACTORS FOR KNEE OSTEOARTHRITIS PREDICT PAIN FLARES IN KNEE OSTEOARTHRITIS? / I. Atukorala* - A. Pathmeswaran - T. Chang - Y. Zhang - D. J. Hunter

SAT0453 DOES RENIN-ANGIOTENSIN-AldOSTERONE SYSTEM BlockADE INFLUENCE PAIN, FUNCTION AND RADIOGRAPHIC PROGRESSION IN KNEE OSTEOARTHRITIS? AN ANALYSIS OF OSTEOARTHRITIS INITIATIVE DATA / L. Shirinsky* - V. Shirinsky


SAT0458 RISK FACTORS FOR LENGTH OF HOSPITAL STAY AFTER TOTAL KNEE ARTHROPLASTY: A FIVE-YEAR CONSECUTIVE CASE SERIES / K. Kawakami*


SAT0460 THE EFFECT OF THERAPEUTIC ULTRASOUND ON PAIN AND PHYSICAL FUNCTION IN THE PATIENTS WITH KNEE OSTEOARTHRITIS / T. Yégin - L. Altan* - M. Kasapoğlu Aksoy


SAT0462 AUTOLOGOUS PLATELET-RICH PLASMA (PRP) IN OSTEOARTHRITIS TREATMENT / L. Smolina - L. Khimion*

SAT0463 THE PREVALENCE OF KNEE OSTEOARTHRITIS ESTIMATED BY VALIDATED SCREENING QUESTIONNAIRE IN THE GENERAL POPULATION OF SINGAPORE / M. Noviani* - J. Thumboo - C. M. Lee - I. Soh - S. Ma - Y. Y. Leung


SAT0465 SENSORIMOTOR PERFORMANCE AND FUNCTION IN PEOPLE WITH OSTEOARTHRITIS OF THE HAND: A CASE-CONTROL COMPARISON / N. Magni* - P. McNair - D. Rice

SAT0466 PROGRESSION OF PAIN AND ULTRASOUND DETECTED SYNOVITIS IN PATIENTS WITH EROSIVE HAND OSTEOARTHRITIS OVER ONE YEAR / O. Sleglova* - O. Ruzickova - K. Pavelka - L. Senolt

SAT0467 NEUROPATHIC PAIN IN KNEE OSTEOARTHRITIS: IS ITS PREVALENCE RELATED TO A GREATER IMPACT? O. Akkar* - L. Lehlohu - L. Ichchou


SAT0470 VALIDITY AND RELIABILITY OF THE CHINESE VERSION OF THE PAINDETECT QUESTIONNAIRE IN SUBJECTS WITH KNEE OSTEOARTHRITIS / R. F. Zhang* - Y. Y. Leung


SAT0473 POOR DIETARY CARBOHYDRATE QUALITY IS ASSOCIATED WITH SYMPTOMATIC KNEE OSTEOARTHRITIS IN WOMEN: A CROSS-SECTIONAL STUDY / S. Lee* - M. W. So - J. S. Oh

SAT0474 A PROTEOMIC PANEL PREDICTS DRUG RESPONSE TO THE COMBINATION OF GLUCOSAMINE AND CHONDROITIN SULFATE / V. Kraus* - H. Martinez - M. Herrero - J. Verges

SAT0475 HEALTH SYSTEM FRUSTRATION EXPRESSED BY PATIENTS WITH KNEE OSTEOARTHRITIS / V. Salaru* - V. Sadovici-Bobeica - L. Mazur-Nicorici - A. Stirbul - T. Rotaru - M. Mazur


* Presenting author
**Infection-related rheumatic diseases**

**SAT0481** CLINICAL FEATURES ASSOCIATED WITH HIGHER MORTALITY IN ADULTS WITH SEPTIC ARTHRITIS - A 10-YEAR RETROSPECTIVE STUDY / A. Premkumar* - C. Pawa - M. Lahiri - A. Santosab

**SAT0482** RISK FACTORS FOR SEVERE INFECTION AND OUTCOME OF SECONDARY HYPOGAMMAGLOBULINAEMIA IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES TREATED WITH RITUXIMAB: PRELIMINARY RESULTS FROM 400 PATIENTS AT A SINGLE CENTRE / M. Y. Md Yusof* - E. M. Hensor - S. Das - E. M. Vital - P. Emery - S. Savic

**SAT0483** ULTRASONOGRAPHY CHANGES DURING THE COURSE OF SEPTIC ARTHRITIS ARE ASSOCIATED WITH FUNCTIONAL OUTCOME / E. Gaugnecux - G. Cormier - O. Merot - Y. Maugars - B. Le Goff

**SAT0484** LONG-TERM SAFETY OF NON-TNF INHIBITOR BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS WITH CHRONIC OR PAST HEPATITIS B VIRUS INFECTION / C. Koutsiansas - K. Thomas - E. Hadziyannis - A. Makris - A. Lazzarini - D. Vassilopoulos


**SAT0487** SCREENING FOR PAST INFECTION WITH HEPATITIS B IN PATIENTS RECEIVING RITUXIMAB: AN AUDIT / M. Cates - C. Gut


**SAT0490** POOR LONG-TERM ADHERENCE TO SECONDARY PENICILLIN PROPHYLAXIS AMONG PAEDIATRIC PATIENTS WITH RHEUMATIC FEVER / G. Amarilys - G. Chodick - I. Someh - J. Zalcman - L. Harel


**SAT0497** EPIDEMIOLOGY OF INFECTION OF SPONDYLOYSIS IN A TUNISIAN CENTER: ABOUT 118 CASES / K. Baccouche - N. Elamri - S. Belghali - L. Ouaoula - E. Baccouche

**SAT0498** IMPORTANCE OF ANTI-BORRELIA IGG AS A MARKER DIFFERENTIATING HEPATITIS WITH RHEUMATIC FEVER / G. Amarilyo - G. Chodick - I. Somekh - J. Zalcman - L. Harel


**SAT0500** A COMPARATIVE ANALYSIS OF RADIOLOGICAL FINDINGS BETWEEN TUBERCULOUS AND BRUCELLAR SPONDYLODISCITIS / S. Bouden - O. Saidane - I. Mahmoud - M. Sahli - R. Tekaya - L. Abdelmoula

**SAT0501** HLA SYSTEM IN CHLAMYDIA TRACHOMATIS-INDUCED REACTIVE ARTHRITIS / V. Dostanko - N. Dostanko - V. Yagur - K. Chizh

**Back pain, mechanical musculoskeletal problems, local soft tissue disorders**


* Presenting author
SAT054 PREVALENCE AND CORRELATES OF HOUSEHOLD WORK RELATED MUSCULOSKELETAL DISORDERS IN LOW BACK REGION AMONG SRI LANKAN HOUSEWIVES / P. D. Ranasinghe* - I. Atukorala - A. Samaranayake - N. S. Gunawardana


SAT056 TELEVISION VIEWING TIME, PHYSICAL ACTIVITY AND LOW BACK PAIN IN COMMUNITY-BASED ADULTS: RESULTS FROM A PROSPECTIVE COHORT STUDY / S. M. Hussain* - D. M. Urquhart - Y. Wang - D. Dunstan - J. E. Shaw - D. J. Maglione - A. E. Wuika - F. M. Cicuttini

SAT057 COMPARISON OF ORAL SPLENDING AND KINESIOTAPING IN TEMPOROMANDIBULAR JOINT PAIN / K. Baldaci*


SAT059 FEASIBILITY OF ULTRASOUND-GUIDED FACET JOINT INJECTIONS THROUGH A LONGITUDINAL APPROACH C. Darrieutort-Laffite* - A. Colomby - J. Glemarec - Y. Maugars - B. Le Goff

SAT060 PAINFUL SHOULDER: RELEVANCE OF CLINICAL AND SONOGRAPHIC DATA ON CORTICOSTEROID INJECTION OUTCOME / M. Cerqueira* - J. Sousa Neves - D. Santos Faria - F. Teixeira - M. C. Afonso - J. A. Costa

SAT061 MANAGEMENT OF ADHESIVE CAPSULITIS WITH LANDMARK GUIDED HIGH VOLUME STEROID INJECTIONS IN THE COMMUNITY BASED MUSCULOSKELETAL CLINIC / S. Ballserak*

SAT062 DOES SWITCHING FROM ONE NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO ANOTHER IMPROVE PAIN CONTROL? / A. Karateev* - N. Gontarenko - A. Tsurgan


SAT064 EFFECTIVENESS OF ABDOMINAL CORE STABILIZATION EXERCISES IN PATIENTS WITH LOW BACK PAIN. OVERVIEW OF SYSTEMATIC REVIEWS (PRELIMINARY RESULTS) / M. B. Nishishinya - C. A. Pereda* - A. C. Cis - M. Guerra Balic - G. Urrutia - M. Solana-Tramunt


SAT068 LOW BACK PAIN PREVALENCE IN ITALIAN ADOLESCENTS AND ITS ASSOCIATION WITH QUALITY OF LIFE / A. C. Serce


SAT072 EFFICACY AND SAFETY OF ULTRASONOGRAPHIC GUIDED PERCUTANEOUS NEEDLE PLANTER FASCITIS AS A TREATMENT FOR CHRONIC PLANTER FASCITIS / M. Mortada* - D. M. Sharaf - M. A. H. Hammad - N. Ezzeldin

SAT073 EFFICACY OF LOCAL CORTICOSTEROID IN TREATMENT OF PLANTAR FASCIITIS; AN ULTRASONOGRAPHIC EVALUATION / M. Mortada* - D. M. Sharaf - M. A. H. Hammad - N. Ezzeldin

SAT074 COMPARISON OF ULTRASONOGRAPHY-GUIDED INJECTION WITH BLIND INJECTION IN FACET SYNDROME; A 6-WEEK RANDOMIZED CONTROLLED TRIAL / M. Karkucak* - I. Batmaz - S. Kerimoglu - A. Ayar


SAT076 IMPROVE PAIN CONTROL? / A. Karateev* - N. Gontarenko - A. Tsurgan


** Presenting author

Diagnostics and imaging procedures


SAT0530  DEEP CLINICAL REMISSION - AN OPTIMIZED TARGET IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS? EXPERIENCE FROM AN ULTRASONOGRAPHY STUDY / Y. Geng* - Z. Zhang

SAT0531  CAN HISTOLOGICALLY DEFINED PERIARTICULAR VASCULAR CHANNELS BE IDENTIFIED ON HIGH-RESOLUTION ULTRASONOGRAPHY (PUS) IN PATEINTS WITH BASAL NEGATIVE ACUTE PHASE REACTANTS? A STUDY AS PART OF A LONG-TERM STUDY ON THE PREDICTION OF RHEUMATOID ARTHRITIS IN AT RISK POPULATIONS / A. Scharmaga* - K. K. Keller - M. Peters - A. van Tubergen - J. van den Bergh - B. van Rietbergen - R. Weijers - D. Loeffen - E. M. Hauge - P. Geusens

SAT0532  TIBIAL CORTICAL THICKNESS MEASURED BY HIGH-RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY DISCRIMINATES VERTEBRAL FRACTURES IN PATIENTS ON LONG-TERM GLUCOCORTICOIDS INDEPENDENT OF AARE BONE MINERAL DENSITY / J. Shen* - L.-S. Tam on behalf of Hong Kong GIOP study group

SAT0533  KNEE SYNOVITIS: ULTRASONOGRAPHIC FINDINGS STRONGLY CORRELATE WITH SYNOVIAL MEMBRANE HISTOLOGY / A. Najm* - C. Orr - U. Fearon - D. Veale

SAT0534  HOW TO DEFINE SONOGRAPHIC SIGNS OF AXILLARY VASCULITIS IN GIANT CELL ARTERITIS? / M. Milchert* - M. Brzosko


SAT0536  UTILITY OF 18F-FLOROB-DIDEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR THE DIAGNOSIS OF POLYMYALGIA RHUMATIZICA: A CONTROLLED STUDY / M. Marenco* - X. Guillot - F. Herhoeven - O. Blagosklonov - C. Prati - H. Boualahdour - D. Wendlung*

SAT0537  SENSITIVITY AND SPECIFICITY OF ULTRASOUND SCORE FOR THE DIAGNOSIS OF GOUT / M. M. Basaric* - G. Rudunovic - N. Damjanov - M. Perovic-Radak


SAT0549  VALIDATION OF 3 NOVEL AUTOANTIGENS FOR SYSTEMIC SCLEROSIS / J. Schulte-Pelkum - C. Orr - U. Fearon - D. Veale

SAT0550  PREDICTIVE VALUE OF POWER DOPPLER ULTRASONOGRAPHY (PUS) FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS IN PATIENTS WITH BASAL NEGATIVE ACUTE PHASE REACTANTS / L. Mayordomo* - M. L. Velloso - C. Almeida - A. Gutiérrez-Leonard - P. González-Moreno - J. L. Marenco

SAT0551  PREDICTIVE VALUE OF ULTRASOUND FOR RADIOGRAPHIC PROGRESSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / L. Mayordomo* - C. Curado - C. Almeida - M. L. Velloso - M. L. Jimenez-Lifian - J. L. Marenco


SAT0553  DIAGNOSTIC VALUE OF QUANTITATIVE SIALOSCLINTGRAPHY COMPARED TO LABIAL SALIVARY GLAND BIOPSY IN PATIENTS WITH SUSPECTED SJÖGREEN'S SYNDROME / M. Garcia Gonzalez* - H. Sanchez Perez - I. Ferraz Amaro - V. Hernandez Hernandez - B. Rodriguez Lozano - S. Bustabad Reyes


* Presenting author
Epidemiology, health services and outcome research


SAT0570 LIVER FAT INDICES RELATE WITH INFLAMMATORY PROFILE IN INFLAMMATORY ARTHRITIS PATIENTS / A. Salumé - E. Deschepper - V. Smith

SAT0571 CONTRAST ANALYSIS IN A SYSTEMIC SCLEROSIS COHORT / V. Lambrecht* - M. Cutolo - F. De Keyser - S. Decuman - A. Dara


**SAT0604** DUTCH QUALITY REGISTRY RHEUMATOID ARTHRITIS: DEVELOPMENT OF QUALITY INDICATORS
S. Mahmood* - L. van Tuyl - J. Braspenning - P. van Riel - R. Landewé

**SAT0605** TOWARDS A TAXONOMY THAT IS SCIENCE-BASED AND CLINICALLY USEFUL: THE NEW WHO - ICD11 CLASSIFICATION OF MUSCULOSKELETAL PAIN DISORDERS / S. Perrot* - M. Cohen


**SAT0607** PATTERNS OF ADOPTION OF TREAT-TO-TARGET APPROACHES IN RHEUMATOID ARTHRITIS AND THEIR IMPACT ON PATIENT BURDEN IN EUROPE / S. Narayanan* - Y. Lu - R. Hutchings - S. Mentzer

**SAT0608** PERCEPTION OF ANTI-TNF BIOSIMILARS AMONG PAYERS IN EUROPE / S. Narayanan* - Y. Lu - R. Hutchings - S. Mentzer


**SAT0611** THE IMPACT OF ADHERENCE TO BIOLOGIC AGENTS ON HEALTH CARE RESOURCE UTILIZATION FOR PATIENTS WITH RHEUMATOID ARTHRITIS / U. Lathia* - F. Nantel - E. Ewara

**SAT0612** PREVALENCE OF COMORBIDITIES IN CARERA PATIENTS WITH EARLY RHEUMATOID ARTHRITIS AT DISEASE ONSET / V. Stouten* - D. De Cock - R. Westhovens - J. Joly - K. van der Elst - P. Verschueren

**SAT0613** DEPRESSION AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) USING A TREAT-TO-TARGET (T2T) APPROACH TO THERAPY VERSUS USUAL CARE / N. Princic - D. Fugh - B. C. Chu - V. Garg*


**Rehabilitation**

**SAT0615** INFLUENCE OF FUNCTIONAL CAPACITY ON SELF-REPORTED PHYSICAL FUNCTION, AND ASSOCIATIONS WITH MECHANICAL MUSCLE FUNCTION IN SPORADIC INCLUSION BODY MYOSITIS PATIENTS / A. N. Jørgensen* - P. Aagaard - J. L. Nielsen - M. Christiansen - L. G. Hvid - U. Frandsen - L. P. Diederichsen


**SAT0617** 12-MONTH COMPLEX REHABILITATION PROGRAM FOR RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGIC DMARDS / E. Orlova* - D. Karateev - L. Denisov - A. Kochetkov - E. Nasonov

**SAT0618** EFFICACY OF TWO LONG-TERM EXERCISE PROGRAMS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RESULTS OF 12-MONTH RANDOMIZED CONTROLLED TRIAL / E. Orlova* - D. Karateev - L. Denisov - A. Kochetkov - E. Nasonov

**SAT0619** RELATIONSHIP BETWEEN HAQ DISABILITY SCORES AND MEASURES OF OBSERVED FUNCTIONAL ABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS, OSTEOARTHRITIS AND FIBROMYALGIA AND THE ASSOCIATION TO PAIN AND FATIGUE / K. Amris* - L. E. Kristensen - E. E. Wahrens


**SAT0622** CO-CREATING AN ONLINE REHABILITATION PROGRAMME FOR PEOPLE WITH CHRONIC KNEE/HIP PAIN / M. Hurley* - J. Pearson - N. Walsh - D. Carter

**SAT0623** THE ROLE OF REHABILITATION IN AVASCULAR NECROSIS OF THE HUMERAL HEAD - RANDOMIZED STUDY / R. Traistaru* - A. M. Bumbea - D. Kamal - C. Kamal - O. Rogoveanu

**SAT0624** EFFICACY OF A 4-WEEK TEAM-REHABILITATION PROGRAM IN WARM CLIMATE ON DISABILITY, HEALTH AND BODY FUNCTION FOR UP TO ONE YEAR: A PROSPECTIVE STUDY IN SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES / S. Ajeganova* - M. Wörnert - I. Hafström


**SAT0626** LOCAL CRYOTHERAPY (PULSED CO2 OR ICE) DECREASES IL-6, IL-1B AND VEGF SYNOVIAL LEVELS IN KNEE ARTHRITIS / X. Guillot* - N. Tordi - C. Laheurte - L. Pazart - C. Prati - P. Saas - D. Wendling

* Presenting author
HPR Programme
Health Professionals in Rheumatology

WEDNESDAY, 8 JUNE 2016

13:30 - 14:30  Capital Suite 07
Health Professionals session
Health Professionals Welcome session

Learning objectives:
• To learn about EULAR Health Professionals activities
• To learn about planned mentoring and networking activities for EULAR Health Professionals

Chairperson(s):
Michael Backhouse (United Kingdom)
Patricia Cornell (United Kingdom)
Christina H. Opava (Sweden)

13:35
Update on HPR scientific and educational subcommittees work
Anthony Redmond (United Kingdom)

13:45
Update on HPR standing committee
Jo Adams (United Kingdom)

13:55
HPR mentoring and networking activities
Faculty

14:05
Interaction with the faculty

14:30 - 15:00 Exhibition (S5-S9)
Break

15:00 - 16:30  Capital Suite 07
Health Professionals session
Different perspectives on pain in osteoarthritis

Learning objectives:
• Understanding peripheral and central mechanisms of pain in patients with arthritis
• Influence of exercise and pain medication in patients with osteoarthritis
• Cognitive behavioural influences on pain in patients with arthritis

Chairperson(s):
Martin van der Esch (Netherlands)
Ricardo Ferreira (Portugal)

15:05
Lars Arendt-Nielsen (Denmark)
Abstract N° SP0014
Peripheral and central pain sensitivity in osteoarthritis

15:23
George M. Peat (United Kingdom)
Abstract N° SP0015
Pain trajectory groups in persons with osteoarthritis

15:41
Marike van der Leeden (Netherlands)
Abstract N° SP0016
Pain and inflammation in osteoarthritis: pharmacological and physical management

15:59
Jari P. Arokoski (Finland)
Abstract N° SP0017
The effect of non-pharmacological interventions for hand OA

16:17
T. Bieler (Denmark)
Abstract N° OP0006-HPR
Even in the long run Nordic Walking is superior to strength training and home based exercise for improving physical function in older people with hip osteoarthritis - a RCT

16:30 - 17:00 Exhibition (S5-S9)
Coffee break

17:00 - 18:30  Capital Suite 07
Health Professionals session
Hand osteoarthritis: State of the art and future perspectives

Learning objectives:
• Increase knowledge about hand OA
• Update on treatment, research and outcome measures

Chairperson(s):
Rikke H. Moe (Norway)
Jo Adams (United Kingdom)
Francis Berenbaum (France)

17:05
How do we understand hand osteoarthritis?
Krysia Dziedzic (United Kingdom)

17:23
Functional consequences of hand osteoarthritis
Els van den Ende (Netherlands)

17:41
Assessing hand OA in clinical care and research
Ingvild Kjeken (Norway)

17:59
Effectiveness of a progressive resistance strength program on hand osteoarthritis: a randomised controlled trial

18:17
M. V. Nery (Brazil)
A. Jones, F. Jennings, M. C. Souza, J. Natour
Abstract N° OP0019-HPR
The effect of non-pharmacological interventions for hand OA
HPR Abstract session

Developing evidence-based non-pharmacological care

Chairperson(s):
Tanja Stamm (Austria)
Francoise Alliot (France)
M. Ndosi (United Kingdom)

Abstract N° OP0060-HPR
Cross-cultural validation of the systemic sclerosis quality of life questionnaire in six European countries: a tool validation study

C. Hendricks (South Africa)
R. Parker, J. Jelsma

Abstract N° OP0061-HPR
The effect of a contextually relevant non-pharmacological intervention on the functioning of South African women with osteoarthritis: a randomized controlled trial

M. De Rooij (Netherlands)

Abstract N° OP0062-HPR
Efficacy of tailored exercise therapy in patients with knee osteoarthritis and comorbidity: a randomized controlled trial

M. van der Esch (Netherlands)
P. Juch, M. van der Leeden, M. Jansen, W. Wirth, L. Roorda, W. F. Lems, J. Dekker

Abstract N° OP0063-HPR
High proportion of non-contractile tissue in the vastus medialis muscle is associated with muscle weakness in patients with knee osteoarthritis; results from the AMS-OA cohort

B. Alcacer-Pitarch (United Kingdom)
A. Redmond, F. Del Galdo, M. Buch, A.-M. Keenan

Abstract N° OP0064-HPR
A model including foot-related factors impacting on quality of life (QoL) in systemic sclerosis

F. Estévez-López (Netherlands)

Abstract N° OP0066-HPR
Axial spondyloarthritis know-how: what are the benefits of a brief exercise and self-management education group programme? A qualitative investigation

G. Gronhaug (Norway)

Abstract N° OP0067-HPR
Excercise as medicine? Description of OA treatment in discharge reports

Poster viewing & lunch

HPR/PARE joint session
"Fewer words - more action" - tailored care for men with rheumatic diseases?

Learning objectives:
- To highlight how men with a rheumatic disease experience life
- To discuss the use of different coping strategies and if they are different from women
- To learn and spark ideas, across different disciplines and countries on how we could look at gender differences to optimise the management for men with rheumatic diseases

Chairperson(s):
Milena Gobbo Montoya (Spain)
Dieter Wiek (Germany)
Mathilda Björk (Sweden)
Frank Demtröder (Germany)
Bente Appel Esbensen (Denmark)
Caroline Flurey (United Kingdom)
M. Martin (United Kingdom)
H. Fiddler

Abstract N° SP0082
Disability in men and women with RA. Does it differ and does it matter?

Abstract N° SP0083
Balancing work and life: ”When is a man a man?”

Abstract N° SP0084
”Being physically active is a salvation“ - men’s preferences for physical activity

Abstract N° SP0085
Design of a self-management intervention for men with RA

Abstract N° SP0088
Axial spondyloarthritis know-how: what are the benefits of a brief exercise and self-management education group programme? A qualitative investigation
Health Professionals session
Physical activity assessment - what do we know, what do we do, how does it work?

Learning objectives:
• To gain knowledge on awareness and use of physical activity assessment among health care professionals
• To gain knowledge on awareness and use of physical activity assessments among patients with RMDs
• To gain knowledge on measurement properties of some physical activity assessments available for use in RMDs

Chairperson(s):
Nina Brodin (Sweden)
Norelee Kennedy (Ireland)
Birgitta Nordgren (Sweden)

Birgitta Nordgren (Sweden) 15:35
Abstract N° SP0099
Awareness and use of objective and subjective assessments of physical activity among health professionals and barriers for implementation

Bente Appel Esbensen (Denmark) 15:53
Abstract N° SP0100
Awareness and use among patients with inflammatory rheumatic disease of objective and subjective assessments of physical activity

Thijs Swinnen (Belgium) 16:11
Abstract N° SP0101
When to use objective and subjective assessment of physical activity - issues of reliability, validity and usability

Claire Kinneavy (Ireland) 16:29
Abstract N° SP0102
Perspectives from patients with arthritis

K. Hörnberg (Sweden) 16:47
B. Sundström, S. Wällberg Jonsson
Abstract N° OP0147-HPR
Aerobic capacity over 16 years in patients with rheumatoid arthritis; relations to risk factors for cardiovascular disease

EULAR projects in Health Professionals
The Health Professionals’ approach to pain management in inflammatory arthritis and osteoarthritis

Learning objectives:
• To learn about changes in the physiotherapeutic approach to pain management
• To understand methods of systematic literature reviews and meta-analysis
• To learn about the work on EULAR recommendations on HPRs’ approach to pain management and the scientific evidence underpinning them

Chairperson(s):
Susan Oliver (United Kingdom)
Nola Kamala (United States)
Pernilla Asenlöf (Sweden) 15:35

Pernilla Asenlöf (Sweden) 15:35
Abstract N° SP0118
The ongoing shift of paradigms within physiotherapy and pain management

Robin Christensen (Denmark) 15:53
Abstract N° SP0119
Systematic reviews and meta-analyses for dummies: a tutorial on how, when, and why to get started

Rinie Geenen (Netherlands) 16:11
Abstract N° SP0120
Recommendations for prompt pain management in inflammatory arthritis and osteoarthritis

Cécile Overman (Netherlands) 16:29
Abstract N° SP0121
The benefits of prompt pain management in inflammatory arthritis and osteoarthritis. A systematic literature review and meta-analysis

C. Fongen (Norway) 16:47
Abstract N° OP0154-HPR
Spinal mobility is impaired in patients with chronic back pain of short duration, but does not discriminate between patients with axial spondyloarthritis and other forms of CBP
FRIDAY, 10 JUNE 2016

10:15 - 11:45  Capital Suite 07

HPR Abstract session
Shared decision-making

Chairperson(s):
Annette de Thurah (Denmark)
Bente Appel Ebensen (Denmark)

C. Hudry (France)  10:20
A. Lebrun, B. Moura, O. Backers, H. Herman-Demars
Abstract N° OP0191-HPR
Usability study of a new auto-injector in the management of rheumatoid arthritis

R. Rawat (India)  10:30
S. S. Baghel, R. Thakran, C. Messi, S. Kapoor, S. Garg, A. N. Malaviya
Abstract N° OP0192-HPR
Teaching methotrexate self-injection technique to the patients in a routine rheumatology out-patient clinic: factors favouring or countering acceptability

E. Moholt (Norway)  10:40
Abstract N° OP0193-HPR
Aiming for remission in early RA: impact on pain during the first 2 years of treatment

G. Piemonte (Italy)  10:50
K. El Aoufi, F. Braschi, M. Poli, S. Guiducci, S. Bellando Randone, L. Rasero, M. Matucci Cerinic
Abstract N° OP0194-HPR
Nursing triage in rheumatology: three months experience in an outpatient clinic of the University of Florence (Italy)

F. Fayet (France)  11:00
M. Rodere, C. Savel, B. Pereira, M. Soubrier, M. Couderc
Abstract N° OP0195-HPR
Comparison of educational models for maintaining optimal safety in the self-management of biotherapy amongst rheumatoid arthritis and spondyloarthritis patients

L. van Rossen (United Kingdom)  11:10
C. Harris, R. Withrington, A. Keat
Abstract N° OP0196-HPR
Dose reduction of biologic drugs in axial spondyloarthritis in clinical practice

J. M. Hazes (Netherlands)  11:20
Abstract N° OP0197-HPR
Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis

G. Daker-White, A. Barton, K. Payne
Abstract N° OP0198-HPR
Exploring factors which influence anti-TNF treatment decisions for rheumatoid arthritis in England - a qualitative analysis

11:45 - 13:30  Exhibition (S5-S9)

11:50 - 13:30  Poster area

Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area, on a “first-come-first-served” basis the day of the poster tour. For full details regarding the guided poster tours on Friday, please refer to pages 101 to 108.

HPR Poster tour
F14: Focus on rehabilitation

Chairperson(s): Anthony Redmond (United Kingdom)
Rikke H. Moe (Norway)
Abstract N° FRI0643-HPR - FRI0652-HPR

13:30 - 15:00  Capital Suite 07

Health Professionals session
Collaboration for success.
User-centred design for improvement of health services

Learning objectives:
• To understand the concept and characteristics of participatory design and, in particular, experience based co-design.
• To understand how user involvement can improve healthcare services
• To recognise different approaches for user involvement in the development of healthcare services

Chairperson(s):
Annette Sverker (Sweden)
Mwidimi Ndosi (United Kingdom)
Joanna Goodrich (United Kingdom)

S. Gavan (United Kingdom)  11:30
G. Daker-White, A. Barton, K. Payne
Abstract N° OP0198-HPR
Exploring factors which influence anti-TNF treatment decisions for rheumatoid arthritis in England - a qualitative analysis

13:35

Joanna Goodrich (United Kingdom)
Using experience-based co-design to improve the quality of healthcare services

Asa Revenäs (Sweden)  13:53
Abstract N° SP0135
Co-designing a mobile internet service for self-management of physical activity in RA

Abstract N° SP0135
Co-designing a mobile internet service for self-management of physical activity in RA
Sanne van der Weegen (Netherlands) 14:11
Abstract N° SP0136
User involvement in the development of e-health products

Karin Hakansson (Sweden) 14:29
Abstract N° SP0137
A user's experience of co-design

E. Kuijpers (Netherlands) 14:47
J. W. Luites, J. E. Vriezekolk
Abstract N° OP0269-HPR
Patient participation in multidisciplinary team care: views of patients and health care professionals

15:00 - 15:30  Exhibition (S5-S9)
Coffee break

15:30 - 17:00  Capital Suite 07
HPR/Primary Care joint session
Telemedicine and e-health in community care

Learning objectives:
- To explore the practical issues surrounding implementation of telehealth and the ethical implications

Chairperson(s):
- Thijs Swinnen (Belgium)
- Stefan Bergman (Sweden)
- Trevor Russell (Australia) 15:35
  Internet-based multidisciplinary assessment
- Ruth Chambers (United Kingdom) 15:53
  Abstract N° SP0157
  E-health in general practice
- Tom Dawson (United Kingdom) 16:11
  Abstract N° SP0158
  Technological challenges in implementing e-health
- Maartje Niezen (Netherlands) 16:29
  Abstract N° SP0159
  Ethical implications of employing e-health solutions to promote healthy lifestyles
- T. Thomsen (Denmark) 16:47
  Abstract N° OP0286-HPR
  The efficacy of motivational counselling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial

SATURDAY, 11 JUNE 2016

08:30 - 10:00  Capital Suite 07
Health Professionals session
Getting active against rheumatoid arthritis fatigue

Learning objectives:
- Develop an understanding of the relationship between physical activity and fatigue in rheumatoid arthritis
- Consider barriers to, and practical facilitators of, physical activity in the presence of fatigue
- Identify practical methods for monitoring physical activity

Chairperson(s):
- Yvonne van Eijk-Hustings (Netherlands)
- Yeliz Prior (United Kingdom)
- Fiona Cramp (United Kingdom) 08:35
  Abstract N° SP0174
  Development of a physical activity programme for people with rheumatoid arthritis fatigue
- Keegan Knittle (Finland) 08:55
  Abstract N° SP0175
  Health behaviour change techniques to effectively promote physical activity in people with rheumatoid arthritis
- Norelee Kennedy (Ireland) 09:15
  Abstract N° SP0176
  Activity monitoring to support patient goals and assess progress
- S. G. McKenna (Ireland) 09:35
  Abstract N° OP0294-HPR
  Sleep quality, sleep disturbances and physical activity: a national survey of Irish people who have inflammatory arthritis
- T. O'Dwyer (Ireland) 09:45
  Abstract N° OP0295-HPR
  Increasing physical activity in ankylosing spondylitis (INPACT-AS): a randomised controlled trial

10:00 - 12:00  Exhibition (S5-S9)
Poster viewing & coffee break
Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area, on a “first-come-first-served” basis the day of the poster tour.
For full details regarding the guided poster tours on Saturday, please refer to pages 176 to 183.

HPR Poster tour
S15: Getting around rheumatic disease
Chairperson(s): Anthony Redmond (United Kingdom)
Camilla Fongen (Norway)
Abstract N° SAT0637-HPR - SAT0644-HPR

12:00 - 13:30  Capital Suite 07
Health Professionals session
Intimate life and sexual relations in RA

Learning objectives:
To increase knowledge on experiences, assessment and clinical implications regarding intimate life and sexual relations in RA

Chairperson(s):
Andrea Domjan (Hungary)
Hana Smucrová (Czech Republic)

Annette Sverker (Sweden) 12:05
Abstract N° SP0190
Lived experiences of intimate life in men and women with early RA

Kristina Areskoug (Sweden) 12:23
Abstract N° SP0191
Sexual health in rheumatoid arthritis - the role of the physiotherapist

Sarah Ryan (United Kingdom) 12:41
Abstract N° SP0192
Disease impact on sexuality and its management in rheumatology care

Codruta Zabalan (Romania) 12:59
Abstract N° SP0193
Nine years of marriage and three in bed - myself, my husband and my RA

P. Santos-Moreno (Colombia) 13:17
L. Villarreal, J. Bello, N. Palacio, C. Castro, D. Buitrago-Garcia
Abstract N° OP0308-HPR
Precipitating, predisposing and maintenance factors associated with sexual disorders in patients with rheumatoid arthritis

PARE/HPR joint session
There is more than drugs

Learning objectives:
How to boost your vitality

Chairperson(s):
Jürgen Clausen (Germany)
Rikke H. Moe (Norway)

Klaus Pfeifer (Germany) 12:05
Abstract N° SP0201
Sports and exercise for arthritis patients

Christian Schubert (Austria) 12:25
Abstract N° SP0202
Psychoneuroimmunology: from psyche to immune activity and back

Diana J. Pedersen (Denmark) 12:45
Abstract N° SP0203
How the Danish Rheumatism Association works with alternative and complementary treatment

E. Löfberg (Sweden) 13:05
Abstract N° OP0313-PARE
The Swedish Rheumatism Association's blog about training - a new way of learning

F. van der Giesen (Netherlands) 13:15
F. van Gaalen, R. de Jong, M. van Goeverden, H. Sloatweg, T. Vliet Vlieland
Abstract N° OP0314-PARE
Group exercise therapy in ankylosing spondylitis (AS): the patients’ perspective

13:45 - 14:45  Capital Suite 07
Highlight session
HPR Highlight session

Chairperson(s):
Els van den Ende (Netherlands)
Pedro Munuera (Spain)

Daniel Aletaha (Austria) 13:50
Highlights from the Scientific programme

Yeliz Prior (United Kingdom) 14:08
Highlights from the Health Professionals’ programme

Joep Welling (Netherlands) 14:26
Highlights from the PARE programme
Friday, 10 June 2016

**Poster tour F14: Focus on rehabilitation**

Chairperson(s): Anthony Redmond (United Kingdom), Rikke H. Moe (Norway)

FRI0643-HPR
A MULTICENTRE FOCUS GROUP STUDY ON IMPORTANT OUTCOMES FOR PATIENTS WITH PSORIATIC ARTHRITIS / E. Dures* - W. Tillett - J. Lord - C. Bowen - N. McHugh - S. Hewlett

FRI0644-HPR
PERCEIVED PHYSICAL ACTIVITY BENEFITS AND BARRIERS IN RHEUMATOID ARTHRITIS PATIENTS / L. Sammut* - P. Clayton - J. Arnold - B. Davidson

FRI0645-HPR
FREQUENTLY ASKED QUESTIONS OF PATIENTS WITH OSTEOARTHRITIS: A CONSENSUS EXERCISE / A. Claassen* - S. Koëter - J. Botman - H. Schers - C. van den Ende on behalf of project group "Towards a regional approach of osteoarthritis"

FRI0646-HPR
DOES PAINFUL HAND ARTHRITIS INFLUENCE MOTOR CORTEX EXCITABILITY AND MOTOR SKILL LEARNING? / R. Parker* - G. Lewis - D. Rice - P. McNair

FRI0647-HPR
PHYSICAL ACTIVITY AND AEROBIC CAPACITY ASSESSMENT - A SURVEY AMONG PATIENTS WITH RHEUMATIC DISEASE IN SWEDEN, IRELAND AND DENMARK / N. Brodin* - N. Kennedy - T. Swinnen - B. Appel Esbensen - S. McKenna - S. Willemijns - N. M. Hammer - B. Nordgren

FRI0648-HPR

FRI0649-HPR
INNOVATION IN HEALTH CARE - LABORATORY VALIDITY AND RELIABILITY OF A NEW SENSOR DEVELOPED TO MEASURE CERVICAL ROTATION / C. Fongen* - N. Østerås - F. R. Andersen - V. Berre - A. T. Tveter - K. B. Hagen

FRI0650-HPR

FRI0651-HPR
THREE YEAR TRENDS IN PHYSICAL ACTIVITY IN ADULTS WITH RHEUMATOID ARTHRITIS / M. Iversen* - H. Lundgaard Seberg - G. Engen - I. Kjeken

Saturday, 11 June 2016

**HPR Poster tour S15: Getting around rheumatic disease**

Chairperson(s): Anthony Redmond (United Kingdom), Camilla Fongen (Norway)

SAT0637-HPR

SAT0638-HPR
DELAYS IN DIAGNOSING OF PATIENTS WITH RHEUMATIC DISEASES IN POLAND / J. Grygielska* - P. Samel-Kowalik - A. Klak - M. Mańczak - F. Raciborski

SAT0639-HPR
THE MOST FREQUENT INQUIRIES OF PATIENTS ON SUBCUTANEOUS ANTI-TNF ALPHA THERAPIES / M. Pavic Nikolic* - A. Hocevar

SAT0640-HPR

SAT0641-HPR
REASONS TO STOP DRINKING ALCOHOL AMONG PATIENTS WITH RHEUMATOID ARTHRITIS - A MIXED METHOD STUDY / M. Andersson* - I. Larsson

SAT0642-HPR

SAT0643-HPR

SAT0644-HPR
## Miscellaneous forms of clinical care

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU0639-HPR</td>
<td>A NEW ELECTROMECHANICAL PLATFORM FOR SUBCUTANEOUS DRUG DELIVERY: RESULTS FROM AN EU USABILITY STUDY / B. Domanska* - S. Poon - C. Pichon - O. Stumpp</td>
<td></td>
</tr>
<tr>
<td>THU0643-HPR</td>
<td>PREVALENCE OF FOOT PROBLEMS IN PEOPLE WITH INFLAMMATORY ARTHRITIS IN SINGAPORE / K. Carter* - M. Lahiri - P. Cheung - A. Santos - K. Rome</td>
<td></td>
</tr>
<tr>
<td>THU0646-HPR</td>
<td>EXPERIENCES OF LIFE WITH BIOLOGIC DRUG THERAPY: 'I'M DOING MORE THAN I THOUGHT POSSIBLE 3-4 YEARS AGO!' / L. Sanders*</td>
<td></td>
</tr>
<tr>
<td>THU0651-HPR</td>
<td>STRUCTURE, PROCESS AND OUTCOME OF PRIMARY CARE RHEUMATOLOGY NETWORKS FOR PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES IN THE NETHERLANDS / W. F. Peter* - F. J. van der Giesen - S. de Jong - Y. Kat - E. H. van den Ende - J. Dekker - T. P. Vliet Vlieland on behalf of Rheumatology Network project group</td>
<td></td>
</tr>
</tbody>
</table>

* Presenting author
Friday, 10 June 2016

Physiotherapy & Miscellaneous forms of clinical care


FRI0614-HPR DELAYED DIAGNOSIS, PAIN AND LOSS OF FUNCTION ARE SOME OF THE CONSEQUENCES OF SPONTANEOUS FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS - A QUALITATIVE ANALYSIS OF PATIENTS' EXPERIENCE / A. Havelund Rasmussen* - D. Melgaard - A. Turtsøv - P. Simonsen Lenzt

FRI0615-HPR BLUNTED CARDIAC AUTONOMIC RESPONSE TO THE ACTIVE STANDING IS RELATED TO THE IMPACT OF FIBROMYALGIA ON QUALITY OF LIFE / A. R. Zamuner* - C. P. Andrade - M. Forti - E. Silva

FRI0616-HPR CARDIAC AUTONOMIC RESPONSE TO OSTHOSTATIC CHANGES IN FIBROMYALGIA SYNDROME / C. P. Andrade* - A. R. Zamuner - M. Forti - E. Silva

FRI0617-HPR AN AUDIT OF THE ROLE OF A CLINICAL SPECIALIST PHYSIOTHERAPIST IN RHEUMATOLOGY TRIAGE / C. M. Cullen* - M. Phelan - S. Harney - J. Ryan


FRI0621-HPR REFERENCE VALUES FOR THE MODIFIED FUNCTIONAL REACH TEST IN YOUNGER AND MIDDLE-AGED TURKISH POPULATION / E. Yuksel* - D. Ilgin - H. Kul Karaali - O. Ozcans - B. Unver


FRI0623-HPR KINESIOPHOBIA AFFECTS RANGE OF KNEE FLEXION AT EARLY STAGE FOLLOWING ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION / I. Demirbüken* - B. Özgül - E. Arıkan - E. Tonga - M. G. Polat


FRI0625-HPR LEARNING TO GUIDE PEOPLE WITH RHEUMATOID ARTHRITIS TO HEALTH-ENHANCING PHYSICAL ACTIVITY BEHAVIOR: PHYSIOTHERAPISTS' KNOWLEDGE, BELIEFS AND BEHAVIOR / T. Nessen - C. H. Opava - I. Demmelmaier*

FRI0626-HPR PHYSIOTHERAPISTS' MANAGEMENT OF CHALLENGING SITUATIONS IN GUIDING PERSONS WITH RHEUMATOID ARTHRITIS TO HEALTH-ENHANCING PHYSICAL ACTIVITY / T. Nessen - C. H. Opava - C. Martin - I. Demmelmaier*

FRI0627-HPR IN PATIENTS WITH INFLAMMATORY MYOPATHY QUANTITATIVE MUSCLE TESTING HAS A HIGHER RELIABILITY THAN MANUAL MUSCLE TESTING / I. Sterkele* - P. Baschung Pfister - E. D. de Bruin - B. Maurer - R. H. Knols


FRI0629-HPR BACK TO ACTION: A GUIDE TO EXERCISING SAFELY IN THE GYM WITH ANKYLOSING SPONDYLITIS - BOOK / B. Monek - A. Mikula - G. Poór


FRI0631-HPR A NEW IMPULSE RESPONSE METHOD TO ASSESS EARLY KNEE OSTEOARTHRITIS DIFFERENCES BETWEEN YOUNG AND ELDERLY WOMEN / K. Aimoto* - K. Hase - T. Sakai - Y. Itoh - I. Kondo - S. Ota

FRI0632-HPR PATIENT EDUCATION EVENT: "WHY DOES MY BACK HURT?" / L. van Rossen*

FRI0633-HPR "IT MIGHT HURT, BUT STILL IT'S GOOD": PEOPLE WITH RHEUMATOID ARTHRITIS BELIEFS AND EXPECTATIONS ABOUT PHYSICAL ACTIVITY INTERVENTIONS / L. Larkin* - N. Kennedy - A. Fraser - S. Gallagher

FRI0634-HPR COMPLEX TREATMENT OF PATIENTS WITH GOUTY ARTHRITIS / N. G. Nikolov* - M. S. Krastanova - M. S. Panchovka


* Presenting author
**Satuday, 11 June 2016**

**Nursing & Miscellaneous forms of clinical care & Psychology/Social sciences & Occupational therapy**

**SAT0627-HPR**  {E}du{c}ational{a} needs of French {r}heumato{log}y nurses {a}re not {l}imited to {i}mmun{atory} arthritis management. {r}esults of the {m}ult{i}centr{ic} "caire" survey / {c} Beauvais* - {s} Pouplin - {a} Mulliez - {e} Fayet - {r} Moulard - {l} Gossec - {s} Perrot - {c} Lamour - {m}o - {m}ezières - {m} P Aubert - {n} Jaccaz Vallée - {c} Savid

**SAT0628-HPR** Cardiovascular risk assessment in inflammatory arthritis patients in a nurse-led clinic and supported by ultrasonography / {j} de la Torre-Aboki* - {c} García-González - {m} Andrés - {p} Vela

**SAT0629-HPR** Rapid access triage clinic: A nursing service that shortens rheumatology clinic waiting time and facilitates early treatment / {s} K G Kwock - {l} M M Tang* - {h} Y J Chung - {k} Y C Yuen - {t} K C Ho - {c} S Lau

**SAT0630-HPR** Variables predictive of the sleep disorders in patients with psoriatic arthritis and spondyloarthritis / {l} Cano-García* - {s} Manrique-Arija - {n} Mena-Vázquez - {m} C Ordoñez-Cañizares - {c} M Romero-Barco - {c} Domic-Bueno - {m} Rojas-Giménez - {c} Fueyo-Valera - {f} G Jiménez-Núñez - {l} Ureña-Garnica - {m} V Irigoyen-Oyarzábal - {v} Coret-Cagigal - {a} Belmonte-López - {a} Fernández-Nebro

**SAT0631-HPR** Chronic disease and self-identification: Ethnographic investigations into the patient experience during treatment / {m} H Schiff* - {m} Aris - {s} Saunders - {l} Mountian - {p} Hartley

**SAT0632-HPR** The efficacy of biologics on health status including psychological status, self-efficacy and patient satisfaction in patients with rheumatoid arthritis / {m} Fusama* - {k} Yukioka - {t} Kuroiwa - {c} Yukioka - {m} Inoue - {h} Ogawa - {n} Murata - {t} Kuritani - {k} Maeda - {h} Sano - {m} Yukioka - {h} Nakahara

**SAT0633-HPR** Social support may be important for improving patient satisfaction and health status in patients with rheumatoid arthritis treated with biologics / {m} Fusama* - {k} Yukioka - {t} Kuroiwa - {c} Yukioka - {m} Inoue - {h} Ogawa - {n} Murata - {t} Kuritani - {k} Maeda - {h} Sano - {m} Yukioka - {h} Nakahara

**SAT0634-HPR** Treat to target access, care and outcome: A nurse led care initiative / {p} Minnock* on behalf of Irish Rheumatology Nursing Forum

**SAT0635-HPR** Effects and costs of a community-based self-management support program for Korean medical aid beneficiaries with osteoarthritis: 12-month follow-up / {y} H Ahn*
SAT0636-HPR STARTING CARE AT THE PEEP OF RHEUMATOID ARTHRITIS - A PATIENT EDUCATION AND EMPOWERMENT PROGRAM / Y. S. Cheung* - P. F. Lee - S. K. Tang


SAT0638-HPR DELAYS IN DIAGNOSING OF PATIENTS WITH RHEUMATIC DISEASES IN POLAND / J. Grygielska* - P. Samel-Kowalik - A. Klak - M. Mateczak - E. Raciborski

SAT0639-HPR THE MOST FREQENT INQUIRIES OF PATIENTS ON SUBCUTANEOUS ANTI-TNF ALPHA THERAPIES / M. Pavic Nikolic* - A. Hocevar


SAT0641-HPR REASONS TO STOP DRINKING ALCOHOL AMONG PATIENTS WITH RHEUMATOID ARTHRITIS - A MIXED METHOD STUDY / M. Andersson* - I. Larsson


SAT0644-HPR BELIEFS, KNOWLEDGES AND REPRESENTATIONS OF PATIENTS WITH GOUT DISEASE FOLLOWED BY GENERAL HEALTHCARE AND HOSPITAL RHEUMATOLOGY: FROM DIONYSUS TO THE SWORD OF DAMOCLES / C. Sarran* - C. Bougeois Saran - C. Deproux - M. Guignot - E. Hang Korng

SAT0645-HPR RESULTS OF A GOAL MANAGEMENT INTERVENTION FOR PATIENTS WITH POLYARTHRITIS WITH MILD DEPRESSIVE SYMPTOMS / R. Arends - C. Bode - E. Taal* - M. van de Laar


SAT0649-HPR WOMEN WITH EARLY RA PREFER TO USE INTERACTION AND ADJUSTMENT STRATEGIES TO DEAL WITH THEIR EVERYDAY LIFE DILEMMAS (THE TIRA PROJECT) / A. Sverker* - M. Björk - I. Thyberg - G. Östlund
PARE Programme
People with Arthritis/Rheumatism in Europe Programme

14:30 - 15:00  Exhibition (S5-S9)
Break

15:00 - 16:30  Room S19
PARE/Clinical joint session
Optimizing treatment and patient care through precision medicine:
A threat or an opportunity for patients and patient organisations?

Learning objectives:
To highlight new developments in personalised treatment and related themes such as biobank research, tight control, goal setting and improving adherence and the management of comorbidities

Chairperson(s):
Ailsa Bosworth (United Kingdom)
Bernard Combe (France)

Gerd R. Burmester  (Germany)  15:05
Introduction to precision medicine in the field of rheumatology: is there a new role for patients?

Bruce Kirkham  (United Kingdom)  15:23
The patient perspective on treat-to-target:
Is remission an achievable goal for all patients?

Bente Glintborg  (Denmark)  15:41
Abstract N° SP0032

Yvonne van Eijk-Hustings  (Netherlands)  15:59
Abstract N° SP0033
Improving the screening and management of comorbidities in rheumatic diseases

J. van Rompay  (Belgium)  16:17
A. Hoet, C. Geysen, E. Binnard, G. Patteet, L. Ovaere, W. Wilmots, K. van der Elst, R. Westhovens
Abstract N° OP0014-PARE
Updating the patient partner educational program for rheumatoid arthritis in Belgium: a systematic, scientific-based approach led by patient experts

16:30 - 17:00  Exhibition (S5-S9)
Coffee break

17:00 - 18:30  Room S19
PARE session
Patient organisations in action

Learning objectives:
• Health democracy - patient participation in policy and decision-making
• Skilling your organisation for tomorrow's challenges

Chairperson(s):
Maria Ekroth  (Finland)
Codruta Zabalan  (Romania)
Athanasia Pappa  (Greece)

How a change to a user-led concept of a patient organisation is leading to success?  17:05
Eirini Agapidaki  (Greece)  tbc
Involving patients in shaping health policy: research findings  17:25
Karen Facey  (United Kingdom)
Abstract N° SP0061
The role of patient organisations in health technology assessment  17:45
D. P. Richards  (Canada)
L. Wilhelm, L. Proulx, N. Robertson
Abstract N° OP0024-PARE
Development and use of a Canadian arthritis patient charter  18:05

A. I. Vázquez Lojo  (Spain)  18:15
V. Romero Pazos, C. van Riel, F. J. Carreira Roca
on behalf of Liga Reumatolóxica Galega
Abstract N° OP0025-PARE
Informative and preventive campaigns at the city councils in the Galician region  18:25
THURSDAY, 9 JUNE 2016

10:15 - 11:45 Room S19

PARE session
Designing solutions to support young people to address the challenges of living with a rheumatic or musculoskeletal disease

Learning objectives:
Help to equip and inspire young people to become empowered, involved in shared decision-making and involved in healthcare decisions

Chairperson(s):
Linda van Nieuwkoop (Netherlands)
Sofia Ramiro (Netherlands)

Petra Balazova (Slovakia) 10:20
Abstract N° SP0071
The role of Young PARE in getting organised: the Virtual Knowledge Centre

Alessia Alunno (Italy) 10:40
Abstract N° SP0072
The role of health professionals in improving shared decision-making with young people with RMDs

Irene Murphy (Ireland) 11:00
Abstract N° SP0073
Empowering young people with RMDs to find their voice and claim their space

W. Olsder (Netherlands) 11:20
L. van Nieuwkoop, R. van Boerdonk, N. des Bouvrie
Abstract N° OP0116-PARE
Development of the guide for national online youth platforms including implementation in three countries

M. Ekroth (Finland) 11:30
M. Ekroth, T. Pakkala
Abstract N° OP0117-PARE
Iloa elämäin - peer support and networking event for children, youth and families with MSD disease

11:45 - 13:30 Exhibition (S5-59)
Poster viewing & lunch

11:50 - 13:30 Poster area

Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area, on a “first-come-first-served” basis the day of the poster tour.
For full details regarding the guided poster tours on Thursday, please refer to pages 47 to 54.

PARE Poster tour
T15: PARE - Poster tour I
Chairperson(s): Diana Skingle (United Kingdom)
Maarten de Wit (Netherlands)
Abstract N° PARE0001 - PARE0008

13:30 - 15:00 Capital Suite 07

HPR/PARE joint session
"Fewer words - more action" - tailored care for men with rheumatic diseases?

Learning objectives:
• To highlight how men with a rheumatic disease experience life
• To discuss the use of different coping strategies and if they are different from women
• To learn and spark ideas, across different disciplines and countries, on how we could look at gender differences to optimise the management for men with rheumatic diseases

Chairperson(s):
Milena Gobbo Montoya (Spain)
Dieter Wiek (Germany)

Mathilda Björk (Sweden) 13:35
Abstract N° SP0082
Disability in men and women with RA. Does it differ and does it matter?

Frank Demtröder (Germany) 13:53
Abstract N° SP0083
Balancing work and life: "When is a man a man?"

Bente Appel Esbensen (Denmark) 14:11
Abstract N° SP0084
"Being physically active is a salvation" - men’s preferences for physical activity

Caroline Flurey (United Kingdom) 14:29
Abstract N° SP0085
Design of a self-management intervention for men with RA

M. Martin (United Kingdom) 14:47
H. Fiddler
Abstract N° OP0132-HPR
Axial spondyloarthritis know-how: what are the benefits of a brief exercise and self-management education group programme? A qualitative investigation

13:30 - 15:00 Room S19

PARE session
Digital applications for the benefit of the patient

Learning objectives:
How e-health and m-health solutions can improve health care provision
Chairperson(s): Kirsten Lerstroem (United Kingdom)\nDora Papastavrou (Greece)\n
Sofia Ernestam (Sweden) 13:35\nAbstract N° SP0091\nCan individual patients benefit from registries?\n
Elizabeth Murray (United Kingdom) 13:55\nAbstract N° SP0092\nDigital interventions to improve self-care\n
Simon Stones (United Kingdom) 14:15\nAbstract N° SP0093\nHow innovative technologies can support individuals to better self-manage their conditions\n
L. Grange (France) 14:35\nJ. D. Cohen, S. Trope, D. Poivret, C. Bonnet, B. Allenet, C. Stadelmann, G. Chales, J. N. Dachicourt\nAbstract N° OP0139-PARE\nThe first serious game EduBioT: a modern therapeutic educational tool for adult patients with chronic inflammatory rheumatic disease, treated with biotherapy\n
G. O’Leary (Ireland) 14:45\nAbstract N° OP0140-PARE\nSelf-management online: from concept to delivery, living well with arthritis online\n
15:00 - 15:30 Exhibition (S5-S9)\nCoffee break

15:30 - 17:00 Room S19\n
PARE session
What is done for people with rare diseases? Can we do more?\n
Learning objectives: To address the value and challenges of international collaboration between researchers and patient organisations in rare diseases: • Raising funds • Initiating research • Developing new successful drugs\n
Chairperson(s): Loreto Carmona (Spain)\nJoep Welling (Netherlands)\n
Leona Wagner (United Kingdom) 15:35\nLiving with alkaptonuria and my activities for the alkaptonuria society\n
Christos Sotirelis (United Kingdom) 15:55\nRare disease patients’ perspective on improving access to orphan drugs and opportunities for better collaboration\n
Peter N. Robinson (Germany) 16:15\nPhenomizer: the ultimate app to diagnose rare diseases

J. Andersen (Switzerland) 16:35\nAbstract N° OP0152-PARE\nStarting a disease specific youth group on a national level\n
A. Marchal (Belgium) 16:45\nI. De Keyser on behalf of ReumaNet vzw - ORKA\nAbstract N° OP0153-PARE\nReumaMama’s en –Papa’s: info sessions for (future) parents with RMDs and for parents with children with juvenile arthritis\n
FRIDAY, 10 JUNE 2016\n
10:15 - 11:45 Room S19\n
Abstract session\nPARE Abstract session\n
Chairperson(s): Kate Betteridge (United Kingdom)\nJolanta Grygielska (Poland)\n
N. Caeyers (Belgium) 10:20\non behalf of ReumaNet vzw\nAbstract N° OP0247-PARE\nSurvey: what do patients think about their care, caretakers and the role of patient organisations?\n
C. Koehn (Canada) 10:30\nA. Dikranian, A. Maniccia, E. Bananis\nAbstract N° OP0248-PARE\nUnderstanding the importance of a patient’s role in the management of RA: results from a patient-based survey developed by the RA narrative global advisory panel\n
K. Mace (Australia) 10:40\nAbstract N° OP0249-PARE\n25 years of camp freedom - a 6 day camp for children 7-17 years old with arthritis\n
E. Kritza (Greece) 10:50\nAbstract N° OP0250-PARE\nShared decision-making in rheumatoid arthritis - patients/doctors workshop\n
Z. Paskins (United Kingdom) 11:00\nC. Jinks, W. Mahmood, P. Jayakumar, S. Gwilym, S. Blackburn, A. Worrall on behalf of Research Institute for Primary Care and Health Sciences Research User Group and National Osteoporosis Society\nAbstract N° OP0251-PARE\nPatient and public involvement in design, analysis and reporting of a public priority setting exercise for research in osteoporosis\n
K. Blidberg (Sweden) 11:10\nAbstract N° OP0252-PARE\nIncreasing the interest in research in rheumatology
N. Lopuhaä (Netherlands) 11:20
A. M. Zimmerman
Abstract N° OP0253-PARE
“Samen reuma” - a closed group on facebook for people with rheumatic diseases

W. B. Nowell (United States) 11:30
Abstract N° OP0254-PARE
Rheumatoid arthritis patient characteristics and willingness to participate in research among members of the creakyjoints arthritis patient community: results from a patient survey

11:50 - 13:30 Poster area

Guided Poster tours
Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area, on a “first-come-first-served” basis the day of the poster tour. For full details regarding the guided poster tours on Friday, please refer to pages 101 to 108.

PARE Poster tour
F15: PARE - Poster tour II
Chairperson(s): Dieter Wiek (Germany)
               Petra Balazova (Slovakia)
Abstract N° PARE0009 - PARE0017

13:30 - 15:00 Room S19

PARE session
It’s in your hands

Learning objectives:
- To empower patients to acquire knowledge
- To identify strategic actions
- To develop skills to act on that knowledge

Chairperson(s):
Jenny de la Torre-Aboki (Spain)
Boryana Boteva (Bulgaria)

Wilfried Mau (Germany) 13:35
Abstract N° SP0147
A self-determined life with a rheumatic disease - how can social participation be preserved or obtained and how can barriers be overcome

Margarida Fonseca Santos (Portugal) 13:55
Abstract N° SP0148
Learning to control - when knowledge becomes power over the day-to-day setbacks

Peter Tugwell (Canada) 14:15
Does enhancing health literacy improve equity and empowerment?

Simon Stones (United Kingdom) 14:35
Stene Prize essay: Living with a rheumatic or musculoskeletal disease (RMD): how I take action to enjoy life to the full

E. S. Rösch (Switzerland) 14:45
Abstract N° OP0278-PARE
Patient empowerment: national action week with informative lectures in Layman’s terms for those who are affected by rheumatism

15:00 - 15:30 Exhibition (S5-S9)

15:30 - 17:00 Room S19

PARE session
What’s new: latest advances in treatment and management of systemic sclerosis and fibromyalgia

Learning objectives:
An overview of the latest advances in the treatment and management of systemic sclerosis and fibromyalgia

Chairperson(s):
Kim Fligelstone (United Kingdom)
Joop van Griensven (Belgium)

Ulf Müller-Ladner (Germany) 15:35
Abstract N° SP0161
Latest advances in the treatment and management of systemic sclerosis

José A. P. da Silva (Portugal) 16:15
Fibromyalgia: body and mind pathways to disease control

SATURDAY, 11 JUNE 2016

10:15 - 11:45 Room S19

PARE session
New approaches to understanding and managing chronic musculoskeletal pain

Learning objectives:
To provide insights into the latest advances in pain research, new approaches to pain control and opportunities for self-management

Chairperson(s):
Elsa Mateus (Portugal)
Neil Betteridge (United Kingdom)

Frances Williams (United Kingdom) 10:20
Abstract N° SP0180
Advances in the genetics of chronic pain syndromes: how twin studies help
Pete Moore (United Kingdom) 10:40
Self-management of pain: the Pain Toolkit and its use in everyday life

Catarina Marques (Portugal) 11:00
Abstract N° SP0181
Chronic pain control: a Portuguese patient group initiative

G. O’Leary (Ireland) 11:20
Abstract N° OP0302-PARE
Supporting people working with rheumatic and musculoskeletal diseases (RMDs)

B. Svanberg (Sweden) 11:30
Abstract N° OP0303-PARE
Raising public awareness on osteoarthritis through an educational campaign

10:00 - 12:00  Exhibition (S5-S9)
Poster viewing & coffee break

12:00 - 13:30  Room S19
PARE/HPR joint session
There is more than drugs

Learning objectives:
How to boost your vitality

Chairperson(s):
Jürgen Clausen (Germany)
Rikke H. Moe (Norway)

Klaus Pfeifer (Germany) 12:05
Abstract N° SP0201
Sports and exercise for arthritis patients

Christian Schubert (Austria) 12:25
Abstract N° SP0202
Psychoneuroimmunology: from psyche to immune activity and back

Diana J. Pedersen (Denmark) 12:45
Abstract N° SP0203
How the Danish Rheumatism Association works with alternative and complementary treatment

E. Löfberg (Sweden) 13:05
Abstract N° OP0313-PARE
The Swedish Rheumatism Association’s blog about training - a new way of learning

F. van der Giesen (Netherlands) 13:15
F. van Gaalen, R. de Jong, M. van Goeverden, H. Slootweg, T. Vliet Vlieland
Abstract N° OP0314-PARE
Group exercise therapy in ankylosing spondylitis (AS): the patients’ perspective

13:45 - 14:45  Room S19
Highlight session
PARE Highlight session

Learning objectives:
• To provide an overview of learning and outcomes from the 2016 congress from health professionals and the scientific perspectives
• To receive the first feedback from the PARE delegates

Chairperson(s):
Marios Kouloumas (Cyprus)
Dieter Wieck (Germany)

Anna Moltó (France) 13:50
Highlights from the Scientific programme

Thijs Swinnen (Belgium) 14:15
Highlights from the Health Professionals programme
PARE Poster tours & Posters
People with Arthritis/Rheumatism in Europe Poster Session

PARE Posters Thursday to Saturday

PARE posters will be presented form Thursday to Friday next to the PARE booth in the EULAR Village. In addition two guides poster tours are proposed.

PARE Poster tour
Thursday, 9 June 2016

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area, on a “first-come-first-served” basis on the day of the poster tour.

PARE Poster tour T15: PARE Poster tour I

Chairperson(s): Diana Skingle (United Kingdom), Maarten de Wit (Netherlands)

PARE0001 THE "SWEDISH YOUNG RHEUMATICS" PARTNERED UP WITH ANOTHER YOUNG IMID ASSOCIATION AND ABBVIE TO PRODUCE AN INFORMATIVE AND HOPE GIVING BOOK ON "STARTING A FAMILY". THE COLLABORATION RESULTED A HIGHLY INFORMATIVE BOOK THAT PROVIDES A WEALTH OF INFORMATION ON FAMILY PLANNING / M. Beermann*

PARE0002 A PHOTO-PROJECT ABOUT YOUNG PEOPLE SUFFERING FROM JUVENILE ARTHRITIS / B. Ziegler*

PARE0003 WHAT DO I WANT TO TALK ABOUT? / T. Bellerby* - D. Stevens - L. Williamson

PARE0004 TOOLS FOR A CUSTOMIZED HEALTHCARE PLAN FOR DUTCH PEOPLE WITH RHEUMATIC DISEASES R. van den Brink* - E. Schouws

PARE0005 BRIEF OVERVIEW OF ENCA (EUROPEAN NETWORK FOR CHILDREN WITH ARTHRITIS) / Y. Egert* - W. Costello - M. Kepic

PARE0006 IDENTIFICATION AND PRIORITIZATION OF RESOURCES FOR RHEUMATIC PATIENTS (REUMAPPA) / M. Gobbo* - L. Carmona

PARE0007 A SUCCESFULL CAPS RECYCLING PROJECT "NOT SATIATE CAPS" / A. Phoka Charalambous*

PARE0008 SETTING UP A YOUTH GROUP: A CHALLENGE WORTH TACKLING ANMAR'S STEP ZERO PROJECT / U. G. Viora - S. Ostuzzi* - S. Rosi - S. Severoni

PARE Poster tour
Friday, 10 June 2016

PARE Poster tour F15: PARE Poster Tour II

Chairperson(s): Dieter Wiek (Germany), Petra Balazova (Slovakia)

PARE0009 ESTONIAN YOUTH AWARENESS OF INVISIBLE CHRONIC DISEASES / L. Kullamaa*


PARE0011 LIGAFLASH, BEYOND AN IMAGE. A PHOTOGRAPHIC EXHIBITION / V. Romero Pazos* - F. J. Carreira Roca - A. I. Vázquez Lojo - C. van Riel on behalf of Liga Reumatolóxica Galega

PARE0012 REVMA CHALLENGE 2015 - GIVE A HELPING GLOVE AND SUPPORT A PATIENT WITH RHEUMATOID ARTHRITIS / H. Smucrova*

PARE0013 JUVENILE IDIOPATHIC ARTHRITIS: IT'S NOT JUST AN OLD PERSON'S DISEASE / S. R. Stones* on behalf of MyJIA Virtual Expert Advisory Group

PARE0014 PATIENT ADVOCACY FOR BETTER INFORMATION ON BIOSIMILARS AND SWITCHING / G. Korevaar*

PARE0015 PATIENT INVOLVEMENT IN THE DESIGN OF TECHNOLOGICALLY-ENHANCED CLOTHING TO HELP MANAGE MUSCULOSKELETAL CONDITIONS / S. de Souza* - A. Chan - C. Simpson - D. Atkinson - D. Williams - H. Lempp


* Presenting author
# EULAR Related Meetings

**By invitation only**

## Wednesday, 8 June 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Room/Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>Capital Lounge 4</td>
<td>EULAR ACR Board meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>Room S12</td>
<td>EULAR Standing Committee Clinical Affairs business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>Room S25</td>
<td>EULAR Standing Committee for Health Professionals business meeting</td>
</tr>
<tr>
<td>08:00 - 11:00</td>
<td>Room S16</td>
<td>5th Systemic Sclerosis World Congress 2018 - preparatory meeting</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td>Room S13</td>
<td>ATACC-RA Steering Committee meeting</td>
</tr>
<tr>
<td>10:00 - 12:00</td>
<td>Capital Lounge 4</td>
<td>ACR Executive Committee meeting</td>
</tr>
<tr>
<td>10:00 - 13:00</td>
<td>Room S14</td>
<td>Examining ulcers in SSc investigator meeting</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>Room S25</td>
<td>Journal of Scleroderma and Related Disorders Steering Board meeting</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>Capital Suite 17</td>
<td>GRAPPA adjacent to EULAR</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>Room S13</td>
<td>SLE Classification Criteria Steering Committee meeting</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>Room S17</td>
<td>GCA study group</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>Room S11</td>
<td>EMEUNET ambassador programme meeting</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>Room S12</td>
<td>Foot &amp; ankle study group</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>Room S15</td>
<td>ScleroID</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>Room S18</td>
<td>EULAR Standing Committee on PARE Business meeting</td>
</tr>
</tbody>
</table>

## Thursday, 9 June 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Room/Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td>Room S14</td>
<td>Physio study group</td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td>Room S25</td>
<td>Nurses study group, research &amp; strategy</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>Capital Lounge 4</td>
<td>APLAR Executive Committee meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>Room S11</td>
<td>EULAR Standing Committee on Musculoskeletal Imaging Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>Room S12</td>
<td>EULAR Standing Committee on Paediatric Rheumatology Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>Room S13</td>
<td>EMEUNET Leadership meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>Room S16</td>
<td>EULAR Synovitis study group (ESSG)</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>Room S17</td>
<td>EULAR Patient Research Partner Network coordinators meeting</td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td>Room S15</td>
<td>EULAR Standing Committee on Epidemiology and Health Services business meeting</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>Room S14</td>
<td>AGORA meeting</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>Room S25</td>
<td>Rheumatology Editorial Board meeting</td>
</tr>
<tr>
<td>14:00 - 16:00</td>
<td>Capital Lounge 4</td>
<td>ILAR Board meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>Room S14</td>
<td>EMEUNET country liaisons meeting</td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>Room S15</td>
<td>EULAR study group on SLE meeting</td>
</tr>
</tbody>
</table>
17:00 - 18:15 Room S25 Editorial Board meeting ARD
17:00 - 19:00 Room S11 EULAR Standing Committee on Investigative Rheumatology Business meeting
17:00 - 19:00 Room S17 EULAR study group on Microcirculation in Rheumatic Diseases
17:00 - 19:00 Room S29 Osteoarthritis study group
18:00 - 19:00 Room S14 EMEUNET Mentor-Mentee meeting
18:00 - 19:00 Room S15 EULAR Lupus Nephritis Trials Network study group
18:15 - 19:00 Room S25 Editorial Board meeting RMD Open

Friday, 10 June 2016

08:00 - 09:00 Room S16 OA trial bank
08:00 - 10:00 Capital Suite 17 EUSTAR Business meeting
08:00 - 10:00 Room S11 Hand osteoarthritis
08:00 - 10:00 Room S14 Study group for Risk Factors for RA
08:00 - 10:00 Room S15 HP Scientific Subcommittee meeting
08:00 - 10:00 Room S17 EULAR PARE CEO Exchange Interim meeting
08:00 - 10:00 Room S25 EMEUNET Business meeting
08:00 - 10:00 Room S29 Arthritis Research & Therapy Editorial Board meeting
08:30 - 10:00 Room S12 Scandinavian Society for Rheumatology - Board meeting 2016
09:00 - 10:00 Room S16 ATACC-RA Steering Committee Cooperation meeting
17:00 - 18:00 Room S11 Educational study group
17:00 - 18:00 Room S12 ESOS Investigator’s meeting
17:00 - 18:00 Room S13 Study group psychology
17:00 - 18:00 Room S16 Nurses study group clinical
17:00 - 19:00 Capital Suite 17 ASAS meeting
17:00 - 19:00 Room S14 ATACC-RA Business meeting
17:00 - 19:00 Room S17 EuroTEAM project - final Steering Committee meeting
17:00 - 19:00 Room S23 EULAR Standing Committee for Education and Training Business meeting
17:00 - 19:00 Room S25 EMEUNET subgroups workshop
17:00 - 19:00 Room S29 Sjögren’s syndrome study group - essential
A clear reflection of innovation, accessibility, and efficacy

A clear reflection of what has been added to the treatment paradigm.

Evidence based switching.

Evidence supports biosimilar infliximab, Remsima.
Satellite Symposia

Status as of 1 May 2016

**WEDNESDAY, 8 JUNE 2016**

13:00-14:30  Hall B

**AbbVie**

**Advancing RA care through enhancing the patient-clinician connection**

Chairperson(s):
Josef S. Smolen (Austria)

Daniel Aletaha (Austria)  13:00
Treating to target is connecting with patients: are we getting to a shared decision?

Josef S. Smolen (Austria)  13:15
To connect with patients we need to know what drives them: insights from studying patients’ beliefs about medication

Filip van den Bosch (Belgium)  13:35
Supporting the patients to stop disease progression: how can we enhance patient adherence and persistence?

Philip Conaghan (United Kingdom)  13:50
“I feel much better: do I need to maintain all my medication?” How should we manage the success of our treatment strategies?

All  14:10
Panel discussion

13:00-14:30  Hall C

**Novartis**

**IL-17A inhibition: a new frontier in the management of psoriatic arthritis**

Chairperson(s):
Paul Emery (United Kingdom)

Paul Emery (United Kingdom)  13:00
Welcome and introduction

Kristian Reich (Germany)  13:05
Psoriasis and psoriatic arthritis: a shared pathophysiology?

Laure Gossec (France)  13:20
Current goals in the treatment of psoriatic arthritis

Peter Nash (Australia)  13:40
IL-17A inhibition: a new treatment option in psoriatic arthritis

All  14:00
Panel discussion: hot topics in psoriatic arthritis

Paul Emery (United Kingdom)  14:20
Summary and Q&A

13:00-14:30  Hall A

**Pfizer**

**From inflammation signalling pathways to shared decision-making: meeting the goals and expectations of clinicians and patients with RA**

Chairperson(s):
Peter C. Taylor (United Kingdom)

Peter C. Taylor (United Kingdom)  13:00
Welcome and introduction

Evolving unmet needs: meeting the expectations of today’s patient with RA

All  13:10
Question and answer session
James D. Clark (United States) 13:20
Peter C. Taylor (United Kingdom) 13:20
The impact of past, present, and emerging signalling pathways in RA treatment

Rieke Alten (Germany) 13:50
Boulos Haraoui (Canada) 13:50
Shared decision-making: a holistic approach in RA treatment selection

Peter C. Taylor (United Kingdom) 14:25
Closing remarks and wrap-up

### 13:00-14:30  Capital Suite 02  
**Janssen**

**How much do we know about PsA?**

*Chairperson(s):*
Désirée van der Heijde (Netherlands)

**Désirée van der Heijde (Netherlands) 13:00**
Welcome and introduction

**Frank Behrens (Germany) 13:10**
**Dominique Baeten (Netherlands) 13:10**
Interactive discussion:
- How are different cytokines involved in the pathogenesis of PsA and inflammatory disease?
- Which are the most important clinical assessment outcomes in PsA?
- PsA treatment: are current drugs hitting the mark?
- PsA treatment: what does the future hold?

**Frank Behrens (Germany) 13:20**
**Dominique Baeten (Netherlands) 13:20**
Which are the most important clinical assessment outcomes in PsA?

**Frank Behrens (Germany) 13:35**
**Dominique Baeten (Netherlands) 13:35**
PsA treatment: are current drugs hitting the mark?

**Frank Behrens (Germany) 14:05**
**Dominique Baeten (Netherlands) 14:05**
PsA treatment: what does the future hold?

**Désirée van der Heijde (Netherlands) 14:25**
Conclusions and closing remarks

### 13:00-14:30  Capital Suite 09  
**IBSA**

**What treatment should we adopt as the preferred long-term therapy in knee OA**

*Chairpersons:*
Marc Hochberg (United States)
Jean-Yves Reginster (Belgium)

**Marc Hochberg (United States) 13:00**
Welcome and introduction

**Daniel Uebelhart (Switzerland) 13:05**
Current guidelines in OA regarding the conduct of clinical trials and its treatment

**Jean-Yves Reginster (Belgium) 13:20**
Pharmaceutical grade chondroitin sulphate is as efficacious as Celecoxib and better than placebo: results of the ChONDroitin vs CElecoxib vs Placebo Trial (CONCEPT)

**Emmanuel Maheu (France) 13:40**
Clinical relevance of current OA treatment recommendations: expert opinion vs clinical practice

**Marc Hochberg (United States) 13:55**
Oral symptomatic therapies for osteoarthritis: 2016 update on their benefit-risk ratios

**Jean-Yves Reginster (Belgium) 14:10**
Discussion and conclusion
THURSDAY, 9 JUNE 2016

08:15-09:45 Hall B  
**AbbVie**

**A vision for tomorrow - treating beyond the joints**

The value of building enduring collaborations in rheumatology & ophthalmology

Chairperson(s):
- Robert Landewé (Netherlands)
- Muhammad Haroon (Ireland)
- Athimalaipet Ramanan (United Kingdom)
- Antoine Brézin (France)

**08:15**
- Welcome and introduction
  - Robert Landewé (Netherlands)

**08:30**
- Uveitis as an early feature of SpA
  - Muhammad Haroon (Ireland)

**08:45**
- Insights into the management of anterior uveitis associated with JIA
  - Athimalaipet Ramanan (United Kingdom)

**09:05**
- Current evidence for the therapeutic response in non-infectious uveitis
  - Antoine Brézin (France)

**09:25**
- Roundtable discussion: Optimizing the care of rheumatologic patients with ocular manifestations

**09:40**
- Summary
  - Robert Landewé (Netherlands)

08:15-09:45 Hall C  
**Bristol-Myers Squibb**

**Targeting unmet needs of autoantibody-driven inflammatory diseases: focus on seropositive rheumatoid arthritis**

Chairperson(s):
- Paul Emery (United Kingdom)
- Maurizio Cutolo (Italy)
- Tom Huizinga (Netherlands)

**08:15**
- Welcome and introduction
  - Paul Emery (United Kingdom)

**08:17**
- A mechanistic approach to RA treatment: identifying appropriate cells and pathways of response
  - Maurizio Cutolo (Italy)

**08:30**
- Can we identify a patient type? Exploring the evidence for predictive and prognostic role of autoantibodies
  - Tom Huizinga (Netherlands)

**08:45**
- Questions and discussion of the first two presentations

**08:55**
- Immune synapse and the adaptive immune response: systems that drive autoantibody formation
  - Georg Schett (Germany)

**09:10**
- What does the future hold? Exploring commonalities amongst autoantibody-driven inflammatory diseases
  - Rohit Aggarwal (United States)

**09:25**
- Questions and discussion of the last two presentations

**09:35**
- Panel discussion, symposium summary and close

08:15-09:45 Hall E  
**Hospira, a Pfizer company**

**Biosimilars in rheumatology: where, what, why and how?**

Chairperson(s):
- Joseph S. Smolen (Austria)
- Ulf Müller-Ladner (Germany)
- Silvio Danese (Italy)
- Georg Schett (Germany)

**08:15**
- Welcome and introduction
  - Josef S. Smolen (Austria)

**08:20**
- Where are we now?
  - João Gonçalves (Portugal)

**08:45**
- A mechanistic approach to RA treatment: identifying appropriate cells and pathways of response
  - Ulf Müller-Ladner (Germany)

**09:05**
- Current evidence for the therapeutic response in non-infectious uveitis
  - Silvio Danese (Italy)

**09:25**
- Roundtable discussion: Optimizing the care of rheumatologic patients with ocular manifestations

**09:40**
- Summary
  - Josef S. Smolen (Austria)

08:15-09:45 Hall A  
**Sanofi Genzyme Regeneron**

**IL-6 as a driver of joint destruction in rheumatoid arthritis: translating complex science into patient benefits**

Chairperson(s):
- Ernest Choy (United Kingdom)
- Georg Schett (Germany)

**08:15**
- Welcome and introduction
  - Ernest Choy (United Kingdom)

**08:20**
- The biology of IL-6 and its role in the pathogenesis of joint destruction
  - Georg Schett (Germany)

**08:40**
- Imaging joint damage in RA: From clinical trials to clinical practice
  - Désirée van der Heijde (Netherlands)

**09:00**
- Managing joint damage in RA: how successful are we?
  - Mark Genovese (United States)

**09:20**
- Panel discussion/Q&A
Medscape Education supported by an independent educational sponsorship from Eli Lilly

Evolution or revolution in RA clinical practice? Ask the experts

Chairperson(s):
Peter Taylor (United Kingdom)
Bruno Fautrel (France)
Ronald van Vollenhoven (Sweden)
Maxime Dougados (France)

Managing RA: current successes and failures
Scientific advances in RA targets: what’s new?
The future of managing RA: changing the paradigm in RA Care

“From gold to platinum standard: best practice and future perspectives of subcutaneous methotrexate”

Chairperson(s):
Stanley Cohen (United States)
Jürgen Braun (Germany)
Eugeny Nasonov (Russia)
J. M. W. Hazes (Netherlands)

Value of SC MTX in daily practice
MTX in the age of biosimilars and biologics
Cardiovascular effects of methotrexate in rheumatoid arthritis (RA): recent insights (Professor Nasonov)
Patient adherence to Methotrexate in RA therapy - the crucial role of rheumatologists

Introducing new biosimilars into current treatment algorithms: interactive panel discussion

Chairperson(s):
John Isaacs (United Kingdom)

John Isaacs (United Kingdom) 08:15
Opening and introduction

Interactive panel discussion 08:20
Moderated by John Isaacs

Faculty:
Arnold Vulto (Netherlands)
Thomas Dörner (Germany)
Tore Kvien (Norway)

Discussion topics:
Establishing comparability
Proving pharmacokinetic equivalence
Confirming similarity with reference product
Translating the totality of evidence into clinical practice

John Isaacs (United Kingdom) 09:40
Conclusions

Unravelling the mystery between structure and sustained clinical outcomes

Chairperson(s):
Edward Keystone (Canada)

Edward Keystone (Canada) 17:30
How biologics work: what we know and what we don’t know

Leigh Revers (Canada) 17:40
Structural to function relationship of monoclonal antibody therapies

Edward Keystone (Canada) 18:00
What we know: evidence on long-term data and immunogenicity

Thomas Dörner (Germany) 18:20
What we don’t know: data generation needs to support switching of stable patients

All 18:45
Questions and answers

“Persistence on therapy: a key factor in the successful management of rheumatic diseases”

Douglas Veale (Ireland) 17:30
Welcome and introductions

Dominique Baeten (Netherlands) 17:40
Persistence on therapy in rheumatology patients: a still unmet need

Douglas Veale (Ireland) 18:00
How are biologic therapies performing on persistence rates?

Xenofon Baraliakos (Germany) 18:25
What is the relevance of persistence on therapy in daily practice for physicians and patients?

All 18:40
Q&A
### 17:30-19:00  Hall C

**Roche**

**Precision medicine: maximising treatment benefit for RA patients**

**Chairperson(s):**
Ernest Choy (United Kingdom)

**Ernest Choy (United Kingdom)** 17:30
Introduction

**Eric Ruderman (United States)** 17:35
Reviewing the role of glucocorticoids in RA management

**Cem Gabay (Switzerland)** 17:53
Monotherapy in the RA treatment landscape

**Georg Schett (Germany)** 18:11
Can biomarkers help guide biologic treatment approaches?

**Ernest Choy (United Kingdom)** 18:29
Innovating future treatment approaches in RA through previous clinical experiences

**Ernest Choy (United Kingdom)** 18:47
Summary

**All** 18:50
Panel Q&A

### 17:30-19:00  Capital Suite 07

**Celgene**

**The challenge with PsA - it’s complicated…**

**Chairperson(s):**
Helena Marzo-Ortega (United Kingdom)

**Helena Marzo-Ortega (United Kingdom)** 17:30
Introduction

**Georg Schett (Germany)** 18:14
PsA immunopathology: Decoding the complex interplay in PsA

**Q&A** 17:55

**Frank Behrens (Germany)** 18:00
PsA: Managing a heterogeneous disease

**Q&A** 18:15

**Alvin Wells (United States)** 18:20
The PsA clinical challenge: treating its complexity with PDE4 inhibition

**Q&A** 18:35

**All** 18:40
Case study presentations and discussion

**Helena Marzo-Ortega (United Kingdom)** 18:55
Summary and close

### 17:30-19:00  Hall A

**Pfizer**

**Shaping the RA treatment paradigm: the evolution of biologic therapy**

**Chairperson(s):**
Robert J. Moots (United Kingdom)

**Robert J. Moots (United Kingdom)** 17:30
Welcome and introduction

**Robert J. Moots (United Kingdom)** 17:35
Biologics: an era of discovery

**Juan Gómez-Reino (Spain)** 17:50
Learning from the past: evidence and experience

**Eduardo Mysler (Argentina)** 18:15
Looking forward to the future: evolving our thinking

**Robert J. Moots (United Kingdom)** 18:40
Finding the right balance

**Close** 19:00

### 17:30-19:00  Capital Suite 11

**Sandoz**

**The evolving landscape of rheumatology: biosimilarity and extrapolation**

**Chairperson(s):**
Peter Taylor (United Kingdom)

**Peter Taylor (United Kingdom)** 17:30
Welcome and introductions

**Emily Shacter (United States)** 17:40
Laying the foundation: analytical and functional characterisation of protein products and the demonstration of molecular similarity

**Craig Leonardi (United States)** 18:00
Building the totality-of-the-evidence: confirming biosimilarity and supporting extrapolation

**Peter Taylor (United Kingdom)** 18:20
Impacting the clinical landscape: the role of biosimilar therapies in rheumatology

**All** 18:40
Panel discussion and summary

**Close** 19:00
Amgen
Setting your sights on biosimilars: perspectives on antibodies in rheumatology

Chairperson(s):
Denis Choquette (Canada)

Denis Choquette (Canada) 17:30
Opening remarks and objectives

Joel Kremer (United States) 17:35
Outlook on the biosimilar landscape in rheumatology and panel discussion

Leonard Calabrese (United States) 18:00
A critical look at biosimilar development and manufacturing

Denis Choquette (Canada) 18:25
Viewpoints and clinical considerations for biosimilars

All 18:50
Panel discussion and question and answer session

Janssen
Think rheumatoid arthritis - causes, consequences and management

Josef S. Smolen (Austria) 17:30
Welcome and Introduction

Costantino Pitzalis (United Kingdom) 17:35
Pathophysiology of RA

Simon Jones (United Kingdom) 17:50
Comorbidities and adverse events associated with IL-6 intervention in rheumatic disease

Frank McKenna (United Kingdom) 18:05
The psychological impact of rheumatic disease

Josef S. Smolen (Austria) 18:20
Upcoming therapeutic approaches in RA

Josef S. Smolen (Austria) 18:45
Q&A, conclusions, and closing remarks

GSK
Optimising patient care in SLE: An interactive case-based workshop

Chairperson(s):
Andrea Doria (Italy)

Andrea Doria (Italy) 17:30
Welcome and introduction
- Burden of disease and unmet needs in SLE management
- Treatment options in SLE and the role of biologics
- Continuing challenges: who to treat and when to treat

Greg Dennis (United States) 17:45
Optimising patient care in SLE: A state-of-the-art, interactive case study-based workshop
- Key considerations for diagnosis and initial choice of treatment
- Optimising standard of care
- Short- and long-term aims of treatment
- Measuring treatment success
- When to consider newer agents

Andrea Doria (Italy) 18:50
Summary of key learnings and concluding remarks

AbbVie
Advancing quality of care in SpA

Chairperson(s):
Josef S. Smolen (Austria)

Josef S. Smolen (Austria) 08:15
Treat-to-target strategy: learning from RA?

William Tillett (United Kingdom) 08:30
Assessment tools and targets for tailored treatment in PsA.

Joachim Sieper (Germany) 08:50
Treat-to-target in axSpA: implications for clinical practice.

Maria A. D’Agostino (France) 09:05
Is the use of imaging techniques to detect the subclinical inflammation in SpA a worthwhile approach?

Dafna Gladman (Canada) 09:20
So that is the evidence - can we translate it into PsA and axSpA clinical practice?

All 09:35
Panel discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
<th>Chairperson(s)</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15-09:45</td>
<td>Hall E</td>
<td><strong>UCB</strong>&lt;br&gt;Optimising patient outcomes throughout the rheumatoid arthritis (RA) patient journey: the exception, the standard and the rule</td>
<td>Peter Taylor (United Kingdom)</td>
<td>Ronald van Vollenhoven (Netherlands)&lt;br&gt;When to start biologics: the standard RA patient&lt;br&gt;How to optimise biologics: the rule&lt;br&gt;Wrap-up and conclusion&lt;br&gt;Q&amp;A</td>
</tr>
<tr>
<td>08:15-09:45</td>
<td>Hall A</td>
<td><strong>Pfizer</strong>&lt;br&gt;Clinical and patient perspectives: A “joint” approach for improving the management of psoriatic arthritis</td>
<td>Douglas Veale (Ireland)</td>
<td>Laura Coates (United Kingdom)&lt;br&gt;Jo Lambert (Belgium)&lt;br&gt;Douglas Veale (Ireland)&lt;br&gt;Laura Coates (United Kingdom)&lt;br&gt;Jo Lambert (Belgium)&lt;br&gt;Douglas Veale (Ireland)&lt;br&gt;Douglas Veale (Ireland)&lt;br&gt;Douglas Veale (Ireland)&lt;br&gt;Douglas Veale (Ireland)&lt;br&gt;Douglas Veale (Ireland)&lt;br&gt;Douglas Veale (Ireland)&lt;br&gt;Douglas Veale (Ireland)</td>
</tr>
<tr>
<td>08:15-09:45</td>
<td>Hall C</td>
<td><strong>Novartis</strong>&lt;br&gt;IL-17A inhibition: advances in the treatment of ankylosing spondylitis</td>
<td>Dominique Baeten (Netherlands)</td>
<td>Dominique Baeten (Netherlands)&lt;br&gt;New insights into the pathophysiology of ankylosing spondylitis&lt;br&gt;Treatment targets in ankylosing spondylitis: current perspectives&lt;br&gt;IL-17A inhibition: a new target in the treatment of ankylosing spondylitis&lt;br&gt;Discussion: structural progression in ankylosing spondylitis&lt;br&gt;Summary and Q&amp;A</td>
</tr>
<tr>
<td>08:15-09:45</td>
<td>Capital Suite 07</td>
<td><strong>Samsung Bioepis</strong>&lt;br&gt;Biosimilar: Your questions answered</td>
<td>Paul Emery (United Kingdom)</td>
<td>Paul Emery (United Kingdom)&lt;br&gt;Brian Min (Republic of Korea)&lt;br&gt;Michael Rawlins (United Kingdom)&lt;br&gt;Thomas Dörner (Germany)&lt;br&gt;Paul Emery (United Kingdom)&lt;br&gt;Paul Emery (United Kingdom)&lt;br&gt;Q&amp;A</td>
</tr>
</tbody>
</table>
### BIOIBERICA

**New facts on osteoarthritis treatment: building the mosaic**

**Chairperson(s):**
- Philip Conaghan (United Kingdom)
- Jean-Pierre Pelletier (Canada)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Philip Conaghan (United Kingdom)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>08:18</td>
<td>Weiya Zhang (United Kingdom)</td>
<td>Overall treatment effect and contextual effect of osteoarthritis treatments: meta-analysis of RCTs</td>
</tr>
<tr>
<td>08:30</td>
<td>Philip Conaghan (United Kingdom)</td>
<td>Drug use and risk of comorbidities in osteoarthritis</td>
</tr>
<tr>
<td>08:42</td>
<td>George Peat (United Kingdom)</td>
<td>Chondroitin sulphate for hand osteoarthritis: a randomized, placebo-controlled trial in primary care: the FACTUAL study</td>
</tr>
<tr>
<td>08:54</td>
<td>Jean-Pierre Pelletier (Canada)</td>
<td>MOSAIC: 24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrl with Chondroitin sulphate</td>
</tr>
<tr>
<td>09:06</td>
<td>Johanne Martel-Pelletier (Canada)</td>
<td>Long-term effects of treatment on the progression of structural changes in knee osteoarthritis: new follow-up data from the Osteoarthritis Initiative cohort</td>
</tr>
<tr>
<td>09:18</td>
<td>Ali Guermazi (United States)</td>
<td>Long-term use of analgesics and risk of osteoarthritis progression and knee replacement from the Osteoarthritis Initiative cohort</td>
</tr>
</tbody>
</table>

**Q&A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Concluding remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:45</td>
<td></td>
</tr>
</tbody>
</table>

### Biosimilar Medicines Group, Medicines for Europe

**Biosimilar Medicines for Rheumatologists: understanding the science of extrapolation**

**Chairperson(s):**
- Matthias Schneider (Germany)
- Christof Iking-Konert (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:20</td>
<td>Fernando de Mora (Spain)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>08:50</td>
<td>Elena Wolff-Holz (Germany)</td>
<td>Biosimilars: the science of extrapolation and interchangability</td>
</tr>
<tr>
<td>09:10</td>
<td>Ferdinand Breedveld (Netherlands)</td>
<td>The EULAR position in the making</td>
</tr>
</tbody>
</table>

**Panel discussion, Q&A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:40</td>
<td>Fernando de Mora (Spain)</td>
<td>Summary and close</td>
</tr>
</tbody>
</table>

### Chugai and Roche

**Rheumatology TODAY Highlights of EULAR 2016**

Syposium in German language

**Chairperson(s):**
- Torsten Witte (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Christof Specker (Germany)</td>
<td>Collagenoses</td>
</tr>
<tr>
<td>17:45</td>
<td>Peer M. Aries (Germany)</td>
<td>Vasculitis</td>
</tr>
<tr>
<td>18:00</td>
<td>Frank Behrens (Germany)</td>
<td>Psoriatic arthritis</td>
</tr>
<tr>
<td>18:15</td>
<td>Xenofon Baraliakos (Germany)</td>
<td>Axial spondylarthitis</td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Oxford Immunotec

**Ask the experts: Tuberculosis testing in patients with rheumatic diseases**

A case-based, interactive session

**Chairperson(s):**
- Roy Chemaly (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>Roy Chemaly (United States)</td>
<td>Welcome &amp; introductions</td>
</tr>
<tr>
<td>17:35</td>
<td>Roy Chemaly (United States)</td>
<td>Overview of TB and diagnosis: what rheumatologists need to know</td>
</tr>
<tr>
<td>18:05</td>
<td>Jean Tayar (United States)</td>
<td>Case presentations &amp; discussion with audience participation</td>
</tr>
<tr>
<td>18:55</td>
<td>Roy Chemaly (United States)</td>
<td>Concluding remarks</td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td>Conclusion of program</td>
</tr>
</tbody>
</table>
IN RHEUMATOID ARTHRITIS (RA),

AS IL-6 ELEVATES,
THE EFFECTS
GO BEYOND
THE JOINTS

LEARN MORE ABOUT THE ROLE OF IL-6 IN RA AT BOOTH 410
FOR MORE INFORMATION, PLEASE VISIT www_RAandIL6_co.uk*


*For UK healthcare professionals only.
Company Profiles

Status as of 1 May 2016

Booth N°600+605+915

ABBVIE

1 North Waukegan Road
North Chicago, IL 60064
United States
www.abbvie.com

Abbvie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, Abbvie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Booth N°V12

AGORA

1 Kamelias str.
3110, Limassol
Cyprus
www.agora-platform.eu
www.agora-pait.com

Agora is a platform of organizations representing people with Rheumatic and Musculoskeletal Diseases in Southern Europe, which has been active since 2011. Agora aims to raise awareness, create a stronger voice for people with RMDs and motivate them to become more active and conscious through its various projects and initiatives. Furthermore, Agora aims in assisting the foundation and development towards user-led organizations of people with RMDs in Southern Europe, as well as promote supportive attitudes towards RMDs and enable patients to live independently and participate fully in society.

Booth N°V27

AMERICAN COLLEGE OF RHEUMATOLOGY

2200 Lake Boulevard NE
Atlanta, GA 30319
United States
www.rheumatology.org

The American College of Rheumatology is a professional membership society committed to improving the care of patients with rheumatic disease and advancing the rheumatology subspecialty. The ACR is a global medical society that serves over 9,500 physicians, health professionals and scientists worldwide. Stop by the ACR stand for information on: the Annual Meeting, November 11-16, 2016, Washington, DC; educational programs and products, such as SessionSelect; the Rheumatology Image Library; Arthritis & Rheumatology, Arthritis Care & Research, The Rheumatologists; and the benefits of membership.
AMGEN

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
www.amgen.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

APLAR

PICO Creative Centre, 2nd floor,
20 Kallang Avenue
Singapore 339411
Singapore
www.aplar.org/

APLAR strives to stimulate and promote the awareness, knowledge, and the means of prevention, treatment, rehabilitation and relief of symptoms of rheumatic and musculo-skeletal disorders within the Asia Pacific region. APLAR is affiliated to ILAR. Every year, APLAR Congress brings together rheumatologists, internists, orthopedic surgeons, clinical immunologists, psychiatrists, physical and occupational therapists, pediatricians and researchers from allied disciplines on a common platform so as to provide the best forum in the region for deliberations on all aspects of musculoskeletal diseases.

ARMA, Bride House,
18-20 Bride Lane, London,
EC4Y 8EE
United Kingdom
www.arma.uk.net/

The Arthritis and Musculoskeletal Alliance (ARMA) is the alliance representing the musculoskeletal (MSK) community in the UK. Our membership includes all major professional, research and patient-led organisations working across all areas of MSK disorders.

Our vision is that musculoskeletal (MSK) disorders are a priority in policy and practice in the UK. Our mission is to work collectively and collaboratively with our members and partners to achieve this vision. Our Vision, Mission and activities are determined and guided by our members and our purpose is to facilitate collaborative working and to enable the MSK community to speak with a unified voice.

ASIF

4 Albion Court, Hammersmith
London W6 0QT
United Kingdom
www.asif.info

ASIF’s Vision is to be the global voice of those living with Ankylosing Spondylitis. Its Mission is to increase awareness of Ankylosing Spondylitis (AS) and disseminate knowledge of the disease around the world to all key stakeholders be they people living with AS, health professionals, researchers, pharmaceutical organisations, policy makers or the general public.

Former in 1988, ASIF represents 37 AS organizations from 35 countries.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
**Booth N°800**

**BAYER PHARMA AG**

Muellerstr. 178  
Zip Code, City 13353 Berlin  
Germany  
www.bayer.com

Bayer: Science For A Better Life  
Bayer is a global enterprise with core competencies in the Life Science fields of healthcare and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

**Booth N°620**

**BIOGEN INTERNATIONAL GMBH**

Landis & Gyrstrasse 3  
6300, Zug  
Switzerland  
www.biogen.com

Through cutting-edge science and medicine, Biogen discovers,develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is the world’s oldest independent biotechnology company. In 2012, Biogen entered into a joint venture with Samsung Biologics to form Samsung Bioepis to develop, manufacture and market biosimilars of advanced biologics. Biogen has commercialization rights for three anti-TNF biosimilar candidates in Europe, Japan, Turkey and Russia. These therapies will be manufactured in the company’s large-scale manufacturing facility in Hillerød, Denmark, which is one of the largest in the world.

**Booth N°805**

**BIOIBERICA**

Plaza Francesc Macià, 7  
08029, Barcelona  
Spain  
www.bioiberica.com

BIOIBERICA is a biotechnology company specialized in osteoarthritis (OA) and chondroprotection. Based on a holistic approach of the disease, it has a full range of chondroprotective drugs such as Condrosan* / Cartexan* (Chondroitin Sulfate), Cartisorb* (Glucosamine Sulfate) and Droglican*, the first combination of chondroitin and glucosamine approved as an ethical reimbursed drug product. BIOIBERICA is also positioned within the OA Personalized Medicine field, with genetic tests, biomarkers, tissue engineering and cell therapy.

**Booth N°810**

**BMJ**

BMA House, Tavistock Square  
WC1H9JR, London  
United Kingdom  
www.bmj.com

Annals of the Rheumatic Diseases (ARD), a collaboration between EULAR and BMJ, is the #1 ranked journal in the field of rheumatology (impact factor 10.377) and the flagship in the Essential Rheumatology portfolio. It is supported by RMD Open, an open access journal expanding the breadth of rheumatic and musculoskeletal diseases, and Lupus Science & Medicine - the world’s first lupus specific open access journal. The package also comprises the newest edition of the EULAR Textbook on Rheumatic Diseases, the EULAR textbook on Systemic Sclerosis and the newly launched EULAR Textbook on Musculoskeletal Ultrasound in Rheumatology.

**Booth N°115**

**BOEHRINGER INGELHEIM**

Binger Strasse 173  
55216 Ingelheim  
Germany  
www.boehringer-ingelheim.com/

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
BRISTOL-MYERS SQUIBB
777 Scudders Mill Road
Plainsboro, NJ 08543
United States
www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis. The Bristol-Myers Squibb Foundation's philanthropic programs seek to promote health equity and improve the health outcomes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world's most vulnerable people.

CELGENE CORPORATION
86 Morris Avenue
Summit, New Jersey 07901
United States
www.celgene.com

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com.

CELLTRION HEALTHCARE
4F, 19, Academy-ro 51 beon-gil Yeonsu-gu
406-840, Incheon
South Korea
www.celltrionhealthcare.com

Celltrion Healthcare is a global biopharmaceutical company committed to delivering more affordable advanced therapeutics for patients.
Celltrion Healthcare conducts worldwide marketing, sales, and distribution of Celltrion, Inc.'s biosimilar and biological medicines to treat disease areas including rheumatology, gastroenterology, immunology and oncology.
Remsima® is the first biosimilar mAb to be approved by the European Medicines Agency (EMA) for the treatment of rheumatoid arthritis, ankylosing spondylitis other autoimmune diseases that its reference medicinal product is indicated for.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

CLINICAL CARE OPTIONS, LLC
12001 Sunrise Valley Drive,
Suite 300
Reston, VA 20191
United States
www.clinicaloptions.com

As a global leader in the development of continuing medical education programs, Clinical Care Options (CCO) envisions, produces and distributes the highest-quality interactive educational activities in both live and online formats. CCO's advanced technology platform allows for personalization of the clinician's experience and the integration of moderated social media. Educational content developed specifically for rheumatologists and clinicians who manage patients with rheumatologic conditions can be found at CCO Immunology (http://www.clinicaloptions.com/Immunology.aspx).

CRESCENDO BIOSCIENCE
341 Oyster Point Blvd
South San Francisco,
CA 94080
United States
www.trackmyra.com
www.crescendobio.com

Crescendo Bioscience (a subsidiary of Myriad Genetics) focuses on enabling more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients. Crescendo Bioscience's current products are: Vectra® DA, the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity, and MyRA, a free mobile app designed to empower people living with RA to regularly track multiple aspects of their RA and easily share the information with their physician. www.Vectra-DA.com; www.crescendobio.com; www.TrackMyRA.com
RheumaKit is a set of tools for the management of arthritis patients. It provides an early differential diagnosis for undifferentiated arthritis by combining a transcriptomic signature and 3 clinical factors into a mathematical model implemented in a web application. It also provides clinicians with a summary of the activity of 7 metabolic pathways playing a role in the pathogenesis or being direct targets of existing DMARDs. RheumaKit is a first step in the introduction (IVD) of biomarker-based in vitro diagnostic tools in rheumatology. It is the 1st IVD product developed by DNAlytics (BE).

Esaote is a top-10 diagnostic imaging company offering innovative clinical solutions from prevention to therapy. It focuses exclusively on ultrasound and office-based MRI, boasting an extended range of products specifically tuned to rheumatology applications and able to satisfy any clinical need. The ultrasound MyLab family boasts a complete range of rheuma-dedicated systems, from portable to premium-end products. Whilst the dedicated MRI line represents an optimal solution for excellent rheuma images with low installation requirements and costs per exam. Come visit Esaote Booth 920B.

EMEUNET, the EMerging EULAR NETwork, is a EULAR working group of young clinicians and researchers in rheumatology promoting education, research, widening collaborations and integrating with EULAR activities. The principal objectives of EMEUNET include the development of a European-wide network of young emerging rheumatologist and rheumatology-oriented researchers, enabling continued excellence in research and promoting and facilitating a comprehensive higher educational platform for all rheumatology trainees across Europe.

The EULAR Health Professional Standing Committee (HPSC) represents health professionals working in the field of rheumatic and musculoskeletal diseases (RMDs) across Europe, to improve the standard of care for people with RMDs and ensure they have access to optimal health care. The role of the patient as an active and empowered member of the multi-disciplinary team is a key component of our work. The HPSC collaborates across Europe to raise standards, encourage high quality research that is effectively disseminated and implemented, together with supportive educational activities.
The EULAR Standing Committee of PARE gathers representatives of rheumatic and musculoskeletal user groups around Europe to work together towards improving the quality of life for more than 120 million people in Europe living with these conditions. The committee’s vision is of people with rheumatic and musculoskeletal diseases (RMDs) in Europe being empowered to lead full and independent lives. To achieve this, the committee organises a range of high-quality activities and programmes. Activities may include lobbying at the national level, e.g., raising awareness of the disease, defending the civil rights of people with RMDs, or having access to the latest and most appropriate treatments.

The EuroTEAM (Towards Early diagnosis and biomarker validation in Arthritis Management) project has been funded by the European Union for 4 years and started in November 2012. The key objective of the EuroTEAM consortium is to specifically identify diagnostic biomarkers and disease mechanisms operating during the transition from health to RA. Through EuroTEAM, approaches will be developed to predict the onset of Rheumatoid Arthritis (RA) in people who do not yet have the disease. Ultimately, this will help in the development of treatments to prevent people from getting RA in the first place.

With our knowledge and experience from more than 200 mobility projects, we offer our customers comprehensive advice, implement mobile solutions and provide long-term support for them.

FESCA aisbl., founded in 2007, is an umbrella group of currently 23 national scleroderma patient support and advocacy organizations in 18 European countries. Friends of FESCA aisbl, includes the USA, Canada, and Australia, giving us a global presence and unity of purpose with other groups in the world. FESCA’s objectives include encouraging the active involvement of politicians and pharmaceutical companies, working with doctors to secure earlier diagnosis and better treatments, and creating greater awareness of scleroderma so that those who suffer from it can access proper, equitable care.

Fidia Farmaceutici s.p.a. is an Italian pharma company, with R&D, manufacturing, marketing and sales capabilities, and an extensive product portfolio mainly based on hyaluronan (HA) in Joint Care, Wound Care and Aesthetics. Over 50 years of R&D have placed Fidia at the forefront in the production of natural and functionalized HA, with different ranges of MW. Manufacturing operation is FDA-approved, and complies with the strictest international regulations and safety standards. Fidia extends its global reach through local partners in 100 countries worldwide, and wholly-owned subsidiaries in USA, Kazakhstan, Germany, Spain, Russia and Middle East.
**GE HEALTHCARE**

Beethovenstrasse 239  
42665 Solingen  
Germany  
www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

**GLAXOSMITHKLINE**

GSK House, Great West Road, Brentford  
TW8 9GS  
United Kingdom  
www.gsk.com

GSK It’s a global healthcare company on a mission. We’re a science-led global healthcare company with a mission to help people do more, feel better, live longer.

Our vaccines, consumer healthcare products and medicines touch the lives of millions of people.

Today we are working to overcome some of the biggest healthcare challenges and create change to improve people’s lives.

**HEMICS**

Torenallee 20  
5617 BC Eindhoven  
Netherlands  
www.hemics.com

Hemics is a medical device company active in the field of inflammatory joint diseases. Hemics developed the Hemics® HandScan, a new non-invasive optical imaging device. It supports rheumatologists in objective assessment of inflammatory status in patients with Rheumatoid Arthritis (RA). The technique is time saving, non-invasive, safe and operator independent, perfectly fitting the workflow in the rheumatologist’s office.

**GRIFOLS**

Av. de la Generalitat 153-150  
08174 Sant Cugat. Barcelona  
Spain  
www.grifols.com

Grifols is a global healthcare company that produces and markets plasma-derived medicines, hospital products and diagnostic and testing equipment designed to improve the health and well-being of patients around the world.

Since 1940, Grifols has pioneered many of the tools and techniques used to collect human plasma and transform it into medicines for the treatment of life-threatening diseases. From its humble beginnings in Barcelona, Spain, Grifols has evolved into the third largest global producer of plasma derived medicines with the largest network of plasma collection centers in the world. Today, Grifols employs more than 11,000 people worldwide, and our products are sold in more than 100 countries. Our affiliate offices in 25 countries enable us to serve a large number of hospitals, healthcare professionals and patients who rely on the quality, safety and effectiveness of our products.
IBSA INSTITUT BIOCHIMIQUE SA

IBSA Institut Biochimique SA
Via del Piano
6915 Pambio Noranco
Switzerland
www.ibsa-international.com

IBSA is an international pharmaceutical company based in Lugano, Switzerland, active in different therapeutic areas. For OA and related syndromes, IBSA’s portfolio includes a wide range of pharmaceutical options such as pharmaceutical-grade chondroitin sulphate for oral intake (Condrosulf®, Chondrosulf®), a highly purified intra-articular hyaluronic acid of biofermentative origin (Sinovial®, Yaral®, Intrigel®), topical and oral forms of diclofenac epolamine (Flector®) and an innovative subcutaneous injection of diclofenac also available at low dosages and in form of pre-filled syringe (Akis®, Dicloin®).

IMAGE ANALYSIS

Image Analysis,
QABC Minister House
272-274 Vauxhall Bridge Road
London, SW1V 1BA
United Kingdom
www.imageanalysis.org.uk

Image Analysis is the expert medical imaging company, supporting clinical research and validation of efficacy and safety of new compounds for inflammatory, auto-immune and degenerative musculoskeletal conditions. We work with bio-pharmaceutical sponsors assisting with time and cost efficient delivery of their clinical trials and feasibility studies. Our expertise is in implementing novel biomarkers and efficient imaging protocols in early phase studies, to allow sponsors to make early decisions on the treatment impact and to objectively assess the unique properties of the new drug candidates.

INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (ILAR)

2200 Lake Boulevard NE
Atlanta, GA 30319
United States
www.rheumatology.org

The International League of Associations for Rheumatology’s mission is to advance rheumatology in developing countries. The ILAR Executive Committee consists of the Presidents and Presidents-Elect of ACR, EULAR, PANLAR, APLAR and AFLAR. The collaboration of the leaders of these international organizations has resulted in a renewed commitment to support programs that lead to progress in the practice and education of rheumatology in countries where there is an exceptional need.

JANSSEN PHARMACEUTICA NV

Turnhoutseweg 30,
2340, Beerse
Belgium
www.janssen.com/emea/

Janssen's commitment to immunology

Janssen Immunology is proud to have one of the strongest treatment portfolios for some of the most common immune and inflammatory diseases across rheumatology, gastroenterology and dermatology.

We are working with our partners in academia and biotechnology to develop new, tailored therapeutic options that aim to provide the right treatment for the right person in every part of the world.

Together we aim to provide new hope and good health for people and their families living with immune and inflammatory diseases.

JAPAN COLLEGE OF RHEUMATOLOGY

1-22-16 Toranomon
Minato-ku, Tokyo 105-0001
Japan
eng.ryumachi-jp.com

The Japan College of Rheumatology (JCR) holds the Annual Scientific Meeting every spring and provides a platform for rheumatologists and other specialists to share knowledge on the prevention and treatment of rheumatic diseases. The Meeting welcomes thousands of rheumatologists and researchers from Japan, as well as from the rest of the world.

The JCR publishes its official journal, Modern Rheumatology, which provides information on the latest developments in rheumatic diseases.
LA LETTRE DU RHUMATOLOGUE

Edimark, 2 rue Sainte Marie
92400 Courbevoie
France
www.edimark.fr/lettre-rhumatologue

La Lettre du Rhumatologue is a French monthly publication specialized in rheumatology, which editor in chief is Prof. Bernard Combe.
The publication is released in 3,000 copies issued 10 times a year.

LABORATOIRES EXPANSIENCE

10, avenue de l’Arche
92419 Courbevoie Cedex
France
www.expanscience.com

In 2015, Expanscience - a French independently-owned pharmaceutical and dermo-cosmetics laboratory - generated turnover of €271 M*, 51% of which was through exports. Its solid reputation as an innovator and as a specialist in skin and the treatment of arthritis has been built around its leading brands – Piasclédine 300 and Mustela in particular.

In figures
• Date created: 1950
• Turnover*: €271 M
• 84 distributing countries
• 14 subsidiaries
• Nearly 1,000 employees
• 66 M products manufactured
• Activities: Dermo-Cosmetics, Dermatology, Rheumatology, Cosmetic active ingredients

*Estimated

LCA PHARMACEUTICAL

9, Allée Promthéée
28 000, Chartres
France
www.lca-pharma.com

LCA Pharmaceutical is expert in osteoarthritis with sodium hyaluronate joint injections of high molecular weight and high concentration:
ARTHRUM H 2% 3 weekly intra-articular injections
ARTHRUM 75 single injection for knee osteoarthritis
COXARTHURM single injection for hip osteoarthritis
RHIZARTHURM for small joints injection

Two other new innovative products are also available with the first combination of chondroitin sulfate and sodium hyaluronate indicated for treatment of osteoarthritis: pain relief and joint function recovery.
SYNOVIUM HCS single injection
ARTHRUM HCS 3 weekly intra-articular injections

LETTER TO EDITOR RHEUMATOLOGY

Kore Şehitleri Caddesi
Onurşul İş Merkezi No:35/6
34394 Şişli – İstanbul
Turkey
www.clinexprheumatol.org/

With this printed edition of LER&CER we initiate a formal section on solicited controversy in which the journal editors will ask well-known experts in the field to present their expertise in a brief and succinct manuscript of mostly 1,500 words and an abstract of 100 words. We start with Emire Seyahi and myself about our understanding and views on the long-debated issue of anticoagulation in managing thrombosis in Behçet’s. In this new series we also plan to invite formal pro and con contributions of important controversies by different authors. Unsolicited controversies will also be considered, on the understanding that proposed authors send us beforehand a title and an abstract of 100 words, prior to formal assignment of the full manuscript. We look forward to receiving fair contributions on controversies, in which rheumatology and related disciplines abound, to guide us in our practice and research.

LUPUS EUROPE

St. James House
27-43 Eastern Road
RM1 3NH,
Romford, Essex
United Kingdom
www.lupus-europe.org

Strategic Drivers 2013-2017 are: LUPUS EUROPE was founded in 1989 and today unites 26 members representing national lupus groups of 24 countries in Europe:
It is the Vision of LUPUS EUROPE to have a fulfilling life for all people with lupus in Europe until we have reached a world without lupus.
LUPUS EUROPE Mission is to be the voice of lupus in Europe and to empower the national organisations for people living with lupus.
1. People with lupus in Europe participate in and benefit from research in lupus
2. Enthusiasm and empowerment to member organizations.
3. LUPUS EUROPE is heard & acting
### MALLINCKRODT SPECIALTY PHARMACEUTICALS IRELAND

**Booth N°159**

MALLINCKRODT SPECIALTY PHARMACEUTICALS IRELAND

---

### MCI SUISSE S.A. – EULAR OFFICIAL HOUSING BUREAU

**Booth N°152**

MCI SUISSE S.A. – EULAR OFFICIAL HOUSING BUREAU

75 rue de Lyon
1211 Geneva 13
Switzerland

www.mci-group.com

MCI Suisse S.A. is EULAR’s Official Housing Bureau since 2007. Come and visit us on stand n°152 to get more information on our list of selected hotels for EULAR 2017 in Madrid.

---

### MEDAC

**Booth N°205**

MEDAC

Theaterstrasse 6
2280 Wedel
Germany

www.medac.de

medac Gesellschaft für klinische Spezialpräparate mbH is a privately held German pharmaceutical company located in Wedel, Tornesch and Hamburg. Medicinal products from medac support doctors and patients throughout the world in overcoming acute and chronic diseases in the indication areas of oncology, haematology, urology and autoimmune disorders. In addition, medac develops and markets special diagnostic test systems. Since 1970 medac has been committed to unifying therapeutic and diagnostic areas under one roof. You can find further information about the company and its products at www.medac.de.

---

### MEDI

**Booth N°155**

MEDI

Medicusstr. 1
95448 Bayreuth
Germany

www.medi.de

Founded in Germany in 1951, medi GmbH & Co. KG has become one of the world’s leading manufacturers of medical aids. Thanks to the dedication of our international distribution partners and 1700 employees, the company exports to over 90 countries worldwide. Our orthopaedic assortment consists of supports and braces for the treatment of joint conditions and injuries for all parts of the human body such as back, shoulder/spine, hip, knee, ankle, wrist, elbow or foot. Our full range of premiumquality products are the first choice of many renowned healthcare professionals all across the globe especially for indications like osteoarthritis, osteoporosis, cruciate ligament rupture, post-operative shoulder immobilization and much else besides. For further information please visit our website www.medi.de.

---

### METEOR

**Booth N°V18**

METEOR

P.O. Box 9600
2300 RC Leiden
Netherlands

www.meteorfoundation.com

METEOR is an online tool to improve treatment of patients with rheumatoid arthritis (RA) by allowing rheumatologists to regularly measure and follow individual patients while at the same time a database is constructed for benchmarking and research purposes.

METEOR aims to:
- Encourage rheumatologists to undertake regular monitoring of disease activity
- Help rheumatologists setting goals and sharing treatment progress with patients
- Create a central database that can be used for research and benchmarking
- Allows data upload of local databases and download for local databases
Today’s MSD is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD. Be Well. For more information, visit www.merck.com.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

Oxford Immunotec Global PLC is a global, high growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. Our proprietary T-SPOT® technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.

The T-SPOT.TB test, which is used to test for tuberculosis infection has been approved for sale in over 50 countries, including the United States, where it has received market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test is the Company’s latest product and the first in a series of products intended for the transplantation market. For more information, please visit www.oxfordimmunotec.com.

Oxford University Press is a leading publisher in rheumatology journals, books and online products and our worldwide publishing furthers the University’s objectives of excellence in scholarship, research, and education. Visit us at stand 161 today to pick up your FREE copy of Rheumatology, enter our competition and browse our extensive collection of books, available to buy with an exclusive 20% conference discount.

At Pfizer, we apply science and global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Regeneron and Sanofi have collaborated to discover, develop, manufacture and commercialize fully human monoclonal antibodies utilizing Regeneron’s proprietary VelociSuite® of technologies.

Rheumatology News® is the leading independent newspaper for the practicing rheumatologist. Readers rely on Rheumatology News® for breaking news and insightful commentary - in a clear, concise, accessible format - that can be used daily in practice.

Rheumatology News® is published monthly by Frontline Medical Communications (www.FrontlineMedCom.com) and circulates to over 7,500 rheumatologists and selected primary care physicians. All articles - researched, written, and produced by a full-time staff of professional medical journalists - can be found at www.rheumatologynews.com.

Samsung Bioepis is a biopharmaceutical company focused on realizing healthcare that is affordable and available to all. Through innovations in product development and a firm commitment to superior quality, Samsung Bioepis continues to advance a broad pipeline of 13 biosimilars that include six “first wave” products covering the therapeutic areas of immunology, oncology and diabetes. For more information, please visit: www.samsungbioepis.com.
SAMUMED

9381 Judicial Drive
92121, San Diego, CA
United States
www.samumed.com

Samumed, LLC is a pharmaceutical platform company that has made groundbreaking advances in the biology of tissue regeneration. Our platform is rooted in its discoveries of new targets and biological processes in the Wnt pathway, an essential component of cellular biology of tissue regeneration. Samumed researchers are developing and testing drug therapies that regulate tissue regeneration and/or target other causes of diseases such as systemic inflammation. Samumed is currently conducting clinical trials in osteoarthritis, androgenetic alopecia, cancer and idiopathic pulmonary fibrosis.

SANUMED

Sandoz International GmbH
Industriestr. 25
83607 Holzkirchen
Germany
www.sandoz.com

Sandoz, a Novartis company, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2015 sales of USD 9.2 billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.

SANOFI GENZYME

Sanofi Genzyme
500 Kendall Street
Cambridge, MA 02142
United States
www.sanofi.com

Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Regeneron and Sanofi have collaborated to discover, develop, manufacture and commercialize fully human monoclonal antibodies utilizing Regeneron's proprietary VelociSuite® of technologies.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Aarhus University Hospital,
Norrebrogade 44
DK-8000 Aarhus
Denmark
scandjrheumatol@editorialoffice.dk
www.scandjrheumatol.dk

The Scandinavian Journal of Rheumatology publishes international, peer reviewed, high quality, original reports of clinical and basic research, as well as editorials, review articles and informative case reports covering all aspects of rheumatology.

Subscriptions include print, online access, and supplements to the Journal.

Published since 1955 by the Scandinavian Society for Rheumatology.

Detailed information is available on our website www.scandjrheumatol.dk

SOBI

1 Tomtebodvägen 23A
112 76 Stockholm
Sweden
www.sobi.com

Sobi is an international specialty healthcare company dedicated to rare diseases.

Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Kineret® is indicated in adults for the treatment of the signs and symptoms of Rheumatoid Arthritis (RA) in combination with methotrexate, with an inadequate response to methotrexate alone. Kineret® is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Booth N°149

TAYLOR & FRANCIS

Taylor & Francis Group
Routledge, CRC Press
4 Park Square, Milton Park, Abingdon
Oxon OX14 4RN
United Kingdom
http://taylorandfrancisgroup.com

Taylor & Francis Group partners with researchers, scholarly societies, universities and libraries worldwide to bring knowledge to life. As part of our Medical portfolio we are one of the world’s leading publishers of scholarly journals, books, ebooks and reference works in Rheumatology and related disciplines.

Booth N°V10

THE BRITISH SOCIETY FOR RHEUMATOLOGY

Bride House, 18 -20 Bride Lane
London EC4Y 8EE
United Kingdom
www.rheumatology.org.uk

The British Society for Rheumatology (BSR) promotes excellence in the treatment of people with rheumatic and musculoskeletal disorders and supports those delivering care. It is a professional association with its own journal “Rheumatology”, and with members in over 40 countries representing the whole multi-disciplinary team for adults, adolescents and paediatrics: consultant rheumatologists, trainees, specialised nurses, physiotherapists, occupational therapists, and GPs with special interest in rheumatology. Visit us at the BSR stand to find out more about the work we do.

Booth N°625

THE MENARINI GROUP

Via Sette Santi 3, 50131 Florence
Italy
www.menarini.com

A.Menarini is the largest Italian pharmaceutical group: it ranks the world's number 37 and the Europe's number 17. Menarini is present in more than 100 countries worldwide. Menarini Group is investing 9.1% of its revenues from prescription drugs in R&D, mainly in cardiovascular field, oncology, pain-inflammation and asthma. Febuxostat, a drug for the treatment of chronic hyperuricemia in gout, is the first non-purine, selective xanthine oxidase inhibitor and is a highly effective therapy to lower and maintain serum uric acid to the EULAR target of ≤6 mg/dl. Available in 80mg and 120mg doses.

Booth N°156

TRB CHEMEDICA INTERNATIONAL

Rue Michel-Servet 12
P.O. Box 352
1211 Geneva 12
Switzerland
www.trbchemedica.com

TRB Chemedica International SA is a Swiss pharmaceutical company, with a focus on research, development and marketing of innovative niche products in rheumatology. Our product portfolio consists of:

- DIACEREIN, an oral interleukin-1 inhibitor for the treatment of osteoarthritis with beneficial symptom- and structure-modifying effects.
- OSTENIL* Line, i.a. hyaluronic acid-based injections for the symptomatic treatment of osteoarthritis of large and small joints.
- OSTENIL* TENDON, hyaluronic acid-based injection for the treatment of pain and restricted mobility in tendon disorders.

Booth N°500

UCB BIOPHARMA SPRL

Allée de la Recherche 60
1070 Brussels
Belgium
www.ucb.com


Booth N°160

WISEPRESS MEDICAL BOOKSHOP

25 High Path
SW19 2JL, London
United Kingdom
www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.
The World Scleroderma Foundation, supported by Alexander Klee, as patron of the association, and his family, is a nonprofit, non-governmental foundation dedicated to initiating and supporting research in scleroderma in all its aspects in all regions of our planet. Its commitment is to facilitate patient oriented research independently but also in collaboration with existing other organizations and learned societies working in this field. WSF although is connected with societies, industries and government in an open and dynamic fashion, remains independent of any kind of pressures.

Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. The Zydus group bagged the India Pharma Overall Excellence Award and India Pharma Innovation of the Year Award from the Govt. of India in 2016. The group employs over 19,000 people worldwide and is dedicated to creating healthier communities globally.

Acknowledgements

The EULAR 2016 Organising Committee wishes to express its gratitude to all satellite symposia organisers and exhibitors as well as to the following partners:

- **Novartis Pharmaceuticals**
  - Congress programme on mobile devices

- **MSD**
  - Pocket programme

- **Sanofi**
  - Cyber café

- **Lilly**
  - Mobile charging stations
A “Joint” Approach for Improving the Management of Psoriatic Arthritis

Exploring Challenges in the Diagnosis and Assessment of Psoriatic Arthritis

Shared Decision-Making Strategies for Optimising the Management of Psoriatic Arthritis

Taking Action: Integrating Our Learnings Into Future Clinical Practice

Friday, 10 June 2016 • 8:15-9:45 • ExCeL London, UK, Hall A

Douglas Veale, MD—Chair
University College Dublin, Ireland

Laura Coates, MBChB, MRCP, PhD
University of Leeds, UK

Jo Lambert, MD, PhD
Ghent University Hospital, Belgium

Scan this QR code to discover PsA through the eyes of the patient!
Plan - Overview

North Halls Level 1

South Halls Level 1

Rooms N08-N19

Boulevard

East Entrance

West Entrance

Custom House for ExCeL (West)

East

West

DLR

EULAR Village

Catering Café

Exhibition Posters

Capital Suites

South Halls Level 1

Rooms N08-N19

Level 1

Level 0

Level 2

Level 3

Level 4

Level 5

Level 6

Level 7

Level 8

Level 9

Level 10

Level 11
### Exhibitors' List

**Status as of 1 May 2016**

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>600+605+915</td>
</tr>
<tr>
<td>AMGEN</td>
<td>305</td>
</tr>
<tr>
<td>ASTRAZENECA</td>
<td>715</td>
</tr>
<tr>
<td>BAYER PHARMA AG</td>
<td>800</td>
</tr>
<tr>
<td>BIOGEN INTERNATIONAL GMBH</td>
<td>620</td>
</tr>
<tr>
<td>BIOIBERICA, S.A</td>
<td>805</td>
</tr>
<tr>
<td>BMJ</td>
<td>810</td>
</tr>
<tr>
<td>BOEHRINGER INGELHEIM</td>
<td>115</td>
</tr>
<tr>
<td>BRISTOL-MYERS SQUIBB</td>
<td>610+615+705</td>
</tr>
<tr>
<td>CELGENE CORPORATION</td>
<td>105</td>
</tr>
<tr>
<td>CELLTRION HEALTHCARE</td>
<td>630</td>
</tr>
<tr>
<td>CLINICAL CARE OPTIONS, LLC</td>
<td>150</td>
</tr>
<tr>
<td>CRECENDO BIOSCIENCE</td>
<td>151</td>
</tr>
<tr>
<td>DNAlytics</td>
<td>148</td>
</tr>
<tr>
<td>ELI LILLY AND COMPANY</td>
<td>210+310</td>
</tr>
<tr>
<td>ESAOTE</td>
<td>920B</td>
</tr>
<tr>
<td>EULAR</td>
<td>910</td>
</tr>
<tr>
<td>FIDIA FARMACEUTICI</td>
<td>905</td>
</tr>
<tr>
<td>FUTURE EVENTS</td>
<td>157</td>
</tr>
<tr>
<td>GE HEALTHCARE</td>
<td>130</td>
</tr>
<tr>
<td>GLAXOSMITHKLINE</td>
<td>100</td>
</tr>
<tr>
<td>GRIFOLS</td>
<td>147</td>
</tr>
<tr>
<td>HEMICS</td>
<td>154</td>
</tr>
<tr>
<td>HOSPIRA, A PFIZER COMPANY</td>
<td>405</td>
</tr>
<tr>
<td>IBSA INSTITUT BIOCHIMIQUE SA</td>
<td>900</td>
</tr>
<tr>
<td>IMAGE ANALYSIS</td>
<td>158</td>
</tr>
<tr>
<td>JANSSEN</td>
<td>215+220+315</td>
</tr>
<tr>
<td>LA LETTRE DU RHUMATOLOGUE</td>
<td>230</td>
</tr>
<tr>
<td>LABORATOIRES EXPANSIENCE</td>
<td>710</td>
</tr>
<tr>
<td>LCA PHARMACEUTICAL</td>
<td>146</td>
</tr>
<tr>
<td>MALLINCKRODT SPECIALTY</td>
<td>159</td>
</tr>
<tr>
<td>PHARMACEUTICALS IRELAND</td>
<td></td>
</tr>
<tr>
<td>MCI SUISSE S.A - EULAR OFFICIAL HOUSING BUREAU</td>
<td>152</td>
</tr>
<tr>
<td>MEDAC</td>
<td>205</td>
</tr>
<tr>
<td>MEDI</td>
<td>155</td>
</tr>
<tr>
<td>MSD</td>
<td>700</td>
</tr>
<tr>
<td>NOVARTIS PHARMACEUTICAL</td>
<td>415+515+520</td>
</tr>
<tr>
<td>OXFORD IMMUNIOTEC</td>
<td>153</td>
</tr>
<tr>
<td>OXFORD UNIVERSITY PRESS</td>
<td>161</td>
</tr>
<tr>
<td>PFIZER</td>
<td>400+405</td>
</tr>
<tr>
<td>REGENERON</td>
<td>410</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROCHE</td>
<td>300</td>
</tr>
<tr>
<td>SAMSUNG BIOEPIS</td>
<td>200</td>
</tr>
<tr>
<td>SAMUMED LLC</td>
<td>120</td>
</tr>
<tr>
<td>SANDOZ</td>
<td>520</td>
</tr>
<tr>
<td>SANOFI GENZYME</td>
<td>410</td>
</tr>
<tr>
<td>SOBI</td>
<td>815</td>
</tr>
<tr>
<td>TAYLOR &amp; FRANCIS</td>
<td>149</td>
</tr>
<tr>
<td>THE MENARINI GROUP</td>
<td>625</td>
</tr>
<tr>
<td>TRB CHEMEDICA INTERNATIONAL</td>
<td>156</td>
</tr>
<tr>
<td>UCB BIOPHARMA SRL</td>
<td>500</td>
</tr>
<tr>
<td>WISEPRESS MEDICAL BOOKSHOP</td>
<td>160</td>
</tr>
<tr>
<td>ZYDUS CADIILA</td>
<td>110</td>
</tr>
</tbody>
</table>

### EULAR Village Exhibitor's List

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGORA</td>
<td>V12</td>
</tr>
<tr>
<td>AMERICAN COLLEGE OF RHEUMATOLOGY</td>
<td>V27</td>
</tr>
<tr>
<td>APLAR</td>
<td>V19</td>
</tr>
<tr>
<td>ARTHRITIS AND MUSCULOSKELETAL ALLIANCE (ARMA)</td>
<td>V8</td>
</tr>
<tr>
<td>ASIF</td>
<td>V23</td>
</tr>
<tr>
<td>CLINICAL AND EXPERIMENTAL RHEUMATOLOGY</td>
<td>V13</td>
</tr>
<tr>
<td>EMEUNET</td>
<td>V31</td>
</tr>
<tr>
<td>EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY</td>
<td>V24</td>
</tr>
<tr>
<td>EULAR PARE</td>
<td>V1</td>
</tr>
<tr>
<td>EUROTEAM</td>
<td>V21</td>
</tr>
<tr>
<td>EYELI - MOBILE DEVICES HELP DESK</td>
<td>V29A</td>
</tr>
<tr>
<td>FEDERATION OF SCLERODERMA ASSOCIATIONS aisl. (FESCA)</td>
<td>V14</td>
</tr>
<tr>
<td>INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (ILAR)</td>
<td>V27</td>
</tr>
<tr>
<td>JAPAN COLLEGE OF RHEUMATOLOGY</td>
<td>V22</td>
</tr>
<tr>
<td>LETTER TO EDITOR RHEUMATOLOGY</td>
<td>V20</td>
</tr>
<tr>
<td>LUPUS EUROPE</td>
<td>V29B</td>
</tr>
<tr>
<td>METEOR</td>
<td>V18</td>
</tr>
<tr>
<td>RHEUMATOLOGY NEWS</td>
<td>V30</td>
</tr>
<tr>
<td>ROMANIAN SOCIETY OF RHEUMATOLOGY</td>
<td>V15</td>
</tr>
<tr>
<td>SCANDINAVIAN JOURNAL OF RHEUMATOLOGY</td>
<td>V16</td>
</tr>
<tr>
<td>THE BRITISH SOCIETY FOR RHEUMATOLOGY</td>
<td>V10</td>
</tr>
<tr>
<td>WORLD SCLERODERMA FOUNDATION</td>
<td>V17</td>
</tr>
</tbody>
</table>
Pfizer is one of the world’s leading biopharmaceutical companies, operating in 175 countries worldwide.

At Pfizer, we apply science and our global resources to improve health and wellbeing at every stage of life.

Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s leading biopharmaceutical companies, we also collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

*Please visit us at booths 400 and 405.*
SOLVING THE WORLD’S TOUGHEST HEALTH CHALLENGES TAKES ALL OF US.

AbbVie starts with research and innovation to develop and deliver new treatments to manage some of the world’s most difficult diseases.

Our global biopharmaceutical company builds our pipeline to provide solutions in therapeutic areas served by our proven expertise.

To make new solutions available to patients, we team with scientific peers, physicians, governments and advocacy groups.

When we all work together, the results can have a remarkable impact on patients’ lives and the healthcare systems that serve them.

abbvie.co.uk

170+ Countries
28,000+ Employees
20 R&D and Manufacturing Sites